<SEC-DOCUMENT>0001161697-25-000103.txt : 20250312
<SEC-HEADER>0001161697-25-000103.hdr.sgml : 20250312
<ACCEPTANCE-DATETIME>20250312162801
ACCESSION NUMBER:		0001161697-25-000103
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250312
DATE AS OF CHANGE:		20250312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KORU Medical Systems, Inc.
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39086
		FILM NUMBER:		25732107

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE DRIVE
		CITY:			MAHWAH
		STATE:			NJ
		ZIP:			07430
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE DRIVE
		CITY:			MAHWAH
		STATE:			NJ
		ZIP:			07430

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REPRO MED SYSTEMS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form_10-k.htm
<DESCRIPTION>FORM 10-K ANNUAL REPORT FOR 12-31-2024
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:krmd="http://korumedical.com/20241231">
<head>
     <title>Form 10-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2024%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_039_krmd_korumedical.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DDocumentFiscalYearFocus_2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000704440 -->
<!-- Field: Set; Name: xdx; ID: xdx_077_XDX_D%2D%2D\EDGARbiz\Clients (D)\KORU (fka Repro%2DMed)\10%2DK 2024%2D12%2D31 KORU %2D Current\form__10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_N_0_Number -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000007" name="dei:EntityCentralIndexKey">0000704440</ix:nonNumeric>
  <ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForOtherTaxes" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0453" decimals="INF" unitRef="N">1</ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember" id="xdx2ixbrl0465" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">P6Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember" id="xdx2ixbrl0467" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">P20Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="xdx2ixbrl0492" decimals="0" unitRef="USD">7080843</ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MinimumMember" id="xdx2ixbrl0498" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MaximumMember" id="xdx2ixbrl0500" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_EquipmentAndToolingMember_srt_MinimumMember" id="xdx2ixbrl0502" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_EquipmentAndToolingMember_srt_MaximumMember" id="xdx2ixbrl0504" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P12Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0564" decimals="0" unitRef="USD">2803669</ix:nonFraction>
  <ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="xdx2ixbrl0627" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P6Y2M30D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member" id="xdx2ixbrl0673" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">P7Y4M24D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl0791" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P5Y1M6D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl0793" name="us-gaap:LesseeOperatingLeaseRenewalTerm">P6Y10M25D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31" id="xdx2ixbrl0795" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">P2Y8M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31" id="xdx2ixbrl0797" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">P3Y8M12D</ix:nonNumeric>
  <ix:nonFraction name="krmd:FinanceLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2024-12-31" id="xdx2ixbrl0827" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0856" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0857" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0860" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0862" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0863" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0866" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0874" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0875" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0877" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0878" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0880" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:DeferredTaxAssetsDeferredLeaseLiability" contextRef="AsOf2023-12-31" id="xdx2ixbrl0905" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0937" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0938" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0957" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="krmd:IncomeTaxReconciliationDeferredTaxTrueUps" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0963" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="krmd-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EquipmentAndToolingMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EquipmentAndToolingMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OmnibusEquityIncentivePlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:OmnibusEquityIncentivePlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OmnibusEquityIncentivePlan2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:OmnibusEquityIncentivePlan2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OmnibusEquityIncentivePlan2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:OmnibusEquityIncentivePlan2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StockOptionPlans2015And2021CombinedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TimeVestingStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TimeVestingStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceVestingStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TimeVestingStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PerformanceVestingStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceVestingStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PerformanceVestingStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceVestingStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_custom_DomesticBankLenderMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:DomesticBankLenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_custom_DomesticBankLenderMember_custom_TermLoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:DomesticBankLenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">krmd:TermLoanFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-082025-03-08_custom_DomesticBankLenderMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:DomesticBankLenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-08</xbrli:startDate>
        <xbrli:endDate>2025-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-082025-03-08_custom_DomesticBankLenderMember_custom_TermLoanFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:DomesticBankLenderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">krmd:TermLoanFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-08</xbrli:startDate>
        <xbrli:endDate>2025-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:SecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SecurityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:SecurityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000704440</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>krmd:Number</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<div style="width: 7.5in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_908_edei--DocumentType_c20240101__20241231_zDSvM1a5YkPd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000014" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--DocumentAnnualReport_c20240101__20241231_zHVBWGzc0AIi"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span>&#160;&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the fiscal year ended <span id="xdx_909_edei--DocumentPeriodEndDate_c20240101__20241231_znLeAYSB0vXk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate">December 31, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">OR</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--DocumentTransitionReport_c20240101__20241231_z9ttUPO14Hv2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span>&#160;&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ____________ to __________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Commission file number <span id="xdx_909_edei--EntityFileNumber_c20240101__20241231_z1EMPxnMBkdb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityFileNumber">0-12305</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityRegistrantName_c20240101__20241231_zAqfjnjzByf4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:EntityRegistrantName">KORU MEDICAL SYSTEMS, INC.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: bottom">
    <td style="width: 3.5in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20240101__20241231_zHpRrOPAgSK1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></td>
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 3.5in; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20240101__20241231_z2yfRlnr9zea"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">13-3044880</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">(State or other jurisdiction of incorporation or organization)</td>
    <td>&#160;</td>
    <td style="text-align: center">(I.R.S. Employer Identification No.)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityAddressAddressLine1_c20240101__20241231_zsAKlhjyLjl2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">100 Corporate Drive</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20240101__20241231_zBPLBe26BoBb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressCityOrTown">Mahwah</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20240101__20241231_zyI1bW6irvI7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000024" name="dei:EntityAddressStateOrProvince">New Jersey</ix:nonNumeric></span></span></b></td>
    <td>&#160;</td>
    <td style="text-align: center"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityAddressPostalZipCode_c20240101__20241231_zmpGbYRCQqb1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressPostalZipCode">07430</ix:nonNumeric></span></span></b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td>&#160;</td>
    <td style="text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">(<span id="xdx_907_edei--CityAreaCode_c20240101__20241231_zgLcvdGvP2vh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:CityAreaCode">845</ix:nonNumeric></span>)-<span id="xdx_901_edei--LocalPhoneNumber_c20240101__20241231_zTpFd7aBqHec"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:LocalPhoneNumber">469-2042</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&#8217;s telephone number, including area
code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top">
    <td style="width: 2.5in"><span style="text-decoration: underline">Title of each class</span></td>
    <td style="width: 2.5in"><span style="text-decoration: underline">Trading Symbol(s)</span></td>
    <td style="width: 2.5in"><span style="text-decoration: underline">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td><b><span id="xdx_904_edei--Security12bTitle_c20240101__20241231_zFbly3E8upp8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:Security12bTitle">common stock, $0.01 par value</ix:nonNumeric></span> </b></td>
    <td><b><span id="xdx_900_edei--TradingSymbol_c20240101__20241231_zkldcZwu20M6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:TradingSymbol">KRMD</ix:nonNumeric></span></b></td>
    <td><b><span id="xdx_90D_edei--SecurityExchangeName_c20240101__20241231_zqXKCHkaZtZc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">The Nasdaq Stock Market</ix:nonNumeric></span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(g) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">None</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Title of Class)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act. Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_90D_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_z4fPyYst1eAe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000031" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_90B_edei--EntityVoluntaryFilers_c20240101__20241231_z5vQ7owVlCe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
<span id="xdx_90B_edei--EntityCurrentReportingStatus_c20240101__20241231_zmGlUUc9sTqh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T &#160;(&#167; 232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) <span id="xdx_902_edei--EntityInteractiveDataCurrent_c20240101__20241231_zTYNwEsdsP4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top">
    <td style="width: 3.75in">Large accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="width: 3.75in">Accelerated filer <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_90A_edei--EntityFilerCategory_c20240101__20241231_zqmZDQjS0x27"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000035" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td>
    <td>Smaller reporting company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntitySmallBusiness_c20240101__20241231_zymDAkUNQyn4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000036" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20240101__20241231_z9IyJcSjEg18"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has filed a report on and
attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b)
of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If securities are registered pursuant to Section 12(b) of the Act, indicate
by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously
issued financial statements. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether any of those error corrections are restatements
that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during
the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zwtvSWdsgK6e"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Act). Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<span id="xdx_905_edei--EntityShellCompany_c20240101__20241231_zdH2R1Zhwrk5"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Based on the closing sales price of June 30, 2024, the aggregate market
value of the voting and nonvoting common equity held by non-affiliates of the registrant was $<span id="xdx_900_edei--EntityPublicFloat_iI_c20240630_zeWnpWRPSha7"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,518,701</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 12, 2025, <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20250312_ztb9i9w0rQCe"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-12" id="Fact000041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,957,115</ix:nonFraction></span> shares of common stock, $0.01 par value per share,
were outstanding, which excludes <span id="xdx_90B_eus-gaap--TreasuryStockCommonShares_iI_pid_uShares_c20250312_zKgt5xKYW3Ga"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-03-12" id="Fact000042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,438,526</ix:nonFraction></span> shares of Treasury Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">DOCUMENTS INCORPORATED BY REFERENCE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Portions of the registrant&#8217;s proxy statement for the 2025 Annual
Meeting of Shareholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein.
Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended
December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="toc"></span><b>INDEX TO FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif">
  <tr>
    <td style="vertical-align: top; width: 0.7in">&#160;</td>
    <td style="vertical-align: top; width: 6.3in">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 0.5in; text-align: center">Page</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART I</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_1">Item 1.</a></td>
    <td><a href="#Item_1">Business</a></td>
    <td style="text-align: center">3</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_1A">Item 1A.</a></td>
    <td><a href="#Item_1A">Risk Factors</a></td>
    <td style="text-align: center">10</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_1B">Item 1B.</a></td>
    <td><a href="#Item_1B">Unresolved Staff Comments</a></td>
    <td style="text-align: center">25</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_2">Item 2.</a></td>
    <td><a href="#Item_2">Properties</a></td>
    <td style="text-align: center">25</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_3">Item 3.</a></td>
    <td><a href="#Item_3">Legal Proceedings</a></td>
    <td style="text-align: center">25</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_4">Item 4.</a></td>
    <td><a href="#Item_4">Mine Safety Disclosures</a></td>
    <td style="text-align: center">25</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART II</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_5">Item 5.</a></td>
    <td><a href="#Item_5">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></td>
    <td style="text-align: center">25</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_6">Item 6.</a></td>
    <td><a href="#Item_6">RESERVED</a></td>
    <td style="text-align: center">26</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_7">Item 7.</a></td>
    <td><a href="#Item_7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td style="text-align: center">26</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_7A">Item 7A.</a></td>
    <td><a href="#Item_7A">Quantitative and Qualitative Disclosures about Market Risk</a></td>
    <td style="text-align: center">31</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_8">Item 8.</a></td>
    <td><a href="#Item_8">Financial Statements and Supplementary Data</a></td>
    <td style="text-align: center">31</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_9">Item 9.</a></td>
    <td><a href="#Item_9">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_9A">Item 9A.</a></td>
    <td><a href="#Item_9A">Controls and Procedures</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_9B">Item 9B.</a></td>
    <td><a href="#Item_9B">Other Information</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_9C">Item 9C.</a></td>
    <td><a href="#Item_9C">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART III</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_10">Item 10.</a></td>
    <td><a href="#Item_10">Directors, Executive Officers, and Corporate Governance</a></td>
    <td style="text-align: center">51</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_11">Item 11.</a></td>
    <td><a href="#Item_11">Executive Compensation</a></td>
    <td style="text-align: center">51</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_12">Item 12.</a></td>
    <td><a href="#Item_12">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></td>
    <td style="text-align: center">51</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_13">Item 13.</a></td>
    <td><a href="#Item_13">Certain Relationships and Related Transactions, and Director Independence</a></td>
    <td style="text-align: center">51</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_14">Item 14.</a></td>
    <td><a href="#Item_14">Principal Accountant Fees and Services</a></td>
    <td style="text-align: center">51</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>PART IV</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_15">Item 15.</a></td>
    <td><a href="#Item_15">Exhibits and Financial Statement Schedules</a></td>
    <td style="text-align: center">52</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Item_16">Item 16.</a></td>
    <td><a href="#Item_16">Form 10-K Summary</a></td>
    <td style="text-align: center">53</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><a href="#Signatures">Signatures</a></td>
    <td>&#160;</td>
    <td style="text-align: center">54</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- ii -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Throughout this report, the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to KORU Medical Systems, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>FORWARD LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221;
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. &#160;Forward-looking statements can be identified by words such as: &#8220;mission,&#8221; &#8220;believe,&#8221; &#8220;plan,&#8221;
&#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;expect,&#8221; &#8220;will,&#8221; and similar references to future
periods. Examples of forward-looking statements include, among others, statements we make under &#8220;Our Strategy&#8221; in Business
under Item 1 of this Form 10-K and &#8220;Liquidity and Capital Resources&#8221; in Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations under Item 7 of this Form 10-K, and statements regarding, completion of a next-generation pump and
consumable system, compliance with EU MDR, needs for additional capital, capital investments, plans for expansion of our share position
and products, and increase in patient SCIg prescriptions. Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.&#160; Because forward-looking
statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to
predict and many of which are outside of our control. &#160;Our actual results and financial condition may differ materially from those
indicated in the forward-looking statements. Therefore, readers should not rely on any of these forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Important factors that could cause our actual results and financial condition
to differ materially from those indicated in the forward-looking statements include, among others, those discussed in this Annual Report
on Form 10-K, and in particular, the risks discussed under the caption &#8220;Risk Factors&#8221; in Item 1A, and those discussed in other
documents we file with the Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Any forward-looking statement made by us in this Annual Report on Form
10-K is based only on information currently available to us and speaks only as of the date on which it is made. &#160;We undertake no
obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a
result of new information, future developments or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RISK FACTOR SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our business faces many risks and uncertainties. These risks and uncertainties
could lead to events or circumstances that have a material adverse effect on our business, financial condition, results of operations
and prospects. You should carefully review and consider the full discussion of our risk factors described under Item 1A, Risk Factors
of this Annual Report together with other information in this Annual Report and our other filings with the SEC, before making an investment
decision regarding our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">If we are unable to successfully introduce new products or fail to keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Our business depends on an adequate supply of drugs to be administered by our products.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Our compliance with EU MDR regulations by December 2028 will require significant investment and, if we are not in compliance by that time, we will not be able to sell our products in the EU.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Interruption of our manufacturing or our contract manufacturing operations could adversely affect our business.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, a negative effect on our business.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>If we are unable to compete successfully in our highly competitive industry, our business and financial condition may be adversely affected.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Technological developments by others may disrupt our business and negatively impact our revenues.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We are subject to costly and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Healthcare policy changes and industry cost-containment measures could result in downward pricing pressure for our products and limit our sales.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Issues with product quality could have an adverse effect upon our business, subject us to regulatory actions, cause a loss of customer confidence in us or our products, among other negative consequences.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Defects or quality issues associated with our products could adversely affect the results of our operations.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We are subject to lawsuits.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>If we are unable to protect our patents or other proprietary rights, or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 1 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">We need to attract and retain key employees to be competitive.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We sell a majority of our products through only a few distributors on whom we depend, and our financial results depend on their purchasing patterns.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We and the biopharmaceutical companies with whom we do novel therapies business (&#8220;our biopharma customers&#8221;) are subject to extensive regulation by governments around the world, and if these regulations are not complied with, existing and future operations may be curtailed, and we could be subject to liability.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>The therapeutic efficacy of certain of our biopharma customers&#8217; products that may utilize our device are either unproven in humans or has only been proven in limited circumstances, and we may not be able to successfully develop and sell our products in combination with our biopharma customers&#8217; products.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Certain of the injectable therapies being targeted for use with our products are not approved but are in various phases of clinical development. These injectable therapies may be independently terminated by their makers prior to submission of a regulatory filing or even after regulatory approval and pharmaceutical developers may cease their efforts with us, resulting in the cessation of any revenue associated with that contract or program.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Our commercial success depends upon the attainment of significant market acceptance of drug product candidates to be included in our biopharma customers&#8217; products that may utilize our device, if approved, among physicians, patients, healthcare payers or the medical community.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Most brand name injectable therapies will face future competition from generic or biosimilar therapies, which could significantly reduce their commercial viability.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Most of our components and raw materials, including all of our consumables subassemblies, are sourced from single suppliers. If we are unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price, or if we experience other supply difficulties, our business and results of operations may be adversely affected.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Our failure to comply with laws and regulations relating to reimbursement of healthcare products may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition and cash flows.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We may need additional funding in the future, and if we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate our product development, commercial efforts, or sales efforts.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We are required to comply with certain financial and operating covenants under our credit facility. Failure to comply with these covenants would prevent us from drawing on our facility and, once drawn, could cause amounts borrowed to become immediately due and payable.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We may experience difficulties resulting from our relatively new management structure and executive team.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Changes in tax or labor laws or exposure to additional income tax liabilities could increase our costs and reduce our margins.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>A downturn in global economic conditions could adversely affect our operations.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We are subject to foreign currency exchange risk.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Our distribution network and other operations outside the U.S. subject us to certain risks.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We are dependent on information technology systems and subject to privacy and security laws, and our systems and infrastructure face certain risks, including from cyber security breaches and data leakage.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We cannot guarantee that any of our strategic acquisitions, investments or alliances will be successful.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Our operating results and financial condition may fluctuate.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Future material impairments in the value of our long-lived assets could negatively affect our operating results.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Actions of activist stockholders could have an adverse effect on our business.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Natural disasters, war and other events could adversely affect our suppliers and customers.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Our insurance coverage may be inadequate to cover all the liabilities we may incur.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Rising inflation increases economic uncertainty and may require us to raise prices in order to maintain our operating margins.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Brexit may impact our business in the United Kingdom.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We could be adversely affected, directly or indirectly, by the effects of an increased focus on environmental, social and governance issues.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>There may be circumstances in which the interests of our significant stockholders could be in conflict with your interests as a stockholder.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We do not currently intend to pay dividends on our common stock.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Future sales and issuances of shares of our common stock or rights to purchase our common stock, including pursuant to our equity compensation plans, could result in additional dilution of the percentage ownership of our stockholders.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>There has been volatility in the price of shares of our common stock.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>If we do not maintain compliance with the listing standards of the Nasdaq Capital Market, Nasdaq may delist our common stock from trading on its exchange.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>We are a smaller reporting company and non-accelerated filer, and we cannot be certain if the reduced disclosure requirements applicable to us will make our common stock less attractive to investors.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>The price of our common stock may be adversely affected by the future issuance and sale of shares of our common stock or other equity securities.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>You may find it difficult to sell our common stock.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 2 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_1"></span><b>ITEM 1. BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU Medical develops, manufactures and commercializes innovative and patient-centric
large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United States Food
and Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management.
Our focus is primarily concentrated on our mechanical infusion products, the FREEDOM Infusion Systems (which we refer to as the &#8220;FREEDOM
System&#8221; when used with one or more accessories), which include the FREEDOM60&#174; Syringe Driver, the FreedomEdge&#174; Syringe Driver,
HIgH-Flo Subcutaneous Safety Needle Sets&#8482; and Precision Flow Rate Tubing&#8482;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the FREEDOM System, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency Diseases
(&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies revenues consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including product innovation, testing
and registration services) received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial
use across multiple drug categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company originally incorporated in March 1980.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR MISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our mission is to improve the quality of life of patients around the world
by delivering innovative, effective, and easy-to-use drug delivery systems that can be used at home or alternate site settings, for patient
self-administration of drug therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR STRATEGY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our goal is to strengthen our position as a leading provider of large-volume
subcutaneous infusion systems (&#8805;10ml) for self-administration in the home and for administration by healthcare professionals in infusion
centers. We aim to achieve this by expanding our leadership and market penetration in the domestic and international subcutaneous immunoglobulin
(SCIg) market while extending our expertise into emerging subcutaneous drug therapies. Both SCIg and novel drug therapies will leverage
our Freedom Infusion System and upcoming innovations within the platform, supporting healthcare providers in delivering optimized, efficient,
and patient-friendly infusion solutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To reinforce our leadership in SCIg, we have identified key market trends
driving its continued growth, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in"><b>Increasing diagnoses of Primary Immunodeficiency Diseases (PIDD)</b>, which frequently require immunoglobulin (Ig) treatment.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td><b>Expansion of on-label SCIg indications</b>, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Secondary Immunodeficiency Diseases (SIDD), and additional conditions currently in clinical development.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td><b>Growth in SCIg treatment options</b>, such as the introduction of Cutaquig&#174; and Xembify&#174; in the United States and Europe, along with the planned launches of Cuvitru&#174; and HyQvia&#174; in Japan.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td><b>Ongoing biopharmaceutical investment in SCIg therapies</b>, including prefilled syringe formats designed to enhance ease of use and expand patient eligibility for SCIg treatment.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td><b>Increasing availability of donated plasma</b>, which supports the growing global supply of Ig medications.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td><b>Patient preference and cost-effectiveness of at-home SCIg therapy</b>, which offers a favorable side effect profile and health economic advantages compared to intravenous Ig (IVIg) treatment.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As we continue to advance subcutaneous infusion therapy, we are focused
on delivering solutions that not only improve patient outcomes but also enhance the overall infusion experience for both patients and
caregivers. Our commitment to innovation extends beyond product development&#8212;we work closely with healthcare providers and specialty
pharmacies to drive therapy optimization through advanced infusion solutions and evidence-based insights. By reducing the complexity of
infusions, improving workflow efficiencies, and supporting economic sustainability for providers, we help ensure that SCIg therapy remains
a viable and preferred option for a growing number of patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 3 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Through ongoing clinical and product innovation, strategic partnerships, and commercial excellence, we will continue
to expand our presence in the SCIg market. By improving treatment protocols, expanding geographic reach, and executing commercially, we
aim to enhance our global market position and increase the number of patients benefiting from SCIg therapy over IVIg.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In our goal to expand into novel therapies outside of SCIg, we estimate
that at least 100 large-volume drugs, greater than 2ml, are in clinical development utilizing subcutaneous infusion, with approximately
20% greater than 10ml. The pipeline is driven by the need to deliver high therapeutic doses, difficulty in formulating large molecules
into small volumes, nursing shortage, pharmaceutical companies shifting development programs toward at-home and infusion clinic subcutaneous
therapy, and patient preference. Biopharmaceutical manufacturers seek device partners during the drug development process. We intend to
partner with them during clinical development&#8212;generating non-recurring services revenues to prepare and customize our products for
use during the clinical trial process and to obtain regulatory clearance for use with their drug. Post launch, we intend to commercialize
our products for use with these drugs, working with our pharmaceutical partners, our distributors and our specialty pharmacy partners
who distribute and train patients on the use of these products both in the home and in infusion centers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe our track record of achieving regulatory clearances and successful
patient use, combined with our channel access, position KORU to both maximize our growth in the core SCIg market and expand into new therapeutic
areas.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OUR PRODUCTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU&#8217;s infusion devices work together as a system to deliver life-saving
therapies to patients with chronic illnesses, such as PIDD and CIDP. &#160;The FREEDOM System comprises the FREEDOM60 Syringe Driver (standard
60/50ml syringe compatible) and FreedomEdge Syringe Driver (standard 30ml and 20ml syringe and prefilled syringe compatible), HIgH-Flo
Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. &#160;The systems are portable, easy to operate, maintenance free and
do not require batteries or electricity. The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains
a balance between what a patient&#8217;s subcutaneous tissues can tolerate and what the system delivers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our FREEDOM System is FDA 510(k) cleared and certified outside the United
States for delivery of several on-label subcutaneous indications including Cutaquig &#174;, Cuvitru&#174;, Hizentra&#174;, Xembify, Empaveli&#174;
(branded Aspaveli&#174; outside the United States), and Gammagard Liquid&#174;. Additionally, our FREEDOM System has specific FDA clearance
for &#160;selected intravenously administered antibiotics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Infusion systems such as the FREEDOM System are most prevalent in the home
care and alternate infusion clinic markets. The SCIg products administered by the FREEDOM System are indicated for a variety of conditions,
including Primary Immunodeficiency Disease (PIDD ) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the United States and
PIDD, CIDP and Secondary Immunodeficiency Disorder (&#8220;SIDD&#8221;) outside of the United States. Empaveli&#174; is indicated for Paroxysmal
Nocturnal Hemoglobinuria (&#8220;PNH&#8221;). The use of the FREEDOM System for SCIg drug delivery continues to increase, and it remains
the market leading delivery system in the U.S. for these treatments. In recent years Hizentra&#174; and HyQvia&#174; has received an expanded
indication for treatment of CIDP in the United States. Multiple SCIg drugs have received indications for SID outside of the United States.
It is expected that patient access to SCIg will expand as new drugs are developed, existing drugs are approved and/or marketed in new
countries, and existing drugs receive new indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">HIgH-Flo Subcutaneous Safety Needle Sets are an important element of the
FREEDOM System. The needle sets are available in 26- and 24-gauge sizes and feature unique design elements specific to subcutaneous self-administration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Precision Flow Rate Tubing is designed for repeatable flow rates without
allowing unrestricted flow. &#160;The tubing regulates the flow rate and infusion time for various applications when used with the FREEDOM
System. &#160;Each tubing set provides a different level of flow restriction and consistently delivers medication with low residual volume
to minimize drug waste.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>SALES AND DISTRIBUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FREEDOM System is sold through both direct sales and medical device
distributors to pharmaceutical companies, specialty pharmacy customers and home infusion providers.&#160; Our products are sold principally
through a small number of distributors so our specialty pharmacy customers receive the benefit of remote inventory management and one-stop
shopping.&#160; We sell the majority of our products through three distributors in the U.S. and three distributors outside the U.S. &#160;As
of December 31, 2024, these six distributors comprised approximately 75% of our net revenues with one of our U.S. distributors contributing
approximately 35%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Specialty pharmacies, home infusion providers, and distributors are our
primary sales contacts, although we provide education and training materials to clinicians, patients, and patient advocates both in the
field and online.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 4 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>MANUFACTURING AND RAW MATERIALS</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently manufacture 100% of our pump product volume and approximately
15% of our consumables volume at our Mahwah, NJ facility. The remaining 85% of our consumable supply is sourced from Command Medical Products,
Inc. (&#8220;Command&#8221;), &#8239;a contract manufacturing organization with operations in Nicaragua.&#160;&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to meet customer demand depends, in part, on our ability to
obtain timely and adequate delivery of components for our products. All of the components that go into the manufacturing of our products
and accessories are sourced from third-party suppliers on a single source basis. The Company uses single-source suppliers in part due
to governmental approval and validation requirements. A change in supplier, or the use of multiple suppliers of the same materials, often
would necessitate additional approvals and validations, which the Company seeks to avoid unless and until the need arises. The Company
does not have any contracts with suppliers that impose material binding obligations on the Company or provide the Company with any material
rights or benefits, other than the Company&#8217;s agreement with Command. Command currently stores our finished goods in their warehouse
located in Miami, Florida once the products are released and shipped from Nicaragua.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESEARCH AND DEVELOPMENT</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize the importance of innovation to our long-term success and
are committed to research and new product development activities. &#160;Our product development team along with outside engineering resources
are continuously engaged in improving existing product performance and innovating on new product opportunities to enhance our product
portfolio. &#160;We spent $5.3 million and $5.7 million on research and development for the years ended December 31, 2024 and 2023, respectively.
&#160;We intend to make additional investments in research and development for a &#8220;next-generation&#8221; infusion pump and consumable
system as well as for future innovation.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>REGULATORY</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our medical devices and technologies, as well as our business activities,
are subject to a complex set of regulations and rigorous enforcement, principally by the FDA, and numerous other federal, state, and non-U.S.
governmental authorities. &#160;To varying degrees, each of these agencies requires us to comply with laws and regulations governing the
development, testing, manufacturing, labeling, marketing and distribution of our products.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA regulates, among other things, the research, development, testing,
manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion, marketing, distribution, post approval monitoring and
reporting, import and export of medical devices in the U.S. to assure the safety and effectiveness of medical products for their intended
use. &#160;Thus, both before and after a product is commercially released, we have ongoing responsibilities under the FDA. For instance,
all medical devices marketed in the U.S. must be manufactured in accordance with the FDA&#8217;s quality system regulations (&#8220;QSRs&#8221;).
&#160;Accordingly, our facility and procedures and those of our applicable suppliers are also subject to periodic inspections by the FDA
to determine compliance with applicable laws and regulations. &#160;The Federal Trade Commission also regulates the advertising of our
products. &#160;Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training
and other practices to government scrutiny.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our business is also affected by patient privacy laws and government payor
cost containment initiatives, as well as environmental health and safety laws and regulations.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>U.S. Device Classification and Clearance</i></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Except where an exemption applies, each new or significantly modified medical
device we seek to commercially distribute in the U.S. will require either a premarket notification to the FDA requesting permission for
commercial distribution under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act (&#8220;FFDCA&#8221;), also known as a 510(k)
clearance, approval of a pre-market approval (&#8220;ra&#8221;) application, or as part of a drug-device combination product through a
Biologics License Application (&#8220;BLA&#8221;) or New Drug Application (&#8220;NDA&#8221;). &#160;For example, the use of our FREEDOM
System with therapies not covered by the existing FDA clearance will require additional 510(k) clearance , BLA, NDA or PMA approval.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the 510(k) process, applicants must demonstrate to the FDA that a
device is as safe and effective as, or substantially equivalent to, a legally marketed device, known as the &#8220;predicate&#8221; device.
&#160;Applicants must submit performance data to establish substantial equivalence. &#160;In some instances, data from human clinical
trials must also be submitted in support of a 510(k), and this data must be collected in a manner that conforms to the applicable Investigational
Device Exemption (&#8220;IDE&#8221;) regulations. &#160;The FDA must issue a substantial equivalence determination before commercial distribution
can occur. &#160;Changes to cleared devices that will not significantly affect the safety or effectiveness of the device can generally
be made without additional 510(k) submissions. &#160;Changes that will significantly affect the safety or effectiveness of the device
will require a new 510(k) prior to marketing of the modified device. &#160;We cannot predict with any certainty how future reforms to
Federal regulations may impact our business. &#160;See &#8220;ITEM 1A. RISK FACTORS.&#8221;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 5 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the PMA application process, the applicant must demonstrate that
the device is safe and effective for its intended use. &#160;This approval process applies to most Class III devices, and generally requires
clinical data to support the safety and effectiveness of the device, obtained in conformance with IDE regulations. &#160;The FDA will
approve a PMA application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose,
and that the proposed manufacturing is in compliance with the QSRs. &#160;For novel technologies, the FDA will seek input from an advisory
panel of medical experts regarding the safety and effectiveness of, and their benefit-risk analysis for the device. &#160;The PMA process
is generally more detailed, lengthier and more expensive than the 510(k) process, though both processes can be expensive and lengthy,
and requires payment of significant user fees, unless an exemption is available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are also required to comply with the regulations of every other country
where we commercialize products before we can launch or maintain new products on the market. &#160;Many countries that previously did
not have medical device regulations, or had minimal regulations, are now introducing them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">International sales of medical devices manufactured in the U.S. that are
not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export
requirements. &#160;Additionally, exported devices are subject to the regulatory requirements of each country to which the device is exported.
&#160;Some countries do not have medical device regulations, but in many foreign countries, medical devices are regulated. &#160;Frequently,
regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing regulatory requirements;
however, other countries require approval in the country of origin first. &#160;Most countries outside of the U.S. require that product
approvals be recertified on a regular basis, generally every three to five years. &#160;The recertification process requires that we evaluate
any device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate testing to document
continued compliance. &#160;Where recertification applications are required, they must be approved in order to continue selling our products
in those countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Post-Approval Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even after a device is cleared or approved by FDA for marketing, numerous
regulatory requirements continue to apply. &#160;The FDA and other worldwide regulatory agencies and competent authorities actively monitor
compliance to local laws and regulations through review and inspection of design and manufacturing practices, record-keeping, reporting
of adverse events, labeling and promotional practices. &#160;The FDA can ban certain medical devices, detain or seize adulterated or misbranded
medical devices, order repair, replacement or refund of these devices and require notification of health professionals and others with
regard to medical devices that present unreasonable risks of substantial harm to the public health. &#160;The FDA may also enjoin and
restrain a company for certain violations of the FFDCA and the Safe Medical Devices Act pertaining to medical devices or initiate action
for criminal prosecution of such violations. &#160;In addition, FDA and other governmental agencies such as the Department of Justice
can take action against a company that promotes &#8220;off-label&#8221; uses. &#160;Regulatory agencies and authorities in the countries
where we do business can halt production in or distribution within their respective country or otherwise take action in accordance with
local laws and regulations. &#160;Any adverse regulatory action, depending on its magnitude, may restrict a company from effectively marketing
and selling its products, may limit a company&#8217;s ability to obtain future premarket clearances or approvals, and could result in
a substantial modification to a company&#8217;s business practices and operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Manufacturing Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We must also comply with FDA and foreign agency regulations governing medical
device manufacturing practices.&#160; The FDA and foreign agencies require manufacturers to register their establishments, and they monitor
compliance with device manufacturing requirements through inspections of manufacturing facilities.&#160; If an investigator observes conditions
that might be violative, the manufacturer must correct those conditions or explain them satisfactorily or face potential regulatory action
that might include physical removal of the product from the marketplace. &#160;We are an FDA-registered medical device manufacturer and
must demonstrate that we comply with the FDA&#8217;s QSR and Current Good Manufacturing Practices (&#8220;cGMPs&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that our products and procedures are in compliance with all
applicable FDA and international regulations.&#160; There is no assurance, however, that other products we are developing or products
that we may develop in the future will be cleared by the FDA and classified as Class II products, or that additional regulations restricting
the sale of our present or proposed products will not be promulgated by the FDA or other foreign agencies.&#160; In addition, changes
in FDA, or other federal or state health, environmental or safety regulations or their applications could adversely affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Other Healthcare Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are subject to additional healthcare regulation and enforcement by the
federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. &#160;These laws include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 6 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs. &#160;A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal third-party payors that are false or fraudulent. &#160;In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>federal criminal laws that prohibit executing a scheme to defraud any federal healthcare benefit program or making false statements relating to healthcare matters;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain healthcare professionals beginning in 2022, and teaching hospitals and ownership and investment interests held by the physicians described above and their immediate family members, and payments or other &#8220;transfers of value&#8221; to such physician owners; and</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to track and report information related to payments and other &#8220;transfers of value&#8221; to physicians and other healthcare providers or pricing, marketing expenditures and information; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Violations of any of the laws described above include civil and criminal
penalties, damages, fines, the curtailment or restructuring of an entity&#8217;s operations, the debarment, suspension or exclusion from
federal and state healthcare programs and/or imprisonment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Coverage and Reimbursement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our profitability and operations are subject to changes in legislative,
regulatory and reimbursement policies and decisions as well as changes in private payer reimbursement coverage and payment decisions and
policies. &#160;Our products are purchased by specialty pharmacies and ambulatory service providers or hospitals that typically bill various
third-party payors, such as governmental programs (e.g., Medicare, Medicaid, and comparable non-U.S. programs), private insurance plans
and managed care plans, for the healthcare services and products provided to their patients. &#160;The ability of our customers to obtain
appropriate coverage and reimbursement for our products and the drugs they administer is critical because it affects which products customers
purchase and the price they are willing to pay. &#160;Third-party payors are increasingly reducing coverage and reimbursement for certain
healthcare services and products and challenging prices charged for healthcare services and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Environmental Health and Safety Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are required to comply with federal, state, and local environmental
laws; however, there is no significant effect of compliance on capital expenditures, earnings, or competitive position. &#160;We do not
use significant amounts of hazardous materials in the assembly of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 7 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>COMPETITION AND THE MARKET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition for the FREEDOM System includes electronic (volumetric) pumps,
elastomeric (infuser) pumps, and fully mechanical pumps as well as other types of pumps. &#160;Safety, ease of use, familiarity, cost
effectiveness, accuracy, and sustainability are the principal driving influencers of pump selection. &#160;Electronic pumps deliver drugs
at a programmed flow rate. &#160;They are more costly and require electricity or batteries, extensive training and maintenance and must
be programmed by a qualified pharmacist or clinician. Elastomeric pumps are one-time-use balloon type devices used for infusion of drugs
in intravenous and surgical wound site applications. &#160;Pharmacies are required to fill them with drugs and deliver them to the patient.
&#160;They are easy to use from the patient point of view but can be more costly and time consuming to fill, are temperature sensitive
and have larger residual volumes than other delivery systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition for infusion devices for new drugs includes a variety of technologies
and companies. No single technological approach&#8212;autoinjectors, electronic (volumetric pumps), mechanical pumps, needle-free injectors,
on-body wearable devices, pen injectors, and pre-filled syringes&#8212;will meet the needs of all or even a majority of drugs. For drugs
requiring infusion volumes over 3 ml, the segment most similar to the SCIg drugs currently delivered by the FREEDOM System, the most relevant
approaches include mechanical pumps, on-body wearable devices, and simple electronic pumps. Challenges to their successful commercialization
include high costs per infusion, increased environmental impact, complexity for users, and complex mechanisms with multiple failure modes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>HUMAN CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, we had 80 full time employees, including 3 international
employees. &#160;As of December 31, 2024, approximately 49% of the Company&#8217;s workforce was female and approximately 31% of the Company&#8217;s
employees in managerial roles were female. &#160;Approximately 43% were minorities (non-White) in the Company workforce as of December
31, 2024. &#160;None of our employees are represented by a collective bargaining agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To help drive consistent execution of our business strategy, including
our customer focused philosophy, and support their development, we provide training opportunities to our employees that align with their
responsibilities over their career with us. &#160;We maintain a dedicated internet-based learning platform with a broad portfolio of written,
audio-visual and interactive enterprise-wide and discipline-specific policy and training materials. &#160;This platform includes a library
of self-directed courses and virtual, instructor-led programs for employees at all levels of our organization. &#160;Managers and supervisors
are provided training to help their employees progress in their professional development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe our employees are key to achieving our business objectives.
&#160;Our key human capital measures include employee safety, turnover, absenteeism and production. &#160;We frequently benchmark our
compensation practices and benefits programs against those of comparable industries and in the geographic areas where our facilities are
located. &#160;We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled and unskilled
labor throughout our organization. &#160;Our notable health, welfare and retirement benefits include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Company subsidized health insurance</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>401(k) Plan with Company matching contributions</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td style="text-align: justify">Paid time off</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Life and disability insurance</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We strive to maintain an inclusive environment free from discrimination
of any kind, including sexual or other discriminatory harassment. &#160;Our employees have multiple avenues available through which inappropriate
behavior can be reported, including a confidential hotline. &#160;All reports of inappropriate behavior are promptly investigated with
appropriate action taken to stop such behavior.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>PATENTS AND INTELLECTUAL PROPERTY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have patents and other intellectual property that we believe protect
the FREEDOM System, and we continue to file patent applications in connection with our research and development activities. As of December
31, 2024, we own 14 U.S. Patents and 34 foreign patents. In addition, we have 10 pending U.S. patent applications and 10 foreign patent
applications. The fundamental patents protecting our drug delivery systems extend until 2039 and beyond.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 8 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>EXECUTIVE OFFICERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth certain information with respect to our
executive officers as of March 12, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 1.5in"><b>Name</b></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 0.5in; text-align: center"><b>Age</b></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5in"><b>Position / Held Since</b></td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>Linda Tharby</td>
    <td>&#160;</td>
    <td style="text-align: center">56</td>
    <td>&#160;</td>
    <td>Chief Executive Officer and President (since April 2021)</td></tr>
  <tr style="vertical-align: top">
    <td>Tom Adams</td>
    <td>&#160;</td>
    <td style="text-align: center">52</td>
    <td>&#160;</td>
    <td>Chief Financial Officer, Secretary and Treasurer (since August 2023)</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td>Christopher Pazdan</td>
    <td>&#160;</td>
    <td style="text-align: center">42</td>
    <td>&#160;</td>
    <td>Chief Operating Officer (since July 2024)</td></tr>
  <tr style="vertical-align: top">
    <td>Ken Miller</td>
    <td>&#160;</td>
    <td style="text-align: center">56</td>
    <td>&#160;</td>
    <td>Chief Commercial Officer (since November 2023)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Executive officers hold office at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ms. Tharby was appointed as President and CEO in April 2021. Ms. Tharby
has over 25 years of executive leadership experience building and leading strong performing global organizations that develop and commercialize
products and service innovations, while delivering solutions to patients in the home setting. Prior to joining KORU, Ms. Tharby spent
24 years working in various roles of increased responsibility at Becton Dickinson (&#8220;BD&#8221;). Ms. Tharby was a member of the Executive
Leadership team of BD that transformed the company from an $8 billion medical supplies company to an $18 billion global medical technology
company. Ms. Tharby&#8217;s last role at BD was as Chief Customer Experience Officer from July 2018 through December 2020. Prior to that
she served as BD&#8217;s Chief Human Resources Officer, from October 2016 through July 2018. From 1998 to 2016, she held numerous senior
global business leadership roles at BD, including Executive Vice President and President of Life Sciences, Group President of Pre-Analytical
Systems and Biosciences, Worldwide President of Diabetes Care, and Vice President/General Manager of Pharmaceutical Systems. Ms. Tharby
has an Honors Bachelor of Business Administration from Wilfrid Laurier University in Waterloo, Ontario, Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Adams joined KORU Medical in November 2021 as Vice President of Financial
Planning and Analysis, was appointed Interim-Chief Financial Officer in July 2022 and Chief Financial Officer in August 2023. Mr. Adams
has an extensive background in financial planning, corporate finance, commercial and supply chain finance, and mergers and acquisitions
(M&amp;A). Prior to joining KORU Medical, Mr. Adams spent 10 years at Integra Life Sciences in various leadership positions in Finance
and Accounting Controllership with his most recent position as Senior Director of Finance. In this role, Mr. Adams was the head of finance
for Integra&#8217;s Tissue Technology Business where he served a leading role in supporting a $500 million business unit to high growth
and profitability. Previous roles included Group Controller/Head of FP&amp;A Global Supply and prior to Integra Life Sciences, Mr. Adams
served as Director of Finance at Pfizer Inc serving in many domestic and international roles. Mr. Adams earned his Bachelor of Science
in Business Administration-Accounting &amp; Finance from the Ohio State University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Pazdan joined KORU Medical in 2021 as Vice President of Quality Assurance
and Regulatory Affairs before being promoted to Senior Vice President of Operations in 2022, and subsequently to Chief Operating Officer
in July 2024.&#160; As Chief Operating Officer, Mr. Pazdan oversees Research &amp; Development, Manufacturing, Sourcing, Supply Chain,
Quality, Regulatory and Project Management. Prior to joining KORU, Mr. Pazdan spent 17 years in various functions within the Medical Device
industry, most recently serving as Vice President of Quality Assurance at Hillrom. In this role, Mr. Pazdan was head of quality for multiple
business segments comprising $2 billion in annual revenue. Mr. Pazdan earned his Bachelor of Science in Engineering from the University
of Illinois Urbana-Champaign.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Miller joined KORU Medical in November 2023 as Chief Commercial Officer.
Mr. Miller has over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing
strategy, international expansion, and driving sustainable growth and profitability.&#160; As Chief Commercial Officer, Mr. Miller has
oversight of the global commercial function, including U.S. and International sales and marketing organizations. He was President &amp;
CEO of NASCO HealthCare from October 2018 through January 2023. At NASCO, he transformed sales &amp; marketing, and led the consolidation
of NASCO&#8217;s manufacturing footprint which delivered year-over-year double digit revenue and EBITDA growth.&#160; Prior to NASCO,
Ken spent 7 years at BD with his last role as the Worldwide President Diabetes Care where he led the transition from a product focus to
a full-service diabetes management solution provider. Ken also held leadership roles in marketing, sales, and business development with
Novo Nordisk, Adams Respiratory Therapeutics, and Roche Laboratories.&#160; He earned his Bachelor of Arts in Business Management from
State University of New York at Albany and his Master of Business Administration from The University of Chicago, Booth School of Business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 9 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_1A"></span><b>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>An investment in our common stock involves significant risks. &#160;Before
making an investment in our common stock, you should carefully consider all of the information contained in this Annual Report on Form
10-K and our other filings with the SEC including the material risks and uncertainties that we have identified below. &#160;The risks
and uncertainties identified below are not the only risks and uncertainties we face. &#160;If any of the material risks or uncertainties
that we face were to occur, the trading price of our common stock could decline and you could lose part or all of your investment. &#160;Please
note that additional risks not currently known to us or that we currently deem immaterial also may adversely affect our business, operations,
results of operations, financial condition and prospects.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we are unable to successfully introduce new products or fail to
keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We need to successfully introduce new products to achieve our strategic
business objectives. &#160;A significant element of our strategy is to increase revenue growth by investing in innovation and new product
development, which will require substantial resources. &#160;Our successful product development will depend on many factors, including
our ability to attract strong talent to lead our research and development efforts, properly anticipate and satisfy customer needs, adapt
to new technologies, obtain regulatory concurrence on a timely basis, demonstrate satisfactory clinical results, manufacture products
in an economical and timely manner, obtain appropriate intellectual property protection for our products, gain and maintain market acceptance
of our products, and differentiate our products from those of our competitors. &#160;In addition, patents attained by others can preclude
or delay our commercialization of a product. There can be no assurance that any products now in development or that we may seek to develop
in the future will achieve technological</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">feasibility, obtain regulatory concurrence or gain market acceptance. &#160;If
we cannot successfully introduce new products or adapt to changing technologies, our products may become obsolete, and our revenue and
profitability could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our business depends on an adequate supply of drugs to be administered
by our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Demand for our products depends on the availability of drugs to be administered
through our delivery system.. &#160;Currently, most of our products require immunoglobulin therapies that rely on blood plasma collection
for drugs such as Hizentra&#174; and Cuvitru&#174;. &#160;Any disruption in the supply of these drugs for any reason, including contamination,
could significantly adversely affect our business. &#160;The change of any drug indication by the FDA or comparable foreign governmental
agencies could also result in decreased demand for our products. &#160;In addition, pharmaceutical companies and other competitors have
or are developing alternative therapies for disease states that are deliverable with devices we do not offer or without a medical device.
&#160;If there is not an adequate supply of drugs requiring administration by medical devices such as those provided by us or alternative
therapies are developed, our sales may suffer and/or our products may become obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our compliance with EU MDR regulations by December 2028 will require
significant investment and, if we are not in compliance by that time, we will not be able to sell our products in the EU.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the European Union (&#8220;EU&#8221;), we are required to comply with
the new Medical Device Regulation (&#8220;MDR&#8221; or &#8220;EU MDR&#8221;) effective May 2021, which supersedes the prior Medical Device
Directives. Medical devices which have a valid CE certificate to the current Medical Device Directives (issued before May 2021), as do
all of our current products, can continue to be sold until December 2028 or until the CE certificate expires, whichever comes first, providing
there are no significant changes as defined in Article 120 of EU MDR. The MDR was published in May 2017 with a 3-year transition period.
That transition period was extended to May 2021 due to the COVID-19 pandemic. In early 2023, the transition period was further extended
to December 2028 for class IIa products. The CE mark required to sell medical devices in the EU is affixed following conformity assessment
and either approval from an appointed independent notified body or through self-certification by the manufacturer. The selected pathway
to CE marking is based on product risk classification. CE marking indicates conformity to the applicable essential requirements of the
relevant Medical Device Directives and in the future to the general safety and performance requirements for the new MDR. The MDR will
change multiple aspects of the existing regulatory framework for CE marking, such as increased clinical evidence requirements and other
new requirements, including Unique Device Identification (&#8220;UDI&#8221;) as well as many other post-market obligations. MDR also significantly
modifies and increases the compliance requirements for the industry and will require significant investment by us in the near future to
implement.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we are unable to comply with the MDR by December 2028, we will not be
able to sell our products in the EU, which will materially impact our net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 10 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Interruption of our manufacturing or our contract manufacturing operations
could adversely affect our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Command currently provides subassemblies for all of our consumables (needle
and tubing sets), and manufactures, assembles and packages approximately 85% of our consumables. In the event of any interruption in Command&#8217;s
operations or supply of goods, the Company may have to seek alternative sources of subassemblies, which may be not be readily available
on commercially reasonable terms or at all, and increase its capacity for manufacturing finished goods in Mahwah, NJ, which could be time-consuming
and costly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA and other U. S. and non-U.S. government agencies regulate our manufacturing
and contract manufacturing operations for all of our products. Variations in our or Command&#8217;s manufacturing process may result in
production failures which could lead to launch delays, product shortage, unanticipated costs, lost revenues and damage to our reputation.
&#160;A failure to identify and address manufacturing problems prior to the release of products to our customers may also result in a
quality or safety issue that could result in a recall or other inability to sell our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our products are currently manufactured in Nicaragua and Mahwah, NJ, and
stored in warehouse space at our corporate headquarters in Mahwah, NJ. &#160;Loss or damage to our manufacturing or contract manufacturing
and storage site due to weather, vandalism, terrorism, a natural disaster, issues in our manufacturing process, equipment failure or other
factors, could adversely affect our ability to manufacture sufficient quantities of products or otherwise deliver products to meet customer
demand or contractual requirements which may result in a loss of revenue and other adverse business consequences, including damage to
our relationship with customers. Additionally, because Command manufactures and supplies the Company&#8217;s subassemblies and finished
goods for needle sets and tubing products in Nicaragua, there could be a delay in providing the products timely due to their climate and
international boundaries. Command currently stores our finished goods in their warehouse located in Miami Florida once the products are
released from Nicaragua.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We take precautions to safeguard our facility, including acquiring insurance,
adopting health and safety protocols and utilizing off-site storage of computer data. &#160;Our insurance may not cover our losses in
any particular case. &#160;In addition, regardless of the level of insurance coverage, damage to our facility may harm our business, financial
condition and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Public health crises, such as the COVID-19 pandemic, have had, and
could in the future have, a negative effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pandemics or disease outbreaks, such as the COVID-19 pandemic, have created
and may continue to create significant volatility, uncertainty and economic disruption in the markets we sell our products into and operate
in, primarily the U.S., Europe, and Asia-Pacific and may negatively impact business and healthcare activity globally. In response to the
COVID-19 pandemic, governments around the world have imposed measures designed to reduce the transmission of COVID-19 and individuals
continue to respond to the fear of contracting COVID-19. In particular, elective procedures and exams were delayed or cancelled, there
were significant reductions in physician office visits, and hospitals postponed or canceled capital purchases as well as limited or eliminated
services. While elective procedures and exams and capital purchases have increased from initially depressed levels, the reduction in elective
procedures, exams and capital purchases has had, and we believe may continue to have, a negative impact on the sales of our products.
Additionally, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement
rates or the scope of coverage offered, which could further adversely affect sales of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The extent to which fear of exposure to or actual effects of COVID-19,
new variants, disease outbreak, epidemic or a similar widespread health concern impacts our business will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease,
the duration of the outbreak, travel restrictions, the efficacy of vaccination and treatment; impact on the U.S. and international healthcare
systems, the U.S. economy and worldwide economy; the timing, scope and effectiveness of U.S. and international governmental response;
and the impact on the health, well-being and productivity of our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we are unable to compete successfully in our highly competitive
industry, our business and financial condition may be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We operate in a single market &#8211; infusion &#8211; and are
dependent upon our success in that market. We face competition in our market from a wide range of international and domestic companies,
including those that deliver electronic volumetric pumps, elastomeric infuser pumps, other mechanical devices, novel drug delivery devices
and methodologies, and devices and formulation technologies that allow drugs to be delivered in volumes smaller than the FREEDOM System
is designed to deliver.&#160; These include large medical device companies with multiple product lines, some of which may have greater
financial and marketing resources than we do. &#160;We also face competition from companies that are even more specialized than ours with
respect to particular markets or product lines. &#160;Some of those companies have greater financial and sales and marketing resources
than we do or offer products at a lower price point than ours. &#160;In addition, former employees may develop products that are competitive
with ours or capitalize on customer relationships developed while employed with us, subject to their continuing obligations under confidentiality
agreements and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 11 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">other restrictive covenants that may survive their employment. &#160;We
face competition on the basis of product features, clinical or economic outcomes, product quality, availability, price, services, technological
innovation and other factors. &#160;In addition, we face changing customer preferences and requirements, changes in the ways healthcare
services are delivered, including the transition of high-acuity care to lower-acuity, and non-acute care settings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Competition may increase further as additional companies begin to enter
our market or modify their existing products to compete directly with ours. &#160;If we are forced to reduce our prices due to increased
competition, our business could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The medical technology industry has also experienced a significant amount
of consolidation, resulting in larger companies with greater access to markets. &#160;Pharmaceutical manufacturers, healthcare systems,
other healthcare companies and even retail pharmacies are also consolidating, resulting in greater purchasing power for these companies.
&#160;As a result, competition among medical device suppliers to provide goods and services has increased. &#160;Group purchasing organizations
and integrated health delivery networks have also served to concentrate purchasing decisions for some customers, which has led to downward
pricing pressure for medical device suppliers. &#160;Further consolidation in the industry could intensify competition among medical device
suppliers and exert additional pressure on the prices of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidation in the medical industry could have a negative impact with
payor and provider relationships and distributor relationships, as we could lose market share as consolidation occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Technological developments by others may disrupt our business and
negatively impact our revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The medical device industry is subject to rapid technological change and
discovery and frequent product introductions. &#160;The development of new or improved products, processes or technologies by other companies
that provide better features, pricing or clinical outcomes or economic value may render our products or proposed products obsolete or
less competitive. &#160;If our competitors respond more quickly to new or emerging technologies and changes in customer requirements or
we do not introduce new versions or upgrades to our product portfolio in response to those requirements, our products may not be marketable.
&#160;If competitors develop more effective or affordable products or achieve earlier patent protection or product commercialization for
new products than we do, our operations will likely be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to costly and complex laws and governmental regulations
and any adverse regulatory action may materially adversely affect our financial condition and business operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our medical devices and technologies, as well as our business activities,
are subject to a complex set of regulations and rigorous enforcement, principally by the FDA, numerous other federal, state, and non-U.S.
governmental authorities and equivalent regulatory bodies of other countries. &#160;To varying degrees, each of these agencies requires
us to comply with laws and regulations governing the design, development, and manufacturing; testing, labeling, content and language of
instructions for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, promotion,
and distribution of our products; premarket clearance and approval; record keeping procedures; advertising and promotion; recalls and
field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if
they were to recur, could lead to death or serious injury; post-market approval studies; and product import and export.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the U.S., our device products are subject to clearance or approval by
FDA under the FFDCA. &#160;Before we can market a new medical device, or a new use of, new claim for, or significant modification to,
an existing product, we must first receive either 510(k) clearance or approval of a PMA application from the FDA, unless an exemption
applies. &#160;Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device
is &#8220;substantially equivalent,&#8221; as defined in the statute, to a legally marketed predicate device. &#160;To be &#8220;substantially
equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological
characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or
effectiveness than the predicate device. &#160;If the manufacturer is unable to demonstrate substantial equivalence to FDA&#8217;s satisfaction,
or if there is no available predicate device, then the manufacturer may be required to seek approval through the PMA application process,
which is generally more costly and time consuming than the 510(k) process. &#160;Through the PMA application process, the applicant must
submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use. &#160;Accordingly,
a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development,
pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators
in device studies. In the future our device products may be approved as part of a drug submission under a combination product regulatory
pathway. Under the combination product approval process, our device would typically be submitted as part of a drug application, typically
a BLA or NDA in the United States. The proof required for approval as a combination product is similar to that required for a 510(k),
but may differ in material ways. In addition, the regulatory approval is held by the pharmaceutical manufacturer, not KORU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 12 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot guarantee that we will be able to obtain or maintain FDA 510(k)
clearance or premarket approval for our new products or enhancements or modifications to existing products (including the use of our FREEDOM
System with therapies not covered by the existing FDA clearance), and the failure to maintain approvals or clearances, or obtain approval
or clearance could have a material adverse effect on our business, results of operations, financial condition and cash flows. Even if
we are able to obtain approval or clearance, it may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">take a significant amount of time</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>require the expenditure of substantial resources</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>involve stringent clinical and pre-clinical testing, as well as increased post-market surveillance</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>involve modifications, repairs, or replacements of our products, and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>limit the proposed uses of our products.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Both before and after a product is commercially released, we have ongoing
responsibilities under the FDA and other applicable non-U.S. government agency laws and regulations. &#160;The FDA and other worldwide
regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing
practices, recordkeeping, reporting of adverse events, labeling and promotional practices. &#160;The results of these inspections can
include inspectional observations on the FDA&#8217;s Form 483, warning letters, or other forms of enforcement. &#160;If the FDA or any
state or foreign regulatory authorities were to conclude that we are not in compliance with any applicable laws or regulations, or that
any of our medical products are ineffective or pose an unreasonable health risk, they could deem our products adulterated or misbranded,
and take enforcement action against us. &#160;FDA and state and foreign regulatory authorities have broad enforcement powers. &#160;Possible
enforcement actions include, but are not limited to:&#160; temporarily or permanently suspending the sale and/or distribution of such
medical products; detaining or seizing all adulterated or misbranded medical products; ordering recall, repair, replacement, or refund
of such products; refusing to grant pending pre-market approval or 510(k) clearance applications; and/or requiring us to notify health
professionals and others that the devices present unreasonable risks of substantial harm to the public health. &#160;In addition, the
FDA prohibits device manufacturers from promoting their products for uses and indications other than those set forth in the approved product
labeling, and failure to comply with this prohibition could subject us to significant civil or criminal exposure, administrative obligations
and costs, and/or other potential penalties from, and/or agreements with, the federal government. &#160;The FDA and other non-U.S. government
agencies may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide
basis. &#160;The FDA may also recommend prosecution to the U.S. Department of Justice. &#160;Any adverse regulatory action, depending
on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future pre-market
clearances or approvals, and could result in a substantial modification to our business practices and operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Regulations regarding the development, manufacture and sale of medical
devices are evolving and subject to future change and have tended to become more stringent over time. &#160;Regulatory changes could result
in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. We
cannot predict what impact, if any, those changes might have on our business; however, failure to comply with applicable regulatory requirements
could have a material adverse effect on our business, financial condition, and results of operations. &#160;Later discovery of previously
unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory clearances or approvals, seizures
or recalls of products, physician advisories or other field actions, operating restrictions and/or criminal prosecution. &#160;We may
also initiate field actions as a result of a failure to strictly comply with our internal quality policies. &#160;The failure to receive
product approval clearance on a timely basis, suspensions of regulatory clearances, seizures or recalls of products, physician advisories
or other field actions, or the withdrawal of product approval by the FDA or by comparable agencies in foreign countries could have a material
adverse effect on our business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Governmental regulations outside the U.S. have also, and may continue to,
become increasingly stringent and common. &#160;Penalties for regulatory non-compliance could be severe, including fines and revocation
or suspension of a company&#8217;s EU device approval, ability to distribute products and criminal sanctions. &#160;Future foreign governmental
laws and regulations may have a material adverse effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, exported devices are subject to the regulatory requirements
of each country to which the device is exported. &#160;Some countries do not have medical device regulations, but in most foreign countries,
medical devices are regulated. &#160;Frequently, regulatory approval may first be obtained in a foreign country prior to application in
the U.S. due to differing regulatory requirements; however, other countries, such as China for example, require approval in the country
of origin or legal manufacturer first. &#160;Most countries outside of the U.S. require that product approvals be renewed or recertified
on a regular basis, generally every four to five years. &#160;The renewal or recertification process requires that we evaluate any device
changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance.
&#160;Where renewal or recertification applications are required, they may need to be renewed and/or approved in order to continue selling
our products in those countries. &#160;There can be no assurance that we will receive the required approvals for new products or modifications
to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive post market
study requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 13 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our global regulatory environment is becoming increasingly stringent and
unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals for our products, as well as the clinical
and regulatory costs of supporting those approvals. &#160;Several countries that did not have regulatory requirements for medical devices
have established such requirements in recent years and other countries have expanded on existing regulations. &#160;Certain regulators
are exhibiting less flexibility and are requiring local preclinical and clinical data in addition to global data. &#160;While harmonization
of global regulations has been pursued, requirements continue to differ significantly among countries. &#160;In the United Kingdom, for
example, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating the UK medical device market. &#160;With
recent changes in the United Kingdom&#8217;s membership with the European Union, the MHRA has and will continue to impose new regulatory
obligations for medical device manufacturers. &#160;We expect this global regulatory environment will continue to evolve, which could
impact our ability to obtain future approvals for our products or could increase the cost and time to obtain such approvals in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Healthcare policy changes and industry cost-containment measures
could result in downward pricing pressure for our products and limit our sales.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Most of our customers, and those to whom our customers supply medical devices,
rely on third-party payers, including government programs and private health insurance plans, to reimburse some or all the cost of the
medical devices we manufacture. &#160;The continuing efforts of governmental authorities, insurance companies and other payers of healthcare costs to contain or reduce these costs and, more generally, to reform the healthcare system, could limit the prices we are able
to charge for our products or the amounts of reimbursement available for our products or the drugs that they administer, which would put
pressure on us to reduce our prices for our products and/or limit our sales. &#160;The adoption of some or all of these proposals could
have a material adverse effect on our business, results of operations, financial condition and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Issues with product quality could have an adverse effect upon our
business, subject us to regulatory actions, cause a loss of customer confidence in us or our products, among other negative consequences.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Quality management plays an essential role in determining and meeting customer
requirements, preventing defects, improving our products and services, and assuring the safety and efficacy of our products. &#160;Our
future success depends on our ability to maintain and continuously improve our quality management program. &#160;While we have a quality
system that covers the lifecycle of our products, quality and safety issues may occur with respect to any of our products. &#160;A quality
or safety issue may result in adverse inspection reports, voluntary or official action indicated, warning letters, import bans, product
recalls (either voluntary or required by the FDA or similar governmental authorities in other countries) or seizures, monetary sanctions,
injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government
to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. &#160;An inability to address
a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or
our current or future products, which may result in the loss of sales and difficulty in successfully launching new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Defects or quality issues associated with our products could adversely
affect the results of our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The design, manufacture and marketing of medical devices involve certain
inherent risks. &#160;Manufacturing or design defects, component failures, unapproved or improper use of our products, or inadequate disclosure
of risks or other information relating to the use of our products can lead to injury or other serious adverse events. &#160;We are subject
to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we
receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death
or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious
injury. &#160;The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature
of the event. &#160;If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled
letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearances or
approvals, seizure of our products, or delay in clearance or approval of future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These adverse events could also lead to safety alerts relating to our products
or recalls (either voluntary or as required by the FDA or similar governmental authorities in other countries), and could result, in certain
cases, in the removal of a product from the market. &#160;A recall could result in significant costs and lost sales and customers, enforcement
actions and/or investigations by state and federal governments or other enforcement bodies, as well as negative publicity and damage to
our reputation that could reduce future demand for our products. &#160;Any corrective action, whether voluntary or involuntary, as well
as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business
and may harm our reputation and financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 14 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Personal injuries relating to the use of our products can also result in
significant product liability claims being brought against us. &#160;A product liability claim, regardless of its merit or outcome, could
not only result in significant legal defense costs, but also have a material adverse effect on our business and reputation and ability
to attract and retain customers for our products. &#160;In some circumstances, adverse events could also cause delays in regulatory approval
of new products or the imposition of post-market approval requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to lawsuits.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have been and may be party to lawsuits, settlement discussions, mediations,
arbitrations and other disputes, including patent and product liability claims, whether brought by companies, individuals or governmental
authorities. &#160;These matters may result in a loss of patent protection, reduced revenue, incurrence of significant liabilities and
diversion of our management&#8217;s time, attention and resources. Our insurance coverage may not provide adequate protection against
actual losses. &#160;In addition, we are subject to the risk that one or more of our insurers may become insolvent and become unable to
pay claims that may be made in the future. &#160;Even if we maintain adequate insurance, claims could have a material adverse effect on
our financial condition, liquidity and results of operations and on our ability to obtain suitable, adequate or cost-effective insurance
in the future. &#160;Litigation and other disputes, including any adverse outcomes, may have an adverse impact on our business, operations
or financial condition. &#160;Even claims without merit could subject us to adverse publicity and require us to incur significant legal
fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we are unable to protect our patents or other proprietary rights,
or if we infringe the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Patent and other proprietary rights are essential to our business. &#160;We
own patents, trade secrets, trademarks and/or other intellectual property rights related to many of our products. &#160;Our success depends
to a significant degree on our ability to obtain and enforce patents, both in the U.S. and in other countries. &#160;We can lose the protection
afforded by these intellectual property assets through patent expirations, legal challenges or governmental action. &#160;Additionally,
our intellectual property rights may be challenged or infringed upon by third parties, particularly in countries where property rights
are not highly developed or protected, or we may be unable to enter into license agreements with third-party owners of intellectual property
on reasonable terms. &#160;Unauthorized use of our intellectual property rights or inability to preserve existing intellectual property
rights could adversely impact our competitive position and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The patent position of a medical device company is often uncertain and
involves complex legal and factual questions. &#160;Significant litigation concerning patents and products is pervasive in our industry.
&#160;Patent claims include challenges to the coverage and validity of our patents on products or processes as well as allegations that
our products infringe patents held by competitors or other third parties. &#160;A loss in any of these types of cases could result in
a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially
affect future results of operations. &#160;We also rely on trademarks, trade secrets and know-how to develop, maintain and strengthen
our competitive positions. &#160;Third parties may know, discover or independently develop equivalent proprietary information or techniques,
or they may gain access to our trade secrets or disclose our trade secrets to the public.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Although our employees, consultants, parties to collaboration agreements
and other business partners are generally subject to confidentiality or similar agreements to protect our confidential and proprietary
information, these agreements may be breached, and we may not have adequate remedies in the event of a breach of confidence. &#160;To
the extent that our employees, consultants, parties to collaboration agreements and other business partners use intellectual property
owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Furthermore, our intellectual property, other proprietary technology and
other sensitive company data is potentially vulnerable to loss, damage or misappropriation from system malfunction, computer viruses,
unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events. &#160;While we
have invested to protect our intellectual property, confidential information and other data, and continue to work diligently in this area,
there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber incidents or other events. Such events
could have a material adverse effect on our reputation, business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Misappropriation or other loss of our intellectual property from any of
the foregoing would have an adverse effect on our competitive position and may cause us to incur substantial litigation costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 15 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We need to attract and retain key employees to be competitive.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to compete effectively depends upon our ability to attract
and retain executives and other key employees, including people in technical, marketing, sales, research and development, quality assurance
and regulatory compliance positions. &#160;We depend on key management personnel and attracting and retaining other qualified personnel,
and our business could be harmed if we lose key management personnel or cannot attract and retain other qualified personnel. &#160;We
do not maintain any &#8220;key man&#8221; insurance policies on the lives of any of our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The failure to attract, integrate, motivate, and retain skilled and qualified
personnel could have a material adverse effect on our business. &#160;We compete for such personnel against numerous companies, including
larger, more established companies with significantly greater financial resources than we possess. &#160;Our ability to recruit such talent
will depend on a number of factors, including compensation and benefits, work location and work environment. &#160;There can be no assurance
that we will be successful in attracting or retaining such personnel and the failure to do so could have a material adverse effect on
our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We sell a majority of our products through only a few distributors
on whom we depend, and our financial results depend on their purchasing patterns.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Most of our customers prefer to purchase our products through distributors,
rather than directly from us, because of &#8220;one-stop shopping&#8221; convenience and their ability to ship directly to patients. &#160;We
sell most of our products through a small number of distributors, three in the U.S. and three outside the U.S. &#160;As of December 31,
2024, these six distributors comprised approximately 75% of our net revenues with one U.S. distributor contributing 35%. &#160;Purchasing
patterns by these distributors cannot always be predicted and fluctuate from quarter to quarter and year to year based on, among other
things, their expectations of customer demand.&#160; Any decline in business with the distributors outside the U.S. could have an adverse
impact on our business. &#160;If we were unable to sell through the distributors outside the U.S., we would have to find other distributors
or broaden our customer base and expand direct relationships with customers. &#160;Other distributors may not be available or may not
agree to arrangements that are commercially reasonable. &#160;In the U.S. we could transition to direct customer purchase; however, customers
may not want to purchase directly from us and may decide to purchase competitors&#8217; products through their distributors. &#160;Moreover,
a transition from distributors to direct customer purchase would be time consuming and costly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We and the biopharmaceutical companies with whom we do novel therapies
business (&#8220;our biopharma customers&#8221;) are subject to extensive regulation by governments around the world, and if these regulations
are not complied with, existing and future operations may be curtailed, and we could be subject to liability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our devices and our biopharma customers&#8217; products that may utilize
our device are subject to extensive regulation by governmental authorities in the United States, Europe and other countries, including
the FDA. &#160;Not only do these regulations present challenges during the regulatory approval process, but after our devices or our biopharma
customers&#8217; products that may utilize our device are approved for new indications and placed in the market, numerous regulatory requirements
will apply. &#160;These include, but are not limited to QSR, labeling regulations and FDA prohibitions against the promotion of products
for uncleared, unapproved or &#8220;off label&#8221; uses, medical device reporting regulations and post-market surveillance regulations,
and laws and regulations that govern the development, testing, manufacturing, advertising, marketing and distribution of medical devices,
including our devices and our biopharma customers&#8217; products that may utilize our device. &#160;The FDA has broad post-market and
regulatory enforcement powers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the European Union (&#8220;EU&#8221;), we are required to comply with
the new Medical Device Regulation (&#8220;MDR&#8221; or &#8220;EU MDR&#8221;) effective May 2021, which will supersedes the prior Medical
Device Directives. &#160;Class IIa medical devices which have a valid CE certificate to the current Medical Device Directives can continue
to be sold until December 2028 or until the CE certificate expires, whichever comes first, providing there are no significant changes
as defined in Article 120 of EU MDR. &#160;The MDR was published in May 2017 with a 3-year transition period. &#160;That transition period
was extended to May 2021 due to the COVID-19 pandemic. &#160;In 2023, the transition period was extended further to December 2028 for
Class IIa products. The CE mark required to sell medical devices in the EU is affixed following conformity assessment and either approval
from an appointed independent notified body or through self-certification by the manufacturer. &#160;The selected pathway to CE marking
is based on product risk classification. &#160;CE marking indicates conformity to the applicable essential requirements of the relevant
Medical Device Directives and in the future to the general safety and performance requirements for the new MDR. &#160;The MDR will change
multiple aspects of the existing regulatory framework for CE marking, such as increased clinical evidence requirements and other new requirements,
including Unique Device Identification (&#8220;UDI&#8221;) as well as many other post-market obligations. &#160;MDR also significantly
modifies and increases the compliance requirements for the industry and will require significant investment in the near future to implement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 16 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If our devices are commercialized as part of a drug-delivery combination
product we, as the manufacturer of the device component of that combination product, we are subject to unannounced and preapproval inspections
by the FDA of our manufacturing facility to determine our compliance with QSR and cGMP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 0">Failure to comply with applicable regulatory requirements can result in
an enforcement action by the FDA or other regulatory authority, which may include any or all of the following sanctions: fines, injunctions,
consent decrees and civil penalties, recall or seizure of our products or our biopharma customers&#8217; products, operating restrictions,
partial suspensions or total shutdown of production, refusing our biopharma customers&#8217; requests for regulatory approvals of their
drug-device combination products or new intended uses, as applicable, refusing our requests for regulatory approval of our devices, withdrawing
our biopharma customers&#8217; or our regulatory approvals that may be granted and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The therapeutic efficacy of certain of our biopharma customers&#8217;
products that may utilize our device are either unproven in humans or has only been proven in limited circumstances, and we may not be
able to successfully develop and sell our products in combination with our biopharma customers&#8217; products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">While some of our biopharma customers use our products with established,
approved drugs, in certain instances, the benefits of those drugs as injectable therapies are either unproven or have only been proven
in limited circumstances. &#160;Our ability to generate revenue from our products will depend heavily on the successful development, commercialization
and sales of our biopharma customers&#8217; products, which is subject to many potential risks. &#160;For example, data developed in clinical
trials or following the commercialization of our biopharma customers&#8217; products may show that such therapies do not prove to be effective
treatments for the targets they are being designed to act against (or as effective as other treatments available). In clinical trials
or following commercialization, it may be shown that those drugs interact with human biological systems in unforeseen, ineffective or
harmful ways. &#160;If those drugs are associated with undesirable side effects or have characteristics that are unexpected, the pharmaceutical
companies that make those drugs may need to abandon clinical development or discontinue commercial sales or limit clinical development
or sales to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe
or more acceptable from a risk-benefit perspective. &#160;As a result of these and other risks described herein that are inherent in the
development and sale of therapeutic agents, pharmaceutical companies may never successfully develop or successfully commercialize their
drugs, or the commercialization of their drugs may be abandoned or severely limited, which may limit our profitability with respect to
biopharma customers with drugs or drug-device combination products including those drugs and our device, and we may not be successful
in achieving commercial scale production and sales of our injectable drug delivery systems in combination with certain drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Certain of the injectable therapies being targeted for use with our
products are not approved but are in various phases of clinical development. These injectable therapies may be independently terminated
by their makers prior to submission of a regulatory filing or even after regulatory approval and pharmaceutical developers may cease their
efforts with us, resulting in the cessation of any revenue associated with that contract or program.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We work with pharmaceutical and biotechnology companies who are targeting
the use of our products with a variety of injectable therapies. &#160;When we collaborate with pharmaceutical developers, they may engage
us in a variety of ways, including <i>in vitro </i>feasibility testing, product customization and validation (&#8220;development&#8221;),
non-interventional user testing of our devices, animal or human clinical research using our devices, regulatory submissions, manufacturing
development, and commercialization. Certain of those injectable therapies are not FDA approved and are in various phases of clinical development.
&#160;The clinical development of these pipeline therapies can be terminated by their developers at any stage. &#160;Our biopharma customers
may choose to continue their drug program without use of our devices. Use in one stage of work does not guarantee use in a future development
stage or in commercialization. Furthermore, these pharmaceutical companies could obtain regulatory approval for their injectable therapies
and decide for business reasons not to require or encourage utilization of our device. &#160;Prior investments we have made in manufacturing
capacity or research and development will then not result in the generation of revenue that would have previously been anticipated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our commercial success depends upon the attainment of significant
market acceptance of drug product candidates to be included in our biopharma customers&#8217; products that may utilize our device, if
approved, among physicians, patients, healthcare payers or the medical community.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if biopharmaceutical companies obtain regulatory approval for their
drug product candidates, their product candidates may not gain sufficient levels of market acceptance among physicians, healthcare payers,
patients or the medical community to make them commercially feasible. Market acceptance of our biopharma customers&#8217; product candidates,
if they receive approval, depends on a number of factors, including the:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 17 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">efficacy and safety of the product candidates;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>clinical indications for which the product candidates are approved;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>acceptance by physicians, patients and the medical community of the product candidates as a safe and effective treatment;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>potential and perceived advantages of the product candidates over alternative treatments;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>safety of the product candidates seen in a broader patient group;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>prevalence and severity of any side effects;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>product labeling or product insert requirements of the FDA or other regulatory authorities;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>timing of market introduction of the product candidates as well as competitive products;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>cost of treatment in relation to alternative treatments;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>availability of coverage and adequate reimbursement and pricing by third party payers and government authorities;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>relative convenience and ease of administration; and</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>effectiveness of the pharmaceutical companies&#8217; sales and marketing efforts.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If pharmaceutical companies&#8217; candidates are approved but fail to
achieve market acceptance among physicians, patients or healthcare payers, we may not be able to generate anticipated revenue. &#160;This
may limit our ability to generate anticipated revenue from our prior investments. &#160;Moreover, even if we achieve commercial scale
production and sales of our injectable drug delivery systems in combination with certain injectable therapies, the makers of such therapies
may face indirect competition from companies who develop and market other brand name, biosimilar or generic injectable therapies as well
as alternative treatments and delivery methods that compete with our biopharma customers&#8217; products that may utilize our device,
which may have a material adverse effect on our results of operations, our financial condition and/or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Most brand name injectable therapies will face future competition
from generic or biosimilar therapies, which could significantly reduce their commercial viability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Brand name injectable therapies will usually become exposed to competition
from generic or biosimilar rivals at some time after their regulatory approval and commercial launch. &#160;The average selling price
and market share of brand name injectable therapies can be significantly diminished following the introduction of generic or biosimilar
competition. &#160;These factors may result in our biopharma customers using our products with their brand name injectable therapies seeking
to withdraw such injectable therapy from the market or change market tactics in a way that makes the use of our products cost prohibitive.
&#160;This may result in reduction of revenues due to lower demand, termination of supply contracts, and other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Most of our components and raw materials, including all of our consumables
subassemblies, are sourced from single suppliers. If we are unable to obtain sufficient components or raw materials on a timely basis
or for a cost-effective price, or if we experience other supply difficulties, our business and results of operations may be adversely
affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ability to meet customer demand depends, in part, on our ability to
obtain timely and adequate delivery of raw materials and components for our products. &#160;A majority of the materials and components
that go into the manufacturing of our products, including all of our consumables subassemblies. are single-sourced from third-party suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The price and supply of materials and components for our products may be
impacted or disrupted for reasons beyond our control. A significant price increase from a single-source supplier could have a material
impact on our financial results. While we work with suppliers to ensure continuity of supply, no assurance can be given that these efforts
will be successful. &#160;Although we do carry strategic inventory and maintain insurance to help mitigate the potential risk related
to any supply disruption, there can be no assurance that such measures will be sufficient or effective. &#160;The termination, reduction
or interruption in supply of raw materials and components and an inability to quickly develop acceptable alternative sources for such
supply, could adversely impact our ability to manufacture and sell our products in a timely or cost-effective manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We do not have long-term agreements in place with any of our suppliers,
with the exception of a five- year agreement with Command which we entered in 2020. Due to regulatory requirements relating to the qualification
of suppliers, we are not likely to be able to establish additional or replacement sources on a timely basis or without excessive cost.
&#160;We are in the process of establishing alternative sources of supply for our raw materials and components, but there can be no assurance
we will be able to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Additionally, volatility in our cost of energy, raw materials, components,
subassemblies, transportation/freight, and manufacturing and distribution could adversely affect our results of operations. &#160;Climate
change (including laws or regulations passed in response to it) could increase our costs, in particular our costs of supply, energy and
transportation/freight. &#160;Material or sustained increases in the price of oil and natural gas could have an adverse impact on the
cost of many of the plastic materials we use to make and package our products, as well as our transportation/freight costs. &#160;These
outcomes may in turn result in customers transitioning to available competitive products, loss of market share, negative publicity, reputational
damage, loss of customer confidence or other negative consequences (including a decline in stock price).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 18 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our failure to comply with laws and regulations relating to reimbursement
of healthcare products may subject us to penalties and adversely impact our reputation, business, results of operations, financial condition
and cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our devices are purchased principally by specialty pharmacies and ambulatory
service providers or hospitals that typically bill various third-party payers, such as governmental programs (e.g., Medicare, Medicaid
and comparable non-U.S. programs), private insurance plans and managed care plans, for the healthcare services provided to their patients.
&#160;The ability of those customers to obtain appropriate reimbursement from third-party payers for our products and the drugs they administer
is critical because it affects which products customers purchase and the prices they are willing to pay. &#160;As a result, our devices
are subject to regulation regarding quality and cost by U.S. governmental agencies, including the Centers for Medicare &amp; Medicaid
Services (&#8220;CMS&#8221;), as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of healthcare goods and services, including laws and regulations related to kickbacks, false claims, self-referrals and healthcare fraud. &#160;Many
states have similar laws that apply to reimbursement by state Medicaid and other funded programs, and in some cases to all payers. &#160;In
certain circumstances, insurance companies can attempt to bring a private cause of action against a manufacturer for causing a false claim
to be filed under the Federal Racketeer Influenced and Corrupt Organizations Act. In addition, as a manufacturer of FDA-approved devices
reimbursable by federal healthcare programs, we are subject to the Physician Payments Sunshine Act, which requires us to annually report
certain payments and other transfers of value we make to U.S.-licensed physicians or U.S. teaching hospitals. &#160;Any failure to comply
with these laws and regulations could subject us or our officers and employees to criminal and civil financial penalties. &#160;Similar
reporting requirements applicable to medical device manufacturers have also been implemented by some states. Failure to comply with these
state requirements could result in civil monetary penalties being assessed against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These laws and regulations, among other things, constrain our business,
marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with
hospitals, physicians or other potential purchasers of our products. Due to the breadth of these laws, the narrowness of statutory exceptions
and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current
or future practices might be challenged under one or more of these laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To enforce compliance with the healthcare regulatory laws, certain enforcement
bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to
a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be
time-and resource-consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these investigations,
healthcare providers and entities may have to agree to additional compliance and reporting requirements as part of a consent decree or
corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our
business. &#160;Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to respond
to. &#160;If our operations are found to be in violation of any of the healthcare laws or regulations described above or any other healthcare
regulations that apply to us, we may be subject to penalties, including administrative, civil and criminal penalties, damages, fines,
exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, contractual damages, reputational
harm, disgorgement and the curtailment or restructuring of our operations. &#160;In addition, we are subject to the U.S. Foreign Corrupt
Practices Act and similar anti-corruption laws outside the U.S. Actual or alleged violation of these laws by our employees, consultants,
sales agents or distributors could subject us to investigations by the U.S. or foreign governments, significant criminal or civil sanctions
and other liabilities, and damage our reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may need additional funding in the future, and if we are unable
to raise capital when needed, we may be forced to delay, reduce or eliminate our product development, commercial efforts, or sales efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Producing and marketing our developed products is costly. &#160;Although
we believe we currently have adequate capital to fulfill our near-term funding needs, we may need to raise additional capital in the future
in order to execute our business plan and help us fund the development and commercialization of new products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may finance future cash needs through public or private equity offerings
and may also use debt financings or strategic collaboration and licensing arrangements. &#160;We may seek to access the public or private
equity markets whenever conditions are favorable, even if we do not have an immediate need for additional capital. &#160;To the extent
that we raise additional funds by issuing equity securities, our shareholders may experience additional dilution; any debt financing,
if available, may involve restrictive covenants and could result in high interest expense. &#160;If we raise additional funds through
collaboration and licensing arrangements, it may require us to relinquish certain enumerated rights to our product candidates, processes,
technologies, or development projects, or to enter into licenses on terms that are not favorable to us. &#160;We cannot be certain that
additional funding will be available on acceptable terms, or at all. &#160;If adequate funds are not available from the foregoing sources,
we may consider additional strategic financing options, or we may be required to delay, reduce the scope of, or eliminate our research
or development and/or some of our commercialization efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 19 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are required to comply with certain financial and operating covenants
under our credit facility. Failure to comply with these covenants would prevent us from drawing on our facility and, once drawn, could
cause amounts borrowed to become immediately due and payable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we want to draw on our credit facility, we must comply with specified
financial and operating covenants under our credit facility and make payments, limiting our ability to operate our business as we otherwise
might. Our failure to comply with any of these covenants or to meet any debt payment obligations could result in an event of default which,
if not cured or waived, would result in any amounts outstanding, including any accrued interest and/or unpaid fees, becoming immediately
due and payable. We might not have sufficient working capital or liquidity to satisfy any repayment obligations in the event of an acceleration
of those obligations. In addition, if we are not in compliance with the financial and operating covenants under the credit facility at
the time we wish to borrow funds, we will be unable to borrow funds. The financial and operating covenants under the credit facility may
limit our ability to borrow funds or capital, including for general corporate purposes and strategic acquisitions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may experience difficulties resulting from our relatively new
and evolving management structure and executive team.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have made a number of changes to our management structure throughout
the organization in recent years. &#160;Although, we believe the persons who currently serve in these positions are qualified to do so,
they may have difficulties integrating into the organization and with each other. &#160;Many of these persons have or will have had little
to no experience with our company prior to joining us, which may result in delays in our ability to implement our business plans. &#160;If
we are unable to integrate, motivate and retain the services of our relatively new executives and other managers, or if integration takes
longer than we expect, it may have an adverse effect on our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Changes in tax or labor laws or exposure to additional income tax
liabilities could increase our costs and reduce our margins.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Changes to the tax and labor laws in the U.S. or other countries in which
we operate could have an adverse effect on our operating results. &#160;Certain changes in tax rates, deductibility of interest, deductibility
of executive compensation expense, expensing of capital expenditures, the ability to use certain tax credits, taxation on earnings from
international business operations, and the system of taxation (from worldwide to territorial) could adversely affect our financial condition
and results of operations. &#160;Taxing authorities may audit us from time to time and disagree with certain positions we have taken in
respect of our tax liabilities. &#160;We regularly assess the likely outcomes of these audits in order to determine the appropriateness
of our tax provision. &#160;However, we may not accurately predict the outcome of these audits, and as a result the actual outcome of
these audits may have an adverse impact on our financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our manufacturing operations depend on low-cost labor. &#160;Recent increases
in U.S. minimum wage requirements, as well as those imposed by the state of New York and New Jersey will increase our costs for employees
to support those operations, reduce our margins and negatively impact our profit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">President Trump has indicated his willingness to
increase the use of tariffs by the U.S. to accomplish certain U.S. policy goals. On February 1, 2025, President Trump signed three executive
orders announcing his intent to impose 25% tariffs on imports from Canada and Mexico and a 10% additional tariff on imports from China.
While the implementation of tariffs on imports from Mexico and Canada were paused, the Chinese tariffs took effect as scheduled and China
responded by implementing 15% tariffs on certain U.S. imports. The implementation of new tariffs on imports from Canada, Mexico, China
or other countries for an extended period and without specific exemptions for our products, and any reciprocal tariffs or other reactions
by other countries thereto, could have a material adverse impact on our financial condition, results of operations and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>A downturn in global economic conditions could adversely affect our
operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deterioration in the global economic environment, particularly in countries
with government-sponsored healthcare systems, may cause decreased demand for our products and increased competition, which could result
in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of new technologies.
&#160;A weakening of economic conditions in the U.S. and/or abroad may also adversely affect our suppliers, which could result in interruptions
in supply. Further, sanctions, tariffs, or other measures that restrict international trade, as well as instability resulting from global
conflicts, could negatively affect our business operations and results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 20 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to foreign currency exchange risk.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A portion of our revenues is currently, and we expect in the future to
be, derived from international operations. &#160;Our revenues from sales outside the U.S. may be adversely affected by fluctuations in
foreign currency exchange rates. &#160;We cannot predict with any certainty changes in foreign currency exchange rates or our ability
to mitigate these risks. &#160;We may experience additional volatility as a result of inflationary pressures and other macroeconomic factors.
&#160;If we cannot adequately mitigate foreign currency exchange rates, our revenues and profit may suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our distribution network and other operations outside the U.S. subject
us to certain risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Approximately 20% of our net revenues in the year ended December 31,
2024, came from our operations outside the U.S., and we intend to continue to pursue growth opportunities in foreign markets.
&#160;Our foreign operations subject us to certain risks, including, among others, the effects of fluctuations in foreign currency
exchange, uncertainties with respect to local economic and political conditions, competition from local companies, trade
protectionism and restrictions on the transfer of goods across borders, including tariffs or other barriers to market participation,
pricing pressure that we may experience internationally, U.S. diplomatic and trade relations with the governments of the foreign
countries in which we operate, foreign regulatory requirements or changes in such requirements, local product preferences and
product requirements, longer payment terms for accounts receivable than we experience in the U.S., difficulty in establishing,
staffing and managing foreign operations, changes to international trade agreements and treaties, changes in tax laws, weakening or
loss of the protection of intellectual property rights in some countries, and import or export licensing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There may be greater uncertainty and market volatility
following U.S. and global elections, resulting from potential shifts in trade policies, tariffs or other trade protection measures,
and the reaction of other countries thereto, or changes to international trade agreements, which could have a material adverse effect
on our operations, including our ability to source and manufacture products in a timely and cost effective manner, financial condition,
results of operations and/or liquidity. Geopolitical developments related to various global conflicts are sources of uncertainty and may
cause disruptions to global or regional markets, supply chains or operations in the regions. Sanctions and export restrictions may continue
to proliferate, leading to greater uncertainty in emerging and growth markets. Any significant changes in the political, economic, financial,
competitive, legal and regulatory or reimbursement conditions where we conduct, or plan to expand, our international operations may have
a material impact on our business, financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are dependent on information technology systems and subject to
privacy and security laws, and our systems and infrastructure face certain risks, including from cyber security breaches and data leakage.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Despite the implementation of security measures, our internal computer
systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism,
war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside
our organization, or persons with access to systems inside our organization. &#160;While we do not believe that we have experienced any
such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our systems, it could
result in a material disruption of our operations. &#160;To the extent that any disruption or security breach results in a loss of or
damage to our data or applications or other data applications relating to our technology, or inappropriate disclosure of confidential
or proprietary information, we could incur liabilities, damage to our reputation, and the further development of our product candidates
could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We cannot guarantee that any of our strategic acquisitions, investments
or alliances will be successful.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may seek to supplement our internal growth through strategic acquisitions,
investments and alliances. &#160;Such transactions are inherently risky, and the integration of any newly acquired business requires significant
effort and management attention. &#160;The success of any acquisition, investment or alliance may be affected by a number of factors,
including our ability to properly assess and value the potential business opportunity or to successfully integrate any business we may
acquire into our existing business. &#160;There can be no assurance that any past or future transaction will be successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our operating results and financial condition may fluctuate.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our operating results and financial condition may fluctuate from quarter
to quarter and year to year for a number of reasons. &#160;Events such as a delay in product development, increases in litigation expenses,
changes to our expectations or strategy or even a relatively small revenue shortfall may cause financial results for a period to be below
our expectations or projections. &#160;As a result, we believe that period-to-period comparisons of our results of operations should not
be relied upon as an indication of future performance. &#160;Our operating results and financial condition are also subject to fluctuation
from all of the risks described throughout this section. &#160;These fluctuations may adversely affect our results of operations and financial
conditions and our stock price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 21 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Future material impairments in the value of our long-lived assets
could negatively affect our operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We review our long-lived assets, including identifiable intangible assets
and property, plant and equipment, for impairment. &#160;Long-lived assets are reviewed when there is an indication or triggering event
that impairment may have occurred. &#160;Changes in market conditions or other changes in the future outlook of value may lead to impairment
charges in the future. &#160;In addition, we may from time to time sell assets that we determine are not critical to our strategy. &#160;Future
events or decisions may lead to asset impairments and/or related charges. Certain non-cash impairments may result from a change in our
strategic goals, business direction or other factors relating to the overall business environment. &#160;Material impairment charges could
negatively affect our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Actions of activist stockholders could have an adverse effect on
our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">From time to time, we may be subject to proposals by stockholders urging
us to take certain corporate actions. &#160;If activist stockholder activities ensue, our business could be adversely affected because
responding to proxy contests and reacting to other actions by activist stockholders can be costly and time-consuming, disrupt our operations
and divert the attention of management and our employees. For example, we may be required to retain the services of various professionals
to advise us on activist stockholder matters, including legal, financial and communications advisors, the costs of which may negatively
impact our future financial results. &#160;In addition, perceived uncertainties as to our future direction, strategy or leadership created
as a consequence of activist stockholder initiatives may result in the loss of potential business opportunities, harm our ability to attract
new investors, customers, employees, and joint venture partners, and cause our stock price to experience periods of volatility or stagnation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Natural disasters, war and other events could adversely affect our
suppliers and customers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Natural disasters (including pandemics), war, terrorism, labor disruptions
and international conflicts, and actions taken by the U.S. and other governments or by our customers or suppliers in response to such
events, could cause significant economic disruption and political and social instability in the U.S. and areas outside of the U.S. in
which we operate. &#160;Most of our products are assembled and packaged in Nicaragua, where there is currently civil unrest whose outcome
cannot be predicted. &#160;This and similar events could increase the costs for or cause interruptions in the supply of materials, result
in decreased demand for our products or adversely affect our manufacturing and distribution capabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our insurance coverage may be inadequate to cover all the liabilities
we may incur.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We face the risk of exposure to liability claims if any product that we
develop causes injury. &#160;Although we carry insurance at levels customary for companies in our industry, such coverage may become unavailable
or be inadequate to cover all liabilities we may incur. &#160;There can be no assurance that we will be able to continue to maintain such
insurance, or obtain comparable insurance at a reasonable cost, if at all. &#160;If we are unable to obtain sufficient insurance coverage
at an acceptable cost or otherwise, or if the amount of any claim against us exceeds the coverage under our policies, we may face significant
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Rising inflation increases economic uncertainty and may require us
to raise prices in order to maintain our operating margins.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For much of the past two years, inflation rates have risen or held steady
at rates not seen in a generation or more. Higher level of inflation not only reduces the real value of the profits we generate from our
business (and in turn our returns to investors), but it also increases the costs of goods and services, including those from our single-source
suppliers, that we need to run our business. Should such trends continue, it would not only have a destabilizing macroeconomic effect
on the broader U.S. and global economy, but it may also require us to increase the price of our products in order to maintain sufficient
operations margins. Any increase in the prices we charge our customers could reduce the demand for our products, perhaps significantly.
We will continue to monitor inflation trends and will make adjustments to our business as necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Brexit may impact our business in the United Kingdom.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">One of our two most significant international distributors is located in
the United Kingdom (&#8220;UK&#8221;), and the other is in Finland, a member of the European Union (&#8220;EU&#8221;). &#160;The June
2016 referendum resulted in the UK&#8217;s decision to exit the EU (commonly known as &#8220;Brexit&#8221;), and the subsequent commencement
of the official withdrawal process by the UK government in March 2017, has created uncertainties affecting business operations in the
UK and the EU. &#160;On January 31, 2020, the UK withdrew from the EU. Under the withdrawal agreement agreed between the UK and the EU,
the UK was subject to a transition period until December 31, 2020 (the &#8220;Transition Period&#8221;) during which EU rules continued
to apply. &#160;During the Transition Period, negotiations between the UK and the EU continued in relation to the future customs and trading
relationship between the UK and the EU following the expiration of the Transition Period. Due to the current COVID-19 global pandemic,
negotiations between the UK and the EU were delayed. &#160;However, on December 24, 2020, the negotiators from the EU and UK reached an agreement
on a new partnership. &#160;This agreement sets out the</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 22 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">rules that apply between the EU and the UK as of January 1, 2021. &#160;New regulations
require medical device registration with the Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA") before being placed
on the Great Britain market (England, Wales, and Scotland). Additionally, all medical devices will require a UK Conformity Assessment
mark (&#8220;UKCA&#8221;) by June 30, 2030. CE marks issued by Notified Bodies will remain valid until this time. Therefore, we must be
compliant with applicable legislation in order to identify our devices with the UKCA mark and continue to market and sell our devices
in Great Britain beyond June 30, 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We could be adversely affected, directly or indirectly, by the effects
of an increased focus on environmental, social and governance issues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recently, shareholders generally have increased their focus on environmental,
social and governance ("ESG") issues, specifically regarding how companies are addressing climate change, diversity, and human
rights, among other ESG-related issues. Our failure to comply with shareholder expectations and standards regarding ESG issues, which
are still evolving and can vary considerably, or the perception that we have not responded appropriately to ESG-related issues, could
result in reputational harm, and could have an adverse effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Climate change could present immediate and long-term risks to our industry
and our customers. The potential for increased severe weather events could have a material adverse effect on our operations and infrastructure
or the operations and infrastructure of our suppliers. In addition, the effects of climate change could include long-term changes in temperature
levels and water availability, increased energy costs, and increased supply costs impacted by those increasing energy costs. The cost
of mitigating or responding to ESG issues could be significant; however, these costs are too uncertain to predict. In addition, the approaches
taken by the U.S. or foreign governments to regulate ESG issues, which may include legislative or regulatory changes, could adversely
impact our business, results of operations, financial condition, and prospects, and are too uncertain to predict.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Risks Related to Ownership of Our Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>There may be circumstances in which the interests of our significant
stockholders could be in conflict with your interests as a stockholder.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Three stockholders, together with
their respective affiliates, beneficially own approximately 13%, 10%, and 9% of our outstanding common stock, respectively. &#160;An
affiliate of Horton Capital Management LLP. currently serves on our Board of Directors. &#160;Circumstances may arise in which these stockholders
may have an interest in exerting influence to pursue or prevent acquisitions, divestitures or other transactions, including the issuance
of additional shares or debt, that, in their judgment, could enhance their investment in us or another company in which they invest. &#160;Such
transactions might adversely affect us or other holders of our common stock. Furthermore, our significant concentration of share ownership
may adversely affect the trading price of our common stock because investors may perceive disadvantages in owning shares in companies
with significant stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We do not currently intend to pay dividends on our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have never paid dividends on our common stock, and we do not intend
to pay any dividends to holders of our common stock for the foreseeable future. &#160;We currently intend to invest our future earnings,
if any, to fund our growth. &#160;Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future.
If we do not pay dividends, a return on our stockholders&#8217; investment will only occur if our stock price appreciates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Future sales and issuances of shares of our common stock or rights
to purchase our common stock, including pursuant to our equity compensation plans, could result in additional dilution of the percentage
ownership of our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may need additional capital in the future to continue our planned operations.
&#160;To the extent we raise additional capital by issuing equity and/or convertible securities, our stockholders may experience substantial
dilution. &#160;We may sell our common stock, convertible securities or other equity securities in one or more transactions at prices
and in a manner, we determine from time to time. If we sell our common stock, convertible securities or other equity securities, investors
may be materially diluted. &#160;These sales may also result in material dilution to our existing stockholders, and new investors could
gain rights superior to our existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide and intend to continue to provide additional equity-based compensation
to our employees, directors and consultants under our three equity compensation plans. We may issue equity-based compensation outside
of our equity compensation plans as inducement for new employees. &#160;If our Board elects to issue additional stock options or other
equity-based compensation, our stockholders may experience additional dilution, which could cause our stock price to decline. &#160;Because
stock options granted under our equity compensation plans will generally only be exercised when the exercise price for such option is
below the then market value of the common stock, the exercise of such options or the issuance of shares will cause dilution to the book
value per share of our common stock and to existing and new investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 23 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>There has been volatility in the price of shares of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Since our common stock was listed on the Nasdaq Capital Market on October
17, 2019, it has traded between $1.82 per share to $12.84 per share. &#160;Our stock price is subject to wide fluctuations in response
to a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">quarterly variations in operating results;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>announcement of new products or customers by our competitors;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>changes in financial estimates by securities analysts;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>trading volume on the Nasdaq Capital Market;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>announcements related to litigation;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>general economic conditions; or</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>other events or factors that are beyond our control.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the stock market has experienced significant price and volume
fluctuations that have particularly affected the trading prices of equity securities of many biotechnology companies. &#160;These fluctuations
have often been unrelated or disproportionate to the operating performance of these companies. &#160;Any negative change in the public&#8217;s
perception of the prospects of medical device companies could further depress our stock price regardless of our results. &#160;Sales of
substantial amounts of our common stock, particularly by our two most significant stockholders, or the perception that such sales might
occur, could adversely affect prevailing market prices of our common stock and our stock price may decline substantially in a short time
and our stockholders could suffer losses or be unable to liquidate their holdings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we do not maintain compliance with the listing standards of the
Nasdaq Capital Market, Nasdaq may delist our common stock from trading on its exchange</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Nasdaq Capital Market on which our common stock trades has continued
listing standards that we must maintain on an ongoing basis in order to continue the listing of our common stock. &#160;If we fail to
meet these continued listing requirements, our common stock may be subject to delisting. &#160;If our common stock is delisted and we
are not able to list our common stock on another national securities exchange, we expect our securities would be quoted on an over-the-counter
market. &#160;If this were to occur, our stockholders could face significant material adverse consequences, including limited availability
of market quotations for our common stock and reduced liquidity for the trading of our common stock. &#160;In addition, we could experience
a decreased ability to issue additional securities and obtain additional financing in the future, if or when needed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are a smaller reporting company and non-accelerated filer, and
we cannot be certain if the reduced disclosure requirements applicable to us will make our common stock less attractive to investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are currently a &#8220;smaller reporting company&#8221; and a &#8220;non-accelerated
filer&#8221;, as those terms are defined in the Securities Act. &#160;Accordingly, we take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not &#8220;smaller reporting companies&#8221; and &#8220;non-accelerated
filers,&#8221; including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports
and proxy statements and exemptions from the provisions of Section&#160;404(b) of the Sarbanes-Oxley Act of 2002 requiring that independent
registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting. &#160;Decreased
disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; and &#8220;non-accelerated filer&#8221;
may make it harder for investors to analyze our results of operations and financial prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot predict if investors will find our common stock less attractive
if we rely on these exemptions. &#160;If some investors find our common stock less attractive as a result, there may be a less active
trading market for our common stock and our share price may be more volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The price of our common stock may be adversely affected by the future
issuance and sale of shares of our common stock or other equity securities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We cannot predict the size of future issuances or sales of our common stock
or other equity securities future acquisitions or capital raising activities, or the effect, if any, that such issuances or sales may
have on the market price of our common stock. The issuance and sale of substantial amounts of common stock or other equity securities
or announcement that such issuances and sales may occur, could adversely affect the market price of our common stock. Any decline in the
price of our common stock may encourage short sales, which could place further downward pressure on the price of our common stock and
may impair our ability to raise additional capital through the sale of equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 24 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>You may find it difficult to sell our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Only recently has there been any active trading market in our common stock.
&#160;We cannot assure you that such an active trading market for our common stock will be sustained. &#160;Regardless of whether an active
and liquid public market exists, negative fluctuations in our actual or anticipated operating results will likely cause the market price
of our common stock to fall, making it more difficult for you to sell our common stock at a favorable price, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_1B"></span><b>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_1C"></span><b>ITEM 1C. CYBERSECURITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management has responsibility for developing and coordinating the Company&#8217;s
cybersecurity policy and strategy, and for managing the prevention, detection, mitigation and remediation of cybersecurity incidents.
We utilize various risk assessment tools and technologies to identify potential cyber and information security threats and risks, including
engaging a third-party information technology services provider to perform risk evaluation and testing. In addition, the Company is in
the process of implementing a program for all team members to participate in ongoing training and awareness programs that include periodic
assessments to drive adoption and awareness of cybersecurity processes and controls.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We promote a company-wide culture of cybersecurity risk management intended
to protect the confidentiality, integrity, and availability of our critical systems and the information contained therein. No risks from
cybersecurity threats or previous cybersecurity incidents have materially affected, or are reasonably likely to materially affect, our
business strategy, financial condition or results of operations. However, there can be no assurance that the controls and procedures in
place to monitor and mitigate the risks of cyber threats will be successful or sufficient to avoid material losses or consequences in
the future. Additionally, while we have insurance coverage in place that is designed to address certain aspects of cyber risks, such insurance
coverage may be insufficient to cover all insured losses or all types of claims that may arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Board of Directors, as a whole and through its committees, oversees
risk management, including cybersecurity risks. The Board has delegated risk management responsibilities, including but not limited to
cybersecurity risk, to the Nominating and Governance Committee. Specifically, the Nominating and Governance Committee periodically reviews
our cybersecurity policies, data security programs and plans that management has established to monitor compliance and assess preparedness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_2"></span><b>ITEM 2. PROPERTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently rent 43,975 square feet of a building located at 100 Corporate
Drive, Mahwah, New Jersey with the lease having commenced on March 1, 2022 and expiring August 31, 2032. This facility is used as our
headquarters and for our in-house manufacturing operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_3"></span><b>ITEM 3. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the ordinary course of our business, we may be subject to various claims,
pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising
out of the normal conduct of our business. We are not aware of any current material pending legal proceedings to which we are a party
or of which any of our properties is the subject.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_4"></span><b>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_5"></span><b>ITEM 5. MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our common stock is traded on the Nasdaq Capital Market under the symbol
&#8220;KRMD.&#8221; &#160;We have not paid any cash dividends on our common stock and do not plan to pay any such dividends in the foreseeable
future. &#160;We currently intend to use all available funds for our business operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 25 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are authorized to issue 77,000,000 shares of capital stock, of
which 75,000,000 are designated common stock, $0.01 par value per share, and 2,000,000 are designated preferred stock. &#160;As of
March 12, 2025, 45,957,115 shares of our common stock were issued and outstanding held by approximately 431 stockholders of record.
&#160;There were no shares of preferred stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Dividend Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have never declared or paid cash dividends on our capital stock. We
currently intend to retain all future earnings for the operation and expansion of our business and, therefore, do not anticipate declaring
or paying cash dividends in the foreseeable future. The payment of dividends will be at the discretion of our Board of Directors and will
depend on our results of operations, capital requirements, financial condition, prospects, contractual arrangements, any limitations on
payments of dividends present in any of our future debt agreements and other factors our Board of Directors may deem relevant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information relating to our equity compensation plans as of December&#160;31,
2024, under which our equity securities were authorized for issuance, is included in Item 12 of Part III of this Annual Report and such
information is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_6"></span><b>ITEM 6. RESERVED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_7"></span><b>ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>The following discussion and analysis of our financial condition and
results of operations should be read together with our consolidated financial statements and related notes included under ITEM 8 of this
Annual Report on Form 10-K. &#160;This discussion contains forward-looking statements about our business and operations. &#160;Our actual
results may differ materially from those we currently anticipate as a result of many factors, including those described under Part I &#8211;
FORWARD LOOKING STATEMENTS and elsewhere in this Annual Report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OVERVIEW</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company develops, manufactures and commercializes innovative patient-centric
large volume subcutaneous solutions primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug
Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues derive from three business sources: (i) domestic core (which
consists of US and Canada), (ii) international core, and (iii) novel therapies.&#160; Our domestic core and international core revenues
consist of sales of our products for the delivery of subcutaneous drugs that are FDA cleared for use with the FREEDOM Infusion System,
with the primary delivery for immunoglobulin to treat Primary Immunodeficiency Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory
Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies revenues consist of product revenues from our infusion system (syringe
drivers, tubing and needles) for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical
companies in the drug development process as well as non-recurring engineering services revenues (&#8220;NRE&#8221;) received from biopharmaceutical
companies to ready or customize the FREEDOM System for clinical and commercial use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company ended the 2024 fiscal year with $33.6 million in net revenues,
an 18.0% increase compared with $28.5 million in the same period last year driven by growth in our core domestic and international business
of 12.3% and 31.5% respectively, and further driven by a 61.9% increase in our novel therapies business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gross profit, for the year ended December 31, 2024, was $21.3 million,
an increase of 27.7% or $4.6 million from the same period last year. Gross margin was 63.4% for the year ended December 31, 2024, an increase
from 58.6% from the prior year. We define gross margin as gross profit stated as a percentage of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating expenses for the year ended December 31, 2024, were $27.8 million,
up from $27.0 million for the same period last year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Year Ended December 31, 2024 compared to Year Ended December 31, 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our net revenues for the years ended December
31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 26 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td>
    <td>&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><b>% of Net Revenues</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 24%"><b>Net Revenues</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 7%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 7%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 7%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in">Domestic Core</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">25,214,613</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">22,446,519</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">2,768,094</td>
    <td>&#160;</td>
    <td style="text-align: right">12.3%</td>
    <td>&#160;</td>
    <td style="text-align: right">74.9%</td>
    <td>&#160;</td>
    <td style="text-align: right">78.7%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 0.1in">International Core</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">6,043,979</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">4,596,097</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">1,447,882</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">31.5%</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">18.0%</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">16.1%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in">Total Core</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">31,258,592</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">27,042,616</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,215,976</td>
    <td>&#160;</td>
    <td style="text-align: right">15.6%</td>
    <td>&#160;</td>
    <td style="text-align: right">92.9%</td>
    <td>&#160;</td>
    <td style="text-align: right">94.8%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in">Novel Therapies</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">2,387,871</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">1,475,050</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">912,821</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">61.9%</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">7.1%</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">5.2%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E8E8E8">
    <td><b>Total</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">33,646,463</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">28,517,666</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">5,128,797</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">18.0%</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">100%</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">100%</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total net revenues increased $5.1 million, or 18.0%, to $33.6 million,
for the year ended December 31, 2024, as compared with the same period last year. Domestic core growth of 12.3% was primarily driven by
volume growth in pumps and consumables attributed to overall SCIg market growth and new account share gains. International core growth
of 31.5% was driven by overall SCIg market growth, increased penetration in several established EU markets, and the entry into multiple
new geographic markets. Novel therapies net revenues increased $0.9 million, or 61.9%, driven primarily by an increase in NRE collaborations
and an increase in clinical trial supply shipments when compared to the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Gross Profit</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our gross profit for the years ended December 31, 2024, and 2023 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="width: 43%">Gross Profit</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">$</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right">21,331,858</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">$</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right">16,708,282</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">$</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right">4,623,576</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: right">27.7%</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 11.9pt">Gross Margin</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">63.4%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">58.6%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gross profit increased $4.6 million, or 27.7%, to $21.3 million, in the
year ended December 31, 2024, compared to the same period in 2023 driven by the increase in net revenues of $5.1 million coupled with
significant gross margin improvement. Gross margin increased to 63.4% in the year ended 2024 compared to 58.6% for the year ended 2023,
primarily driven by increased manufacturing productivity, improved margin on product revenue mix, and increases in average selling prices
versus the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our selling, general and administrative, research and development and depreciation
and amortization expenses for the years ended December 31, 2024, and 2023 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>Years Ended December 31,</b></td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 43%">Selling, general and administrative</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">21,631,674</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">20,365,617</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">1,266,057</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 8%; text-align: right">6.2%&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Research and development</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,257,942</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,742,254</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(484,312</td>
    <td>)</td>
    <td style="text-align: right">(8.4)%&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">888,473</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">870,390</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">18,083</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">2.1%&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Total Operating Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">27,778,089</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">26,978,261</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">799,828</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">3.0%&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Selling, general and administrative expenses increased $1.3 million, or
6.2%, to $21.6 million, during the year ended December 31, 2024 compared with the same period last year, primarily due to a $1.7 million
increase in compensation and benefits-related bonus accrual and sales commission related to year over year company performance, partially
offset by lower recruiting expenses and liability insurance costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Research and development expenses decreased $0.5 million, or 8.4%, to $5.3
million, during the year ended December 31, 2024 compared with the same period last year, primarily due to lower overall project spend
driven by timing, partially offset by CTO severance costs and an increase in compensation and benefits-related bonus accrual related to
year over year company performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Depreciation and amortization expense remained flat at $0.9 million during
the year ended December 31, 2024, as compared to $0.9 million during the same period in 2023, primarily driven by capital spending related
to projects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; vertical-align: top; text-align: center"><b>Change from Prior Year</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>$</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>%</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 43%">Net Loss</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">(6,066,633</td>
    <td style="width: 3%">)</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">(13,741,062</td>
    <td style="width: 3%">)</td>
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">7,674,429</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 8%; text-align: right">55.9%</td></tr>

  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 27 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our net loss decreased $7.7 million in the year ended December 31, 2024
compared with the same period last year, mostly driven by lower net operating losses of $3.8 million as a result of our gross profit improvement
of 27.7%, and an operating expense increase of 3%. In the prior year we established an allowance for the non-realization of deferred tax
assets which reversed a tax benefit of $4.0 million, partially offsetting in the current year was lower interest income of $0.1 million
driven by a lower cash balance coupled with lower yields.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LIQUIDITY AND CAPITAL RESOURCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our principal source of liquidity is our cash on hand of $9.6 million as
of December 31, 2024. &#160;Our principal source of operating cash inflows is from sales of our products in our core business, NRE services,
and clinical trial products to our customers. Our principal cash outflows relate to the purchase and production of inventory, funding
of research and development, and selling, general and administrative expenses. To develop new products, support future growth, achieve
operating efficiencies, and maintain product quality, we are continuing to invest in research and development, innovation, and equipment.
Operating expenses for the 2024 fiscal year were $27.8 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our inventory position was $2.8 million at December 31, 2024, which reflects
a decrease of $0.7 million from December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect that our cash on hand and cash flows from operations will
be sufficient to meet our requirements at least through the next twelve months. Continued execution on our longer-term strategic
plan may require the Company to draw on our credit facility, take on additional debt, raise capital through issuance of equity, or a
combination. Our future capital requirements may vary from those currently planned and will depend on many factors, including our
rate of sales growth, the timing and extent of spending on various strategic initiatives including research and development, our
international expansion, the timing of new product introductions, market acceptance of our solutions, and overall economic
conditions including inflation and the potential impact of global supply imbalances on the global financial markets. To the extent
that current and anticipated future sources of liquidity are or are expected to be insufficient to fund our future business
activities and requirements, we may be required to draw on our new credit facility or seek additional equity or debt financing
sooner. There can be no assurance the Company will be able to obtain the financing or raise the capital required to fund its
operations or planned expansion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 56%">Net cash used in operating activities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 18%; text-align: right">(319,718</td>
    <td style="width: 4%">)</td>
    <td style="width: 1%">$</td>
    <td style="width: 18%; text-align: right">(4,892,553</td>
    <td style="width: 1%">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>Net cash used in investing activities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(1,333,042</td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(814,597</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net cash used in financing activities</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(248,533</td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(218,867</td>
    <td>)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in operating activities was $0.3 million for the year ended
December 31, 2024. This net cash usage was primarily due to the net loss of $6.1 million, offset by a $2.6 million increase in accrued
expenses for 2024 bonuses and payroll, $0.7 million in lower inventories, and $0.7 million in increased accounts payable, partially offset
by a higher accounts receivable balance of $1.7 million, and $0.2 million of changes in other liabilities, prepaids, and other assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Further contributing to this change were non-cash items of $3.8 million
including stock-based compensation expense of $2.6 million, depreciation and amortization expense of $0.9 million, and $0.3 million for
non-cash leasing charges and losses on disposals of fixed assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in operating activities of $4.9 million for the year ended
December 31, 2023 was primarily due to the net loss of $13.7 million, plus cash flows used to reduce accrued expenses of $1.2 million
primarily from the payment of 2023 employee bonuses, and a decrease in accounts payable of $1.4 million. Partially offsetting these increases
were cash flows generated from a decrease in inventory of $2.9 million, a decrease in accounts receivable of $0.5 million, and other changes
in working capital of $0.4 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Further contributing to this change were the establishment of an allowance
for non-realization of deferred tax assets of $4.0 million, stock-based compensation of $2.8 million, depreciation and amortization of
$0.9 million, and a loss on disposal of fixed assets of $0.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 28 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Investing Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in investing activities of $1.3 million for the year ended
December 31, 2024, was driven by capital expenditures for manufacturing equipment related to our production line for our next generation
consumables.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in investing activities of $0.8 million for the year ended
December 31, 2023, was for capital expenditures for research and development and manufacturing equipment</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Financing Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in financing activities of $0.2 million for the year ended
December 31, 2024 was primarily due to payments on our note payable for insurance premium financing, partially offset by new borrowings
for a subsequent insurance premium financing agreement. In addition, we had payments for taxes related to net share settlement of equity
awards of $0.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Net cash used in financings activities of $0.2 million for the year ended
December 31, 2023, due to payments on our note payable for insurance premium financings, partially offset by the borrowings for the insurance
premium financing, and $0.1 million for payments on our finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Debt and Borrowing Capacity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 5 &#8212; DEBT OBLIGATIONS&#8221; in the accompanying
&#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on Form 10-K for further details regarding debt and borrowing
capacity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease Commitments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office and computer equipment. &#160;Our three operating leases have remaining lease terms of 7.7 years, 4.1 years, and 3.4 years, respectively.
Our three finance leases have remaining lease terms of 2.4 years, 2.0 years, and 3.8 years, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 6 &#8212; LEASES&#8221; in the accompanying &#8220;Notes
to Financial Statements&#8221; appearing in this Annual Report on Form 10-K for further details regarding our operating and finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>SIGNIFICANT ACCOUNTING POLICIES AND CRITICAL ACCOUNTING ESTIMATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with generally accepted
accounting principles of the United States (&#8220;GAAP&#8221;) requires estimates and assumptions that affect the reported amounts of
assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the financial statements and accompanying
notes. &#160;The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of
the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective
judgments, often as a result of the need to make estimates of matters that are inherently uncertain. &#160;Based on this definition, we
have identified some of our more critical accounting estimates below. &#160;We also have other key accounting policies, which involve
the use of estimates, judgments, and assumptions that are significant to understanding our results. &#160;For additional information,
see &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes
to Financial Statements&#8221; appearing in this Annual Report on Form 10-K. &#160;Although we believe that our estimates, assumptions,
and judgments are reasonable, they are based upon information presently available. &#160;Actual results may differ significantly from
these estimates under different assumptions, judgments, or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 29 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs generally are billed to customers and are included
in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#8217;s revenue recognition criteria described above. As of December 31, 2023, the Company has recognized
a contract asset of zero which is included in other accounts receivable in the accompanying balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Inventory</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. We make estimates regarding the future recoverability
of the costs of these products and record provisions based on historical experience, expiration of sterilization dates and expected future
trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by
management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACCOUNTING PRONOUNCEMENTS NOT YET ADOPTED</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Refer to &#8220;NOTE 1 &#8212; NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES&#8221; in the accompanying &#8220;Notes to Financial Statements&#8221; appearing in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 30 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_7A"></span><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_8"></span><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="index_to_fs"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: bottom">
    <td style="width: 7in">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 0.5in; text-align: center">Page</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Audit_Report_1">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID 00<span id="xdx_90F_edei--AuditorFirmId_c20240101__20241231_zuK1ugoTE1f2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000043" name="dei:AuditorFirmId">677</ix:nonNumeric></span>)</td>
    <td style="text-align: center">32</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Audit_Report_2">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID 00256)</td>
    <td style="text-align: center">34</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financial Statements</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Balance_Sheets">Balance Sheets as of December 31, 2024 and 2023</a></td>
    <td style="text-align: center">35</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Statements_Of_Operations">Statements of Operations for the years ended December 31, 2024 and 2023</a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Stockholders_Equity">Statements of Stockholders&#8217; Equity for the years ended December 31, 2024 and 2023</a></td>
    <td style="text-align: center">37</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Cash_Flows">Statements of Cash Flows for the years ended December 31, 2024 and 2023</a></td>
    <td style="text-align: center">38</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td><a href="#Notes_To_Financial_Statements">Notes to Financial Statements</a></td>
    <td style="text-align: center">39</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 31 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<div style="width: 6.5in">

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Audit_Report_1">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><img src="cbh_logo-header.jpg" alt=""/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">To the Board of Directors and</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Stockholders of KORU Medical Systems, Inc.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Mahwah, New Jersey</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">We have audited the accompanying balance sheet of
KORU Medical Systems, Inc (the &#8220;Company&#8221;) as of December 31, 2024, and the related statements of operations, stockholders&#8217;
equity, and cash flows for the year ended December 31, 2024, and the related notes. In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash
flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b>Prior Period Financial Statements</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">The financial statements of the Company as of and
for the year ended December 31, 2023 were audited by other auditors whose report dated March 13, 2024 expressed an unqualified opinion
on those statements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b>Basis for Opinion</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">We conducted our audit in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal
control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b>Critical Audit Matters</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">Critical audit matters are matters arising from the
current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that
(1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective,
or complex judgements. We determined that there were no critical audit matters.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><img src="cbh_logo-footer.jpg" alt=""/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 32 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b>Emphasis of Matter</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">We also have audited the adjustments to the 2023 financial
statements to retrospectively apply the change due to the adoption of Accounting Standards Update 2023-07, <i>Segment Reporting</i>, described
in Note 1. In our opinion, such adjustments are appropriate and have been properly applied. We were not engaged to audit, review, or apply
any procedures to the 2023 financial statements of the Company other than with respect to the adjustments and, accordingly, we do not
express an opinion or any other form of assurance on the 2023 financial statements taken as a whole.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><img src="cbh_signature.jpg" alt=""/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">We have served as the Company&#8217;s auditor since 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span id="xdx_905_edei--AuditorName_c20240101__20241231_z0dKhUMhixT6" style="display: none; visibility: hidden"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000044" name="dei:AuditorName">Cherry Bekaert LLP</ix:nonNumeric></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span id="xdx_90A_edei--AuditorLocation_c20240101__20241231_zgWk2jVNSXai"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000045" name="dei:AuditorLocation">Tampa, Florida</ix:nonNumeric></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">March 12, 2025</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 33 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Audit_Report_2">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><img src="mmq_logo-header2023.jpg" alt=""/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Report of Independent Registered Public Accounting
Firm</b></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Shareholders and the Board of Directors</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">KORU Medical Systems, Inc.</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mahwah, New Jersey</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Opinion on the Financial Statements</p>

<p style="font: bold 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying balance sheet of
KORU Medical Systems, Inc. (the Company) as of December 31, 2023, the related statement of operations, stockholders&#8217; equity and
cash flows for the year then ended, and the related notes to the financial statements (collectively, the financial statements). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023,
and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted
in the United States of America.</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: bold 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basis for Opinion</p>

<p style="font: bold 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audit in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>


<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><img src="mmq_signature2023.jpg" alt=""/>&#160;</p>


<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We served as the Company's auditor from 2014 through
2023.</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Scranton, Pennsylvania</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 13, 2024</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 34 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

</div>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Balance_Sheets"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_301_111_z3ox82IsblC8" summary="xdx: Statement - BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 72%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_493_20241231_zOIs5wjyfBM4" style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49A_20231231_zjxOToKtK8wc" style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zUeDByNmcwCd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>ASSETS</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zG1eWwZ47Vkk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzgpp_zVUiROBLVoJf" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,580,947</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,482,240</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzgpp_zNwVxfrTzAdc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accounts receivable, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,720,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,045,211</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryNet_i02I_maACzgpp_zurjkVZkLQB4" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,803,669</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,481,301</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherReceivables_i02I_maACzgpp_z8DFRBndzfUf" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Other receivables</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-12-31" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,193</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2023-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,889</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_i02I_maACzgpp_zjfEqL7oMlB6" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,851</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,218,288</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_mtACzgpp_maAzX64_zDBJpR9uCKG7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL CURRENT ASSETS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,132,410</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,255,929</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzX64_z3w5db4FQ6E7" style="vertical-align: bottom">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,290,515</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,837,657</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maAzX64_zOZbYBS5Jtdd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 8.25pt; text-indent: -8.25pt">Intangible assets, net of accumulated amortization of $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20241231_zB84baCrbFAa" title="Finite-lived intangible assets, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">458,538</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20231231_zS1LkR2ZPee6" title="Finite-lived intangible assets, accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">390,341</ix:nonFraction></span> at December 31, 2024 and December 31, 2023, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">730,279</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">754,361</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzX64_z6mS5XRqZUh6" style="vertical-align: bottom">
    <td>Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,966,341</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,514,055</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsNoncurrent_i01I_maAzX64_zuNAEqrkn5Cd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Other assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,970</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,970</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01TI_mtAzX64_zfsU5FCIjpH9" style="vertical-align: bottom">
    <td>TOTAL ASSETS</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,218,515</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,460,972</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zM5hFgdVqYX4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td><b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_z9pAjIvK0tR8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_i02I_maLCz2l4_z7bpiN0361yc" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accounts payable</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649,969</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975,193</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCz2l4_z5asGHID6I4h" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accrued expenses</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,924,184</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,427</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NotesPayableCurrent_i02I_maLCz2l4_zn48GudgAuXa" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Note payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,152</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,344</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCz2l4_zLNiulGMrwn2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Other liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,269</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,520</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_maLCz2l4_zq0hCL5x8Rdl" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">811,401</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,941</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCz2l4_zWv4dbZbEgFe" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Finance lease liability &#8211; current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,587</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,540</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCz2l4_z8eeXsfilzU6" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Operating lease liability &#8211; current</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,258</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,313</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_mtLCz2l4_maLzWt0_zTx6hquPCgKl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL CURRENT LIABILITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,201,820</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,454,278</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maLzWt0_zyBV12y1m9gj" style="vertical-align: bottom">
    <td>Finance lease liability, net current portion</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,613</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,623</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzWt0_zprZkoPYXnlb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 45.5pt; text-indent: -45.5pt">Operating lease liability, net of current portion</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,403</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,336,300</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_mtLzWt0_maLASEzp5S_zm0LIX9SrOpb" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,404,836</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,107,201</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommitmentsAndContingencies_i01I_zqEvwlLrxOr6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Commitments and contingencies (Refer to Note 8)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_i01B_zGjmoAyl2FJ5" style="vertical-align: bottom">
    <td>STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommonStockValue_i02I_maSEzfdr_zSkogliLeqWh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Common stock, $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20241231_zSa2VR5k91Xf"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20231231_zOlhuRluQbag"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20241231_zY9Y7IdX3KKe"><span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20231231_zyRxzMuWSP6e"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20241231_zZfhWowI5ifa" title="Common stock, shares, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,377,617</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20231231_zoyay5J4Owia"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,089,864</ix:nonFraction></span> shares issued; <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20241231_zP5qP1xm1by9"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,957,115</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20231231_z84ThROQXmy6"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,669,362</ix:nonFraction></span> shares outstanding at December 31, 2024, and December 31, 2023, respectively</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,776</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,899</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEzfdr_z7FSP53uPvif" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Additional paid-in capital</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,581,303</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,018,707</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--TreasuryStockValue_i02NI_di_msSEzfdr_zpPbtiSeKE15" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Treasury stock, <span id="xdx_90A_eus-gaap--TreasuryStockPreferredShares_iI_pid_uShares_c20241231_zeSinzfG0Wfi" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,438,526</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--TreasuryStockPreferredShares_iI_pid_uShares_c20231231_zhMw3lWkXSm2" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockPreferredShares" contextRef="AsOf2023-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,420,502</ix:nonFraction></span> shares at December 31, 2024 and December 31, 2023, respectively, at cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,882,494</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzfdr_zABVACqDawrh" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Accumulated Deficit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,378,906</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,312,273</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_404_eus-gaap--StockholdersEquity_i02TI_mtSEzfdr_maLASEzp5S_zTu2h6wS4B0k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,813,679</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,353,771</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzp5S_zwLf8xQoZjEa" style="vertical-align: bottom">
    <td>TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,218,515</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,460,972</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 35 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Statements_Of_Operations"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_30B_113_zWwbMvSsmLmi" summary="xdx: Statement - STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 72%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49E_20240101__20241231_zCZtApwIp5j4" style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_490_20230101__20231231_zMWoFpCbuwV7" style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>For the Years Ended<br/>
December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_maGPzoLp_zYppoOKKR52e" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET REVENUES</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,646,463</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,517,666</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfGoodsAndServicesSold_msGPzoLp_zj1mYUgFwvzl" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cost of goods sold</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-01to2024-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,314,605</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,809,384</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_iT_mtGPzoLp_maOILz1Z9_zmOxsRWgNIaj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Gross Profit</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,331,858</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,708,282</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zaALLQxsGkdc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>OPERATING EXPENSES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEzenM_zySfkpOqX8Nd" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Selling, general and administrative</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,631,674</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,365,617</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzenM_zjIJujJTEXk9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Research and development</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,257,942</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,742,254</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_i01_maOEzenM_zaHI3amWmuGa" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">888,473</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">870,390</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpenses_i01T_mtOEzenM_msOILz1Z9_z8Rlib4PYkha" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Operating Expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,778,089</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,978,261</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iT_mtOILz1Z9_maILFCOzy2C_zPowLvv41gF7" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Net Operating Loss</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,446,231</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,269,979</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z8bwZxaxmVX" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Non-Operating Income, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maNIEzQpk_zKDhD8EYIB23" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Loss on foreign currency exchange</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-01to2024-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,991</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-012023-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,124</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_407_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i01_maNIEzQpk_zFjzld0Sqc3b" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Loss on disposal of fixed assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,160</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-012023-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">59,807</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzQpk_zaSlUgsF4uc6" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Interest income, net</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,642</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">561,328</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzQpk_maILFCOzy2C_zJorUERS0H29" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>TOTAL OTHER INCOME</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,491</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">496,397</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_iT_mtILFCOzy2C_maNILzwpS_zCoN0SXCwnvj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>LOSS BEFORE TAXES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2024-01-01to2024-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,063,740</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2023-01-012023-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,773,582</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzwpS_zqGRojx2Impk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Income tax expense</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,893</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,967,480</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_iT_mtNILzwpS_zYVe1qpUuWGj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET LOSS</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,066,633</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,741,062</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareAbstract_iB_zicStFbvO4p9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET LOSS PER SHARE</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zLEwmdZ40ju7" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.30</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_402_eus-gaap--EarningsPerShareDiluted_pid_uUSDPShares_zRjW4SuMe328" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.30</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zEE9XzOFBwqg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_zu9xIlOR65Q3" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Basic</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,802,701</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,601,346</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_zCL6LngEHd64" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Diluted</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,802,701</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,601,346</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 36 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Stockholders_Equity"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_301_114_zJZiO3KrPPb8" summary="xdx: Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 29%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zMkgqDVqhts6" style="width: 7%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_ziNmh5LhXeEb" style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zakyJU4v9og7" style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zjFBRozobb8d" style="width: 9%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_4B2_znrHhhujzt5h" style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Total</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="4" style="border-bottom: black 1pt solid; text-align: center"><b>Common Stock</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Paid-in</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Retained</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Treasury</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Stockholders&#8217;</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Amount</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Capital</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>(Deficit)</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Stock</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Equity</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43E_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zNJMUo0WeIH9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, DECEMBER 31, 2022</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrvB0QB0F9Se" title="Beginning balance (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,861,891</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,619</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,252,117</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,571,211</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000238" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,325,963</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_ecustom--StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity_z18uauHTk681" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Accrued compensation paid in shares</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzQMSp2eRGud" title="Accrued compensation paid (in shares)" style="text-align: right"><ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,973</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,280</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,069</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2023-01-012023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446,349</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zCNUlGyK4Via" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,940,720</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,940,720</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zOkB4v3L7D3i" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to restricted stock awards</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts_pid_uShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfVUfDhAJZCl" title="Compensation expense related to restricted stock awards (in shares)" style="text-align: right"><ix:nonFraction name="krmd:AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">380,801</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,801</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodUponOptionExercised_z8XQqZBk6PJh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance upon options exercised</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zNu9kZ3SBGDe" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000273" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,741,062</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,741,062</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zi9jhBxKmF8a" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, DECEMBER 31, 2023</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfgHERsa5V3e" title="Beginning balance (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,089,864</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,899</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,018,707</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,312,273</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,843,562</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,353,771</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_ecustom--StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity_zBbUBendeOPb" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Accrued compensation paid in shares</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcCilF8LMfse" title="Accrued compensation paid (in shares)" style="text-align: right"><ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">191,946</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,919</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,909</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" contextRef="From2024-01-01to2024-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">454,828</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zcf7PXzkDztk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to stock options</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,509,544</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-01to2024-12-31" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,509,544</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zI8KWLUJWQag" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Compensation expense related to restricted stock awards</td>
    <td>&#160;</td>
    <td id="xdx_984_ecustom--AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGCkyUfiFrh5" title="Compensation expense related to restricted stock awards (in shares)" style="text-align: right"><ix:nonFraction name="krmd:AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000305" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,061</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">551</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,369</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,932</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528,988</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockIssuedDuringPeriodUponOptionExercised_zimzOXBCgTS6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance upon options exercised</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesUponOptionExercised_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrhPP0UB41R7" title="Issuance upon options exercised (in shares)" style="text-align: right"><ix:nonFraction name="krmd:StockIssuedDuringPeriodSharesUponOptionExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,746</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:StockIssuedDuringPeriodUponOptionExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000311" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards_zwGfC0brRtS4" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Payments for taxes related to net share settlement of equity awards</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000316" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,447</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" contextRef="From2024-01-01to2024-12-31" id="Fact000319" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,447</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zRVKJEazaZBk" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Issuance of warrants</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,221</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-01to2024-12-31" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,221</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zudGHbodvcfg" style="vertical-align: bottom">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Net loss</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,066,633</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000331" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,066,633</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_430_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zbFWEHabIRK" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">BALANCE, DECEMBER 31, 2024</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1WGw0mIy542" title="Ending balance (in shares)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000339" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,377,617</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,776</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,581,303</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,378,906</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,882,494</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,813,679</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 37 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Cash_Flows"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" id="xdx_307_112_zKLwwICZxw31" summary="xdx: Statement - STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 72%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_496_20240101__20241231_z4qiN3Skhnh3" style="width: 10%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_49E_20230101__20231231_zQUzGMRD5XQc" style="width: 10%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>For the Years Ended<br/>
December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_znDBQQuwkft3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_i01_maNCPBUzPKn_zam0EQPAxxc1" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Net Loss</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,066,633</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000345" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,741,062</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z27ohJFXa8Vh" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Adjustments to reconcile net loss to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_maCz7fK_maNCPBUzPKn_zSV9nmIbCQ76" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Stock-based compensation expense and warrant expense</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,623,920</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,768,870</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepreciationDepletionAndAmortization_i02_maCz7fK_maNCPBUzPKn_zYVGn4dnVCBa" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Depreciation and amortization</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">888,473</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">870,390</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GainLossOnSaleOfOtherAssets_i02N_di_msNCPBUzPKn_zkAKN67PJBae">
    <td style="vertical-align: bottom; padding-left: 41.15pt; text-indent: -8.25pt">Loss on disposal of fixed assets</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000356" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,160</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">59,807</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeTaxesAndTaxCredits_i02_maNCPBUzPKn_zaCWpkq8t0jl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Deferred income taxes, net of allowance for non-realization of deferred tax asset</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2023-01-012023-12-31" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,967,480</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--NoncashLeaseAdjustments_i02_maNCPBUzPKn_zqce1KhLmGVb" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Non-cash leasing charges</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:NoncashLeaseAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,394</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:NoncashLeaseAdjustments" contextRef="From2023-01-012023-12-31" id="Fact000363" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,988</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zTT25ALl7Ard" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msNCPBUzPKn_zP7F2lfvDCAf" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in accounts receivable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,675,540</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,327</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msNCPBUzPKn_zo3DlzMUDOy6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease in inventory</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-01to2024-12-31" id="Fact000371" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">677,632</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-12-31" id="Fact000372" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,923,566</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOtherReceivables_i02N_di_msNCPBUzPKn_zIiwXMwXty2e" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease in other receivables</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2023-01-012023-12-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">943,507</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msNCPBUzPKn_zf1sc6naJgrb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease in prepaid expenses and other assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">220,133</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000378" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">242,599</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maNCPBUzPKn_zb7CvgU9r5mc" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in accounts payable</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">674,776</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,416,606</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i02_maNCPBUzPKn_zfgoQ1PqTK0a" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in accrued payroll and related taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,460</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,458</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i02_maNCPBUzPKn_z7bz9m9po6j9" style="vertical-align: bottom">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Decrease in other liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000386" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">483,250</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,183</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i02_maNCPBUzPKn_zQ6gzu0atbA3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.8in; text-indent: -8.25pt">Increase in accrued expenses</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000389" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,212,757</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000390" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,178,514</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzPKn_maCCERCzoAE_z7CmxrQqAP2j" style="vertical-align: bottom">
    <td>NET CASH USED IN OPERATING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000392" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">319,718</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000393" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,892,553</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zxBvcE28ufm4" style="vertical-align: bottom">
    <td>CASH FLOWS FROM INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToAcquireProductiveAssets_i01N_di_msNCPBUz71e_zHvQVUffzEs6" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Purchases of property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,297,427</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="From2023-01-012023-12-31" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">782,949</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maNCPBUz71e_zD5k6ggw3Q47" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Proceeds on disposals of property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,500</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUz71e_zD2TuCuzQH9k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Purchases of intangible assets</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,115</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,648</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUz71e_maCCERCzoAE_zdFXueYOClQb" style="vertical-align: bottom">
    <td>NET CASH USED IN INVESTING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000407" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,333,042</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">814,597</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zRoKdpmAQWY3" style="vertical-align: bottom">
    <td>CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--BorrowingsFromIndebtedness_i01_maNCPBUz4Cw_zkj5V9fVVFRi" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Borrowings from insurance finance indebtedness</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:BorrowingsFromIndebtedness" contextRef="From2024-01-01to2024-12-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">487,516</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:BorrowingsFromIndebtedness" contextRef="From2023-01-012023-12-31" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">565,172</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_ecustom--PaymentsOnIndebtedness_i01N_di_msNCPBUz4Cw_zqrP2bK9J3A4" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Payments on insurance finance indebtedness</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsOnIndebtedness" contextRef="From2024-01-01to2024-12-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">530,707</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:PaymentsOnIndebtedness" contextRef="From2023-01-012023-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">684,123</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsForOtherTaxes_i01N_di_msNCPBUz4Cw_z1xY6kNBt8h8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Payments for taxes related to net share settlement of equity awards</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForOtherTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact000419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,379</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msNCPBUz4Cw_zi4ctXfz1aWd" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Payments on finance lease liability</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-01to2024-12-31" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,963</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-012023-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,916</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivities_mtNCPBUz4Cw_maCCERCzoAE_zhL9BjGfqLTe" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET CASH USED IN FINANCING ACTIVITIES</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000425" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">248,533</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">218,867</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzoAE_zEoTaIIR5HJ9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NET DECREASE IN CASH AND CASH EQUIVALENTS</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000428" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,901,293</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,926,017</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zJW92DEInS6e" style="vertical-align: bottom">
    <td>CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,482,240</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,408,257</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zXgH3Kl04Tx8" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>CASH AND CASH EQUIVALENTS, END OF YEAR</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,580,947</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,482,240</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zklMKBnKV5Te" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Supplemental Information</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_ecustom--CashPaidDuringPeriodsForAbstract_iB_zAtEe3EsQeWc" style="vertical-align: bottom">
    <td style="padding-left: 24.7pt; text-indent: -8.25pt">Cash paid during the years for:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestPaidNet_i01_zKv1QZxnubeb" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Interest</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,934</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,832</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxesPaidNet_i01_zIHwUJoXwnpd" style="vertical-align: bottom">
    <td style="padding-left: 41.15pt; text-indent: -8.25pt">Income taxes</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,160</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying Notes to Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 38 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Notes_To_Financial_Statements"></span><b>KORU MEDICAL SYSTEMS, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000449" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zE6OBrRPhpjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_829_zJm2vJrCg8qh">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000451" name="us-gaap:NatureOfOperations"><p id="xdx_847_eus-gaap--NatureOfOperations_zIjNYMYmOIyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zPEmyeNaHM82">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20241231_z9Agcpgdz5L3" title="Number of segment::XDX::1">one</span> segment.</p>

</ix:nonNumeric><p id="xdx_856_zkmHf5d6gWia" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000455" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zXI2Uody1Zmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zF8Mklpghykf">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain
liability balances within the accompanying December 31, 2023 balance sheet have been reclassified to conform to current period presentation.
There were no changes to the Company&#8217;s results of operations as a result of the reclassification.</p>

</ix:nonNumeric><p id="xdx_852_z5V4AxgymMwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000457" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPMBUvrY36ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zEwql3bDypEd">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;As of December
31, 2024 the Company held cash and cash-equivalents of $<span id="xdx_902_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20241231_zA7VaEMmx5a5" title="Investment securities treasury bill"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="From2024-01-01to2024-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">9.6</ix:nonFraction></span> million, the majority of which was held in a secured US-treasury money market
mutual fund.</p>

</ix:nonNumeric><p id="xdx_851_zxPBRBMqpZn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000461" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zhTKv9KfM2ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zLCvUJtAaI5k">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

</ix:nonNumeric><p id="xdx_854_ztiAij2XIY6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000463" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFuMhSKxU9eb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_z7BkJOfGVajg">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_za08LPcqfXFa" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0465">6</span></span> to <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zCPUt66Qym8f" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0467">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2024 and 2023 was $<span id="xdx_904_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20240101__20241231_zr2imeJVZbW4" title="Amortization expense of intangible assets"><ix:nonFraction name="krmd:AmortizationOfIntangibleAssets1" contextRef="From2024-01-01to2024-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,197</ix:nonFraction></span> and
$<span id="xdx_90F_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20230101__20231231_zbHzPE1Q4Ca4" title="Amortization expense of intangible assets"><ix:nonFraction name="krmd:AmortizationOfIntangibleAssets1" contextRef="From2023-01-012023-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,469</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000473" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_89C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zlKNDwImuqD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_z4bie2HRZKcl">The estimated amortization expense for the succeeding years for the intangible
assets is approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_49C_20241231_zEiqJoSjF1A8" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zxe0WBrGvaWl" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 68%">2025</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">$</td>
    <td style="vertical-align: bottom; width: 24%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,766</ix:nonFraction></td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEB0xT345B19" style="vertical-align: bottom; background-color: white">
    <td>2026</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,969</ix:nonFraction></td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_znbomvaqq1J5" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,620</ix:nonFraction></td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zGkaPxMQjcj4" style="background-color: white">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,620</ix:nonFraction></td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_z8B0JiWwcTt3" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2029</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2024-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,644</ix:nonFraction></td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zsaAdOylyFh7" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2024-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,660</ix:nonFraction></td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zWurP3il377b" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">730,279</ix:nonFraction></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zC0wOOf9B20f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_853_zSMzeSVnJ7s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<ix:exclude><div id="xdx_23B_z4t3foZgXyc4">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 39 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000490" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zTTCQ9fSGV86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_z9SkIaTMXpW">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company accounts for deferred income taxes using the asset and liability
method. Under this method, deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and
their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Temporary differences
are then measured using the enacted tax rates and laws. Determining the appropriate amount of valuation allowance requires management
exercise judgement about future operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes. After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence, we have
a recorded valuation allowance of $<span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dxL_c20241231_ze1iPjfdHWS1" title="Valuation allowance::XDX::7080843"><span style="-sec-ix-hidden: xdx2ixbrl0492">7.1</span></span> million against our net deferred tax assets as of the year ended December 31, 2024. As we continue
to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction
of the valuation allowance in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zdwN7sWFQ5wa" title="Statutory rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%, including U.S. federal R&amp;D credits, U.S. state tax rates, stock-based compensation and changes in our valuation
allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We account for uncertain tax positions in accordance with authoritative
guidance which prescribes a minimum recognition threshold a tax position is required to meet before being recognized in the financial
statements. Our evaluations of tax positions consider various factors including, but not limited to, changes in tax law, the measurement
of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained
during in-process audit activities and changes in facts or circumstances related to a tax position. We accrue interest and penalties related
to unrecognized tax benefits as a component of income tax expense recorded in continuing operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2021 are no longer subject to examination by tax authorities.&#160;</p>

</ix:nonNumeric><p id="xdx_85C_zLzzV10P8xx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000496" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKAkrqmhtghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zMd54PBkEcgb">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziwyiynIzVcl" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0498">3</span></span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zV27rsSADj18" title="Estimated useful lives of property and equipment::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0500">10</span></span> years for furniture
and office equipment, <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MinimumMember_zY1pIaZnUv55" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0502">3</span></span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MaximumMember_zdCfLRbC0TG5" title="Estimated useful lives of property and equipment::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0504">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2024
and 2023 was $<span id="xdx_900_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20240101__20241231_zUHezZUXtQmh" title="Depreciation and amortization, property and equipment"><ix:nonFraction name="krmd:DepreciationAndAmortizationPropertyAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,690</ix:nonFraction></span> and $<span id="xdx_905_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20230101__20231231_zBuvLy7atMcl" title="Depreciation and amortization, property and equipment"><ix:nonFraction name="krmd:DepreciationAndAmortizationPropertyAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,921</ix:nonFraction></span>, respectively.</p>

</ix:nonNumeric><p id="xdx_854_z5VZBtLJoxSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000510" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzHwS4V0OxCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zwEKGtyX6Hrk">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are recognized as compensation expense at their grant date fair value. &#160;The entire compensation expense
of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of restricted stock awards with
time-based vesting were estimated on the date of grant at the current stock price. The fair value of restricted stock awards vesting at
certain annual sales growth thresholds were estimated as of the date of Board acknowledgement of the achievement, at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.</p>

</ix:nonNumeric><p id="xdx_858_zVEdXzkY4aX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><div id="xdx_233_zIsQc41Rvo5e">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 40 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000513" name="us-gaap:UseOfEstimates"><p id="xdx_84F_eus-gaap--UseOfEstimates_za5euHsSBPii" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zaH4ZQWzPnIl">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

</ix:nonNumeric><p id="xdx_853_zH9cboNB18sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000515" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zoxRGXqDzNff" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_z0NOhPwujbR4">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs are included as a component of cost of goods
sold in the accompanying statements of operations and are generally billed to customers, and included in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#8217;s revenue recognition criteria described above. As of December 31, 2024, 2023, and 2022, the
Company has recognized a contract asset of $<span id="xdx_90D_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20240101__20241231_zwc0JIF7EJw" title="Recognition of contract asset"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,623</ix:nonFraction></span>, $<span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20230101__20231231_zqNMfhOR4r8h" title="Recognition of contract asset"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" contextRef="From2023-01-012023-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, and $<span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220101__20221231_zniF0Iday9i8" title="Recognition of contract asset"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" contextRef="From2022-01-012022-12-31" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively, which is included in other accounts receivable in the accompanying
balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000523" name="krmd:ScheduleOfNetSalesByGeography"><p id="xdx_89C_ecustom--ScheduleOfNetSalesByGeography_zGVwXFyhbU69" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zFIXZoKbmR4l">The following table summarizes net revenues by geography for the years
ended December 31, 2024 and 2023:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2024</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__country--US_zSPYR2n8G7Tb" title="Net Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_country_US" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,506,682</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zoejEZjgXhV8" title="Net Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_country_US" id="Fact000527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,676,039</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zUPdwmzFWczg" title="Net Revenues" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_us-gaap_NonUsMember" id="Fact000529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,139,781</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zDXRR3HKO4Td" title="Net Revenues" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_us-gaap_NonUsMember" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,841,627</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_981_eus-gaap--Revenues_c20240101__20241231_zbZwh9xqUJwe" title="Revenues" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,646,463</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--Revenues_c20230101__20231231_zzXAhVOe69kj" title="Revenues" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,517,666</ix:nonFraction></td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zr0V0PmSMAva" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_85A_zj9qVXV2hvVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><div id="xdx_231_zo7cecXUMfob">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 41 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000538" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9KnPXGgn3Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zwPGs6ic3Pn2">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In November 2023 the FASB issued ASU 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures which expands disclosure requirements to require entities to disclose significant
segment expenses that are regularly provided to or easily computed from information regularly provided to the chief operating decision
maker. This update also requires all annual disclosures currently required by Topic 280 to be disclosed in interim periods. The new disclosure
requirements are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after
December 15, 2024. Early adoption is permitted. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have
be applied retrospectively to all prior periods presented in the financial statements. The adoption of this ASU did not have a significant
impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

</ix:nonNumeric><p id="xdx_858_zQ45ollo4te9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000540" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z2T1YjTQiGhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zusmkpmyusWd">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2024.</p>

</ix:nonNumeric><p id="xdx_855_z0epJ816N1Pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000542" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8c7yIvtxlwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zoBBYZEYriXi">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2024.</p>

</ix:nonNumeric><p id="xdx_853_z242Ey0Ok9j3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_813_zAarGsWeWB31" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 42 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000544" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zBCOEIkhMnzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_82D_zEKk7pT6yog9">INVENTORY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000546" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zwh3E8Jy1kQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_z6AVIjRjjtMg">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20241231_zj9nEQwEmqn7" title="Raw materials and work-in-process" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="AsOf2024-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">827,768</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_z2ywVQWvu4ec" title="Raw materials and work-in-process" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="AsOf2023-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,869,356</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20241231_zOqYworObv5f" title="Finished goods" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2024-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,887</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zfJzVB98T9bl" title="Finished goods" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2023-12-31" id="Fact000554" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,862,525</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--InventoryGross_iI_c20241231_zJhshCFEAsb4" title="Inventory, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2024-12-31" id="Fact000556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,807,655</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zXeaoVqfviA2" title="Inventory, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2023-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,731,881</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20241231_zsgYBOtjmES3" title="Less: reserve for obsolete inventory" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2024-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,986</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zp60um2BJMGb" title="Less: reserve for obsolete inventory" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2023-12-31" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,580</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--InventoryNet_iI_dxL_c20241231_zsliOOC9aaP7" title="Inventory::XDX::2803669" style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">2,803,669</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zMBiLCp47QF9" title="Inventory" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,481,301</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zkM1N2e0wOU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_811_zHP2Gyz3LoUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000568" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z92LaPoupTwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_829_zP4P5CdHFyCd">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000570" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zI8IH58L1Go3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B8_z9ifDzZr2Bj9">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zlhKz8kkYAp6" title="Furniture and office equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember" id="Fact000572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,433,622</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zqEFzpMJUT5c" title="Furniture and office equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,412,164</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zHoBFfDYYB4" title="Leasehold improvements" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,953,653</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWh9j3umFTe1" title="Leasehold improvements" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,953,653</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGjBj2uUc3k1" title="Manufacturing equipment and tooling" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentAndToolingMember" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,376,147</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zjz4hCU1zOdh" title="Manufacturing equipment and tooling" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,193,113</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231_zBh99ndGbZdg" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000584" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,763,422</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zxVhlIxozcBd" title="Total property and equipment" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,558,930</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20241231_zJEAAyST5Pdh" title="Less: accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,472,907</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_z0CQp0IN5rLb" title="Less: accumulated depreciation and amortization" style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,721,273</ix:nonFraction></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20241231_zko1jGRWZyOc" title="Property and equipment, net" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,290,515</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z9VRV9fNbZi2" title="Property and equipment, net" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,837,657</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zJLEi9zCh5gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_810_zMvbKwFW3CW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000596" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zNb9xtVVGiLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8212; <span id="xdx_827_zatQWMez0369">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains three equity incentive plans: the 2015 Stock Option
Plan, as amended (the &#8220;2015 Plan&#8221;), the 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;), and the 2024 Omnibus
Equity Incentive Plan (the &#8220;2024 Plan&#8221;). All equity awards issued to employees, consultants, and non-employee directors on
or after May 9, 2024 are issued from the 2024 Plan. The Company has also issued restricted stock and stock options as employment inducement
awards outside of these plans to its Chief Executive Officer and Chief Commercial Officer, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2015 Plan provides for the grant of incentive
stock options and nonqualified stock options. As of December 31, 2024, there were <span id="xdx_905_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEn2UXG3NOch" title="Shares reserved for outstanding awards"><ix:nonFraction name="krmd:SharesReservedForOutstandingAwards" contextRef="From2024-01-012024-12-31_custom_StockOptionPlan2015Member" id="Fact000598" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,035,000</ix:nonFraction></span> shares reserved for outstanding awards under
the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2021 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units, performance share units, stock appreciation rights, and/or
other equity-based awards to employees, consultants and directors. As of December 31, 2024, there were <span id="xdx_90F_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_zUl60yTpIoRk" title="Shares reserved for outstanding awards"><ix:nonFraction name="krmd:SharesReservedForOutstandingAwards" contextRef="From2024-01-012024-12-31_custom_OmnibusEquityIncentivePlan2021Member" id="Fact000600" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,248</ix:nonFraction></span> shares reserved for outstanding
awards under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2024 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units, performance share units, stock appreciation rights and/or
other equity-based awards to employees, consultants and directors. Awards previously made under the 2015 Plan and the 2021 Plan that are
forfeited or cancelled after May 9, 2024 will be available for issuance under the 2024 Plan. As of December 31, 2024, there were <span id="xdx_903_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2024Member_zNskQuoxduN7" title="Shares reserved for outstanding awards"><ix:nonFraction name="krmd:SharesReservedForOutstandingAwards" contextRef="From2024-01-012024-12-31_custom_OmnibusEquityIncentivePlan2024Member" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">799,254</ix:nonFraction></span>
shares reserved for outstanding awards and <span id="xdx_908_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2024Member_zIuEShzJiuXj" title="Shares available for issuance"><ix:nonFraction name="krmd:SharesAvailableForIssuanceShareBasedCompensation" contextRef="AsOf2024-12-31_custom_OmnibusEquityIncentivePlan2024Member" id="Fact000604" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,320,440</ix:nonFraction></span> shares available for issuance under the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each non-employee director of the Company (other than
the Chairman of the Board) is eligible to receive $<span id="xdx_90C_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zhKnVPjOJ3Yg" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2024-01-012024-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember" id="Fact000606" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">110,000</ix:nonFraction></span> annually, <span id="xdx_905_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zklJTZEg7P07" title="Share-based goods and non-employee services transaction"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember" id="Fact000608" name="us-gaap:DeferredCompensationArrangementsOverallDescription">to be paid quarterly in arrears of $12,500 in cash and $15,000 in
common stock.</ix:nonNumeric></span> &#160;The Chairman of the Board is eligible to receive $<span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20241231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zfeJp96k3Ayh" title="Nonemployee services transaction cost"><ix:nonFraction name="krmd:NonemployeeServicesTransactionCost" contextRef="From2024-01-012024-12-31_srt_BoardOfDirectorsChairmanMember" id="Fact000610" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">140,000</ix:nonFraction></span> annually, <span id="xdx_90D_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20241231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zvG1r0MTT44a" title="Share-based goods and non-employee services transaction"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_BoardOfDirectorsChairmanMember" id="Fact000612" name="us-gaap:DeferredCompensationArrangementsOverallDescription">to be paid quarterly in arrears of $12,500 in
cash and $22,500 in common stock.</ix:nonNumeric></span> Prior to May 9, 2024 in the periods presented in this report, non-employee director equity compensation
was issued from the Non-Employee Director Compensation Plan. From and after May 9, 2024 non-employee director equity compensation is issued
from the 2024 Plan. All payments were and are pro-rated for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Restricted stock units (&#8220;RSUs&#8221;) and performance
share units (&#8220;PSUs&#8221;) are equity classified and measured at the fair value of the underlying stock at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of stock granted for non-employee director
fees are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><div id="xdx_234_znTIUoPqG0Z3">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 43 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the year ended December 31, 2024 and December 31, 2023 was $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zJgTextb4rWi"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_StockOptionPlans2015And2021CombinedMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.44</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zprY8FQR32vb"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.84</ix:nonFraction></span>, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
year ended December 31, 2024 and December 31, 2023. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time-Vesting Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000617" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEzP3t462Obe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the inputs into the Black-Scholes model
for all time-vesting stock options granted during the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_z81utUXWETni" style="display: none; visibility: hidden">Schedule of time based stock options</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 62%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z7nDWzQxEbE7" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zBnJgQaURIBc" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MinimumMember" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">51.9</ix:nonFraction></span>% - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zZvflGU81ZPb" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MaximumMember" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">68.04</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zhFzCu7VVjZi" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000625" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zwTcCzzSLxq4" title="Expected term (in years)::XDX::P6Y2M30D"><span style="-sec-ix-hidden: xdx2ixbrl0627">6.25</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_z2JnIwwK1amj" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MinimumMember" id="Fact000629" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.50</ix:nonFraction></span>% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zQCCh5cKtqDl" title="Risk-free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MaximumMember" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.11</ix:nonFraction></span>%</td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zl7HlYZdhqNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000633" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEE4EiplHgug" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the time-based stock options
outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B7_zohm8epPEc8a" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 74%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zFEqBRxzHFAk" title="Outstanding at beginning (in shares)" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_TimeVestingStockOptionsMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,256,250</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zgTKvRJ5gWa4" title="Outstanding at beginning, price" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_TimeVestingStockOptionsMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.66</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_ziLWLRGjDJg6" title="Granted (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">567,024</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zScpa5HlIP3i" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zCiDtWteBaK8" title="Exercised (in shares)" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">237,500</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z45j1tDPoaN3" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.67</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zVSrDjvQ8Sqb" title="Forfeited (in shares)" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">898,750</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zY6SvUp3s2w7" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.86</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at December 31</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zqjj0UoI2DY4" title="Outstanding at ending (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000651" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,687,024</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zE6vzBKy6exe" title="Outstanding at ending, price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Options exercisable at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zPUclYjx0Uzg" title="Options exercisable (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000655" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,383,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zle0yaJaSZp3" title="Options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z0QpHXsd1I4a" title="Weighted average fair value of options granted during the period" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000659" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.44</ix:nonFraction></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zbfvZ0v9WeB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense for time-vested stock options was
$<span id="xdx_90C_ecustom--StockBasedCompensationStockOptions_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z9VX218HCJp1" title="Stock-based compensation expense"><ix:nonFraction name="krmd:StockBasedCompensationStockOptions" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,530,446</ix:nonFraction></span> for the years ended December 31, 2024. <span id="xdx_906_ecustom--CashReceivedFromOptionExercise_do_uUSD_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zn5UsAaELOlg" title="Cash received from option exercise"><span id="xdx_90E_ecustom--CashReceivedFromOptionExercise_do_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zBoszIMXFhCf" title="Cash received from option exercise"><ix:nonFraction name="krmd:CashReceivedFromOptionExercise" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000663" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="krmd:CashReceivedFromOptionExercise" contextRef="From2023-01-012023-12-31_custom_TimeVestingStockOptionsMember" id="Fact000665" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> cash was received from option exercises for the years ended December 31, 2024, and
2023. As of December 31, 2024, the intrinsic value of all time-based stock options was $<span id="xdx_901_ecustom--StockbasedCompensationIntrinsicValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zg5TTd0CzhSe" title="Stock-based compensation intrinsic value"><ix:nonFraction name="krmd:StockbasedCompensationIntrinsicValue" contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,085,186</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000669" name="krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_z95sK4WPWlc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to time-based stock
options outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_znHDlpGsuEmc" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.08-$3.98</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z97F722reGXj" title="Number outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,687,024</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zROvmVLqahJ6" title="Weighted average remaining contractual life::XDX::P7Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0673">7.4</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zgrvMwPMHfo" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zhGByk2yn2Ol" title="Number exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member" id="Fact000677" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,383,750</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2eronAeslml" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.40</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zGQgcd8mQcK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, there was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zFUy73hnfAJd" title="Total unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember" id="Fact000681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,427,181</ix:nonFraction></span> of total unrecognized compensation
cost related to unvested share-based stock compensation awards granted under the Plans. &#160;That cost is expected to be recognized over
a weighted-average period of 25 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><div id="xdx_239_zgCWLYFfJfUf">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 44 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Performance-Vesting Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000684" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"><p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zpHtCUdjQQGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_z9KwfiUsN051">The following table summarizes the activities for our unvested performance-vesting
stock option awards for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 67%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zawJhSm0C2J1" title="Unvested at beginning, shares" style="width: 13%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2023-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000686" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zfN7MUutp6A8" title="Unvested at beginning, price" style="width: 16%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000688" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zD47iwi6517l" title="Granted, shares" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000690" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zuKldYTbr4ue" title="Granted, price" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000692" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zsqIeO74Wx38" title="Vested, shares" style="text-align: right">(<ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">22,000</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zAKjer81Fvxf" title="Vested, price" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000696" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zvd4lDWavMR2" title="Forfeited/canceled, shares" style="text-align: right">(<ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000698" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">44,666</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_z1u2fXXBwMI2" title="Forfeited/canceled, price" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000700" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zlrGowkjmAtl" title="Unvested at ending, shares" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions" contextRef="AsOf2024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000702" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,334</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zSX1C8vq8yD" title="Unvested at ending, price" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_z7ETHM3OOFjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense for performance-vesting stock options
was $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zSw9yLBPqAla" title="Total stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,778</ix:nonFraction></span> year ended December 31, 2024. <span id="xdx_90D_ecustom--CashReceivedFromOptionExercise_do_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zdUJzZ4QoW42" title="Cash received from option exercise"><ix:nonFraction name="krmd:CashReceivedFromOptionExercise" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000708" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></span> cash was received from option exercises for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, there was $<span id="xdx_90E_ecustom--UnrecognizedCompensationCost_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zvu37fbaOjtd" title="Unrecognized compensation cost"><ix:nonFraction name="krmd:UnrecognizedCompensationCost" contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember" id="Fact000710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,206</ix:nonFraction></span> of unrecognized compensation
cost related to unvested employee performance options. This amount is expected to be recognized over a weighted-average period of 36 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Awards, RSUs, and PSUs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000712" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zn92eN7g2kDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zd7DOStXgaB9">The following table summarizes the activities for our unvested restricted
stock awards, RSUs, and PSUs for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 67%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zjqN8brKVLnh" title="Outstanding at beginning, shares" style="width: 13%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">904,496</ix:nonFraction></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zoR0DmgcChJ7" title="Outstanding at beginning, price" style="width: 16%; text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.77</ix:nonFraction></td>
    <td style="width: 0%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zDY3M1ABIITf" title="Granted, shares" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">458,975</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zm7cngsSnVIf" title="Granted, price" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember" id="Fact000720" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.20</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zQAO4jZTtfvb" title="Vested, shares" style="text-align: right">(<ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember" id="Fact000722" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">81,789</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8jxzHMwGn72" title="Vested, price" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.45</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8maZvFHhjUb" title="Forfeited/canceled, shares" style="text-align: right">(<ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">11,745</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_znpAADdIu6v" title="Forfeited/canceled, price" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember" id="Fact000728" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.30</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zlYBBTVqFCa6" title="Outstanding at ending, shares" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" contextRef="AsOf2024-12-31_custom_RestrictedStockAwardsMember" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,269,937</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxvGbF9OTN94" title="Outstanding at ending, price" style="text-align: right"><ix:nonFraction name="krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" contextRef="AsOf2024-12-31_custom_RestrictedStockAwardsMember" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zBSTR2OFBOqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense for restricted stock awards, RSUs,
and PSUs was $<span id="xdx_908_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zDyaiEnzCo2j" title="Total stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember" id="Fact000734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">579,519</ix:nonFraction></span> for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, there was $<span id="xdx_90D_ecustom--UnrecognizedCompensationCost_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zg5riYiUfLk9" title="Unrecognized compensation cost"><ix:nonFraction name="krmd:UnrecognizedCompensationCost" contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember" id="Fact000736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">902,625</ix:nonFraction></span> of unrecognized compensation
cost related to unvested employee restricted stock awards, RSUs, and PSUs. This amount is expected to be recognized over a weighted-average
period of 44 months.</p>

</ix:nonNumeric><p id="xdx_81A_zsQYvxVbfnsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000738" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zvqvHLTW2DZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 &#8212; <span id="xdx_820_zvHNPpOezuvc">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 8, 2024, the Company entered into a loan
and security agreement with a large domestic banking institution, as lender, providing for a $<span id="xdx_90D_eus-gaap--LinesOfCreditCurrent_iI_c20240308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZeyCC8DHBch" title="Revolving credit facility"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2024-03-08_custom_DomesticBankLenderMember_us-gaap_RevolvingCreditFacilityMember" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> revolving credit facility and
a $<span id="xdx_900_ecustom--LinesOfCreditCurrent1_iI_c20240308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zJ8IPO4G6zJ9" title="Term loan facility"><ix:nonFraction name="krmd:LinesOfCreditCurrent1" contextRef="AsOf2024-03-08_custom_DomesticBankLenderMember_custom_TermLoanFacilityMember" id="Fact000742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> term loan facility. Borrowings are secured by a first-priority lien on substantially all of the assets of the Company, subject
to customary exceptions. The revolving credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_907_ecustom--DebtInstrumentInterestPaymentTerms_c20240308__20250308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zXTaNVDJjjmj" title="Debt instrument interest payment terms"><ix:nonNumeric contextRef="From2024-03-082025-03-08_custom_DomesticBankLenderMember_us-gaap_RevolvingCreditFacilityMember" id="Fact000744" name="krmd:DebtInstrumentInterestPaymentTerms">Borrowings under the revolving credit facility will bear interest at the
greater of Prime or 6.50%, payable in arrears on a monthly basis and at maturity.</ix:nonNumeric></span> <span id="xdx_901_ecustom--DebtInstrumentInterestPaymentTerms_c20240308__20250308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zN8zPp0ltAob" title="Debt instrument interest payment terms"><ix:nonNumeric contextRef="From2024-03-082025-03-08_custom_DomesticBankLenderMember_custom_TermLoanFacilityMember" id="Fact000746" name="krmd:DebtInstrumentInterestPaymentTerms">Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with our loan financings agreement dated
March 8, 2024, the Company issued common stock warrants to the lender. The fair value of each warrant is estimated on the date of the
grant using the Black-Scholes option-pricing model. All options and warrants are charged against income at their fair value. &#160;The
entire compensation expense of the grant is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><div id="xdx_23F_z0NMp0nLdXK9">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 45 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The loan and security agreement contains customary affirmative covenants,
a financial maintenance covenant that requires the Company to maintain a minimum Adjusted Quick Ratio (defined as the ratio of the Company&#8217;s
(i) unrestricted and unencumbered cash and cash equivalents maintained with the lender and its affiliates, plus eligible accounts receivable,
to (ii) current liabilities) of not less than 1.50 to 1.00 tested on the last day of each month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, there were no outstanding borrowings under the
term loan nor the revolving credit facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 1, 2024, the Company renewed its commercial insurance premium
finance and security agreement with its insurance provider for the insurance period covering July 1, 2024 through June 30, 2025. As of
December 31, 2024, the aggregate principal amount of the note was $<span id="xdx_90F_eus-gaap--DebtInstrumentIssuedPrincipal_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zfioO21ApDFa" title="Aggregate principal amount of note"><ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="From2024-01-012024-12-31_custom_SecurityAgreementMember" id="Fact000749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,152</ix:nonFraction></span>. The note bears an annual interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zgLLImB8B5X3"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-12-31_custom_SecurityAgreementMember" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.5</ix:nonFraction></span>%. The Company
retains the right to terminate the agreement at any time and pay the remaining balance in full along with a minimal penalty.</p>

</ix:nonNumeric><p id="xdx_817_zN6JYOdhFt58" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000752" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zvFT6gwFiLb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_821_zHrNLnyMKtn7">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office, vehicles, and computer equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#8220;Operating lease right-of-use
assets&#8221; and lease liabilities recognized in &#8220;Operating lease liability &#8211; current&#8221; and &#8220;Operating lease liability,
net of current portion.&#8221; Finance leases are accounted for on the balance sheets recognized in &#8220;Property and equipment, net&#8221;
and lease liabilities recognized in &#8220;Finance lease liability &#8211; current&#8221; and &#8220;Finance lease liability, net of current
portion.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000754" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zuwSL6AIJcy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zmEBGrjkD0t7">The components of lease expense were as follows:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 57%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_492_20240101__20241231_zShb2ZhqBko6" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 3%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_492_20230101__20231231_zPEyZuPWSlM4" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zifrdolfisua" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">487,960</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">448,630</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zKKYkZk8XH6l" style="vertical-align: bottom; background-color: white">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,952</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,483</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zZuEkMCA2foc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,912</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">579,113</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_z9Yc3HBZd6dk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zOL87A1XofA2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,585</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-01-012023-12-31" id="Fact000769" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,566</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zR44tk9uxsAj" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000771" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,896</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,343</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zCk1pqkFSpZ3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact000774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,481</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="krmd:FinanceLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact000775" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,909</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zhTW50IBbTyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000777" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><p id="xdx_896_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHtI5UDOZb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_z2rBG3vO53E1">Supplemental cash flow information related to leases was as follows:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 71.96%">&#160;</td>
    <td style="width: 0.98%">&#160;</td>
    <td style="width: 1.06%; text-align: center">&#160;</td>
    <td id="xdx_492_20240101__20241231_zAGVL7urrDW8" style="width: 10.98%; text-align: center">&#160;</td>
    <td style="width: 1.98%; text-align: center">&#160;</td>
    <td style="width: 1.06%; text-align: center">&#160;</td>
    <td id="xdx_492_20230101__20231231_zzVWBgMzviUh" style="width: 10.98%; text-align: center">&#160;</td>
    <td style="width: 0.98%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zyCsZUvoFrM5" style="vertical-align: bottom; background-color: white">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">501,214</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact000783" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,104</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zKYp2GHfNZm" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,437</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2023-01-012023-12-31" id="Fact000786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,259</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zaOu4Bpqu8Wi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><div id="xdx_23F_z9xwHSdXcCde">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 46 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000789" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><p id="xdx_896_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z1PIw2sIUuV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_z0Muv5NOao1h">Supplemental information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 58%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><b>December 31,<br/>
2024</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: top; width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20241231_zmIb4dGEugo2" title="Operating leases term::XDX::P5Y1M6D"><span style="-sec-ix-hidden: xdx2ixbrl0791">5.1</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zF5FxvE3qPud" title="Operating leases term::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0793">6.9</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20241231_zXFttH55OXo7" title="Finance leases  term::XDX::P2Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0795">2.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zMzK1h0En1D1" title="Operating leases term::XDX::P3Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0797">3.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zD4Wg9VePVna" title="Operating leases discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2024-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.52</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zQTmoa3PK0X5" title="Operating leases discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2023-12-31" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.76</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zFxOZJ43fHoc" title="Finance leases discount rate"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2024-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.34</ix:nonFraction></span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_905_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z5KU3gcUM807" title="Finance leases discount rate"><ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" contextRef="AsOf2023-12-31" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.19</ix:nonFraction></span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zKOEu6GCg5Dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000807" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zwjrDeZbopqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zYzR4mV4G5fj">Maturities of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zTDTK8n3t875" title="2025 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000809" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533,979</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zjUsCnD4icoh" title="2025 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,437</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zH9ljjshPew4" title="2026 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533,979</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zT12UntsoyB3" title="2026 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,437</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zwmfrBeflmF" title="2027 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact000817" format="ixt:numdotdecimal" decimals="0" unitRef="USD">533,979</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zl2F75onMYH5" title="2027 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,194</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20241231_z9NnOEa1yyJ2" title="2028 - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-12-31" id="Fact000821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520,985</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20241231_zPpCYm5GLIAk" title="2028 - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-12-31" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,181</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_z1nEpK0z5Mo4" title="Thereafter - Operating Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2024-12-31" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,833,603</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_zonC4EG7RFYl" title="Thereafter - Finance Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20241231_zf3p9eKVuO16" title="Total undiscounted lease payments - Operating Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal" contextRef="AsOf2024-12-31" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,956,525</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20241231_zPrhrwrXfTOg" title="Total undiscounted lease payments - Finance Leases" style="vertical-align: bottom; text-align: right"><ix:nonFraction name="krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" contextRef="AsOf2024-12-31" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,248</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_989_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20241231_zwRLoURqG6r6" title="Less: imputed interest - Operating Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeOperatingLeaseImputedInterest" contextRef="AsOf2024-12-31" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">555,864</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20241231_zxrD62runzac" title="Less: imputed interest - Finance Leases" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(<ix:nonFraction name="krmd:LesseeFinancingLeaseImputedInterest" contextRef="AsOf2024-12-31" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,048</ix:nonFraction></td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_zNhTlG0JzTd2" title="Total lease liabilities - Operating Leases" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,400,661</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_980_eus-gaap--FinanceLeaseLiability_iI_c20241231_zCdoExEUMXUk" title="Total lease liabilities - Finance Leases" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,200</ix:nonFraction></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AB_zPUoi9iI1osl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_819_zCVOmfyO1dmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000841" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zyiW3AezfoH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_821_zcZFKW4kFts2">FEDERAL AND STATE INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000843" name="krmd:ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss"><p id="xdx_894_ecustom--ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss_zObaKHPM16Pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Domestic and international pre-tax income/(loss) consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zQewyfOXe396" style="display: none; visibility: hidden">Schedule of Components of Domestic and International Pre-Tax Income (Loss)</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zO5tODJ7fD48" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zDEUY1Lei53f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zrYg1RyKPMd5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">United States</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 1.26%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2024-01-01to2024-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,063,740</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; width: 3.92%">)</td>
    <td style="border-bottom: black 2.25pt double; width: 1.26%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-01-012023-12-31" id="Fact000846" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,733,582</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double; width: 0.92%">)</td></tr>
  <tr id="xdx_403_ecustom--LossBeforeIncomeTaxes_zdPRysbo8mNg" style="vertical-align: bottom">
    <td>Loss before income taxes</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:LossBeforeIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact000848" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,063,740</ix:nonFraction></td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:LossBeforeIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact000849" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,733,582</ix:nonFraction></td>
    <td>)</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zrKxQCjbhrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000851" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zg0KcHaDK7P5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense attributable to operations is comprised of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zH40JnISYQZe" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zGYKeQcDzzm9" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zE7qsNHKSDmk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zzbxTfiiFmX1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Current:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_zvU7WS6IzcRd" style="vertical-align: bottom; background-color: white">
    <td style="width: 59.94%">Federal</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">&#8212;</span></td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zgZXNN6pjf4k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact000859" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,893</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentForeignTaxExpenseBenefit_z9jymh33Vcd3" style="vertical-align: bottom; background-color: white">
    <td>International</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentIncomeTaxExpenseBenefit_zpL6pAzdmcz4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact000865" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,893</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zWdkpggOLgQh" style="vertical-align: bottom; background-color: white">
    <td>Deferred:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_z3gOjbuiqj8k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Federal</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000872" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,967,480</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_z3NdOK6ATzC2" style="vertical-align: bottom; background-color: white">
    <td>State</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zMP0YVoZZ05k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>International</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_zEf2RdW2QJX2" style="vertical-align: bottom; background-color: white">
    <td>Total Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000881" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,967,480</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iN_di_z6cJ0yEb8JUl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income Tax Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact000883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,893</ix:nonFraction></td>
    <td style="border-bottom: White 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,967,480</ix:nonFraction></td>
    <td style="border-bottom: White 2.25pt double">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zTClWbRmBpMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><div id="xdx_234_zs1XfrIM3vg8">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 47 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000887" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0c5Ey4UrK04" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes reflect the net tax effects of temporary differences
between carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant
components of our deferred tax assets and liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zkToTvMEmEcb" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zY8Mtci61Uf4" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_z5b5fugGZIv6" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsAbstract_iB_zhvnf78rDXC1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">Deferred Tax Assets:</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">&#160;</td>
    <td style="width: 15.9%; text-align: right">&#160;</td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">&#160;</td>
    <td style="width: 15.9%; text-align: right">&#160;</td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsNetOperatingLoss_iI_zhkUmSrw8zD" style="vertical-align: bottom; background-color: white">
    <td>Net Operating Loss</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:DeferredTaxAssetsNetOperatingLoss" contextRef="AsOf2024-12-31" id="Fact000892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,025,905</ix:nonFraction></td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:DeferredTaxAssetsNetOperatingLoss" contextRef="AsOf2023-12-31" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,566,630</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsCredits_iI_z1rolL4edE12" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Credits</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:DeferredTaxAssetsCredits" contextRef="AsOf2024-12-31" id="Fact000895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,598</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:DeferredTaxAssetsCredits" contextRef="AsOf2023-12-31" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,030</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zGceoJacp2J6" style="vertical-align: bottom; background-color: white">
    <td>Capitalized Research Costs</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,451,496</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact000899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,045,616</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsNQOAndRSAStockOptions_iI_zkLfJ848c1hg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NQO &amp; RSA Stock Options</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:DeferredTaxAssetsNQOAndRSAStockOptions" contextRef="AsOf2024-12-31" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350,484</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:DeferredTaxAssetsNQOAndRSAStockOptions" contextRef="AsOf2023-12-31" id="Fact000902" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,047,608</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsDeferredLeaseLiability_iI_zLVuaAEQfpFa" style="vertical-align: bottom; background-color: white">
    <td>Deferred Lease Liability</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="krmd:DeferredTaxAssetsDeferredLeaseLiability" contextRef="AsOf2024-12-31" id="Fact000904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">647,446</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0905">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_z0zJkTHTaDbl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Accruals &amp; Reserves</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2024-12-31" id="Fact000907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">712,058</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2023-12-31" id="Fact000908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,923</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_z5GXDNHv8qL1" style="vertical-align: bottom; background-color: white">
    <td>Other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact000910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_zOTE2jpPoh73" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Gross Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact000913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,317,035</ix:nonFraction></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,931,849</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_z2oPP38ljvY2" style="vertical-align: bottom; background-color: white">
    <td>Valuation allowance</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact000916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,080,843</ix:nonFraction></td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact000917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,002,777</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iI_zyNMOInNXXWj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,236,192</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">929,072</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zs3Xn5yHq3fa" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Deferred Tax Liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxLiabilitiesIntangibles_iI_z8Gs9Wca3Ing" style="vertical-align: bottom; background-color: white">
    <td>Intangibles</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DeferredTaxLiabilitiesIntangibles" contextRef="AsOf2024-12-31" id="Fact000925" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,170</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DeferredTaxLiabilitiesIntangibles" contextRef="AsOf2023-12-31" id="Fact000926" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">408,260</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesROUAssets_iI_zYnCif48gjta" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>ROU Assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DeferredTaxLiabilitiesROUAssets" contextRef="AsOf2024-12-31" id="Fact000928" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">538,632</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DeferredTaxLiabilitiesROUAssets" contextRef="AsOf2023-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,511</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFixedAssets_iI_zwEV2O7Q2u4e" style="vertical-align: bottom; background-color: white">
    <td>Fixed Assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DeferredTaxLiabilitiesFixedAssets" contextRef="AsOf2024-12-31" id="Fact000931" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">639,390</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:DeferredTaxLiabilitiesFixedAssets" contextRef="AsOf2023-12-31" id="Fact000932" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">515,300</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNI_di_zlb7iPHNdT2j" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Deferred Tax Liabilities</td>
    <td>&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,236,192</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact000935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">929,071</ix:nonFraction></td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_zn8G5rrZqDl2" style="vertical-align: bottom; background-color: white">
    <td>Net Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_z5tZ5ldOUp7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management regularly assesses the ability to realize deferred tax assets
recorded based upon the weight of available evidence, including such factors as recent earnings history and expected future taxable income
on a jurisdiction by jurisdiction basis. In the event that the Company changes its determination as to the amount of realizable deferred
tax assets, the Company will adjust its valuation allowance with a corresponding impact to the provision for income taxes in the period
in which such determination is made. The Company&#8217;s management believes that, based on a number of factors, it is more likely than
not, that all or some portion of the deferred tax assets will not be realized; and accordingly, for the year ended December 31, 2024 the
Company has provided a full valuation allowance against the Company&#8217;s U.S. net deferred tax assets. The net change in the valuation
allowance for the year ended December 31, 2024 was an increase of $<span id="xdx_90C_ecustom--NetChangeInValuationOfAllowanceOnDeferredTaxAssets_uUSD_c20240101__20241231_zEpkPsQ3yIR7" title="Valuation Allowance on Deferred Tax Assets - Net Change"><ix:nonFraction name="krmd:NetChangeInValuationOfAllowanceOnDeferredTaxAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000940" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,078,066</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, the Company had net operating loss carryforwards
for federal and state income tax purposes of approximately $<span id="xdx_906_ecustom--NetOperatingLossCarryforwardsFederal_iI_c20241231_zwyHmBx8KsQg" title="Net operating loss carryforwards, federal"><ix:nonFraction name="krmd:NetOperatingLossCarryforwardsFederal" contextRef="AsOf2024-12-31" id="Fact000942" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,313,421</ix:nonFraction></span> and $<span id="xdx_907_ecustom--NetOperatingLossCarryforwardsStateAndLocal_iI_c20241231_zkwsTGpuAr7j" title="Net operating loss carryforwards, state"><ix:nonFraction name="krmd:NetOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact000944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,533,499</ix:nonFraction></span>, respectively. The state net operating loss carryforwards
will being to expire in 2041 and our federal net operating loss carryforward will last indefinitely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, the Company had federal and state research credit
carryforwards of approximately $<span id="xdx_900_ecustom--FederalResearchCreditCarryforward_iI_c20241231_zQJ6DKOLWKSl" title="Federal Research Credit Carryforward"><ix:nonFraction name="krmd:FederalResearchCreditCarryforward" contextRef="AsOf2024-12-31" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,598</ix:nonFraction></span> and $<span id="xdx_901_ecustom--StateResearchCreditCarryforward_iI_c20241231_zOv154rWwAud" title="State Research Credit Carryforward"><ix:nonFraction name="krmd:StateResearchCreditCarryforward" contextRef="AsOf2024-12-31" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> respectively. The federal research credit carryforwards will being to expire in 2036.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, and 2023 the Company had no gross unrecognized
tax benefits. The Company&#8217;s policy is to recognize accrued interest and penalties related to unrecognized income tax benefits in
the Provision for income taxes should such amounts occur in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company files income tax returns in the US federal and various state
jurisdictions with varying statutes of limitations. The Company is currently under audit by the Internal Revenue Service for tax year
2022. Tax years 2021 through 2023 are open to examination by major taxing jurisdictions to which the Company is subject.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><div id="xdx_238_z3J2aZOzjla6">

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 48 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#index_to_fs">Index to Financial Statements</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div></ix:exclude>


<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000951" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjg1egs04xI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense differed from the amount computed by applying the federal
statutory income tax rate of 21% to pretax income for the years ended December 31, 2024 and December 31, 2023 as a result of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zgINPoOhGq3i" style="display: none; visibility: hidden">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_z4YQfWbICOEb" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zgx2vGgJ2059" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zzqguLtQVMz9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">Federal tax at statutory rate</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact000953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,272,820</ix:nonFraction></td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,052,452</ix:nonFraction></td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zmqbbaIgZGjj" style="vertical-align: bottom; background-color: white">
    <td>State income taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,595</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--IncomeTaxReconciliationChangeInValuationAllowance_zpoRsDnmFHAd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Valuation allowance</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:IncomeTaxReconciliationChangeInValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact000959" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,078,066</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:IncomeTaxReconciliationChangeInValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact000960" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,002,777</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationDeferredTaxTrueUps_zDBVUNxZcObl" style="vertical-align: bottom; background-color: white">
    <td>Deferred tax true ups</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(<ix:nonFraction name="krmd:IncomeTaxReconciliationDeferredTaxTrueUps" contextRef="From2024-01-01to2024-12-31" id="Fact000962" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">352,653</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationOtherItems_zsfIFUrW7kT4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Other items</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="krmd:IncomeTaxReconciliationOtherItems" contextRef="From2024-01-01to2024-12-31" id="Fact000965" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,589</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="krmd:IncomeTaxReconciliationOtherItems" contextRef="From2023-01-012023-12-31" id="Fact000966" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,155</ix:nonFraction></td>
    <td>)</td></tr>
  <tr id="xdx_408_ecustom--IncomeTaxReconciliationNet_zY58pErxH8tf" style="vertical-align: bottom; background-color: white">
    <td>Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="krmd:IncomeTaxReconciliationNet" contextRef="From2024-01-01to2024-12-31" id="Fact000968" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,893</ix:nonFraction></td>
    <td style="border-bottom: White 2.25pt double">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(<ix:nonFraction name="krmd:IncomeTaxReconciliationNet" contextRef="From2023-01-012023-12-31" id="Fact000969" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,967,480</ix:nonFraction></td>
    <td style="border-bottom: White 2.25pt double">)</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zLBgYoXAwQB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_81E_zCKx9zWFYku8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000971" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zdselpWU5u0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_82D_z3oYUcShVtk7">MAJOR CUSTOMERS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the years ended December 31, 2024 and December 31, 2023, approximately
<span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zE2033bgQBi5"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64</ix:nonFraction></span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zGo0zZOtuQ6i"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">66</ix:nonFraction></span>%, respectively, of the Company&#8217;s net product revenues were derived from three major customers that are distributors.
&#160;As of December 31, 2024 and December 31, 2023, accounts receivable due from the three major customers was $<span id="xdx_90D_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20241231_zhRjBHfBZFVe" title="Account eceivable from customers"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="Fact000975" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">3.6</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20231231_zeqAxBz2J5v4" title="Account eceivable from customers"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="Fact000977" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">2.6</ix:nonFraction></span>
million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.</p>

</ix:nonNumeric><p id="xdx_810_zhcGv3Tpk9i5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000979" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zxnmtdBKr6L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212; <span id="xdx_828_zO0XDe5kk54">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OTHER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), pursuant to which Command has agreed to manufacture and supply
the Company&#8217;s subassemblies, needle sets and tubing products pursuant to the Company&#8217;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#8220;Effective
Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.</p>

</ix:nonNumeric><p id="xdx_814_zttlrnqQXvng" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000981" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjdNlYCjSEy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#8212; <span id="xdx_826_zAMT8YAD0pyi">EMPLOYEE BENEFITS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;<span id="xdx_906_ecustom--DescriptionOfMatchingContribution_c20240101__20241231_zNdRfISiqFC5" title="Description of matching contribution"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000983" name="krmd:DescriptionOfMatchingContribution">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation.</ix:nonNumeric></span> &#160;Company matching expense for the years ended December 31, 2024 and
December 31, 2023 was $<span id="xdx_907_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20240101__20241231_z8vJU3nMIUL" title="Matching expense"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000985" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,915</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zN1rS28jYCQi" title="Matching expense"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2023-01-012023-12-31" id="Fact000987" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,447</ix:nonFraction></span>, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.</p>

</ix:nonNumeric><p id="xdx_813_z3ZMSQhfX305" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<div>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 49 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</div>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000989" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zbgpJk3SvH55" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 &#8212; <span id="xdx_829_zv1Dy7I1Bkc9">SEGMENT DISCLOSURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s operations are based in, and revenues are predominately
derived from, the United States, and business activities are managed on a consolidated basis.&#160; The Company operates in one reportable
segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s Chief Executive Officer is the Chief Operating Decision
Maker (&#8220;CODM&#8221;).&#160; The CODM regularly reviews disaggregated revenue data by product line.&#160; However, consolidated net
income is utilized as a measure of profit and loss to assess the performance of the business and to determine how to allocate resources.&#160;
Significant expenses within net income include cost of goods sold, selling, general and administrative, research and development, and
depreciation and amortization, which are each separately presented on the Company&#8217;s Statements of Operations.&#160; Segment asset
information is not used by the CODM to allocate resources.</p>

</ix:nonNumeric><p id="xdx_817_zE6BzsRG46f4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_9"></span><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_9A"></span><b>ITEM 9A. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">An evaluation was performed under the supervision and with the participation
of our management, including our principal executive officer or CEO, and principal financial officer or CFO, of the effectiveness of our
disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;)) as of December 31, 2024. &#160;Based on that evaluation, our management, including our CEO and CFO, concluded that as of
December 31, 2024, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports
that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
SEC&#8217;s rules and forms, and is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions
regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management of the Company is responsible for establishing and maintaining
adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). &#160;The Company&#8217;s internal
control over financial reporting is a process designed under the supervision of the Company&#8217;s principal executive officer and principal
financial officer, and implemented in conjunction with management and other personnel, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of the Company&#8217;s financial statements for external purposes in accordance with generally
accepted accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There are inherent limitations in the effectiveness of any internal control,
including the possibility of human error and the circumvention or overriding of controls. &#160;Accordingly, even effective internal control
can provide only reasonable assurance with respect to financial statement preparation. Further, because of changes in conditions, the
effectiveness of internal control may vary over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management assessed the effectiveness of the Company&#8217;s internal control
over financial reporting as of December 31, 2024. &#160;This assessment was based on criteria for effective internal control over financial
reporting described in &#8220;Internal Control - Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO). &#160;Based on this assessment, management determined that, as of December 31, 2024, the Company maintained
effective internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There has been no change in our internal control over financial reporting
(as defined in Rule 13a-15(f) under the Exchange Act) during the year ended December 31, 2024, that has materially affected, or that is
reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_9B"></span><b>ITEM 9B. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_903_eecd--Rule10b51ArrAdoptedFlag_dbF_c20240901__20241231_zKimtZjdiM75"><span id="xdx_901_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20240901__20241231_zMHfM5Yoy2D6"><span id="xdx_900_eecd--Rule10b51ArrTrmntdFlag_dbF_c20240901__20241231_zeWmwM7Wc4Ka"><span id="xdx_900_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20240901__20241231_zqiKc9Sj3G1f"><ix:nonNumeric contextRef="From2024-09-012024-12-31" format="ixt:booleanfalse" id="Fact000990" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-09-012024-12-31" format="ixt:booleanfalse" id="Fact000991" name="ecd:NonRule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-09-012024-12-31" format="ixt:booleanfalse" id="Fact000992" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-09-012024-12-31" format="ixt:booleanfalse" id="Fact000993" name="ecd:NonRule10b51ArrTrmntdFlag">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_9C"></span><b>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 50 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_10"></span><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information regarding our executive officers required by Item 10 of Part
III is set forth in Item 1 of Part I &#8220;Business &#8212; Executive Officers.&#8221; &#160;Information required by Item 10 of Part
III regarding our directors and any material changes to the process by which security holders may recommend nominees to the Board of Directors
is included in our Proxy Statement under the caption &#8220;2026 Annual Meeting of Shareholders&#8221; relating to our 2025 Annual Meeting
of Shareholders (&#8220;2025 Proxy Statement&#8221;), which is to be filed no later than 120 days after December 31, 2024, and is incorporated
herein by reference. &#160;Information concerning the composition of the Audit Committee and our Audit Committee financial expert is contained
in our 2025 Proxy Statement under the caption &#8220;The Board and Committees of the Board &#8211; Committee Membership and Function &#8211;
Audit Committee&#8221; and is incorporated herein by reference. Information on beneficial ownership reporting compliance will be contained
under the caption &#8220;Delinquent Section 16(a) Reports&#8221;, if applicable, in our 2025 Proxy Statement and is incorporated herein
by reference. Information relating to our Code of Ethics and to compliance with Section 16(a) of the 1934 Act is set forth in our 2025
Proxy Statement relating to our 2025 Annual Meeting of Shareholders and is incorporated herein by reference. &#160;We intend to disclose
amendments to our Code of Ethics, as well as waivers of the provisions thereof, on our website under the heading &#8220;Investors - Governance&#8221;
at www.korumedical.com. Information about the Company&#8217;s insider trading policy is contained in our 2025 Proxy Statement under the
caption &#8220;Corporate Governance &#8211; <span id="xdx_90C_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20240101__20241231_zGksitl9eGh"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000994" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">Insider Trading Policy</ix:nonNumeric></span>&#8221; and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_11"></span><b>ITEM 11. EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 11 of Part III is included in our Proxy Statement
relating to our 2025 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_12"></span><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 12 of Part III is included in our Proxy Statement
relating to our 2025 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_13"></span><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 13 of Part III is included in our Proxy Statement
relating to our 2025 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_14"></span><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Information required by Item 14 of Part III is included in our Proxy Statement
relating to our 2025 Annual Meeting of Shareholders and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 51 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_15"></span><b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">All financial statement schedules have been omitted because they are not
required, not applicable, not present in amounts sufficient to require submission of the schedule, or the required information is otherwise
included.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following exhibits are filed herewith or incorporated by reference
as part of this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 51.35pt"><span style="font-size: 9.5pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 5.8pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 482.85pt"><span style="font-size: 9.5pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">2.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000302/ex_2-1.htm">Agreement and Plan of Merger by and between KORU Medical Systems, Inc., a New York corporation, and KORU Medical Systems, Inc., a Delaware corporation</a> (incorporated by reference to our Form 8-K filed with the SEC on May 17, 2023).</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">3.1(i)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000302/ex_3-1.htm">Certificate of Incorporation of KORU Medical Systems, Inc. effective May 16, 2023</a> (incorporated by reference to our Form 8-K filed with the SEC on May 17, 2023).</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">3.1(ii)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000302/ex_3-2.htm">Bylaws of KORU Medical Systems, Inc.</a> (incorporated by reference to our Form 8-K filed with the SEC on May 17, 2023).</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">4.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_4-1.htm">Description of Securities</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">10.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169716001008/schedule_14a.htm">2015 Stock Option Plan, as amended</a> (incorporated by reference to the Company&#8217;s Proxy Statement on Schedule 14A filed with the SEC on July 28, 2016).</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">10.2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000196/schedule_14a.htm#Koru2021OmnibusEquityIncentivePlan">2021 Omnibus Equity Incentive Plan</a> (incorporated by reference to the Company&#8217;s Proxy Statement on Schedule 14A filed with the SEC on April 5, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">10.3</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-5.htm">Form of Non-Qualified Stock Option</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">10.4</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-6.htm">Form of Incentive Stock Option</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">10.5</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_10-5.htm">Form of Performance Share Unit Award Agreement</a>**</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">10.6</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_10-6.htm">Form of Restricted Stock Unit Award Agreement</a>**</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">10.7</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_10-7.htm">Non-Employee Director Compensation</a>**</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">10.8</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169720000481/ex_10-1.htm">Manufacturing and Supply Agreement dated as of November 11, 2020 between KORU Medical Systems, Inc. and Command Medical Products</a> (incorporated by reference to the Company&#8217;s Form 10-Q filed with the SEC on November 12, 2020). &#160;Certain information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">10.9</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169721000169/ex_10-15.htm">Employment Agreement effective as of March 15, 2021 between KORU Medical Systems, Inc. and Linda Tharby</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 23, 2021).* &#8224;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">10.10</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169724000314/ex_10-1.htm">Amended and Restated Employment Agreement effective as of July 18, 2024 between KORU Medical Systems, Inc. and Christopher Pazdan</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on July 24, 2024).* &#8224; </span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">10.11</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000377/ex_10-1.htm">Employment Agreement effective as of October 20, 2021 between KORU Medical Systems, Inc. and Thomas Adams</a> (incorporated by reference to the Company&#8217;s Form 10-Q filed with the SEC on August 3, 2022).*</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">10.12</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000429/ex_10-1.htm">First Amendment to Employment Agreement effective as of August 1, 2023 between Thomas Adams and KORU Medical Systems, Inc.</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on August 2, 2023).* &#8224;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">10.13</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169723000567/ex_10-1.htm">Employment Agreement effective as of November 6, 2023 between KORU Medical Systems, Inc. and Kenneth Miller</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on November 8, 2023).*</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>continued</i></p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 52 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: Black 1pt solid; width: 53.15pt"><span style="font-size: 9.5pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 8.25pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 478.6pt"><span style="font-size: 9.5pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">10.14</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169722000133/ex_10-16.htm">Lease dated as of January 21, 2022 between the Company and Breit Industrial Canyon NJ1W05 LLC</a> (incorporated by reference to the Company&#8217;s Form 10-K filed with the SEC on March 2, 2022).</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">10.15</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169724000140/ex_10-1.htm">Loan and Security Agreement dated as of March 8, 2024 by and between KORU Medical Systems, Inc. and HSBC Ventures USA Inc.</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on March 13, 2024).+</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">10.16</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="http://www.sec.gov/Archives/edgar/data/704440/000116169724000140/ex_10-2.htm">Stock Purchase Warrant issued to HSBC Ventures USA Inc. issued on March 8, 2024</a> (incorporated by reference to the Company&#8217;s Form 8-K filed with the SEC on March 13, 2024).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E6E6E6">
    <td><span style="font-size: 9.5pt">19</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt">&#160;<a href="ex_19.htm">KORU Medical Systems, Inc. Insider Trading Policy</a>**</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">23.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_23-1.htm">Consent of MMQ &amp; Associates, P.C.</a> (filed herewith).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">23.2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_23-2.htm">Consent of Cherry Bekaert LLP</a> (filed herewith).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">24.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="#Power_of_Attorney">Power of Attorney</a> (included on the signature pages hereto)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">31.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_31-1.htm">Certification of the Principal Executive Officer of registrant required under Section 302 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">31.2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_31-2.htm">Certification of the Principal Financial Officer of registrant required under Section 302 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">32.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_32-1.htm">Certification of the Principal Executive Officer of registrant required under Section 906 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">32.2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_32-2.htm">Certification of the Principal Financial Officer of registrant required under Section 906 of the Sarbanes-Oxley Act of 2002</a> (filed herewith).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">97</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt"><a href="ex_97.htm">Clawback Policy</a>**</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt">Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt">Inline XBRL Taxonomy Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #E7E6E6">
    <td><span style="font-size: 9.5pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 9.5pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.2in"><span style="font-size: 9.5pt">+</span></td>
    <td style="width: 7.3in"><span style="font-size: 9.5pt">Certain schedules, appendices and/or exhibits to this agreement have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished supplementally to the Securities and Exchange Commission staff upon request.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">*</span></td>
    <td><span style="font-size: 9.5pt">Denotes management compensatory agreement or arrangement.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">&#8224;</span></td>
    <td><span style="font-size: 9.5pt">Certain information has been omitted from this exhibit because it is not material and would be competitively harmful if publicly disclosed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">**</span></td>
    <td><span style="font-size: 9.5pt">Filed herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="Item_16"></span><b>ITEM 16. FORM 10-K SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 53 -</p>


<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/><p style="break-before: always"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><i><a href="#toc">Table of Contents</a></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Signatures"></span><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 50%">KORU MEDICAL SYSTEMS, INC.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Dated: March 12, 2025</td>
    <td><span style="text-decoration: underline">/s/ Linda Tharby</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Linda Tharby</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>President and Chief Executive Officer</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>(Principal Executive Officer)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="Power_of_Attorney"></span><b>POWER OF ATTORNEY</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears
below constitutes and appoints Linda Tharby and Thomas Adams, and each of them, acting individually, as her or his attorney-in-fact, each
with full power of substitution and resubstitution, for her or him and in her or his name, place and stead, in any and all capacities,
to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents
in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and
about the premises, as fully to all intents and purposes as she or he might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, or any of them, or their or her or his substitute or substitutes, may lawfully do or cause to
be done by virtue hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 35%"><b>Signature</b></td>
    <td style="border-bottom: Black 1pt solid; width: 40%"><b>Title</b></td>
    <td style="border-bottom: Black 1pt solid; width: 25%"><b>Date</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="text-decoration: underline">/s/ Linda Tharby<br/>
</span>Linda Tharby</td>
    <td><i>President, Chief Executive Officer, Director<br/>
(Principal Executive Officer)</i></td>
    <td>March 12, 2025</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="text-decoration: underline">/s/ Thomas Adams<br/>
</span>Thomas Adams</td>
    <td><i>Chief Financial Officer and Treasurer<br/>
(Principal Financial Officer and Principal Accounting Officer)</i></td>
    <td>March 12, 2025</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="text-decoration: underline">/s/ R. John Fletcher<br/>
</span>R. John Fletcher</td>
    <td><i>Chairman of the Board and Director</i></td>
    <td>March 12, 2025</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="text-decoration: underline">/s/ Edward Wholihan<br/>
</span>Edward Wholihan</td>
    <td><i>Director</i></td>
    <td>March 12, 2025</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="text-decoration: underline">/s/ Robert A. Casella<br/>
</span>Robert A. Casella</td>
    <td><i>Director</i></td>
    <td>March 12, 2025</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="text-decoration: underline">/s/ Joseph M. Manko, Jr.<br/>
</span>Joseph M. Manko, Jr.</td>
    <td><i>Director</i></td>
    <td>March 12, 2025</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="text-decoration: underline">/s/ Shahriar Matin<br/>
</span>Shahriar Matin</td>
    <td><i>Director</i></td>
    <td>March 12, 2025</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="text-decoration: underline">/s/ Donna French<br/>
</span>Donna French</td>
    <td><i>Director</i></td>
    <td>March 12, 2025</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt TIMES NEW ROMAN, TIMES, SERIF; margin: 0; text-align: center">- 54 -</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 2px; width: 100%"/>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>ex_10-5.htm
<DESCRIPTION>FORM OF PERFORMANCE SHARE UNIT AWARD AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 10.5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>KORU MEDICAL SYSTEMS, INC.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2024 Omnibus Equity Incentive Plan</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>PERFORMANCE SHARE UNIT AWARD AGREEMENT</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to this Performance Share
Unit Award Agreement (this &ldquo;<B><I>Award Agreement</I></B>&rdquo;), and subject to the terms and conditions herein and in the KORU
Medical Systems, Inc. 2024 Omnibus Equity Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;), KORU Medical Systems, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;)
grants an Award of performance share units (&ldquo;<B><I>PSUs</I></B>&rdquo;), as set forth below.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="padding: 1pt 4pt; border: Black 1pt solid">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Summary of Award Terms:</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Name of Grantee</U></B>: ___________ (the &ldquo;<B><I>Grantee</I></B>&rdquo;)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Date of Grant</U></B>: ____________ (the &ldquo;<B><I>Grant
Date</I></B>&rdquo;)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Target Number of Shares</U></B>: ___________
(the &ldquo;<B><I>Target Shares</I></B>&rdquo;)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Performance Period</U></B>: ____________ until
the earlier of (i)&nbsp;____________ and (ii)&nbsp;the date of a Change in Control (&ldquo;<B><I>Performance Period</I></B>&rdquo;)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Vesting/Earn-Out</U></B>: The PSUs shall vest
only upon the achievement of the applicable Performance Goals for the above-referenced Performance Period. Depending on the Company&rsquo;s
actual achievements, the Grantee may earn between 0% and 150% of the Target Shares based on ____________, multiplied by between 0.5 to
1.5 times of the earned Target Shares based on ______________, all as further described on <U>Exhibit A</U> to this Award Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Performance Goals</U></B>: The number of PSUs
earned by the Grantee at the end of the Performance Period, if any, will be determined by the Compensation Committee, in its sole but
reasonable discretion, based on the satisfaction of Performance Goals identified in <U>Exhibit A</U> to this Award Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Settlement Date</U></B>: As soon as practicable
following the end of the Performance Period, but no later than March 15<SUP>th</SUP> following the last day of the Performance Period
(the &ldquo;<B><I>Settlement Date</I></B>&rdquo;).</P>

</DIV>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Capitalized terms used in this
Award Agreement, unless otherwise defined, shall have the meanings set forth in the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of PSUs</U></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Section 9 of the Plan, subject to the terms and conditions of this Award Agreement and the Plan, the Company hereby grants to the Grantee
on the Grant Date an Award of PSUs up to the Target Shares. Each <FONT STYLE="font-family: Times New Roman, Times, Serif">PSU</FONT> represents
the right to receive one <FONT STYLE="font-family: Times New Roman, Times, Serif">share</FONT> of Common Stock, subject to the terms and
conditions set forth in this Agreement and the Plan. The number of PSUs that the Grantee actually earns for the <FONT STYLE="font-family: Times New Roman, Times, Serif">Performance</FONT>
Period (up to a maximum of the Target Shares) will be determined by the level of achievement of the <FONT STYLE="font-family: Times New Roman, Times, Serif">Performance</FONT>
Goals in accordance with <U>Exhibit A</U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 1 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Award, including the Compensation Committee&rsquo;s determination of the satisfaction of Performance Goals, shall be subject to adjustment
by the Compensation Committee (i)&nbsp;as provided in the Plan and (ii)&nbsp;in recognition of unusual or nonrecurring events affecting
the Company or any Affiliate, unusual or nonrecurring events affecting the financial statements of the Company or any Affiliate, or changes
in applicable laws, regulations or accounting principles, if the Compensation Committee determines that such adjustments are appropriate
in order to prevent dilution or enlargement of the Award or necessary to comply with applicable laws, rules, or regulations.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Vesting</U></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Award is subject to the vesting terms set forth in the Summary of Award Terms above, except as may otherwise be provided in this Award
Agreement or in the Plan. Any portion of the Award that does not vest for any reason shall automatically be cancelled and terminated and
be of no further force and effect.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Grantee has a Termination of Affiliation prior to the end of the Performance Period for any reason, then except as provided in an
employment agreement between the Company and the Grantee then in effect, the Grantee shall forfeit, and shall have no further rights or
interest with respect to, any of the PSUs granted hereby that remain unvested, with automatic and immediate effect (after giving effect
to any applicable vesting acceleration provision) as of the date of the Grantee&rsquo;s Termination of Affiliation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement
of Award</U></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or as soon as practicable after the Settlement Date, the Company will, in full satisfaction of the PSUs granted hereby, pay to the Grantee
the amount owed, as determined by the Compensation Committee, in whole shares of Common Stock of the Company (the &ldquo;<B><I>Shares</I></B>&rdquo;),
rounded down to the nearest whole Share.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything herein to the contrary, no transfer of Shares shall become effective until the Company determines that such transfer, issuance,
and delivery is in compliance with all applicable laws, regulations of government authority, and the requirements of any securities exchange
on which Shares may be traded.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee may, as a condition to the issuance of Shares, require the Grantee to make covenants and representations and/or
enter into agreements with the Company to reflect the Grantee&rsquo;s rights and obligations as a stockholder of the Company and any limitations
and restrictions on such Shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transfer of Shares pursuant to this Award Agreement shall be effectuated by an appropriate entry on the books of the Company, the issuance
of certificates representing such shares (bearing such legends as the Compensation Committee deems necessary or desirable), the transfer
of shares to a brokerage account in the name of the Grantee, and/or other appropriate means as determined by the Compensation Committee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
and until any Shares are issued in settlement of the Award on the Settlement Date, the Award shall not confer to the Grantee any rights
or status as a stockholder</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 2 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">of the Company. Unless otherwise determined by the
Compensation Committee, t<FONT STYLE="background-color: white">he Grantee shall not be entitled to any Dividend Equivalents </FONT>declared
with respect to Shares deliverable in connection with vested PSUs which have been earned, but not yet delivered to the Grantee<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Clawback</U>.
</B>If the Company&rsquo;s financial statements are the subject of a restatement (i)&nbsp;due to material non-compliance with any financing
reporting requirement under the federal securities laws, even if such restatement was not the result of any misconduct or error of the
Grantee, (ii)&nbsp;in order to correct errors that were immaterial to previously issued financial statements but would result in a material
misstatement if the errors were left uncorrected in future filings under the federal securities laws; or (iii)&nbsp;to correct errors
that are recognized in the current period covered by the financial statements, then, to the extent permitted by governing law, the Company
shall seek reimbursement of excess incentive compensation paid under the Award to the Grantee for the relevant year(s). In seeking such
reimbursement, the Company shall take any and all actions it deems necessary or convenient in order to ensure the prompt reimbursement
of all excess incentive compensation, taking into consideration the speed and cost of available options and the particular facts and circumstances
of each such reimbursement. In addition, if the Company&rsquo;s financial statements are the subject of a restatement or correction of
error due, in whole or in part, to a Grantee&rsquo;s misconduct, to the extent permitted by governing law, the Company may seek reimbursement
of all incentive compensation paid under the Award to the Grantee for the relevant year(s). For purposes hereof, excess incentive compensation
means the positive difference, if any, between (a)&nbsp;the Fair Market Value of the Shares issued to the Grantee and (b)&nbsp;the Fair
Market Value of the Shares that would have been issued to the Grantee had the achievement of the Performance Goals been calculated based
on the Company&rsquo;s financial statements as restated. In addition, the Company may seek reimbursement of any or all Shares issued pursuant
to this Award Agreement in the event the Board or the Compensation Committee determines, in its reasonable judgment, that the Grantee
has, or has been negligent in connection with the supervision of someone who has, (x)&nbsp;engaged in fraud, misrepresentation, theft,
or embezzlement, (y)&nbsp;engaged in other misconduct (including harassment), or (z)&nbsp;been grossly negligent in connection with the
performance of their duties, in each case resulting in Company reputational or financial harm. The foregoing shall be in addition to the
terms and conditions of the Company&rsquo;s Clawback Policy as posted on its website.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nontransferability</U></B>.
Subject to any exceptions set forth in this Award Agreement or the Plan, during the Restricted Period and until such time as the PSUs
are settled in accordance with Section 3, the PSUs or the rights relating thereto may not be assigned, alienated, pledged, attached, sold,
or otherwise transferred or encumbered by the Grantee. Any attempt to assign, alienate, pledge, attach, sell or otherwise transfer or
encumber the PSUs or the rights relating thereto shall be wholly ineffective and, if any such attempt is made, the PSUs will be forfeited
by the Grantee and all of the Grantee&rsquo;s rights to such units shall immediately terminate without any payment or consideration by
the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grantee
Representations</U></B>. By accepting the Award, the Grantee represents and acknowledges the following:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee has received a copy of the Plan, has reviewed the Plan and this Award Agreement in their entirety, and has had an opportunity
to obtain the advice of independent legal counsel prior to accepting the Award.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 3 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee has had the opportunity to consult with a tax advisor concerning the tax consequences of accepting the Award, and understands
that the Company makes no representation regarding the tax treatment as to any aspect of the Award, including the grant, vesting, settlement,
or conversion of the Award.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee understands that neither the grant of this Award nor the Grantee&rsquo;s participation in the Plan confers any right to continue
in the service of the Company or to receive any other award or amount of compensation, whether under the Plan or otherwise, and no payment
of any award under the Plan will be taken into account in determining any benefits under any pension, retirement, profit sharing, group
insurance, or other benefit plan of the Company or any Affiliate except as otherwise specifically provided in such other plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee consents to the collection, use, and transfer, in electronic or other form, of the Grantee&rsquo;s personal data by the Company,
any Affiliate, the Compensation Committee, and any third party retained to administer the Plan for the exclusive purpose of administering
the Award and Grantee&rsquo;s participation in the Plan. The Grantee agrees to promptly notify the Company of any changes in the Grantee&rsquo;s
name, address, or contact information during the entire period of Plan participation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments</U></B>.
If there is a change in the outstanding Shares due to a stock dividend, split, or consolidation, or a recapitalization, corporate change,
corporate transaction, or other similar event relating to the Company, the Compensation Committee may adjust the number of Target PSUs
subject to the Award in accordance with Section 4.2 of the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Liability and Withholding</U></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: windowtext">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext">The
Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the Grantee
pursuant to the Plan, the amount of any required withholding taxes in respect of the PSUs and to take all such other action as the Compensation
Committee deems necessary to satisfy all obligations for the payment of such withholding taxes. The Compensation Committee may permit
the Grantee to satisfy any federal, state or local tax withholding obligation by any of the following means, or by a combination of such
means: (i)&nbsp;tendering a cash payment; (ii)&nbsp;authorizing the Company to withhold Shares from the Shares otherwise issuable or deliverable
to the Grantee as a result of the vesting of the PSUs; <I>provided, however</I>, that no Shares shall be withheld with a value exceeding
the maximum amount of tax required to be withheld by law; and (iii)&nbsp;delivering to the Company previously owned and unencumbered Shares.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: windowtext">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext">Notwithstanding
any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (&ldquo;<B><I>Tax-Related
Items</I></B>&rdquo;), the ultimate liability for all Tax-Related Items is and remains the Grantee&rsquo;s responsibility and the Company
(i)&nbsp;makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting
or settlement of the PSUs or the subsequent sale of any shares; and (ii)&nbsp;does not commit to structure the PSUs to reduce or eliminate
the Grantee&rsquo;s liability for Tax-Related Items.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 4 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Law</U></B>. The issuance and transfer of Shares shall be subject to compliance by the Company
and the Grantee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock
exchange on which the Company&rsquo;s Shares may be listed. No Shares shall be issued or transferred unless and until any then applicable
requirements of state and federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its
counsel.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U></B>.
Any notice required to be delivered to the Company under this Award Agreement shall be in writing and addressed to the Company at the
Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Grantee under this Award Agreement shall be in
writing and addressed to the Grantee at the Grantee&rsquo;s address as shown in the records of the Company. Either party may designate
another address in writing (or by such other method approved by the Company) from time to time.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U></B>. This Award Agreement will be construed and interpreted in accordance with the laws of the State of Delaware
without regard to conflict of law principles.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interpretation</U></B>.
Any dispute regarding the interpretation of this Award Agreement shall be submitted by the Grantee or the Company to the Compensation
Committee (excluding the Grantee if the Grantee serves on the Compensation Committee) for review. The resolution of such dispute by the
Compensation Committee shall be final and binding on the Grantee and the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>PSUs
Subject to Plan</U></B>. This Award Agreement is subject to the Plan. The terms and provisions of the Plan, as it may be amended from time to time, are hereby
incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of
the Plan, the applicable terms and provisions of the Plan will govern and prevail.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U></B>. The Company may assign any of its rights under this Award Agreement. This Award Agreement will be binding
upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein,
this Award Agreement will be binding upon the Grantee and the Grantee&rsquo;s beneficiaries, executors, administrators and the person(s)
to whom the PSUs may be transferred by will or the laws of descent or distribution.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U></B>.
The invalidity or unenforceability of any provision of the Plan or this Award Agreement shall not affect the validity or enforceability
of any other provision of the Plan or this Award Agreement, and each provision of the Plan and this Award Agreement shall be severable
and enforceable to the extent permitted by law.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Discretionary
Nature of Plan</U></B>. The Plan is discretionary and may be amended, cancelled, or terminated by the Company at any time,
in its discretion. The grant of the PSUs in this Award Agreement does not create any contractual right or other right to receive any PSUs
or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination
of the Plan shall not constitute a change or impairment of the terms and conditions of the Grantee&rsquo;s service to the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 5 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U></B>.
The Compensation Committee has the right to amend, alter, suspend, discontinue, or cancel the PSUs, prospectively or retroactively; <I>provided
that</I> no such amendment shall adversely affect the Grantee&rsquo;s material rights under this Award Agreement without the Grantee&rsquo;s
consent.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
409A</U></B>. It is intended that this Award Agreement is exempt from Internal Revenue Code Section 409A and the interpretive guidance
thereunder (&ldquo;<B><I>Section 409A</I></B>&rdquo;), and this Award Agreement shall be administered accordingly, and interpreted and
construed on a basis consistent with such intent. To the extent that any provision of this Award Agreement would fail to comply with applicable
requirements of Section 409A, the Company may, in its sole and absolute discretion and without requiring the Grantee&rsquo;s consent,
make such modifications to this Award Agreement and/or payments to be made thereunder to the extent it determines necessary or advisable
to comply with the requirements of Section 409A. Nothing in this Agreement shall be construed as a guarantee of any particular tax effect
for the Award, and the Company does not guarantee that any compensation or benefits provided under this Award Agreement will satisfy the
provisions of Section 409A. If (i)&nbsp;the Grantee&rsquo;s right to payment is subject to Section 409A, and (ii)&nbsp;the Grantee is
a specified employee (within the meaning of Section 409A) as of the date of the Grantee&rsquo;s Termination of Affiliation, then, to the
extent necessary to comply with Treasury Regulation sections 1.409A-3(i)(2), settlement of the Award shall be delayed until the earlier
of (A)&nbsp;the date which is six months after the Grantee&rsquo;s separation from service, or (B)&nbsp;the date of the Grantee&rsquo;s
death.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U></B>.
This Award Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute
one and the same instrument. Counterpart signature pages to this Award Agreement transmitted by facsimile transmission, by electronic
mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance
of a document, will have the same effect as physical delivery of the paper document bearing an original signature.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acceptance</U></B>.
The Grantee hereby acknowledges receipt of a copy of the Plan and this Award Agreement. The Grantee has read and understands the terms
and provisions thereof, and accepts the PSUs subject to all of the terms and conditions of the Plan and this Award Agreement. The Grantee
acknowledges that there may be adverse tax consequences upon the vesting or settlement of the PSUs or disposition of the underlying shares
and that the Grantee has been advised to consult a tax advisor prior to such vesting, settlement or disposition.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 6 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Award Agreement as of the date first above written.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in"><B>KORU MEDICAL SYSTEMS, INC.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">By:_________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Name:_______________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Title:________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in"><B>GRANTEE</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">____________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Grantee&rsquo;s Name:______________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 7 -</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>ex_10-6.htm
<DESCRIPTION>FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 10.6</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>KORU MEDICAL SYSTEMS, INC.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2024 Omnibus Equity Incentive Plan</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Restricted
Stock Unit </U></FONT><U>AWARD <FONT STYLE="text-transform: uppercase">Agreement</FONT></U></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to this Restricted Stock
Unit Award Agreement (this &ldquo;<B><I>Award Agreement</I></B>&rdquo;), and subject to the terms and conditions herein and in the KORU
Medical Systems, Inc. 2024 Omnibus Equity Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;), KORU Medical Systems, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;)
grants an Award of restricted stock units (&ldquo;<B><I>RSUs</I></B>&rdquo;), as set forth below.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="padding: 1pt 4pt; border: Black 1pt solid">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Summary of Award Terms:</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B><U>Name of Grantee</U></B>: ___________ (the &ldquo;<B><I>Grantee</I></B>&rdquo;)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B><U>Date of Grant</U></B>: ____________, 2024 (the &ldquo;<B><I>Grant
Date</I></B>&rdquo;)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B><U>Number of RSUs Granted</U></B>: ___________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B><U>Vesting Schedule</U></B>: Subject to the Grantee&rsquo;s continued
employment with the Company and the provisions of the Plan and this Award Agreement, the RSUs shall vest in four equal installments on
____________ and on the first, second and third anniversaries thereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B><U>Effect of Change of Control</U></B>: Upon the occurrence of a Change
in Control, 100% of the unvested RSUs shall immediately vest as of the date of the Change in Control.</P>

</DIV>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Capitalized terms used in this
Award Agreement, unless otherwise defined, shall have the meanings set forth in the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><B>Grant
of RSUs</B></U>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Section 10 of the Plan, subject to the terms and conditions of this Award Agreement and the Plan, the Company hereby grants to the
Grantee on the Grant Date an Award consisting of the RSUs. Each RSU represents the right to receive one share of Common Stock, subject
to the terms and conditions set forth in this Award Agreement and the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
RSUs shall be credited to a separate account maintained for the Grantee on the books and records of the Company (the &ldquo;<B><I>Account</I></B>&rdquo;).
All amounts credited to the Account shall continue for all purposes to be part of the general assets of the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Vesting</U></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided herein, provided that the Grantee has not had a Termination of Affiliation on or before the applicable vesting date,
the RSUs will vest in accordance with the Vesting Schedule set forth in the Summary of Award Terms above (the period during which restrictions
apply, the &ldquo;<B><I>Restricted Period</I></B>&rdquo;). Once vested, the RSUs become &ldquo;<B><I>Vested Units</I>.</B>&rdquo;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise specifically provided herein, if the Grantee&rsquo;s Termination of Affiliation occur at any time before all of the Grantee&rsquo;s
RSUs have vested, the Grantee&rsquo;s unvested RSUs shall be automatically forfeited upon the Grantee&rsquo;s Termination of Affiliation
and neither the Company nor any Affiliate shall have any further obligations to the Grantee under this Award Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Settlement
of Award</U></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to Section 9 hereof, promptly following the vesting date, and in any event no later than June 15 of the calendar year following the calendar
year in which such vesting occurs, the Company shall (a)&nbsp;issue and deliver to the Grantee the number of shares of Common Stock of
the Company (&ldquo;<B><I>Shares</I></B>&rdquo;) equal to the number of Vested Units; and (b)&nbsp;enter the Grantee&rsquo;s name on the
books of the Company as the stockholder of record with respect to the Shares delivered to the Grantee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything herein to the contrary, no transfer of Shares shall become effective until the Company determines that such transfer, issuance,
and delivery is in compliance with all applicable laws, regulations of government authority, and the requirements of any securities exchange
on which Shares may be traded.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee may, as a condition to the issuance of Shares, require the Grantee to make covenants and representations and/or
enter into agreements with the Company to reflect the Grantee&rsquo;s rights and obligations as a stockholder of the Company and any limitations
and restrictions on such Shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transfer of Shares pursuant to this Award Agreement shall be effectuated by an appropriate entry on the books of the Company, the issuance
of certificates representing such shares (bearing such legends as the Compensation Committee deems necessary or desirable), the transfer
of shares to a brokerage account in the name of the Grantee, and/or other appropriate means as determined by the Compensation Committee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
and until any Shares are issued in settlement of the Award on the Settlement Date, the Award shall not confer to the Grantee any rights
or status as a stockholder of the Company. Unless otherwise determined by the Compensation Committee, the Grantee will have no rights
to receive Dividend Equivalents in respect of the RSUs.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Nontransferability</U></B>.
Subject to any exceptions set forth in this Award Agreement or the Plan, during the Restricted Period and until such time as the RSUs
are settled in accordance with Section 3, the RSUs or the rights relating thereto may not be assigned, alienated, pledged, attached,
sold, or otherwise transferred or encumbered by the Grantee. Any attempt to assign, alienate, pledge, attach, sell or otherwise transfer
or encumber the RSUs or the rights relating thereto shall be wholly ineffective and, if any such attempt is made, the RSUs will be forfeited
by the Grantee and all of the Grantee&rsquo;s rights to such units shall immediately terminate without any payment or consideration by
the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Grantee
Representations</U></B>. By accepting the Award, the Grantee represents and acknowledges the following:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee has received a copy of the Plan, has reviewed the Plan and this Award Agreement in their entirety, and has had an opportunity
to obtain the advice of independent legal counsel prior to accepting the Award.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee has had the opportunity to consult with a tax advisor concerning the tax consequences of accepting the Award, and understands
that the Company</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 2 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">makes no representation regarding the tax treatment
as to any aspect of the Award, including the grant, vesting, settlement, or conversion of the Award.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee understands that neither the grant of this Award nor the Grantee&rsquo;s participation in the Plan confers any right to continue
in the service of the Company or to receive any other award or amount of compensation, whether under the Plan or otherwise, and no payment
of any award under the Plan will be taken into account in determining any benefits under any pension, retirement, profit sharing, group
insurance, or other benefit plan of the Company or any Affiliate except as otherwise specifically provided in such other plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee consents to the collection, use, and transfer, in electronic or other form, of the Grantee&rsquo;s personal data by the Company,
any Affiliate, the Compensation Committee, and any third party retained to administer the Plan for the exclusive purpose of administering
the Award and Grantee&rsquo;s participation in the Plan. The Grantee agrees to promptly notify the Company of any changes in the Grantee&rsquo;s
name, address, or contact information during the entire period of Plan participation.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Adjustments</U></B>.
If there is a change in the outstanding Shares due to a stock dividend, split, or consolidation, or a recapitalization, corporate change,
corporate transaction, or other similar event relating to the Company, the Compensation Committee may adjust the number of RSUs subject
to the Award in accordance with Section 4.2 of the Plan.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Tax
Liability and Withholding</U></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the Grantee
pursuant to the Plan, the amount of any required withholding taxes in respect of the RSUs and to take all such other action as the Compensation
Committee deems necessary to satisfy all obligations for the payment of such withholding taxes. The Compensation Committee may permit
the Grantee to satisfy any federal, state or local tax withholding obligation by any of the following means, or by a combination of such
means: (i)&nbsp;tendering a cash payment; (ii)&nbsp;authorizing the Company to withhold Shares from the Shares otherwise issuable or deliverable
to the Grantee as a result of the vesting of the RSUs; <I>provided, however</I>, that no Shares shall be withheld with a value exceeding
the maximum amount of tax required to be withheld by law; and (iii)&nbsp;delivering to the Company previously owned and unencumbered Shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (&ldquo;<B><I>Tax-Related
Items</I></B>&rdquo;), the ultimate liability for all Tax-Related Items is and remains the Grantee&rsquo;s responsibility and the Company
(i)&nbsp;makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting
or settlement of the RSUs or the subsequent sale of any shares; and (ii)&nbsp;does not commit to structure the RSUs to reduce or eliminate
the Grantee&rsquo;s liability for Tax-Related Items.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Compliance
with Law</U></B>. The issuance and transfer of Shares shall be subject to compliance by the Company and the Grantee with
all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which
the Company&rsquo;s Shares may be listed. No Shares shall be issued or transferred unless and until any</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 3 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">then applicable requirements of
state and federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notices</U></B>.
Any notice required to be delivered to the Company under this Award Agreement shall be in writing and addressed to the Company at the
Company&rsquo;s principal corporate offices. Any notice required to be delivered to the Grantee under this Award Agreement shall be in
writing and addressed to the Grantee at the Grantee&rsquo;s address as shown in the records of the Company. Either party may designate
another address in writing (or by such other method approved by the Company) from time to time.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Governing
Law</U></B>. This Award Agreement will be construed and interpreted in accordance with the laws of the State of Delaware without
regard to conflict of law principles.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Interpretation</U></B>.
Any dispute regarding the interpretation of this Award Agreement shall be submitted by the Grantee or the Company to the Compensation
Committee (excluding the Grantee if the Grantee serves on the Compensation Committee) for review. The resolution of such dispute by the
Compensation Committee shall be final and binding on the Grantee and the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>RSUs
Subject to Plan</U></B>. This Award Agreement is subject to the Plan. The terms and provisions of the Plan, as it may be amended from time to time, are hereby
incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of
the Plan, the applicable terms and provisions of the Plan will govern and prevail.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Successors
and Assigns</U></B>. The Company may assign any of its rights under this Award Agreement. This Award Agreement will be binding
upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein,
this Award Agreement will be binding upon the Grantee and the Grantee&rsquo;s beneficiaries, executors, administrators and the person(s)
to whom the RSUs may be transferred by will or the laws of descent or distribution.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Severability</U></B>.
The invalidity or unenforceability of any provision of the Plan or this Award Agreement shall not affect the validity or enforceability
of any other provision of the Plan or this Award Agreement, and each provision of the Plan and this Award Agreement shall be severable
and enforceable to the extent permitted by law.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Discretionary
Nature of Plan</U></B>. The Plan is discretionary and may be amended, cancelled, or terminated by the Company at any time, in its
discretion. The grant of the RSUs in this Award Agreement does not create any contractual right or other right to receive any RSUs or
other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination
of the Plan shall not constitute a change or impairment of the terms and conditions of the Grantee&rsquo;s service to the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Amendment</U></B>.
The Compensation Committee has the right to amend, alter, suspend, discontinue, or cancel the RSUs, prospectively or retroactively; <I>provided
that</I> no such amendment shall adversely affect the Grantee&rsquo;s material rights under this Award Agreement without the Grantee&rsquo;s
consent.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 4 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Section
409A</U></B>. This Award Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be
construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section
409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this
Award Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes,
penalties, interest or other expenses that may be incurred by the Grantee on account of non-compliance with Section 409A of the Code.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Counterparts</U></B>.
This Award Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute
one and the same instrument. Counterpart signature pages to this Award Agreement transmitted by facsimile transmission, by electronic
mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance
of a document, will have the same effect as physical delivery of the paper document bearing an original signature.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Acceptance</U></B>.
The Grantee hereby acknowledges receipt of a copy of the Plan and this Award Agreement. The Grantee has read and understands the terms
and provisions thereof, and accepts the RSUs subject to all of the terms and conditions of the Plan and this Award Agreement. The Grantee
acknowledges that there may be adverse tax consequences upon the vesting or settlement of the RSUs or disposition of the underlying shares
and that the Grantee has been advised to consult a tax advisor prior to such vesting, settlement or disposition.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center">[signature page follows]</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 5 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Award Agreement as of the date first above written.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in"><B>KORU MEDICAL SYSTEMS, INC.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">By:_________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Name:_______________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Title:________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in"><B>GRANTEE</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">____________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in">Grantee&rsquo;s Name:______________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- Signature Page -</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>ex_10-7.htm
<DESCRIPTION>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 10.7</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">KORU Medical Systems, Inc.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Summary of Non-Employee Director Compensation</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">The Board of Directors of KORU Medical Systems, Inc.
(the &ldquo;Company&rdquo;) has approved the following compensation for its non-employee directors effective with approval of the Company&rsquo;s
2021 Omnibus Equity Incentive Plan by its shareholders on May 18, 2021.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">In each case payable quarterly on the day following the end of each fiscal
quarter beginning with the quarter ended June 30, 2021 (each, a &ldquo;Payment Date&rdquo;) and subject to proration for partial quarter
service:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">Non-employee Directors (other than Chairman): $110,000 annually,
of which $50,000 is paid in cash and $60,000 is paid in shares of the Company&rsquo;s Common Stock.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Chairman of the Board: $140,000 annually,
of which $50,000 is paid in cash and $90,000 is paid in shares of the Company&rsquo;s Common Stock.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Chairman of the Audit Committee: additional
$15,000 annually paid in cash.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Chairman of the Compensation Committee:
additional $11,500 annually paid in cash.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Chairman of the Nominating and Corporate
Governance Committee: additional $7,500 annually paid in cash.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Compensation payable in shares of Common Stock is based on the arithmetic
mean of the high and low prices of a share of Common Stock, in each case as reported on the last trading day before the Payment Date,
provided that such quotations shall have been made within the ten (10) business days preceding the applicable Payment Date.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>5
<FILENAME>ex_19.htm
<DESCRIPTION>KORU MEDICAL SYSTEMS, INC. INSIDER TRADING POLICY
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 19</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: right">January 2022</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>KORU MEDICAL SYSTEMS, INC.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>POLICY ON INSIDER TRADING</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is very important that all directors, officers
and employees of KORU Medical Systems, Inc. (the &ldquo;Company&rdquo;) be familiar with the Company&rsquo;s policy on trading in securities
of the Company or entities with which the Company does business. <B>Thus, each of you is asked to read this Policy on Insider Trading
(this &ldquo;Policy&rdquo;), carefully, sign the attached acknowledgment, and return the signed acknowledgment to the Company&rsquo;s
Chief Financial Officer.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center">&bull;</TD>
    <TD STYLE="width: 6in; text-align: justify">This Policy provides that, if you are aware of information regarding the Company or any of its customers, vendors, etc. that is material and is not generally known to the public, you may not buy or sell the Company&rsquo;s or that entity&rsquo;s securities, and you may not share that information with others.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD>This Policy provides for &ldquo;blackout periods&rdquo; during which directors, officers and employees are prohibited from buying or selling Company securities.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">This Policy requires that any director, officer or employee provide notice to our Chief Financial Officer before executing a trade.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD>This Policy prohibits certain other transactions involving the Company&rsquo;s securities by directors, officers and employees.</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You should review this Policy in detail and contact
our Chief Financial Officer if you have any questions. <B>You should note, however, that as a matter of law and corporate policy, you
are ultimately responsible for conforming your actions to the requirements of the insider trading laws and this Policy. Regardless of
any advice or information you receive from the Company or others, you will bear the consequences of any legal or policy violations.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Violating the insider trading laws can result in significant
criminal and civil liabilities, including imprisonment and millions of dollars in fines. Furthermore, failure to observe and comply with
all of the provisions contained in this Policy may subject you to disciplinary action by the Company, including discharge.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TRADING IN KORU MEDICAL SYSTEMS, INC. SECURITIES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>YOU ARE NOT PERMITTED TO ENTER INTO TRANSACTIONS
RELATING TO THE COMPANY&rsquo;S SECURITIES AT ANY TIME IF YOU ARE IN POSSESSION OF MATERIAL, NON-PUBLIC INFORMATION</I></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rule 10b-5, promulgated under Section 10(b) of the
Securities Exchange Act of 1934, prohibits &ldquo;deceptive&rdquo; or &ldquo;fraudulent&rdquo; conduct in connection with the purchase
and sale of securities. This Rule is the principal &ldquo;anti-fraud&rdquo; law governing transactions involving the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accordingly, by Company policy and by law, you are
prohibited from trading in any securities of the Company on the basis of &ldquo;material,&rdquo; &ldquo;non-public&rdquo; information.
This conduct is referred to as &ldquo;insider trading&rdquo; and not only is grounds for disciplinary action, but may subject you to severe
civil and criminal penalties as well. The meaning of the terms &ldquo;material&rdquo; and &ldquo;non-public&rdquo; is discussed below.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Policy applies to all transactions in Company-related
securities. Thus, the prohibition of insider trading applies not only to transactions in the Company's common stock (and other public-traded
equity and debt securities existing from time to time), but also to transactions in exchange-traded options covering Company securities
and hedging and other transactions involving Company securities. The exercise of stock options, sale of a put option or the gift of Company
securities may also be considered transactions in Company-related securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under Rule 10b-5 it is considered &ldquo;fraudulent&rdquo;
to purchase or sell securities while in possession of undisclosed material information relating to the securities. If the director, officer
or employee either knows of the non-disclosure, or is reckless or displays an extreme departure from the standards of ordinary care (or
in some situations is negligent (a lower standard)) in not ascertaining the existence of inside information, there is potential liability.
Since directors, officers and other employees of the Company may be thought to have access to material inside information about the Company,
it may be difficult to convince a court or jury that the material undisclosed information in question was not known to such person when
making the purchase or sale.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&ldquo;Tipping&rdquo;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You may not pass material non-public information on
to others (not even your spouse or other family members) or in any way suggest trades in securities to others based on such information.
This conduct is commonly referred to as &quot;tipping&quot;. It also is prohibited and will subject you to disciplinary action and possibly
termination and severe civil and criminal penalties. This may be true even if the person to whom you provide the information trades on
or uses the information without your knowledge or approval.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>What is &ldquo;material,&rdquo; non-public&rdquo; information?</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 2 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.85pt"><B>&ldquo;Material&rdquo; </B>information
generally is information for which there is a substantial likelihood that a reasonable investor would consider it important in deciding
to buy, sell or hold a security, or information that is reasonably certain to have an effect on the price of the Company&rsquo;s securities.
If there is any possibility that information would interest you or others as investors, the information should be considered &ldquo;material.&rdquo;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.85pt"><B>&ldquo;Non-public&rdquo;
</B>information is &ldquo;non-public&rdquo; until it has been effectively communicated to the marketplace. You should consider any information
&ldquo;non-public&rdquo; unless you have read it in a report filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
or sent to stockholders generally, or in a newspaper, magazine or similar publication. Even after the information concerning the Company
has been published, there should be a reasonable period of time for the information to circulate in the marketplace &ndash; generally,
<U>at least</U> 24 hours &ndash; before making any trades in the Company&rsquo;s securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">While it is not possible to identify every type of information that might
be deemed to be material, the following are a few examples:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center">&bull;</TD>
    <TD STYLE="width: 6in; text-align: justify">earnings related information including preliminary financial results or other financial information (including internally developed financial projections and forecasts);</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">plans for transactions (purchases or sales) involving Company securities or financing;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">plans for mergers, acquisitions and/or asset sales or purchases;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">developments in pending or threatened lawsuits, investigations or notifications from regulatory agencies (for example, the SEC, Federal Trade Commission or Food and Drug Administration) or from an exchange or market on which Company securities are listed;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD>new products, services and/or customer or vendor agreements;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD>significant personnel changes;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD>gain or loss of a significant customer or vendor;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD>changes in auditors or notification that an audit report can no longer be relied upon; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&bull;</TD>
    <TD>significant contracts or price changes</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Determinations regarding the &ldquo;materiality&rdquo;
of information are inherently judgment based.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Blackout Periods</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is the Company&rsquo;s policy that officers, directors
and employees of the Company may not enter into transactions relating to the Company&rsquo;s securities during the last two weeks of each
fiscal quarter and until the second business day following the filing of the Company&rsquo;s Quarterly</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 3 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reports on Form 10-Q (generally in May, August and
November) or Annual Report on Form 10-K (generally in March), as applicable, unless otherwise notified by the Chief Financial Officer
or Company legal counsel.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, from time to time, the Company may announce
that all trading is prohibited pending certain corporate developments. Under some circumstances, material information may properly be
withheld from the public for legitimate business considerations of the Company. In such cases, even if the required SEC filings have been
made, the continued existence of material non-disclosed information would preclude trading in the Company&rsquo;s securities by directors,
officers and employees. Rather than run the risk of relying on an argument that you did not actually know or should not have known about
material inside information (even if the Company has not prohibited trades), any officer, director or employee of the Company (who may
have or be thought to have access to material inside information) who intends to purchase or sell securities of the Company should first
ascertain whether at that time there is any material information regarding the Company that has not been publicly disclosed. This is one
of the reasons why <B><I>it is the policy of the Company that any officer, director or employee personnel who intends to engage in any
transaction involving securities of the Company should first notify the Chief Financial Officer.</I></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Policy Exceptions</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event that you are suffering from financial
hardship that is reasonably demonstrated to at least two independent members of the Board of Directors, such members may grant an exemption
to the trading restrictions described in this Policy. No exemption can be granted if you are in possession of material non-public information.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Short-Swing Profits</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If you are an officer or director subject to reporting
under Section 16 of the Securities Exchange Act of 1934, you should be aware that even if you enter into transactions during the permitted
periods described above, you may still be subject to liability under Section 16 for any short-swing profit you may realize.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Prohibited Transactions</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Directors, officers and other employees, including
any of their spouses, other persons living in their households and minor children and entities over which they exercise control, are prohibited
from engaging in the following transactions in the Company's securities unless advance approval is obtained from the Chief Financial Officer:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><B><U>Short sales.</U></B> Such persons
may not sell the Company's securities short;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><B><U>Options trading.</U></B> Such persons
may not buy or sell puts or calls or other derivative securities on the Company's securities;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 4 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><B><U>Trading on margin or pledging.</U></B>
Such persons may not hold Company securities in a margin account or pledge Company securities as collateral for a loan; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><B><U>Hedging.</U></B> Such persons may
not enter into hedging or monetization transactions or similar arrangements with respect to Company securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TRADING IN SECURITIES OF OTHER COMPANIES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>YOU ARE NOT PERMITTED TO ENTER INTO TRANSACTIONS
RELATING TO ANY OTHER COMPANY&rsquo;S SECURITIES AT ANY TIME IF YOU ARE IN POSSESSION OF MATERIAL NON-PUBLIC INFORMATION</I></B>.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The prohibition against trading in securities of the
Company while in possession of material non-public information also applies to trading in securities of other companies. It is against
Company policy and is illegal to trade in any company&rsquo;s stock or other securities based on inside information if that company is
one with which the Company does business or if the information has been obtained in the course of your employment or service to the Company.
Similarly, such information should not be disclosed to others. Even if the information does not relate to an entity with which the Company
does business and has not been obtained in the course of employment, trading on the information or disclosing it to others may be prohibited.
In addition, the information about the other company may have been provided under an agreement restricting its use.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PENALTIES FOR POLICY VIOLATION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Violation of this Policy is grounds for disciplinary
action and even <U>dismissal</U>. Furthermore, you may be suspended, without pay, during the course of any investigation to determine
if there has been a violation of this Policy.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal securities laws impose considerable civil
and criminal penalties on persons who improperly obtain or use material, non-public information in connection with a purchase or sale
of securities. In addition to civil damages of up to three times the profit gained, an individual may be subject to criminal sanctions,
including imprisonment and a criminal fine of up to millions of dollars, for any violation. The SEC and courts have great power to impose
penalties for violations of the insider trading provisions of the federal securities laws, and the SEC and governmental prosecutors vigorously
enforce these laws against both individuals and institutions.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SAFEGUARDING CONFIDENTIAL INFORMATION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To safeguard confidential information, you are required
to follow these procedures:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">1.</TD>
    <TD STYLE="width: 6in; text-align: justify">Papers relating to confidential matters should not be left in conference rooms or anywhere else where they might be seen by visitors to the office.</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 5 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">2.</TD>
    <TD STYLE="width: 6in; text-align: justify">Visitors should not be allowed to wander throughout the offices. Visitors desiring to use a telephone should be directed to an appropriate telephone. Visitors should not be allowed to use a private office unless appropriate precautions are taken to prevent any possible disclosure of information.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">3.</TD>
    <TD STYLE="text-align: justify">You should not disclose any confidential information concerning the Company or its subsidiaries, nor should you disclose any information which you learned about in the course of your work that relates to an entity with which the Company does business, or an entity that is otherwise involved in a transaction with the Company. This includes a prohibition of disclosure to your family members and friends. Highly confidential matters should not be disclosed even to others within the Company unless there is a need for them to have that information.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">4.</TD>
    <TD STYLE="text-align: justify">Confidential matters should not be discussed in reception areas, hallways, elevators, restaurants, taxis, subways, airplanes or other public places.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">5.</TD>
    <TD STYLE="text-align: justify">Inquiries from outside the Company (such as a press reporter, financial analyst&nbsp;&nbsp;&nbsp;or stock broker) with respect to any matter should be referred <U>without comment</U> to the Chief Executive Officer of the Company. If there has been no public announcement of the Company&rsquo;s involvement in a matter, the Company&rsquo;s involvement should not be confirmed, even indirectly. Similarly, the presence of visitors at the Company should not be confirmed, unless specifically authorized.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">6.</TD>
    <TD STYLE="text-align: justify">Communications procedures should be arranged with persons working on each matter in order to maintain security. For example, special precautions may be necessary to secure facsimile or other electronic communications of confidential information, and a &ldquo;confidential&rdquo; legend on envelopes may be necessary to maintain confidentiality.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">7.</TD>
    <TD STYLE="text-align: justify">Use of temporary secretaries and other temporary employees in connection with sensitive matters should be minimized and special care should be taken to ensure their compliance with this Policy.</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ADDITIONAL INFORMATION AND CONSIDERATIONS</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compliance with the law and this Policy is your responsibility.
<U>Before</U> you make a trade in the Company&rsquo;s securities, or securities of entities doing business with the Company, or securities
of entities about which you have learned confidential information in the course of your employment, you should review this Policy and
notify the Chief Financial Officer.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is very important that you fully understand this
Policy and the requirements described above. Accordingly, please contact the Company&rsquo;s Chief Financial Officer to discuss any questions
you</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 6 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">might have. To ensure that everyone is familiar with
the Company&rsquo;s policy with respect to insider trading and tipping, you are required to sign the attached statement acknowledging
your understanding of and compliance with this Policy, and return it to the Chief Financial Officer as promptly as possible. Also, because
continued compliance with this Policy is critical, you may from time to time be asked to acknowledge your continued familiarity with and
adherence to its requirements.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 7 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>POLICY ON INSIDER TRADING</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CERTIFICATE OF RECEIPT AND ACKNOWLEDGEMENT</U></B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">I hereby certify that I have read and understand, and agree to comply with,
the KORU Medical Systems, Inc. Policy on Insider Trading.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Employee:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">(Signature)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">________________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">(Printed Name)</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">Dated:___________________________</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 8 -</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>6
<FILENAME>ex_23-1.htm
<DESCRIPTION>CONSENT OF MMQ & ASSOCIATES, P.C.
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 23.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="mmq_logo-header.jpg">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 1in 0 1in; text-align: justify">We consent to the incorporation by reference in the
Registration Statement on Form S-3 (No. 333-229498), Registration Statement on Form S-3 (No. 333-272026), Registration Statement on Form
S-8 (No. 333-262054), Registration Statement on Form S-8 (No. 333-265943), Registration Statement on Form S-8 (No. 333-280738) and related
Prospectuses of KORU Medical Systems, Inc. of our report dated March 13, 2024 with respect to the financial statements of KORU Medical
Systems, Inc. appearing in this Annual Report on Form 10-K.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify">/s/ MMQ &amp; Associates, P.C.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify">Scranton, Pennsylvania</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in; text-align: justify">March 12, 2025</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right"><IMG SRC="mmq_logo-footer.jpg">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<HR NOSHADE ALIGN="CENTER" WIDTH="100%" SIZE="2">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>7
<FILENAME>ex_23-2.htm
<DESCRIPTION>CONSENT OF CHERRY BEKAERT LLP
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 23.2</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><IMG SRC="cbh_logo-header.jpg"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">We hereby consent to the inclusion or incorporation by reference our
report, dated March 12, 2025, with respect to the Balance Sheet of KORU Medical Systems, Inc. (the &ldquo;Company&rdquo;) as of December 31,
2024, and the related statements of operations, stockholder&rsquo;s equity, and cash flows for the year then ended, in (i) the Company&rsquo;s
Registration Statement on Form S-3 (No. 333-229498), (ii) the Company&rsquo;s Registration Statement on Form S-3 (No. 333-272026), (iii)
the Company&rsquo;s Registration Statement on Form S-8 (No. 333-262054), (iv) the Company&rsquo;s Registration Statement on Form S-8 (No.
333-265943), (v) the Company&rsquo;s Registration Statement on Form S-8 (No. 333-280738).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><IMG SRC="cbh_signature.jpg"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Tampa, Florida</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">March 12, 2025</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><IMG SRC="cbh_logo-footer.jpg" STYLE="width: 40px; height: 12px"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<HR NOSHADE ALIGN="CENTER" WIDTH="100%" SIZE="2">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>8
<FILENAME>ex_31-1.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 31.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Linda Tharby, Principal Executive Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2">I have reviewed this Annual Report on Form 10-K of KORU MEDICAL SYSTEMS, INC.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(a)</TD>
    <TD STYLE="width: 7in">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 12, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>9
<FILENAME>ex_31-2.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 31.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PRINCIPAL FINANCIAL OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Thomas Adams, Principal Financial Officer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>1)</TD>
    <TD COLSPAN="2">I have reviewed this Annual Report on Form 10-K of KORU MEDICAL SYSTEMS, INC.;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>2)</TD>
    <TD COLSPAN="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>3)</TD>
    <TD COLSPAN="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>4)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(a)</TD>
    <TD STYLE="width: 7in">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(c)</TD>
    <TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>5)</TD>
    <TD COLSPAN="2">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(a)</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(b)</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Thomas Adams</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 12, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>ex_32-1.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Annual Report of KORU MEDICAL SYSTEMS, INC. (the
&ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;),
I, Linda Tharby, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">(1)</TD>
    <TD STYLE="width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Linda Tharby</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Linda Tharby</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer and President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 12, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>11
<FILENAME>ex_32-2.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 7.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 32.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Annual Report of KORU MEDICAL SYSTEMS, INC. (the
&ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;),
I, Thomas Adams, Principal Financial Officer and Treasurer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 7.5in; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">(1)</TD>
    <TD STYLE="width: 7in">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Thomas Adams</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Thomas Adams</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer and Treasurer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: March 12, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>12
<FILENAME>ex_97.htm
<DESCRIPTION>CLAWBACK POLICY
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">EXHIBIT 97</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>KORU MEDICAL SYSTEMS, INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CLAWBACK POLICY</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors (the &ldquo;<B>Board</B>&rdquo;)
of KORU Medical Systems, Inc. (the &ldquo;<B>Company</B>&rdquo;) believes that it is in the best interests of the Company and its shareholders
to adopt this Clawback Policy (the &ldquo;<B>Policy</B>&rdquo;), which provides for the recovery of certain incentive compensation in
the event of an Accounting Restatement (as defined below). This Policy is designed to comply with, and shall be interpreted to be consistent
with, Section 10D of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), Rule 10D-1 promulgated under
the Exchange Act (&ldquo;<B>Rule 10D-1</B>&rdquo;) and Nasdaq Listing Rule 5608 (the &ldquo;<B>Listing Standards</B>&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.&nbsp;&nbsp;<B>Administration</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as specifically set forth herein, this Policy
shall be administered by the Board or, if so designated by the Board, a committee thereof (the Board or such committee charged with administration
of this Policy, the &ldquo;<B>Administrator</B>&rdquo;). The administrator is authorized to interpret and construe this Policy and to
make all determinations necessary, appropriate or advisable for the administration of this Policy. Any determinations made by the Administrator
shall be final and binding on all affected individuals and need not be uniform with respect to each individual covered by the Policy.
Any determinations made by the Administrator shall be final and binding on all affected individuals and need not be uniform with respect
to each individual covered by the Policy. In the administration of this Policy, the Administrator is authorized and directed to consult
with the full Board or such other committees of the Board, such as the Audit Committee or the Compensation Committee, as may be necessary
or appropriate as to matters within the scope of such other committee&rsquo;s responsibility and authority. Subject to any limitation
at applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions necessary
or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving
such officer or employee).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.&nbsp;&nbsp;<B>Definitions</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Policy, the following definitions
shall apply:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 6in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Accounting Restatement</B>&rdquo; means an accounting restatement of the Company&rsquo;s financial statements due to the Company&rsquo;s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Administrator</B>&rdquo; has the meaning set forth in Section 1 hereof.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Applicable Period</B>&rdquo; means the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement, as well as any transition period (that results from a change in the Company&rsquo;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal years). The &ldquo;<B>date on which the Company is required to prepare an Accounting Restatement</B>&rdquo; is the earlier to occur of (a) the date the </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 1 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 6in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Board concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement or (b) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement, in each case regardless of if or when the restated financial statements are filed.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Covered Executives</B>&rdquo; means the Company&rsquo;s current and former executive officers, as determined by the Administrator in accordance with the definition of executive officer set forth in Rule 10D-1 and the Listing Standards.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Erroneously Awarded Compensation</B>&rdquo; has the meaning set forth in Section 5 of this Policy.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A &ldquo;<B>Financial Reporting Measure</B>&rdquo; is any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s financial statements, and any measure that is derived wholly or in part from such measure. Financial Reporting Measures include but are not limited to the following (and any measures derived from the following): Company stock price; total shareholder return (&ldquo;<B>TSR</B>&rdquo;); revenues; net income; operating income; profitability of one or more reportable segments; financial ratios (e.g., accounts receivable turnover and inventory turnover rates); earnings before interest, taxes, depreciation and amortization (&ldquo;<B>EBITDA</B>&rdquo;); funds from operations and adjusted funds from operations; liquidity measures (e.g., return on invested capital, return on assets); earnings measures (e.g., earnings per share); sales per square foot or same store sales, where sales is subject to an Accounting Restatement; revenue per user, or average revenue per user, where revenue is subject to an Accounting Restatement; cost per employee, where cost is subject to an Accounting Restatement; any of such financial reporting measures relative to a peer group, where the Company&rsquo;s financial reporting measure is subject to an Accounting Restatement; and tax basis income. A Financial Reporting Measure need not be presented within the Company&rsquo;s financial statements or included in a filing with the Securities Exchange Commission.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Incentive-Based Compensation</B>&rdquo; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation is &ldquo;<B>received</B>&rdquo; for purposes of this Policy in the Company&rsquo;s fiscal period during with the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.&nbsp;&nbsp;<B>Covered Executives; Incentive-Based
Compensation</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Policy applies to Incentive-Based Compensation
received by a Covered Executive (a) at the time of or after beginning services as a Covered Executive; (b) if that person served as a
Covered Executive at any time during the performance period for such Incentive-Based Compensation; and (c) while the Company had a listed
class of securities on a national securities exchange.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP>&nbsp;</SUP></P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 2 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4.&nbsp;&nbsp;<B>Required Recoupment of Erroneously
Awarded Compensation in the Event of an Accounting Restatement</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event of the Company is required to prepare
an Accounting Restatement, the Company shall promptly recoup the amount of any Erroneously Awarded Compensation received by any Covered
Executive, as calculated pursuant to Section 5 hereof, during the Applicable Period.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.&nbsp;&nbsp;<B>Erroneously Awarded Compensation:
Amount Subject to Recovery</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount of &ldquo;<B>Erroneously Awarded Compensation</B>&rdquo;
subject to recovery under the Policy, as determined by the Administrator, is the amount of Incentive-Based Compensation received by the
Covered Executive that exceeds the amount of Incentive-Based Compensation that would have been received by the Covered Executive had it
been determined based on the restated amounts.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Erroneously Awarded Compensation shall be computed
by the Administrator without regard to any taxes paid by the Covered Executive in respect of the Erroneously Awarded Compensation.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">By way of example, with respect to any compensation
plans or programs that take into account Incentive-Based Compensation, the amount of Erroneously Awarded Compensation subject to recovery
hereunder includes, but is not limited to, the amount contributed to any notional account based on Erroneously Award Compensation and
any earnings accrued to date on that notional amount.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Incentive-Based Compensation based on stock price
or TSR: (a) the Administrator shall determine the amount of Erroneously Awarded Compensation based on a reasonable estimate of the effect
of the Accounting Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received; and (b) the company
shall maintain documentation of the determination of that reasonable estimate and provide such documentation to The Nasdaq Stock Market
(&ldquo;<B>Nasdaq</B>&rdquo;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6.&nbsp;&nbsp;<B>Method of Recoupment</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The administrator shall determine, in its sole discretion,
the timing and method for promptly recouping Erroneously Awarded Compensation hereunder, which may include without limitation (a) seeking
reimbursement of all or part of any cash or equity-based award, (b) cancelling prior cash or equity-based awards, whether vested or unvested
or paid or unpaid, (c) cancelling or offsetting against any planned future cash or equity-based awards, (d) forfeiture of deferred compensation,
subject to compliance with Section 409A of the Internal Revenue Code and the regulations promulgated thereunder and (e) any other method
authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may affect recovery under this
Policy from any amount otherwise payable to the Covered Executive, including amounts payable to such individual under any otherwise applicable
Company plan or program, including base salary, bonuses or commissions and compensations previously deferred by the Covered Executive.<SUP>7</SUP></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized pursuant to this Policy
to recoup Erroneously Awarded Compensation in compliance with this Policy unless the Compensation Committee has determined that recovery
would be impracticable solely for the following limited reasons, and subject to the following procedural and disclosure requirements:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 3 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 6in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Administrator must make a reasonable attempt to recover such erroneously awarded compensation, document such reasonable attempt(s) to recover and provide that documentation to Nasdaq;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recovery would violate home country law of the issuer where that law was adopted prior to November 28, 2022. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law of the issuer, the Administrator must satisfy the applicable opinion and disclosure requirements of Rule 10D-1 and the Listing Standards; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to Employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.&nbsp;&nbsp;<B>No Indemnification of Covered Executives</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding the terms of any indemnification or
insurance policy or any contractual arrangement with any Covered Executive that may be interpreted to the contrary, the Company shall
not indemnify any Covered Executives against the loss of any Erroneously Awarded Compensation, including any payment or reimbursement
for the cost of third-party insurance purchased by any Covered Executives to fund potential clawback obligations under this Policy.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8.&nbsp;&nbsp;<B>Administrator Indemnification</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any members of the Administrator, and any other members
of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation
made with respect to this Policy and shall be fully indemnified by the Company to the fullest extent under applicable law and Company
policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification
of the members of the Board under applicable law or Company policy.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.&nbsp;&nbsp;<B>Effective Date; Retroactive Application</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Policy shall be effective as of June 9, 2023
(the &ldquo;<B>Effective Date</B>&rdquo;). The terms of this Policy shall apply to any Incentive-Based Compensation that is received by
Covered Executives on or after the Effective Date, even if such Incentive-Based Compensation was approved, awarded, granted or paid to
Covered Executives prior to the Effective Date. Without limiting the generality of Section 6 hereof, and subject to applicable law, the
Administrator may affect recovery under this Policy from any amount of compensation approved, awarded, granted, payable or paid to the
Covered Executive prior to, on or after the effective date.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 4 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.&nbsp;&nbsp;<B>Amendment; Termination</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may amend, modify, supplement, rescind or
replace all or any portion of this Policy at any time and from time to time in its discretion, and shall amend this Policy as it deems
necessary to comply with applicable law or any rules or standards adopted by a national securities exchange on which the Company&rsquo;s
securities are listed.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11.&nbsp;&nbsp;<B>Other Recoupment Rights; Company
Claims</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board intends that this Policy shall be applied
to the fullest extent of the law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies
or rights of recoupment that may be available to the Company under applicable law or pursuant to the terms of any similar policy in any
employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nothing contained in this Policy, and no recoupment
or recovery as contemplated by this Policy, shall limit any claims, damages or other legal remedies to the Company or any of its affiliates
may have against a Covered Executive arising out of or resulting from any actions or omissions by the Covered Executive.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12.&nbsp;&nbsp;<B>Successors</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Policy shall be binding and enforceable against
all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">13.&nbsp;&nbsp;<B>Exhibit Filing Requirement</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A copy of this Policy and any amendments thereto shall
be posted on the Company&rsquo;s website and filed as an exhibit to the Company&rsquo;s annual report on Form 10-K.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 5 -</P>


<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%"><P STYLE="BREAK-BEFORE: ALWAYS"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">[<I>TO BE SIGNED BY THE COMPANY&rsquo;S EXECUTIVE
OFFICERS</I>]</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Clawback Policy Acknowledgment</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, the undersigned, agree and acknowledge that I am
fully bound by, and subject to, all of the terms and conditions of the KORU Medical Systems, Inc. Clawback Policy (as may be amended,
restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Policy</B>&rdquo;). This Policy is in addition to and not
in lieu of the terms of any employment agreement to which I am party, or the terms of any compensation plan, program or agreement under
which any compensation has been granted, awarded, earned or paid, and in the event of any inconsistency between their terms and the Policy,
the terms of the Policy shall govern. In the event it is determined by the Administrator that any amounts granted, awarded, earned or
paid to me must be forfeited or reimbursed to the Company, I will promptly take any action necessary to effectuate such forfeiture and/or
reimbursement. Any capitalized terms used in this Acknowledgment without definition shall have the meaning set forth in the Policy.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">By: ________________________________</FONT></TD>
    <TD STYLE="width: 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">[Name]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Date</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">[Title]</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">- 6 -</P>

<HR ALIGN="CENTER" NOSHADE SIZE="2" STYLE="WIDTH: 100%">

</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cbh_logo-footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cbh_logo-footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  , "@# 2(  A$! Q$!_\0
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8J-&%G[-JM!I45>*J+]W)WDX-*3NM?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cbh_logo-header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cbh_logo-header.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Q -(# 2(  A$! Q$!_\0
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M-*T:;3!X6.KV5O(T":_XBTKQ)XB\AWL4U=-',>DP_=_[-'P&\-_LO_ KX;_
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MF;BMKZW2>MM^A>_X(=?#_7/B4/VK/^"@WQ#TY8_&O[5GQB\3V?A1[A7E;3?
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cbh_signature.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cbh_signature.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S / # 2(  A$! Q$!_\0
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M% #B<?X]A]:"P!"G@GIZ'';ZUYM\6OB[\-_@/\-?&GQC^,?C7P[\./A=\.]
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MB>EZ3_P3[_94U[]N[3_V3_!]K>P?M'_\+'_X69I5Y^U_XWD\6^#_ !"_Q_\
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MFL0L&4AN 26 )&20V#R"6P<$J3AF9GX<9?\ '^V_X(??L8^&]3^-TGPJUO\
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M7CSX[BROHY-%^ 2:?X2OU@?X\:+J-CP/[4'_  1M\!_M7_#KQ;X&^)7[:/\
MP4'NKSQ#IL%KI&L+^U#XHT[0?"NIP:Q;:DOB.U^%W@JS\#_"_7]86UBO=*MA
MXL\*ZYIUG::I<-;V*W%KI\UMR7[/G_! _P#8X_9,TZWM/V7_ (J?MM? *\N+
M6V_X3'4?AC^U]\6=%M?B5KD%C#II\5>//!U[J&J_#W5/$ M+>&*"XL_".GV=
MI$D-O9V-K!:VRQ '[2Z/I.F:)I6G:)I&FV.DZ1H]A9Z5I.DZ=;06>GZ7IFG6
M\-K8:?86=LD<%I965M!!;VEO#&D<$$,,<:HB*J_CC_P5_P#VD/'FC>&?@E^P
M-^SAITWB_P#:S_;Z\<IX$\,>&X/$B^&+7PC\ ?!<L'BS]HOXG^-]?BT[4[[0
M_ D'P_LKSP+J4NGPP>(M1C\5WB>#KN+Q)IT4B_3E[^P%>ZEH-WX:OOVYO^"@
MTFE7J%)WLOV@-"T+7@"NW=:>,?#OPUTCQIISC (;3O$-J0WS Y)SXY^P7_P2
M4^$7[#WQ]_:4_:1B\>>/OC;\5OCAKEGHO@CQE\8/$_C7XC>-/A!\#].TG1IG
M^&&F^//B1XU\=>*_$.H^+?B!;Z[\1/B!XN-_H5KX@O=2\/:!;>%]-LO"$%[J
MP!YA^Q_^S'_P4!_96^'&I_ CP=\.OV/]&UO57@U3XC?MP>+/C5\7?BSXV^,_
MCR#P]IWA73_B-J7[,=K\$?AC:^'H="\/Z#X<T#PG\'[;]HVT\ _#+PCH6C^
M?!.L2^&]$M'G_1']F#]F?3OV=]!\1WVM^+M9^,7QT^*>I:5XF^/_ .T/XMTK
M3-(\:_&;QGI.DP:%IFHWVBZ%';^&_!OA+PMH<,6@> OAUX0L=+\'^#- B:WT
MO3YM5O\ 7]9UGZE5=O?)QC/XL<_7YN3WZTZ@!,#.<#/K@9XZ<TFU000 ,# P
M ..F/H.PIU% !1110 4444 5+^^L],L;S4M1O+73]/T^VGO;_4+Z>*ULK&RM
M8VGN[R\NIV2"VM;6W22>XN)WCAABC>262.-6=?Q/_:=^)FL?&#X?^+OVE_B/
MX4U;Q=^R)X8TN?P;^RC^R#9WVHZ=JG_!2?XR_$]]%\,_#.[^+_A74[:R2^^$
M?BCQ9<0^&?@]\(/$6G:GX:\3>']9UOX\_%RTNO"5GX2TOP][W_P5,^/WP_\
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M)'IP /0 8 %*F=HW#!Y)'!QDYQQQ@>Q/3J>I=0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1@>G3@>P]*** "BBB@ HHHH **** "BBB@#+NH
MHI6B26**:,R1R>7-$DL8D@020R!)%95DCDPZ2* ZL%(;Y5Q;MF+"0L<GS9!G
MOA79%'X*H'X>N:** +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mmq_logo-footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmq_logo-footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ![ G(# 2(  A$! Q$!_\0
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MB@ HHHH **** /.+WQ7JEM?7ENBV;1P75Q!'OAE+;8I61=Q6X0%B%Y. "<X
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MN?%O[:'B+3[CXL_LLZ)\4?VD+F7Q)\*K%OV7_P!H[5OCU\&? .@_!;1=3D\
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M//Z0Y + E2O(8'!4CD,#V((R/<4M%;&1[)H]\-0TZVNB1YC(4F Q\L\1*3#
M^ZI=2Z9Y*,A/49U*\Y\'7PAN9]/<@)<(;B '/$T2A9D7KR\*A\<86 X'(%=E
MK%^-.TZYN05$BQ[( <',\K"*+Y?X@KL'901E%?. "1BU:5N^WS-E*\;OIO\
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M>GV>BZ.FGZ)!/#?:I'IPU?6M:O\ 4/BB+]ON&?X8>-?B#:_!7Q%/-\-?'_\
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MNUR6E..X\F.13CH6&<9%>5UK!:-]W;[O^',IO5+M^H4A. >^.W4GV P22?0
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M72M.B>_U"6UTU=3\0ZUXA\2ZAK.OZG[G2 Y]??(Q^';GZ#%!8 %B0  3DG
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M;>]ODK=;^9JHI;;^84444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&P1USM.",<Y!Z8[T^BI*/(#9>)YDV2QZQ(I4!EEFF93Z@[Y\'D].?0Y J)=
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MJBA$4*J@*JJ JJH& JJ,!0     !Q@=:=14-M[LM)+9!1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.:EXFT_3Y
M'MQYES<Q\/%"HVHW]V25RJJ1T8)YC(>&3=Q7(7GB[4[@[;?RK&,\ HHEG.>W
MFS+L&><;($8$9STK$O?FU+4=W/\ Q,+X<]<"YEXSU-;/A>PM+^]N$O(%G2*)
M61'+A<DG.Y590X/]UPR^U:\JBF[7M;?ST_X)DG*3WMIT\CGRUU>R,[&ZO9>
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*L>P4445F:'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mmq_logo-header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmq_logo-header.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !B M # 2(  A$! Q$!_\0
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MX)^PI_T>;^RQ_P"'Z^&'_P T]'_#P3]A3_H\W]EC_P /U\,/_FGKM_LW,?\
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M=?M<>/+O68?#^FR^"&D\-> ];UJXE:U@TCPIXAET;Q)XJ\<:E<7NR#3V\'>
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M'Z^&'_S3T?\ #P3]A3_H\W]EC_P_7PP_^:>C^S<Q_P"A=C__  AQG_S*'U_
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M^%6&_P#F@^OZ*^0/^'@G["G_ $>;^RQ_X?KX8?\ S3T?\/!/V%/^CS?V6/\
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MO[+'_A^OAA_\T]']FYC_ -"['_\ A#C/_F4/K^ _Z#L'_P"%6&_^:#Z_HKY
M_P"'@G["G_1YO[+'_A^OAA_\T]'_  \$_84_Z/-_98_\/U\,/_FGH_LW,?\
MH78__P (<9_\RA]?P'_0=@__  JPW_S0?7]%?('_  \$_84_Z/-_98_\/U\,
M/_FGH_X>"?L*?]'F_LL?^'Z^&'_S3T?V;F/_ $+L?_X0XS_YE#Z_@/\ H.P?
M_A5AO_F@^OZ*^0/^'@G["G_1YO[+'_A^OAA_\T]'_#P3]A3_ */-_98_\/U\
M,/\ YIZ/[-S'_H78_P#\(<9_\RA]?P'_ $'8/_PJPW_S0?7]%?('_#P3]A3_
M */-_98_\/U\,/\ YIZ/^'@G["G_ $>;^RQ_X?KX8?\ S3T?V;F/_0NQ_P#X
M0XS_ .90^OX#_H.P?_A5AO\ YH/K^BOD#_AX)^PI_P!'F_LL?^'Z^&'_ ,T]
M'_#P3]A3_H\W]EC_ ,/U\,/_ )IZ/[-S'_H78_\ \(<9_P#,H?7\!_T'8/\
M\*L-_P#-!]?T5\@?\/!/V%/^CS?V6/\ P_7PP_\ FGH_X>"?L*?]'F_LL?\
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M ,T]']FYC_T+L?\ ^$.,_P#F4/K^ _Z#L'_X58;_ .:#Z_HKY _X>"?L*?\
M1YO[+'_A^OAA_P#-/1_P\$_84_Z/-_98_P##]?##_P":>C^S<Q_Z%V/_ /"'
M&?\ S*'U_ ?]!V#_ /"K#?\ S0?7]%?('_#P3]A3_H\W]EC_ ,/U\,/_ )IZ
M/^'@G["G_1YO[+'_ (?KX8?_ #3T?V;F/_0NQ_\ X0XS_P"90^OX#_H.P?\
MX58;_P":#Z_HKY _X>"?L*?]'F_LL?\ A^OAA_\ -/1_P\$_84_Z/-_98_\
M#]?##_YIZ/[-S'_H78__ ,(<9_\ ,H?7\!_T'8/_ ,*L-_\ -!_FZ;%]/U/^
M-&Q?3]3_ (TZBOZC/YZN^XW8OI^I_P :-B^GZG_&G44!=]QNQ?3]3_C1L7T_
M4_XTZB@+ON-V+Z?J?\:-B^GZG_&G44!=]QNQ?3]3_C1L7T_4_P"-.HH"[[C=
MBGJ,_G7]&?\ P;: +^TE^T<  !_PH_PYP/?Q_;U_.=7]&7_!MK_R<G^T=_V0
M_P -_P#J?V]?-<9?\DOG7_8(O_4G"GT'"S?^L&5Z_P#+^?\ ZC8D_L3*J/F
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M;;[I==-K7TO>Z'=]_(38OI^I_P :-B^GZG_&G44"N^XW8OI^I_QHV+Z?J?\
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M=(K,8O$S@DN?"-X-\JFG']-_^"@G['=C\!;G1?@Y\'?AGK'BKQ_X5T7]K/\
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M^"/BMK%R(H(9+S5?CE\2I;R>.W4+$MQ=6VN6LTNU<@;G.W+;=N:6Y_X(&_\
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MM,T+Q?X6TV+X=^"([#PQ\0)+V;QWX<L4\,:8MIH/C6?4;S4-0F\7Z1 (]/\
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M7,4MG<?\(UXJT^WB\-^&-*O;??97MC\.]+\.:7J<<2KJD%_.C3-^9W[?G_!
MWX=^/=)U/XC_ +$-GIOPO^(=E!=7VH_!74=2N8_A?X]*!YVMO"%_J<UR_P ,
MO%$Y+0:?:M</\.KUX[/3I]/\%PS7WB>/^97PK\2?VMOV%OB7K?A?PKXN^,?[
M,_Q*T*^C?Q+X)%WJ?AE+F<-^XNO$/@?5$N?"/C'3+M(UFT[4M3T37M#U6T\B
M^TN[O+5K>Y?[NI0CQE@JBR?B&IA7;FQ.3U\)A\&FTN52Q+P$H8C%*5U;%5)8
MNE-N3E3A-RC+Y"G5?"V*@\SR.&)N[4,SI8FOB;)W?+AEC%*AAY0O+]Q&.&J1
M32A/DU7^EJJA1@?F>I^OOS7.:?XP\*:MXB\1^$=*\3^'=3\5^#XM$G\6^&-/
MUK3KWQ#X7M_$T%Y=>')_$6BVUS)J.B0^(+73[ZYT234[:V35;>RNY[%IXK>5
ME_ACB_X+U_\ !1VR\+76AW/Q ^%-Q>-"V?'E_P#"'0$\7V(51FXB6SO[#P"K
M+C?_ *;X$NH1SE",*/Z$?^")GP)^,WA3X-?%3]J+]H[4O$VI_&O]LGQIHGQ$
MU6?QB'3Q1+X"\+:3=Z9\/K_Q!:RPVXTR[UD:SXAUG1M%MK>TL=$\$7_@_2;3
M3M)2R;2[/XK-^$,9D> K8S,L7@X2<Z='!8?#U)5ZN+JSG>JVITZ+I4J%",ZE
M25I24W2BTE+7ZO+>)L-F^+IX; 8;%22A4JXJM7A&G##TXQM32<:M7VE2K6<8
M15XQY5.6LE9?+7_!RQ+'#\ /V9I)9$B1?CMKQ9Y&5$7_ (MIXD/S,Q"@'&,D
M@<XSDC/\?0U73#G.IV/!Q_Q^6WM_M]/2O]!/]O&UM;W]J/\ X)66E[:VU[:S
M_M;_ !%2>UNX(KFVF0?LN?&B15E@F1XI LB)(@=3MDC21<.BD?HVO@?P454_
M\(?X6Y4'_D7M(]/^O.OH<EXPAPYDF68667RQGUC^T,3SQQ,:/+;,)T>5QE1J
M7^#F33BM;--ZGCYMPQ/.\WS#$QQL,-[%X.AR2P\ZW-_L<:G->-6G;XN6UNG4
M_P M+^U-,_Z"=C_X&6W_ ,71_:FF?]!.Q_\  RV_^+K_ %+_ /A!O!/_ $)_
MA;_PG])_^1*/^$&\$_\ 0G^%O_"?TG_Y$KT?^(H4O^A)4_\ "^G_ /,IP_\
M$/ZW_0UH_P#A#5_^:3_+0_M33/\ H)V/_@9;?_%T?VIIG_03L?\ P,MO_BZ_
MU+_^$&\$_P#0G^%O_"?TG_Y$H_X0;P3_ -"?X6_\)_2?_D2C_B*%+_H25/\
MPOI__,H?\0_K?]#6C_X0U?\ YI/\M#^U-,_Z"=C_ .!EM_\ %T?VIIG_ $$[
M'_P,MO\ XNO]2_\ X0;P3_T)_A;_ ,)_2?\ Y$H_X0;P3_T)_A;_ ,)_2?\
MY$H_XBA2_P"A)4_\+Z?_ ,RA_P 0_K?]#6C_ .$-7_YI/\M#^U-,_P"@G8_^
M!EM_\71_:FF?]!.Q_P# RV_^+K_4O_X0;P3_ -"?X6_\)_2?_D2C_A!O!/\
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M ,RA_P 0_K?]#6C_ .$-7_YI/\M#^U-,_P"@G8_^!EM_\71_:FF?]!.Q_P#
MRV_^+K_4O_X0;P3_ -"?X6_\)_2?_D2C_A!O!/\ T)_A;_PG])_^1*/^(H4O
M^A)4_P#"^G_\RA_Q#^M_T-:/_A#5_P#FD_RT/[4TS_H)V/\ X&6W_P 71_:F
MF?\ 03L?_ RV_P#BZ_U+_P#A!O!/_0G^%O\ PG])_P#D2C_A!O!/_0G^%O\
MPG])_P#D2C_B*%+_ *$E3_POI_\ S*'_ !#^M_T-:/\ X0U?_FD_RT/[4TS_
M *"=C_X&6W_Q=']J:9_T$['_ ,#+;_XNO]2__A!O!/\ T)_A;_PG])_^1*/^
M$&\$_P#0G^%O_"?TG_Y$H_XBA2_Z$E3_ ,+Z?_S*'_$/ZW_0UH_^$-7_ .:3
M_+0_M33/^@G8_P#@9;?_ !=']J:9_P!!.Q_\#+;_ .+K_4O_ .$&\$_]"?X6
M_P#"?TG_ .1*/^$&\$_]"?X6_P#"?TG_ .1*/^(H4O\ H25/_"^G_P#,H?\
M$/ZW_0UH_P#A#5_^:3_+0_M33/\ H)V/_@9;?_%T?VIIG_03L?\ P,MO_BZ_
MU+_^$&\$_P#0G^%O_"?TG_Y$H_X0;P3_ -"?X6_\)_2?_D2C_B*%+_H25/\
MPOI__,H?\0_K?]#6C_X0U?\ YI/\M#^U-,_Z"=C_ .!EM_\ %T?VIIG_ $$[
M'_P,MO\ XNO]2_\ X0;P3_T)_A;_ ,)_2?\ Y$H_X0;P3_T)_A;_ ,)_2?\
MY$H_XBA2_P"A)4_\+Z?_ ,RA_P 0_K?]#6C_ .$-7_YI/\M#^U-,_P"@G8_^
M!EM_\71_:FF?]!.Q_P# RV_^+K_4O_X0;P3_ -"?X6_\)_2?_D2C_A!O!/\
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M4?EJ/^"P'[)0Z>&?VK?_ !#O]H__ .=W2_\ #X']DO\ Z%G]JW_Q#O\ :/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mmq_logo-header2023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmq_logo-header2023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !A G # 2(  A$! Q$!_\0
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MD:_B]@L+5E0Q61_5:\.7GHXG,L30K0YES1YJ5;!4JD5*/O1<J<5*+33L]/\
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MO#/CS6M>C\>Z9X5U.[\7:MXCN?&'@G1-,U7V;X?_  E^+&B_&7PQ\0-1\/\
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M[P+X@\0:AJEFVBW'Q?\ $]QX\U_1/&^E6VG7$^K+X9\6:UK?]A76D:F9-?\
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MW7=AIOB*YT/PS<:Y9VTF8H-3F\/Z-)>1HL[:;:%S$(_L[ _] U/_ ,GZZ_\
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M  BOBW4-6\&/J&EZWJNBZU>>';S6_#^J:IX?O]*U"^^N<CU%']G8'_H%I?\
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M].T[Q%X>;Q/\NAVNN6.I:DFFQ6>H7UE%?ZGIWB#3-/N[G4O#'B6UTKQSX_?
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MA7J/A3Q1_P )IH/ACXI>(_&?@U?$.H'SO!C:MX8C-]:%(==70=5EBLY?N?\
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M:-\%/AUK5A)&@TW7/A5^S]X9^%7P]\1V,($3^-M \3ZT5-UK%W*WZ:_MU?\
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M+P]/X_M-,34+VX34M-6&P'A^RU'7]4N-'T?1-!\.IK-S9Z1:75 '\\G[0/\
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M<0V\<4UQ%8P/+#8QS2(TJV<,LD5L&\J.215\QM.@!NQ=I7:H4]@ !Z=,8X&
M..@%"HJ_=4#  X ' )(' ' ).!T&3CK3J* &!$'15'7HJC.3DDX'7.3]2?6@
M1H.BK_WRO)P1DX R<$CFGT4 ,$<8SA$&3DX4<D=">.HQQZ4>5'P0B@@8!"KP
M.!@9!P.!P/2GT4 ,"( 0% #=0  #SW&,'T^G%(8HR02B$J<C*J>0" <D9R 3
M@Y[GUJ2B@"/RH\%=J[222,#'(P>W<8S]!08HCG,:$'.1M&#D@GMZ@?7O4E%
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MT7^34R#_ %K_ .Z]%%>=+_?*?^-_G(O[+_PK_P!*9!>]$_W(_P#T=;U8MO\
M5'_KK+_,445O/_E__BI_G Q^W\G_ .E(>/NG_KI'_P"BQ3$^\OU3_P!'FBBN
MF?QS]5_Z0.'Q0_PS_(MIU'^Z?_0C4E%%*'PQ]$-;1_PK\@HHHJAA1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mmq_signature2023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmq_signature2023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !2 /L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BO._AC\
M5_A_\9?#^K^*?AMXA3Q+H6@_$3XK_"C5[U-.U?2FL?B!\#_B=XM^#GQ0\/2V
M>N:?IE\S^&/B-X%\4>'QJ,5M)I&MQZ;'KGAW4-7\.ZEI6K7WHE?E#_P2:@O=
M+\+_ +?7AR^>,RZ#_P %7?V_[B&WM[U[VWM;+QU\8)/BM8I$99Y9;66YM/'\
M.HW]D\=JEOJE]?"U@:R:VN;@ _5ZBOYF_P!K/Q5\0?VNKKX*_MX^&?B1\3_"
MO[.WPN_X*-?L _!+]A[P#X4\=7GA[X>?'?3_ !#^WK\"_AC\<?VS?&]AX(\3
MZ1'\3_"7Q?L]5\4_!3]F_P ,^.K_ %7P-%\ M,\4?''0+6]?]IW1+WP!^X_Q
M4_;-_9A^"?QP^!O[-7Q,^,'ASP[\?/VD=3O=,^#'PFAMM;\0>-O%YT^PUC4;
MS5Y=&\,Z5K,_A?PG%;Z!K40\:^,?^$?\(2ZAIMWI,.N2:K$UE0!].T444 %%
M%? ?P-_X*:?LA_M"_!3]K/\ :-^'?CW49_@=^Q;\1_C/\-OC9\2=2\.ZC#H,
M-W\ O >@_$?XE^*?",=@NI:KXK\%Z7X9UZ*XTW6-/TY;G7GL;U]'TV\LY-,O
M-1 /ORBN'^&7Q&\(?&'X;?#[XM_#W4Y]:\ _%+P/X3^(W@C6+G2M7T*XU;PA
MXWT'3_$WAK4Y]$\06&EZ]H\U_HNJ65U+I6MZ9IVKZ=)*UGJ5C:7L,]O'W% !
M1110 445X1^TM^T=\,?V3/@WXB^/'QDU"_TGX<>$]<^'NA^(M7T^TBO'TAOB
M3\2/"7POT75;Y)[JSAMM#TSQ!XSTJ^\1ZG-<I#H_A^#4]6E$B631. >[T45X
M#\(?VJOV;OC]XX^-'PT^"GQN^&WQ1\??LZ^+8/ GQQ\)>"O%.F:]KGPP\77#
M:E#%H?BRRLII)-.N_MVB:_HTI.^"#Q#X:\4>')Y8]>\,Z]IVG 'OU%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5_,UIWB3QMXA^$O[;7[*_PH\3
MW?A;XF?\% _^"SW[3?[+GA_QKX>U6RL/$WP^^$#^#?#FO_M:_%;PI<>:)M.\
M6_#C]GWX6?&?3_ .N!&BT?XX7WPTM[M9+G4;2RO?Z9:_F\_X(]:%:?&;]KW]
MM_XS16-H/"7[)?[3G_!1;]G+PW<PV4975/V@_P!I/_@H=\:/V@OVA/$TNH>1
M&NHW.G_LX^%?V O!6C7JR7$^DQ6GC31$.GK=:E#J ![9_P %G_$WPQ_9!_9"
M_8JU>S\*ZEX>^!'[/7[>G["NHI\+_A-H&IS7,O@/X$>)9O%WP\^%W@#P/X72
MWCU6]D\0^ ? WAWX>^$9I=-\.-XCA\,6^IWNGZ5:RSQ?.H_9O\<>#_V_?^"1
M]_\ 'NW\/^)_VG?VEOC/^V%^W7^V/<6=GI&IZ-I/BSX)_LCZS\,/@5\(O"NI
MS27E]>?"C]BUOVE](^%_P5O;;4VM[S6;GQ7\8+O0H/'OQA\<:V/WF_:!_9N^
M&/[3&C_#+1/BA::Q<VOPB^/?P6_:1\$2Z)J\^CW%C\3O@+XZTOX@>!+N\:))
M8M1T<ZQI:6FM:1=PR0:AI=U=0QO:7GV6^M?B7]I"STP_\%<O^"7.I:JT\;0_
MLW?\%.-+\//#<0HLOBG4G_8BOHK6ZMC'+<3VK^$M$\977F(+>WM[RRLA<7B2
MS6EEJ !]T_M#?M'? _\ 90^$_B;XX?M#_$?0?A=\+_"44+:OXFUW[=<O/>WD
MGD:7H/A[0M&L]3\2>+_%NNW933_#7@WPEH^M^*_$VJ2PZ7X?T;4M1GAM7WO@
MM\9?AG^T1\)/AQ\=?@SXKL_'/PI^+?@W0/'WP^\76-KJ>GP:]X5\3:?!J>DW
MSZ7K=CIFNZ->-;7"1ZCH>OZ7I>O:'J$=UI.MZ9I^J6=W9P_A?_P5-E^'NG?M
ML_"CQ!^UMXR\1_ CX V'[%OQT\,?L8_M87'P]N_'GPE_9N_X*(_$?Q5IGAP_
M%#Q/<Z1;7EAX2^.W@_X<V_@77?V6=2^*<GA[POK&NV_Q+T/X:^);;XDW M9O
MOK_@F%XE^ _A/]BCX5_"?X5_'G4OCMX<_9J^&OAKP7\0/CMXD\&>,OA[X=\3
M^);+1IM<\7>)K*[\::/I>BVNCR7KZCK<>@Z1KWB*/P%X8O= TW6-7FB?3]2U
M( _22OXM+S_@GY\"OBI\#M,U/X;Q_%[P_P""?^"GO_!:WQ?HW@/X+_#7XY_&
M[P/^RKXJ_9C\)_'K5?B#X]^)>K_LP:!XN@^"OC+3?B%^RO\ L4_$_P =>#M?
MUGP/J.DZCX>^(O@_6(FT_2-#\ #P3^Q_[7G[7GQM_;<^"OQO_9Y_X(VZIH/Q
M/^).J^"=9T+7/VX[7Q0=)_91^$D][H?]H7?A'X3_ !QTK1_$N@?&_P#:(\16
M,T?@_2--^$,NO>%O@)KFNR^-/C+X\\%^(_".A_#OQS^8?P?_ ."E'@GXG?'?
M_@F)I'PR_P""8W_!0[P;X9_8S_9O_:VLO#W[-?AGX2^$/&UYX4^*'PPTW]F_
M]CI?#'@#QSXF^,WA?PSK&F_L[Z3X]^,_P:^)6L_$34O!7Q8^'VJ>(?"6F_$C
MX=>"W^)$C0@']>5M;6UE;6]G9V\%I:6D$5M:VMM%'!;6UM!&L4%O;P1*D4,$
M,2+'%%&JQQQJJ(H4 ":OYG?C3_P5K^-W[+7[;E[X_P#V\/@E\:/V0OV9+?\
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M3]HOQQH%_P#&RRTS7'TF]\7:K\-]&US2O#ES\1]?UGQ2ES#IE[<>&)OU$HH
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MO"7[1'P)U7Q1I/CZR\-'X@>'#XN^&?C_ .'WQ'T*TTO3_B)\(_BCX<BU"_\
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MO"?P\_:!_:/_ &;?''_!0I/VQOVI?VZ?V2-,^$?BC]K;]LF#4O"7@;Q=H'P
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M;W5$MIX-)M_#6B?$?5O$AOKR6PA\S28[2#4;/4+JRDK]%/@/\'?"?[._P/\
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M%S1TN_A[\0=?\-V%K:3>-]/\$>(=?;P5/K>B:9XEDTW6+XZ=#Y1%_P $O_\
M@FC!J\OB"#_@GA^PQ#KT]^NJSZW%^R5\ H]7FU1-1AU=-2EU)/A^+V2_35K>
MWU1;QYC<+J,$-Z)!<Q)*OVSIFF:;HFFZ?HVC:?8Z1H^D6-IIFE:5IEI;V&FZ
M9IMA;QVMCI^GV-K'%:V5C96L45M:6EM%%;VUO%'##&D:*H //_!OQC^'7Q \
M=?%_X:^$]?EU/QK\!_$GA;PE\5-&ET/Q%I0\-Z[XT\ ^&OB?X:MK?4M8TC3]
M(\2VNI>"O%^@ZH-5\)ZAKNDVEW<7F@7]]:^(M'UG2=/].HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>krmd-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6I5w7xRiXgen8uPa3csWaSKeaPtzJZyKekxvmx3HWnq7y8j0L8MryFF1g8GscgE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:krmd="http://korumedical.com/20241231" elementFormDefault="qualified" targetNamespace="http://korumedical.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://korumedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - BALANCE SHEETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999012 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Inventory" id="Inventory">
          <link:definition>999013 - Disclosure - INVENTORY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999014 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999015 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/DebtObligations" id="DebtObligations">
          <link:definition>999016 - Disclosure - DEBT OBLIGATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Leases" id="Leases">
          <link:definition>999017 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" id="FederalAndStateIncomeTaxes">
          <link:definition>999018 - Disclosure - FEDERAL AND STATE INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/MajorCustomers" id="MajorCustomers">
          <link:definition>999019 - Disclosure - MAJOR CUSTOMERS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/EmployeeBenefits" id="EmployeeBenefits">
          <link:definition>999021 - Disclosure - EMPLOYEE BENEFITS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/SegmentDisclosure" id="SegmentDisclosure">
          <link:definition>999022 - Disclosure - SEGMENT DISCLOSURE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999024 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/InventoryTables" id="InventoryTables">
          <link:definition>999025 - Disclosure - INVENTORY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999027 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999028 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" id="FederalAndStateIncomeTaxesTables">
          <link:definition>999029 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" id="EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails">
          <link:definition>999030 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" id="FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details">
          <link:definition>999031 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999032 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" id="InventoryConsistsOfDetails">
          <link:definition>999033 - Disclosure - Inventory consists of: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" id="PropertyAndEquipmentConsistsOfFollowingAtDetails">
          <link:definition>999034 - Disclosure - Property and equipment consists of the following at: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" id="ScheduleOfTimeBasedStockOptionsDetails">
          <link:definition>999035 - Disclosure - Schedule of time based stock options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" id="ScheduleOfStatusOfTimeBasedStockOptionsDetails">
          <link:definition>999036 - Disclosure - Schedule of status of time based stock options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" id="ScheduleOfInformationPertainingToOptionsOutstandingDetails">
          <link:definition>999037 - Disclosure - Schedule of information pertaining to options outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" id="FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details">
          <link:definition>999038 - Disclosure - The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" id="FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details">
          <link:definition>999039 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999040 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" id="DebtObligationsDetailsNarrative">
          <link:definition>999041 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" id="ComponentsOfLeaseExpenseWereAsFollowsDetails">
          <link:definition>999042 - Disclosure - The components of lease expense were as follows: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" id="SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails">
          <link:definition>999043 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails" id="SupplementalInformationRelatedToLeasesWasAsFollowsDetails">
          <link:definition>999044 - Disclosure - Supplemental information related to leases was as follows: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" id="MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails">
          <link:definition>999045 - Disclosure - Maturities of lease liabilities are as follows: (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" id="ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails">
          <link:definition>999046 - Disclosure - Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
          <link:definition>999047 - Disclosure - Schedule of provision for income taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsDetails">
          <link:definition>999048 - Disclosure - Schedule of components of deferred tax assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:definition>999049 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative" id="FederalAndStateIncomeTaxesDetailsNarrative">
          <link:definition>999050 - Disclosure - FEDERAL AND STATE INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" id="MajorCustomersDetailsNarrative">
          <link:definition>999051 - Disclosure - MAJOR CUSTOMERS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" id="EmployeeBenefitsDetailsNarrative">
          <link:definition>999052 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="krmd-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="krmd_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_EquipmentAndToolingMember" name="EquipmentAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ManufacturingEquipmentAndToolingMember" name="ManufacturingEquipmentAndToolingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_OmnibusEquityIncentivePlan2021Member" name="OmnibusEquityIncentivePlan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_OmnibusEquityIncentivePlan2024Member" name="OmnibusEquityIncentivePlan2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonEmployeeDirectorAndBoardAdvisorMember" name="NonEmployeeDirectorAndBoardAdvisorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockOptionPlans2015And2021CombinedMember" name="StockOptionPlans2015And2021CombinedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TimeVestingStockOptionsMember" name="TimeVestingStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PerformanceVestingStockOptionsMember" name="PerformanceVestingStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ExercisePrice1Member" name="ExercisePrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DomesticBankLenderMember" name="DomesticBankLenderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SecurityAgreementMember" name="SecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" name="StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" name="StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" name="AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodUponOptionExercised" name="StockIssuedDuringPeriodUponOptionExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockIssuedDuringPeriodSharesUponOptionExercised" name="StockIssuedDuringPeriodSharesUponOptionExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" name="PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NoncashLeaseAdjustments" name="NoncashLeaseAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_BorrowingsFromIndebtedness" name="BorrowingsFromIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_PaymentsOnIndebtedness" name="PaymentsOnIndebtedness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CashPaidDuringPeriodsForAbstract" name="CashPaidDuringPeriodsForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfNetSalesByGeography" name="ScheduleOfNetSalesByGeography" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss" name="ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_AmortizationOfIntangibleAssets1" name="AmortizationOfIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DepreciationAndAmortizationPropertyAndEquipment" name="DepreciationAndAmortizationPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" name="ShareBasedCompensationArrangementByUnvestedAwardOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharesReservedForOutstandingAwards" name="SharesReservedForOutstandingAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_SharesAvailableForIssuanceShareBasedCompensation" name="SharesAvailableForIssuanceShareBasedCompensation" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NonemployeeServicesTransactionCost" name="NonemployeeServicesTransactionCost" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockBasedCompensationStockOptions" name="StockBasedCompensationStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_CashReceivedFromOptionExercise" name="CashReceivedFromOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StockbasedCompensationIntrinsicValue" name="StockbasedCompensationIntrinsicValue" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_UnrecognizedCompensationCost" name="UnrecognizedCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LinesOfCreditCurrent1" name="LinesOfCreditCurrent1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DebtInstrumentInterestPaymentTerms" name="DebtInstrumentInterestPaymentTerms" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost1Abstract" name="FinanceLeaseCost1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseCost" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour" name="FinanceLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" name="LesseeOperatingLeaseLiabilityPaymentsDueTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" name="LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeOperatingLeaseImputedInterest" name="LesseeOperatingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LesseeFinancingLeaseImputedInterest" name="LesseeFinancingLeaseImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_LossBeforeIncomeTaxes" name="LossBeforeIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DeferredTaxAssetsAbstract" name="DeferredTaxAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DeferredTaxAssetsNetOperatingLoss" name="DeferredTaxAssetsNetOperatingLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DeferredTaxAssetsCredits" name="DeferredTaxAssetsCredits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DeferredTaxAssetsNQOAndRSAStockOptions" name="DeferredTaxAssetsNQOAndRSAStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DeferredTaxAssetsDeferredLeaseLiability" name="DeferredTaxAssetsDeferredLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DeferredTaxLiabilitiesIntangibles" name="DeferredTaxLiabilitiesIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DeferredTaxLiabilitiesROUAssets" name="DeferredTaxLiabilitiesROUAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IncomeTaxReconciliationChangeInValuationAllowance" name="IncomeTaxReconciliationChangeInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IncomeTaxReconciliationDeferredTaxTrueUps" name="IncomeTaxReconciliationDeferredTaxTrueUps" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IncomeTaxReconciliationOtherItems" name="IncomeTaxReconciliationOtherItems" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_IncomeTaxReconciliationNet" name="IncomeTaxReconciliationNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets" name="NetChangeInValuationOfAllowanceOnDeferredTaxAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NetOperatingLossCarryforwardsFederal" name="NetOperatingLossCarryforwardsFederal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_NetOperatingLossCarryforwardsStateAndLocal" name="NetOperatingLossCarryforwardsStateAndLocal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_FederalResearchCreditCarryforward" name="FederalResearchCreditCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_StateResearchCreditCarryforward" name="StateResearchCreditCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="krmd_DescriptionOfMatchingContribution" name="DescriptionOfMatchingContribution" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>krmd-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20241231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20241231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20241231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SegmentDisclosure" xlink:href="krmd-20241231.xsd#SegmentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:href="krmd-20241231.xsd#EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20241231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20241231.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20241231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20241231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20241231.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20241231.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20241231.xsd#SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20241231.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:href="krmd-20241231.xsd#ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="krmd-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20241231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20241231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NoncashLeaseAdjustments" xlink:label="loc_krmdNoncashLeaseAdjustments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_krmdNoncashLeaseAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="loc_krmdBorrowingsFromIndebtedness" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdBorrowingsFromIndebtedness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="loc_krmdPaymentsOnIndebtedness" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_krmdPaymentsOnIndebtedness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForOtherTaxes" xlink:label="loc_us-gaapPaymentsForOtherTaxes" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForOtherTaxes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="999012 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="999013 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="999014 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="999015 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="999016 - Disclosure - DEBT OBLIGATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="999017 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="999018 - Disclosure - FEDERAL AND STATE INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="999019 - Disclosure - MAJOR CUSTOMERS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="999021 - Disclosure - EMPLOYEE BENEFITS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SegmentDisclosure" xlink:title="999022 - Disclosure - SEGMENT DISCLOSURE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="999025 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="999027 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="999028 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="999029 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:title="999030 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:title="999031 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="999033 - Disclosure - Inventory consists of: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="999034 - Disclosure - Property and equipment consists of the following at: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="999035 - Disclosure - Schedule of time based stock options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="999036 - Disclosure - Schedule of status of time based stock options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="999037 - Disclosure - Schedule of information pertaining to options outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:title="999038 - Disclosure - The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:title="999039 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999040 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="999041 - Disclosure - DEBT OBLIGATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="999042 - Disclosure - The components of lease expense were as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="999043 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="999044 - Disclosure - Supplemental information related to leases was as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="999045 - Disclosure - Maturities of lease liabilities are as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:title="999046 - Disclosure - Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999047 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="999048 - Disclosure - Schedule of components of deferred tax assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999049 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative" xlink:title="999050 - Disclosure - FEDERAL AND STATE INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="999051 - Disclosure - MAJOR CUSTOMERS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="999052 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>krmd-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20241231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20241231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20241231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SegmentDisclosure" xlink:href="krmd-20241231.xsd#SegmentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:href="krmd-20241231.xsd#EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20241231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20241231.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20241231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20241231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20241231.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20241231.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20241231.xsd#SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20241231.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:href="krmd-20241231.xsd#ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="krmd-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20241231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20241231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" xlink:label="loc_krmdStockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdStockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" xlink:label="loc_krmdStockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdStockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" xlink:label="loc_krmdAdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdAdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockIssuedDuringPeriodUponOptionExercised" xlink:label="loc_krmdStockIssuedDuringPeriodUponOptionExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodUponOptionExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockIssuedDuringPeriodSharesUponOptionExercised" xlink:label="loc_krmdStockIssuedDuringPeriodSharesUponOptionExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesUponOptionExercised_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" xlink:label="loc_krmdPaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdPaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_60" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="999012 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="999013 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="999014 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="999015 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="999016 - Disclosure - DEBT OBLIGATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="999017 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="999018 - Disclosure - FEDERAL AND STATE INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="999019 - Disclosure - MAJOR CUSTOMERS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="999021 - Disclosure - EMPLOYEE BENEFITS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SegmentDisclosure" xlink:title="999022 - Disclosure - SEGMENT DISCLOSURE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="999025 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="999027 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="999028 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="999029 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:title="999030 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:title="999031 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="loc_krmdPatentsAndTrademarksMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_krmdPatentsAndTrademarksMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_EquipmentAndToolingMember" xlink:label="loc_krmdEquipmentAndToolingMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdEquipmentAndToolingMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaapInterestIncomeSecuritiesUSTreasury_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInterestIncomeSecuritiesUSTreasury_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="loc_krmdAmortizationOfIntangibleAssets1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAmortizationOfIntangibleAssets1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:label="loc_krmdDepreciationAndAmortizationPropertyAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdDepreciationAndAmortizationPropertyAndEquipment_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaapContractWithCustomerAssetReclassifiedToReceivable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapContractWithCustomerAssetReclassifiedToReceivable_110" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="999033 - Disclosure - Inventory consists of: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="999034 - Disclosure - Property and equipment consists of the following at: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="999035 - Disclosure - Schedule of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="999036 - Disclosure - Schedule of status of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="999037 - Disclosure - Schedule of information pertaining to options outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:title="999038 - Disclosure - The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PerformanceVestingStockOptionsMember" xlink:label="loc_krmdPerformanceVestingStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceVestingStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:title="999039 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999040 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_OmnibusEquityIncentivePlan2021Member" xlink:label="loc_krmdOmnibusEquityIncentivePlan2021Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdOmnibusEquityIncentivePlan2021Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_OmnibusEquityIncentivePlan2024Member" xlink:label="loc_krmdOmnibusEquityIncentivePlan2024Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdOmnibusEquityIncentivePlan2024Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="loc_krmdStockOptionPlans2015And2021CombinedMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlans2015And2021CombinedMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PerformanceVestingStockOptionsMember" xlink:label="loc_krmdPerformanceVestingStockOptionsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceVestingStockOptionsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SharesReservedForOutstandingAwards" xlink:label="loc_krmdSharesReservedForOutstandingAwards_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesReservedForOutstandingAwards_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="loc_krmdSharesAvailableForIssuanceShareBasedCompensation_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesAvailableForIssuanceShareBasedCompensation_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:label="loc_us-gaapDeferredCompensationArrangementsOverallDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementsOverallDescription_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="loc_krmdStockBasedCompensationStockOptions_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockBasedCompensationStockOptions_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_CashReceivedFromOptionExercise" xlink:label="loc_krmdCashReceivedFromOptionExercise_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdCashReceivedFromOptionExercise_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockbasedCompensationIntrinsicValue" xlink:label="loc_krmdStockbasedCompensationIntrinsicValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockbasedCompensationIntrinsicValue_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_UnrecognizedCompensationCost" xlink:label="loc_krmdUnrecognizedCompensationCost_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdUnrecognizedCompensationCost_140" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="999041 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DomesticBankLenderMember" xlink:label="loc_krmdDomesticBankLenderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdDomesticBankLenderMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TermLoanFacilityMember" xlink:label="loc_krmdTermLoanFacilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_krmdTermLoanFacilityMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SecurityAgreementMember" xlink:label="loc_krmdSecurityAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdSecurityAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LinesOfCreditCurrent1" xlink:label="loc_krmdLinesOfCreditCurrent1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_krmdLinesOfCreditCurrent1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DebtInstrumentInterestPaymentTerms" xlink:label="loc_krmdDebtInstrumentInterestPaymentTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_krmdDebtInstrumentInterestPaymentTerms_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="999042 - Disclosure - The components of lease expense were as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="999043 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="999044 - Disclosure - Supplemental information related to leases was as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="999045 - Disclosure - Maturities of lease liabilities are as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:title="999046 - Disclosure - Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999047 - Disclosure - Schedule of provision for income taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="999048 - Disclosure - Schedule of components of deferred tax assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999049 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative" xlink:title="999050 - Disclosure - FEDERAL AND STATE INCOME TAXES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="999051 - Disclosure - MAJOR CUSTOMERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_CustomerOneMember" xlink:label="loc_krmdCustomerOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_krmdCustomerOneMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="999052 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PerformanceVestingStockOptionsMember" xlink:label="loc_krmdPerformanceVestingStockOptionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceVestingStockOptionsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>krmd-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="krmd_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PatentsAndTrademarksMember" xlink:to="krmd_PatentsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PatentsAndTrademarksMember_lbl" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="krmd_FurnitureAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FurnitureAndOfficeEquipmentMember" xlink:to="krmd_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_EquipmentAndToolingMember" xlink:label="krmd_EquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_EquipmentAndToolingMember" xlink:to="krmd_EquipmentAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_EquipmentAndToolingMember_lbl" xml:lang="en-US">Equipment And Tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">Non-US [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="krmd_ManufacturingEquipmentAndToolingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ManufacturingEquipmentAndToolingMember" xlink:to="krmd_ManufacturingEquipmentAndToolingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ManufacturingEquipmentAndToolingMember_lbl" xml:lang="en-US">Manufacturing Equipment And Tooling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockOptionPlan2015Member" xlink:label="krmd_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_OmnibusEquityIncentivePlan2021Member" xlink:label="krmd_OmnibusEquityIncentivePlan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_OmnibusEquityIncentivePlan2021Member" xlink:to="krmd_OmnibusEquityIncentivePlan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_OmnibusEquityIncentivePlan2021Member_lbl" xml:lang="en-US">Omnibus Equity Incentive Plan 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_OmnibusEquityIncentivePlan2024Member" xlink:label="krmd_OmnibusEquityIncentivePlan2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_OmnibusEquityIncentivePlan2024Member" xlink:to="krmd_OmnibusEquityIncentivePlan2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_OmnibusEquityIncentivePlan2024Member_lbl" xml:lang="en-US">Omnibus Equity Incentive Plan 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_lbl" xml:lang="en-US">Non Employee Director and Board Advisor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="krmd_StockOptionPlans2015And2021CombinedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlans2015And2021CombinedMember" xlink:to="krmd_StockOptionPlans2015And2021CombinedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockOptionPlans2015And2021CombinedMember_lbl" xml:lang="en-US">Stock Option Plans 2015 And 2021 Combined [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="krmd_TimeVestingStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TimeVestingStockOptionsMember" xlink:to="krmd_TimeVestingStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TimeVestingStockOptionsMember_lbl" xml:lang="en-US">Time Vesting Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PerformanceVestingStockOptionsMember" xlink:label="krmd_PerformanceVestingStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PerformanceVestingStockOptionsMember" xlink:to="krmd_PerformanceVestingStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PerformanceVestingStockOptionsMember_lbl" xml:lang="en-US">Performance Vesting Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="krmd_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ExercisePrice1Member" xlink:label="krmd_ExercisePrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ExercisePrice1Member_lbl" xml:lang="en-US">Exercise Price1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DomesticBankLenderMember" xlink:label="krmd_DomesticBankLenderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DomesticBankLenderMember" xlink:to="krmd_DomesticBankLenderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DomesticBankLenderMember_lbl" xml:lang="en-US">Domestic Bank Lender [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TermLoanFacilityMember" xlink:label="krmd_TermLoanFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TermLoanFacilityMember" xlink:to="krmd_TermLoanFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_TermLoanFacilityMember_lbl" xml:lang="en-US">Term Loan Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SecurityAgreementMember" xlink:label="krmd_SecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SecurityAgreementMember" xlink:to="krmd_SecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SecurityAgreementMember_lbl" xml:lang="en-US">Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_CustomerOneMember" xlink:label="krmd_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CustomerOneMember" xlink:to="krmd_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization of $458,538 and $390,341 at December 31, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability &#8211; current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease liability, net current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Refer to Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value, 75,000,000 shares authorized, 49,377,617 and 49,089,864 shares issued; 45,957,115 and 45,669,362 shares outstanding at December 31, 2024, and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 3,438,526 and 3,420,502 shares at December 31, 2024 and December 31, 2023, respectively, at cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="us-gaap_TreasuryStockPreferredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockPreferredShares" xlink:to="us-gaap_TreasuryStockPreferredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockPreferredShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">NET REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Net Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Non-Operating Income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Loss on foreign currency exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">LOSS BEFORE TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" xlink:label="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" xlink:to="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity_lbl" xml:lang="en-US">Accrued compensation paid in shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" xlink:label="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" xlink:to="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares_lbl" xml:lang="en-US">Accrued compensation paid (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Compensation expense related to stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Compensation expense related to restricted stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" xlink:label="krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" xlink:to="krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts_lbl" xml:lang="en-US">Compensation expense related to restricted stock awards (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockIssuedDuringPeriodUponOptionExercised" xlink:label="krmd_StockIssuedDuringPeriodUponOptionExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodUponOptionExercised" xlink:to="krmd_StockIssuedDuringPeriodUponOptionExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockIssuedDuringPeriodUponOptionExercised_lbl" xml:lang="en-US">Issuance upon options exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockIssuedDuringPeriodSharesUponOptionExercised" xlink:label="krmd_StockIssuedDuringPeriodSharesUponOptionExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockIssuedDuringPeriodSharesUponOptionExercised" xlink:to="krmd_StockIssuedDuringPeriodSharesUponOptionExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockIssuedDuringPeriodSharesUponOptionExercised_lbl" xml:lang="en-US">Issuance upon options exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" xlink:label="krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" xlink:to="krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards_lbl" xml:lang="en-US">Payments for taxes related to net share settlement of equity awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense and warrant expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US">Deferred income taxes, net of allowance for non-realization of deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NoncashLeaseAdjustments" xlink:label="krmd_NoncashLeaseAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NoncashLeaseAdjustments" xlink:to="krmd_NoncashLeaseAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NoncashLeaseAdjustments_lbl" xml:lang="en-US">Non-cash leasing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Decrease in other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Decrease in prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase in accrued payroll and related taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Decrease in other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds on disposals of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="krmd_BorrowingsFromIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_BorrowingsFromIndebtedness" xlink:to="krmd_BorrowingsFromIndebtedness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_BorrowingsFromIndebtedness_lbl" xml:lang="en-US">Borrowings from insurance finance indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="krmd_PaymentsOnIndebtedness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_PaymentsOnIndebtedness_lbl" xml:lang="en-US">Payments on insurance finance indebtedness</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForOtherTaxes" xlink:label="us-gaap_PaymentsForOtherTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOtherTaxes" xlink:to="us-gaap_PaymentsForOtherTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForOtherTaxes_lbl" xml:lang="en-US">Payments for taxes related to net share settlement of equity awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH USED IN FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Information</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_CashPaidDuringPeriodsForAbstract" xlink:label="krmd_CashPaidDuringPeriodsForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashPaidDuringPeriodsForAbstract" xlink:to="krmd_CashPaidDuringPeriodsForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CashPaidDuringPeriodsForAbstract_lbl" xml:lang="en-US">Cash paid during the years for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT OBLIGATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">FEDERAL AND STATE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">MAJOR CUSTOMERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT DISCLOSURE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">IMPAIRMENT OF LONG-LIVED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">The estimated amortization expense for the succeeding years for the intangible assets is approximately:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ScheduleOfNetSalesByGeography" xlink:label="krmd_ScheduleOfNetSalesByGeography" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfNetSalesByGeography" xlink:to="krmd_ScheduleOfNetSalesByGeography_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfNetSalesByGeography_lbl" xml:lang="en-US">The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventory consists of:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and equipment consists of the following at:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of time based stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of status of time based stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_lbl" xml:lang="en-US">Schedule of information pertaining to options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US">The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">The components of lease expense were as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Supplemental cash flow information related to leases was as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Supplemental information related to leases was as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Maturities of lease liabilities are as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss" xlink:label="krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss" xlink:to="krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss_lbl" xml:lang="en-US">Schedule of Components of Domestic and International Pre-Tax Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:to="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeSecuritiesUSTreasury_lbl" xml:lang="en-US">Investment securities treasury bill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="krmd_AmortizationOfIntangibleAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_AmortizationOfIntangibleAssets1" xlink:to="krmd_AmortizationOfIntangibleAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_AmortizationOfIntangibleAssets1_lbl" xml:lang="en-US">Amortization expense of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:label="krmd_DepreciationAndAmortizationPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:to="krmd_DepreciationAndAmortizationPropertyAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DepreciationAndAmortizationPropertyAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization, property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:to="us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_lbl" xml:lang="en-US">Recognition of contract asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xml:lang="en-US">Raw materials and work-in-process</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Less: reserve for obsolete inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning, price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at ending (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at ending, price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value of options granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_lbl" xml:lang="en-US">Unvested at beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Unvested at beginning, price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl" xml:lang="en-US">Granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Granted, price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_lbl" xml:lang="en-US">Vested, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Vested, price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_lbl" xml:lang="en-US">Forfeited/canceled, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Forfeited/canceled, price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_2_lbl" xml:lang="en-US">Unvested at ending, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Unvested at ending, price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_lbl" xml:lang="en-US">Outstanding at beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Outstanding at beginning, price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_lbl" xml:lang="en-US">Granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Granted, price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xml:lang="en-US">Vested, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested, price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_lbl" xml:lang="en-US">Forfeited/canceled, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_lbl" xml:lang="en-US">Forfeited/canceled, price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2_lbl" xml:lang="en-US">Outstanding at ending, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2_lbl" xml:lang="en-US">Outstanding at ending, price</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SharesReservedForOutstandingAwards" xlink:label="krmd_SharesReservedForOutstandingAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesReservedForOutstandingAwards" xlink:to="krmd_SharesReservedForOutstandingAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SharesReservedForOutstandingAwards_lbl" xml:lang="en-US">Shares reserved for outstanding awards</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:to="krmd_SharesAvailableForIssuanceShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation_lbl" xml:lang="en-US">Shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="krmd_NonemployeeServicesTransactionCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NonemployeeServicesTransactionCost_lbl" xml:lang="en-US">Nonemployee services transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:to="us-gaap_DeferredCompensationArrangementsOverallDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription_lbl" xml:lang="en-US">Share-based goods and non-employee services transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="krmd_StockBasedCompensationStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationStockOptions" xlink:to="krmd_StockBasedCompensationStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockBasedCompensationStockOptions_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_CashReceivedFromOptionExercise" xlink:label="krmd_CashReceivedFromOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashReceivedFromOptionExercise" xlink:to="krmd_CashReceivedFromOptionExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_CashReceivedFromOptionExercise_lbl" xml:lang="en-US">Cash received from option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockbasedCompensationIntrinsicValue" xlink:label="krmd_StockbasedCompensationIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockbasedCompensationIntrinsicValue" xlink:to="krmd_StockbasedCompensationIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StockbasedCompensationIntrinsicValue_lbl" xml:lang="en-US">Stock-based compensation intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_UnrecognizedCompensationCost" xlink:label="krmd_UnrecognizedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_UnrecognizedCompensationCost" xlink:to="krmd_UnrecognizedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_UnrecognizedCompensationCost_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Revolving credit facility</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LinesOfCreditCurrent1" xlink:label="krmd_LinesOfCreditCurrent1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LinesOfCreditCurrent1" xlink:to="krmd_LinesOfCreditCurrent1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LinesOfCreditCurrent1_lbl" xml:lang="en-US">Term loan facility</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DebtInstrumentInterestPaymentTerms" xlink:label="krmd_DebtInstrumentInterestPaymentTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DebtInstrumentInterestPaymentTerms" xlink:to="krmd_DebtInstrumentInterestPaymentTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DebtInstrumentInterestPaymentTerms_lbl" xml:lang="en-US">Debt instrument interest payment terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Aggregate principal amount of note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="krmd_FinanceLeaseCost1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost1Abstract_lbl" xml:lang="en-US">Finance lease cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FinanceLeaseCost" xlink:label="krmd_FinanceLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Financing cash flows from finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating leases term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US">Operating leases term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating leases discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US">Finance leases discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028 - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028 - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Thereafter - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Thereafter - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US">Total undiscounted lease payments - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US">Total undiscounted lease payments - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="krmd_LesseeOperatingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="krmd_LesseeFinancingLeaseImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_lbl" xml:lang="en-US">Less: imputed interest - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liabilities - Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Total lease liabilities - Finance Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LossBeforeIncomeTaxes" xlink:label="krmd_LossBeforeIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LossBeforeIncomeTaxes" xlink:to="krmd_LossBeforeIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LossBeforeIncomeTaxes_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">International</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">International</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsAbstract" xlink:label="krmd_DeferredTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DeferredTaxAssetsAbstract" xlink:to="krmd_DeferredTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsNetOperatingLoss" xlink:label="krmd_DeferredTaxAssetsNetOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DeferredTaxAssetsNetOperatingLoss" xlink:to="krmd_DeferredTaxAssetsNetOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DeferredTaxAssetsNetOperatingLoss_lbl" xml:lang="en-US">Net Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsCredits" xlink:label="krmd_DeferredTaxAssetsCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DeferredTaxAssetsCredits" xlink:to="krmd_DeferredTaxAssetsCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DeferredTaxAssetsCredits_lbl" xml:lang="en-US">Credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized Research Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsNQOAndRSAStockOptions" xlink:label="krmd_DeferredTaxAssetsNQOAndRSAStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DeferredTaxAssetsNQOAndRSAStockOptions" xlink:to="krmd_DeferredTaxAssetsNQOAndRSAStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DeferredTaxAssetsNQOAndRSAStockOptions_lbl" xml:lang="en-US">NQO &amp; RSA Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsDeferredLeaseLiability" xlink:label="krmd_DeferredTaxAssetsDeferredLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DeferredTaxAssetsDeferredLeaseLiability" xlink:to="krmd_DeferredTaxAssetsDeferredLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DeferredTaxAssetsDeferredLeaseLiability_lbl" xml:lang="en-US">Deferred Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Accruals &amp; Reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross Deferred Tax Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxLiabilitiesIntangibles" xlink:label="krmd_DeferredTaxLiabilitiesIntangibles" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DeferredTaxLiabilitiesIntangibles" xlink:to="krmd_DeferredTaxLiabilitiesIntangibles_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DeferredTaxLiabilitiesIntangibles_lbl" xml:lang="en-US">Intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxLiabilitiesROUAssets" xlink:label="krmd_DeferredTaxLiabilitiesROUAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DeferredTaxLiabilitiesROUAssets" xlink:to="krmd_DeferredTaxLiabilitiesROUAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DeferredTaxLiabilitiesROUAssets_lbl" xml:lang="en-US">ROU Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxLiabilitiesFixedAssets" xlink:label="krmd_DeferredTaxLiabilitiesFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DeferredTaxLiabilitiesFixedAssets" xlink:to="krmd_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DeferredTaxLiabilitiesFixedAssets_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Total Deferred Tax Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal tax at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_IncomeTaxReconciliationChangeInValuationAllowance" xlink:label="krmd_IncomeTaxReconciliationChangeInValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IncomeTaxReconciliationChangeInValuationAllowance" xlink:to="krmd_IncomeTaxReconciliationChangeInValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="krmd_IncomeTaxReconciliationChangeInValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_IncomeTaxReconciliationDeferredTaxTrueUps" xlink:label="krmd_IncomeTaxReconciliationDeferredTaxTrueUps" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IncomeTaxReconciliationDeferredTaxTrueUps" xlink:to="krmd_IncomeTaxReconciliationDeferredTaxTrueUps_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IncomeTaxReconciliationDeferredTaxTrueUps_lbl" xml:lang="en-US">Deferred tax true ups</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_IncomeTaxReconciliationOtherItems" xlink:label="krmd_IncomeTaxReconciliationOtherItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IncomeTaxReconciliationOtherItems" xlink:to="krmd_IncomeTaxReconciliationOtherItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IncomeTaxReconciliationOtherItems_lbl" xml:lang="en-US">Other items</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_IncomeTaxReconciliationNet" xlink:label="krmd_IncomeTaxReconciliationNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IncomeTaxReconciliationNet" xlink:to="krmd_IncomeTaxReconciliationNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IncomeTaxReconciliationNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets" xlink:label="krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets" xlink:to="krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets_lbl" xml:lang="en-US">Valuation Allowance on Deferred Tax Assets - Net Change</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NetOperatingLossCarryforwardsFederal" xlink:label="krmd_NetOperatingLossCarryforwardsFederal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NetOperatingLossCarryforwardsFederal" xlink:to="krmd_NetOperatingLossCarryforwardsFederal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NetOperatingLossCarryforwardsFederal_lbl" xml:lang="en-US">Net operating loss carryforwards, federal</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NetOperatingLossCarryforwardsStateAndLocal" xlink:label="krmd_NetOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NetOperatingLossCarryforwardsStateAndLocal" xlink:to="krmd_NetOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_NetOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Net operating loss carryforwards, state</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FederalResearchCreditCarryforward" xlink:label="krmd_FederalResearchCreditCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FederalResearchCreditCarryforward" xlink:to="krmd_FederalResearchCreditCarryforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_FederalResearchCreditCarryforward_lbl" xml:lang="en-US">Federal Research Credit Carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StateResearchCreditCarryforward" xlink:label="krmd_StateResearchCreditCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StateResearchCreditCarryforward" xlink:to="krmd_StateResearchCreditCarryforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_StateResearchCreditCarryforward_lbl" xml:lang="en-US">State Research Credit Carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk, Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Account eceivable from customers</link:label>
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DescriptionOfMatchingContribution" xlink:label="krmd_DescriptionOfMatchingContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_DescriptionOfMatchingContribution" xlink:to="krmd_DescriptionOfMatchingContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_DescriptionOfMatchingContribution_lbl" xml:lang="en-US">Description of matching contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Matching expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockOptionPlan2015Member" xlink:to="krmd_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockOptionPlan2015Member_doc" xml:lang="en-US">The element represents stock option plan2015 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:to="krmd_SharesAvailableForIssuanceShareBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_SharesAvailableForIssuanceShareBasedCompensation_doc" xml:lang="en-US">The element represents shares available for issuance share based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonemployeeServicesTransactionCost" xlink:to="krmd_NonemployeeServicesTransactionCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonemployeeServicesTransactionCost_doc" xml:lang="en-US">The element represents nonemployee services transaction cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:to="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_NonEmployeeDirectorAndBoardAdvisorMember_doc" xml:lang="en-US">The element represents non employee director and board advisor member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_StockBasedCompensationStockOptions" xlink:to="krmd_StockBasedCompensationStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_StockBasedCompensationStockOptions_doc" xml:lang="en-US">The element represents stock based compensation stock options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:to="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_doc" xml:lang="en-US">The element represents schedule of share based compensation stock options activity amended table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ExercisePrice1Member" xlink:to="krmd_ExercisePrice1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ExercisePrice1Member_doc" xml:lang="en-US">The element represents exercise price1 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_doc" xml:lang="en-US">The element represents share based compensation arrangement by unvested award options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_UnrecognizedCompensationCost" xlink:to="krmd_UnrecognizedCompensationCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_UnrecognizedCompensationCost_doc" xml:lang="en-US">The element represents unrecognized compensation cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_RestrictedStockAwardsMember" xlink:to="krmd_RestrictedStockAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_RestrictedStockAwardsMember_doc" xml:lang="en-US">The element represents restricted stock awards member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options vested in period gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_doc" xml:lang="en-US">The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_TermLoanFacilityMember" xlink:to="krmd_TermLoanFacilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_TermLoanFacilityMember_doc" xml:lang="en-US">The element represents term loan facility member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost1Abstract" xlink:to="krmd_FinanceLeaseCost1Abstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost1Abstract_doc" xml:lang="en-US">The element represents finance lease cost1 abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_FinanceLeaseCost" xlink:to="krmd_FinanceLeaseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_FinanceLeaseCost_doc" xml:lang="en-US">The element represents finance lease cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_doc" xml:lang="en-US">The element represents lessee financing lease lease liability payments due total.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_doc" xml:lang="en-US">The element represents lessee financing lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:to="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal_doc" xml:lang="en-US">The element represents lessee operating lease liability payments due total.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_doc" xml:lang="en-US">The element represents lessee operating lease imputed interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_CashPaidDuringPeriodsForAbstract" xlink:to="krmd_CashPaidDuringPeriodsForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="krmd_CashPaidDuringPeriodsForAbstract_doc" xml:lang="en-US">The element represents cash paid during periods for abstract.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_2_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_PaymentsOnIndebtedness" xlink:to="krmd_PaymentsOnIndebtedness_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_PaymentsOnIndebtedness_2_lbl" xml:lang="en-US">PaymentsOnIndebtedness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOtherTaxes" xlink:to="us-gaap_PaymentsForOtherTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForOtherTaxes_2_lbl" xml:lang="en-US">Payments for Other Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_2_lbl" xml:lang="en-US">Inventory Valuation Reserves</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:to="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Unvested Award Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Number Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_4_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Gross Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Vested in Period Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options Vested in Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:to="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options forfeitures in Period Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:to="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_3_lbl" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award Options forfeitures in Period Weighted Average Exercise Price Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_2_lbl" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeOperatingLeaseImputedInterest" xlink:to="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeOperatingLeaseImputedInterest_3_lbl" xml:lang="en-US">Lessee Operating Lease Imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_LesseeFinancingLeaseImputedInterest" xlink:to="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_LesseeFinancingLeaseImputedInterest_3_lbl" xml:lang="en-US">Lessee Financing Lease Imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="krmd_IncomeTaxReconciliationChangeInValuationAllowance" xlink:to="krmd_IncomeTaxReconciliationChangeInValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="krmd_IncomeTaxReconciliationChangeInValuationAllowance_2_lbl" xml:lang="en-US">IncomeTaxReconciliationChangeInValuationAllowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>krmd-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://korumedical.com/role/Cover" xlink:href="krmd-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheets" xlink:href="krmd-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:href="krmd-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfOperations" xlink:href="krmd-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:href="krmd-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/StatementsOfCashFlows" xlink:href="krmd-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Inventory" xlink:href="krmd-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipment" xlink:href="krmd-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensation" xlink:href="krmd-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligations" xlink:href="krmd-20241231.xsd#DebtObligations" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Leases" xlink:href="krmd-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomers" xlink:href="krmd-20241231.xsd#MajorCustomers" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/CommitmentsAndContingencies" xlink:href="krmd-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefits" xlink:href="krmd-20241231.xsd#EmployeeBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SegmentDisclosure" xlink:href="krmd-20241231.xsd#SegmentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryTables" xlink:href="krmd-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:href="krmd-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationTables" xlink:href="krmd-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/LeasesTables" xlink:href="krmd-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:href="krmd-20241231.xsd#EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="krmd-20241231.xsd#NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:href="krmd-20241231.xsd#InventoryConsistsOfDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:href="krmd-20241231.xsd#PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:href="krmd-20241231.xsd#ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:href="krmd-20241231.xsd#FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="krmd-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:href="krmd-20241231.xsd#DebtObligationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:href="krmd-20241231.xsd#ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20241231.xsd#SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:href="krmd-20241231.xsd#SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:href="krmd-20241231.xsd#MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:href="krmd-20241231.xsd#ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="krmd-20241231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="krmd-20241231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="krmd-20241231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative" xlink:href="krmd-20241231.xsd#FederalAndStateIncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:href="krmd-20241231.xsd#MajorCustomersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:href="krmd-20241231.xsd#EmployeeBenefitsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockPreferredShares" xlink:label="loc_us-gaapTreasuryStockPreferredShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockPreferredShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" xlink:label="loc_krmdStockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdStockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" xlink:label="loc_krmdStockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdStockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" xlink:label="loc_krmdAdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdAdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockIssuedDuringPeriodUponOptionExercised" xlink:label="loc_krmdStockIssuedDuringPeriodUponOptionExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodUponOptionExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockIssuedDuringPeriodSharesUponOptionExercised" xlink:label="loc_krmdStockIssuedDuringPeriodSharesUponOptionExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdStockIssuedDuringPeriodSharesUponOptionExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" xlink:label="loc_krmdPaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_krmdPaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NoncashLeaseAdjustments" xlink:label="loc_krmdNoncashLeaseAdjustments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_krmdNoncashLeaseAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_BorrowingsFromIndebtedness" xlink:label="loc_krmdBorrowingsFromIndebtedness" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdBorrowingsFromIndebtedness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PaymentsOnIndebtedness" xlink:label="loc_krmdPaymentsOnIndebtedness" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_krmdPaymentsOnIndebtedness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForOtherTaxes" xlink:label="loc_us-gaapPaymentsForOtherTaxes" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForOtherTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_CashPaidDuringPeriodsForAbstract" xlink:label="loc_krmdCashPaidDuringPeriodsForAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdCashPaidDuringPeriodsForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="999012 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Inventory" xlink:title="999013 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipment" xlink:title="999014 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensation" xlink:title="999015 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligations" xlink:title="999016 - Disclosure - DEBT OBLIGATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Leases" xlink:title="999017 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxes" xlink:title="999018 - Disclosure - FEDERAL AND STATE INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomers" xlink:title="999019 - Disclosure - MAJOR CUSTOMERS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefits" xlink:title="999021 - Disclosure - EMPLOYEE BENEFITS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SegmentDisclosure" xlink:title="999022 - Disclosure - SEGMENT DISCLOSURE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="999024 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ScheduleOfNetSalesByGeography" xlink:label="loc_krmdScheduleOfNetSalesByGeography" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_krmdScheduleOfNetSalesByGeography" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryTables" xlink:title="999025 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentTables" xlink:title="999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationTables" xlink:title="999027 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:label="loc_krmdScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_krmdScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/LeasesTables" xlink:title="999028 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesTables" xlink:title="999029 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss" xlink:label="loc_krmdScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails" xlink:title="999030 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details" xlink:title="999031 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PatentsAndTrademarksMember" xlink:label="loc_krmdPatentsAndTrademarksMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_krmdPatentsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_EquipmentAndToolingMember" xlink:label="loc_krmdEquipmentAndToolingMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdEquipmentAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaapInterestIncomeSecuritiesUSTreasury" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInterestIncomeSecuritiesUSTreasury" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_AmortizationOfIntangibleAssets1" xlink:label="loc_krmdAmortizationOfIntangibleAssets1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdAmortizationOfIntangibleAssets1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DepreciationAndAmortizationPropertyAndEquipment" xlink:label="loc_krmdDepreciationAndAmortizationPropertyAndEquipment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_krmdDepreciationAndAmortizationPropertyAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaapContractWithCustomerAssetReclassifiedToReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapContractWithCustomerAssetReclassifiedToReceivable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/InventoryConsistsOfDetails" xlink:title="999033 - Disclosure - Inventory consists of: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="loc_us-gaapInventoryWorkInProcessAndRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcessAndRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails" xlink:title="999034 - Disclosure - Property and equipment consists of the following at: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FurnitureAndOfficeEquipmentMember" xlink:label="loc_krmdFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ManufacturingEquipmentAndToolingMember" xlink:label="loc_krmdManufacturingEquipmentAndToolingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_krmdManufacturingEquipmentAndToolingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails" xlink:title="999035 - Disclosure - Schedule of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails" xlink:title="999036 - Disclosure - Schedule of status of time based stock options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails" xlink:title="999037 - Disclosure - Schedule of information pertaining to options outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ExercisePrice1Member" xlink:label="loc_krmdExercisePrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_krmdExercisePrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details" xlink:title="999038 - Disclosure - The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PerformanceVestingStockOptionsMember" xlink:label="loc_krmdPerformanceVestingStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceVestingStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions" xlink:label="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByUnvestedAwardOptions_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details" xlink:title="999039 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested" xlink:label="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999040 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockOptionPlan2015Member" xlink:label="loc_krmdStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_OmnibusEquityIncentivePlan2021Member" xlink:label="loc_krmdOmnibusEquityIncentivePlan2021Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdOmnibusEquityIncentivePlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_OmnibusEquityIncentivePlan2024Member" xlink:label="loc_krmdOmnibusEquityIncentivePlan2024Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdOmnibusEquityIncentivePlan2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockOptionPlans2015And2021CombinedMember" xlink:label="loc_krmdStockOptionPlans2015And2021CombinedMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_krmdStockOptionPlans2015And2021CombinedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NonEmployeeDirectorAndBoardAdvisorMember" xlink:label="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_krmdNonEmployeeDirectorAndBoardAdvisorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TimeVestingStockOptionsMember" xlink:label="loc_krmdTimeVestingStockOptionsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdTimeVestingStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_PerformanceVestingStockOptionsMember" xlink:label="loc_krmdPerformanceVestingStockOptionsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdPerformanceVestingStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_RestrictedStockAwardsMember" xlink:label="loc_krmdRestrictedStockAwardsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_krmdRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SharesReservedForOutstandingAwards" xlink:label="loc_krmdSharesReservedForOutstandingAwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesReservedForOutstandingAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SharesAvailableForIssuanceShareBasedCompensation" xlink:label="loc_krmdSharesAvailableForIssuanceShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdSharesAvailableForIssuanceShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NonemployeeServicesTransactionCost" xlink:label="loc_krmdNonemployeeServicesTransactionCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdNonemployeeServicesTransactionCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:label="loc_us-gaapDeferredCompensationArrangementsOverallDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementsOverallDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockBasedCompensationStockOptions" xlink:label="loc_krmdStockBasedCompensationStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockBasedCompensationStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_CashReceivedFromOptionExercise" xlink:label="loc_krmdCashReceivedFromOptionExercise" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdCashReceivedFromOptionExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StockbasedCompensationIntrinsicValue" xlink:label="loc_krmdStockbasedCompensationIntrinsicValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdStockbasedCompensationIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_UnrecognizedCompensationCost" xlink:label="loc_krmdUnrecognizedCompensationCost" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_krmdUnrecognizedCompensationCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/DebtObligationsDetailsNarrative" xlink:title="999041 - Disclosure - DEBT OBLIGATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DomesticBankLenderMember" xlink:label="loc_krmdDomesticBankLenderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_krmdDomesticBankLenderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_TermLoanFacilityMember" xlink:label="loc_krmdTermLoanFacilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_krmdTermLoanFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_SecurityAgreementMember" xlink:label="loc_krmdSecurityAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_krmdSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LinesOfCreditCurrent1" xlink:label="loc_krmdLinesOfCreditCurrent1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_krmdLinesOfCreditCurrent1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DebtInstrumentInterestPaymentTerms" xlink:label="loc_krmdDebtInstrumentInterestPaymentTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_krmdDebtInstrumentInterestPaymentTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails" xlink:title="999042 - Disclosure - The components of lease expense were as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FinanceLeaseCost1Abstract" xlink:label="loc_krmdFinanceLeaseCost1Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdFinanceLeaseCost1Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FinanceLeaseCost" xlink:label="loc_krmdFinanceLeaseCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krmdFinanceLeaseCost1Abstract" xlink:to="loc_krmdFinanceLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="999043 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails" xlink:title="999044 - Disclosure - Supplemental information related to leases was as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="loc_us-gaapLesseeFinanceLeaseDiscountRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails" xlink:title="999045 - Disclosure - Maturities of lease liabilities are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_krmdFinanceLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdFinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:label="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueTotal" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseLiabilityPaymentsDueTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:label="loc_krmdLesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeOperatingLeaseImputedInterest" xlink:label="loc_krmdLesseeOperatingLeaseImputedInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeOperatingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LesseeFinancingLeaseImputedInterest" xlink:label="loc_krmdLesseeFinancingLeaseImputedInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_krmdLesseeFinancingLeaseImputedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails" xlink:title="999046 - Disclosure - Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_LossBeforeIncomeTaxes" xlink:label="loc_krmdLossBeforeIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdLossBeforeIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="999047 - Disclosure - Schedule of provision for income taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="999048 - Disclosure - Schedule of components of deferred tax assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsAbstract" xlink:label="loc_krmdDeferredTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDeferredTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsNetOperatingLoss" xlink:label="loc_krmdDeferredTaxAssetsNetOperatingLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDeferredTaxAssetsNetOperatingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsCredits" xlink:label="loc_krmdDeferredTaxAssetsCredits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDeferredTaxAssetsCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsNQOAndRSAStockOptions" xlink:label="loc_krmdDeferredTaxAssetsNQOAndRSAStockOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDeferredTaxAssetsNQOAndRSAStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxAssetsDeferredLeaseLiability" xlink:label="loc_krmdDeferredTaxAssetsDeferredLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDeferredTaxAssetsDeferredLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxLiabilitiesIntangibles" xlink:label="loc_krmdDeferredTaxLiabilitiesIntangibles" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDeferredTaxLiabilitiesIntangibles" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxLiabilitiesROUAssets" xlink:label="loc_krmdDeferredTaxLiabilitiesROUAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDeferredTaxLiabilitiesROUAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DeferredTaxLiabilitiesFixedAssets" xlink:label="loc_krmdDeferredTaxLiabilitiesFixedAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdDeferredTaxLiabilitiesFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="999049 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_IncomeTaxReconciliationChangeInValuationAllowance" xlink:label="loc_krmdIncomeTaxReconciliationChangeInValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdIncomeTaxReconciliationChangeInValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_IncomeTaxReconciliationDeferredTaxTrueUps" xlink:label="loc_krmdIncomeTaxReconciliationDeferredTaxTrueUps" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdIncomeTaxReconciliationDeferredTaxTrueUps" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_IncomeTaxReconciliationOtherItems" xlink:label="loc_krmdIncomeTaxReconciliationOtherItems" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdIncomeTaxReconciliationOtherItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_IncomeTaxReconciliationNet" xlink:label="loc_krmdIncomeTaxReconciliationNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdIncomeTaxReconciliationNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative" xlink:title="999050 - Disclosure - FEDERAL AND STATE INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets" xlink:label="loc_krmdNetChangeInValuationOfAllowanceOnDeferredTaxAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdNetChangeInValuationOfAllowanceOnDeferredTaxAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NetOperatingLossCarryforwardsFederal" xlink:label="loc_krmdNetOperatingLossCarryforwardsFederal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdNetOperatingLossCarryforwardsFederal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_NetOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_krmdNetOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdNetOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_FederalResearchCreditCarryforward" xlink:label="loc_krmdFederalResearchCreditCarryforward" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdFederalResearchCreditCarryforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_StateResearchCreditCarryforward" xlink:label="loc_krmdStateResearchCreditCarryforward" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_krmdStateResearchCreditCarryforward" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/MajorCustomersDetailsNarrative" xlink:title="999051 - Disclosure - MAJOR CUSTOMERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_CustomerOneMember" xlink:label="loc_krmdCustomerOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_krmdCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://korumedical.com/role/EmployeeBenefitsDetailsNarrative" xlink:title="999052 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="krmd-20241231.xsd#krmd_DescriptionOfMatchingContribution" xlink:label="loc_krmdDescriptionOfMatchingContribution" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_krmdDescriptionOfMatchingContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272688848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KORU MEDICAL SYSTEMS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000704440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3044880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mahwah<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">469-2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,518,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,957,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock, Common, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,438,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Cherry Bekaert LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tampa, Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273073632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,580,947<span></span>
</td>
<td class="nump">$ 11,482,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">5,720,750<span></span>
</td>
<td class="nump">4,045,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,803,669<span></span>
</td>
<td class="nump">3,481,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">277,193<span></span>
</td>
<td class="nump">28,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">749,851<span></span>
</td>
<td class="nump">1,218,288<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">19,132,410<span></span>
</td>
<td class="nump">20,255,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,290,515<span></span>
</td>
<td class="nump">3,837,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization of $458,538 and $390,341 at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">730,279<span></span>
</td>
<td class="nump">754,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,966,341<span></span>
</td>
<td class="nump">3,514,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">98,970<span></span>
</td>
<td class="nump">98,970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">27,218,515<span></span>
</td>
<td class="nump">28,460,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,649,969<span></span>
</td>
<td class="nump">975,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,924,184<span></span>
</td>
<td class="nump">1,711,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">271,152<span></span>
</td>
<td class="nump">314,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">29,269<span></span>
</td>
<td class="nump">512,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related taxes</a></td>
<td class="nump">811,401<span></span>
</td>
<td class="nump">462,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability &#8211; current</a></td>
<td class="nump">115,587<span></span>
</td>
<td class="nump">109,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability &#8211; current</a></td>
<td class="nump">400,258<span></span>
</td>
<td class="nump">368,313<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">7,201,820<span></span>
</td>
<td class="nump">4,454,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, net current portion</a></td>
<td class="nump">202,613<span></span>
</td>
<td class="nump">316,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">3,000,403<span></span>
</td>
<td class="nump">3,336,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">10,404,836<span></span>
</td>
<td class="nump">8,107,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 75,000,000 shares authorized, 49,377,617 and 49,089,864 shares issued; 45,957,115 and 45,669,362 shares outstanding at December 31, 2024, and December 31, 2023, respectively</a></td>
<td class="nump">493,776<span></span>
</td>
<td class="nump">490,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">49,581,303<span></span>
</td>
<td class="nump">47,018,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 3,438,526 and 3,420,502 shares at December 31, 2024 and December 31, 2023, respectively, at cost</a></td>
<td class="num">(3,882,494)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(29,378,906)<span></span>
</td>
<td class="num">(23,312,273)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">16,813,679<span></span>
</td>
<td class="nump">20,353,771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 27,218,515<span></span>
</td>
<td class="nump">$ 28,460,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373364474256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">$ 458,538<span></span>
</td>
<td class="nump">$ 390,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">49,377,617<span></span>
</td>
<td class="nump">49,089,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">45,957,115<span></span>
</td>
<td class="nump">45,669,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockPreferredShares', window );">Treasury stock, shares</a></td>
<td class="nump">3,438,526<span></span>
</td>
<td class="nump">3,420,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued preferred shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272820320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">NET REVENUES</a></td>
<td class="nump">$ 33,646,463<span></span>
</td>
<td class="nump">$ 28,517,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">12,314,605<span></span>
</td>
<td class="nump">11,809,384<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">21,331,858<span></span>
</td>
<td class="nump">16,708,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">21,631,674<span></span>
</td>
<td class="nump">20,365,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,257,942<span></span>
</td>
<td class="nump">5,742,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">888,473<span></span>
</td>
<td class="nump">870,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">27,778,089<span></span>
</td>
<td class="nump">26,978,261<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net Operating Loss</a></td>
<td class="num">(6,446,231)<span></span>
</td>
<td class="num">(10,269,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-Operating Income, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Loss on foreign currency exchange</a></td>
<td class="num">(45,991)<span></span>
</td>
<td class="num">(5,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="num">(16,160)<span></span>
</td>
<td class="num">(59,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income, net</a></td>
<td class="nump">444,642<span></span>
</td>
<td class="nump">561,328<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME</a></td>
<td class="nump">382,491<span></span>
</td>
<td class="nump">496,397<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">LOSS BEFORE TAXES</a></td>
<td class="num">(6,063,740)<span></span>
</td>
<td class="num">(9,773,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(2,893)<span></span>
</td>
<td class="num">(3,967,480)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (6,066,633)<span></span>
</td>
<td class="num">$ (13,741,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">45,802,701<span></span>
</td>
<td class="nump">45,601,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">45,802,701<span></span>
</td>
<td class="nump">45,601,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273447840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 488,619<span></span>
</td>
<td class="nump">$ 44,252,117<span></span>
</td>
<td class="num">$ (9,571,211)<span></span>
</td>
<td class="num">$ (3,843,562)<span></span>
</td>
<td class="nump">$ 31,325,963<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">48,861,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity', window );">Accrued compensation paid in shares</a></td>
<td class="nump">$ 1,280<span></span>
</td>
<td class="nump">445,069<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">446,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares', window );">Accrued compensation paid (in shares)</a></td>
<td class="nump">127,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,940,720<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,940,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Compensation expense related to restricted stock awards</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">380,801<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">381,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts', window );">Compensation expense related to restricted stock awards (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodUponOptionExercised', window );">Issuance upon options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,741,062)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,741,062)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 490,899<span></span>
</td>
<td class="nump">47,018,707<span></span>
</td>
<td class="num">(23,312,273)<span></span>
</td>
<td class="num">(3,843,562)<span></span>
</td>
<td class="nump">20,353,771<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">49,089,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity', window );">Accrued compensation paid in shares</a></td>
<td class="nump">$ 1,919<span></span>
</td>
<td class="nump">452,909<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">454,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares', window );">Accrued compensation paid (in shares)</a></td>
<td class="nump">191,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Compensation expense related to stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,509,544<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,509,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Compensation expense related to restricted stock awards</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="nump">567,369<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38,932)<span></span>
</td>
<td class="nump">528,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts', window );">Compensation expense related to restricted stock awards (in shares)</a></td>
<td class="nump">55,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodUponOptionExercised', window );">Issuance upon options exercised</a></td>
<td class="nump">$ 407<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,066,633)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,066,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockIssuedDuringPeriodSharesUponOptionExercised', window );">Issuance upon options exercised (in shares)</a></td>
<td class="nump">40,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards', window );">Payments for taxes related to net share settlement of equity awards</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(58,447)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(58,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,221<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,221<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 493,776<span></span>
</td>
<td class="nump">$ 49,581,303<span></span>
</td>
<td class="num">$ (29,378,906)<span></span>
</td>
<td class="num">$ (3,882,494)<span></span>
</td>
<td class="nump">$ 16,813,679<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">49,377,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockIssuedDuringPeriodSharesUponOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockIssuedDuringPeriodSharesUponOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockIssuedDuringPeriodUponOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockIssuedDuringPeriodUponOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273148880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (6,066,633)<span></span>
</td>
<td class="num">$ (13,741,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense and warrant expense</a></td>
<td class="nump">2,623,920<span></span>
</td>
<td class="nump">2,768,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">888,473<span></span>
</td>
<td class="nump">870,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">16,160<span></span>
</td>
<td class="nump">59,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes, net of allowance for non-realization of deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,967,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NoncashLeaseAdjustments', window );">Non-cash leasing charges</a></td>
<td class="nump">243,394<span></span>
</td>
<td class="num">(21,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(1,675,540)<span></span>
</td>
<td class="num">(486,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease in inventory</a></td>
<td class="nump">677,632<span></span>
</td>
<td class="nump">2,923,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">943,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease in prepaid expenses and other assets</a></td>
<td class="nump">220,133<span></span>
</td>
<td class="nump">242,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">674,776<span></span>
</td>
<td class="num">(1,416,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase in accrued payroll and related taxes</a></td>
<td class="nump">348,460<span></span>
</td>
<td class="num">(79,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Decrease in other liabilities</a></td>
<td class="num">(483,250)<span></span>
</td>
<td class="nump">255,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Increase in accrued expenses</a></td>
<td class="nump">2,212,757<span></span>
</td>
<td class="num">(1,178,514)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(319,718)<span></span>
</td>
<td class="num">(4,892,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(1,297,427)<span></span>
</td>
<td class="num">(782,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds on disposals of property and equipment</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(44,115)<span></span>
</td>
<td class="num">(31,648)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(1,333,042)<span></span>
</td>
<td class="num">(814,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_BorrowingsFromIndebtedness', window );">Borrowings from insurance finance indebtedness</a></td>
<td class="nump">487,516<span></span>
</td>
<td class="nump">565,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_PaymentsOnIndebtedness', window );">Payments on insurance finance indebtedness</a></td>
<td class="num">(530,707)<span></span>
</td>
<td class="num">(684,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForOtherTaxes', window );">Payments for taxes related to net share settlement of equity awards</a></td>
<td class="num">(97,379)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease liability</a></td>
<td class="num">(107,963)<span></span>
</td>
<td class="num">(99,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="num">(248,533)<span></span>
</td>
<td class="num">(218,867)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(1,901,293)<span></span>
</td>
<td class="num">(5,926,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">11,482,240<span></span>
</td>
<td class="nump">17,408,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">9,580,947<span></span>
</td>
<td class="nump">11,482,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CashPaidDuringPeriodsForAbstract', window );"><strong>Cash paid during the years for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">71,934<span></span>
</td>
<td class="nump">50,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_BorrowingsFromIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_BorrowingsFromIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CashPaidDuringPeriodsForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents cash paid during periods for abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CashPaidDuringPeriodsForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NoncashLeaseAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NoncashLeaseAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_PaymentsOnIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_PaymentsOnIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOtherTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for taxes classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForOtherTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373271834800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (6,066,633)<span></span>
</td>
<td class="num">$ (13,741,062)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373268547344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273118976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272095712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zE6OBrRPhpjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_829_zJm2vJrCg8qh">NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_847_eus-gaap--NatureOfOperations_zIjNYMYmOIyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zPEmyeNaHM82">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20241231_z9Agcpgdz5L3" title="Number of segment::XDX::1">one</span> segment.</p>

<p id="xdx_856_zkmHf5d6gWia" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zXI2Uody1Zmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zF8Mklpghykf">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain
liability balances within the accompanying December 31, 2023 balance sheet have been reclassified to conform to current period presentation.
There were no changes to the Company&#8217;s results of operations as a result of the reclassification.</p>

<p id="xdx_852_z5V4AxgymMwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPMBUvrY36ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zEwql3bDypEd">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;As of December
31, 2024 the Company held cash and cash-equivalents of $<span id="xdx_902_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20241231_zA7VaEMmx5a5" title="Investment securities treasury bill">9.6</span> million, the majority of which was held in a secured US-treasury money market
mutual fund.</p>

<p id="xdx_851_zxPBRBMqpZn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zhTKv9KfM2ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zLCvUJtAaI5k">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<p id="xdx_854_ztiAij2XIY6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFuMhSKxU9eb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_z7BkJOfGVajg">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_za08LPcqfXFa" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0465">6</span></span> to <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zCPUt66Qym8f" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0467">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2024 and 2023 was $<span id="xdx_904_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20240101__20241231_zr2imeJVZbW4" title="Amortization expense of intangible assets">68,197</span> and
$<span id="xdx_90F_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20230101__20231231_zbHzPE1Q4Ca4" title="Amortization expense of intangible assets">64,469</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zlKNDwImuqD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_z4bie2HRZKcl">The estimated amortization expense for the succeeding years for the intangible
assets is approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_49C_20241231_zEiqJoSjF1A8" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zxe0WBrGvaWl" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 68%">2025</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">$</td>
    <td style="vertical-align: bottom; width: 24%; text-align: right">66,766</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEB0xT345B19" style="vertical-align: bottom; background-color: white">
    <td>2026</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">65,969</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_znbomvaqq1J5" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">65,620</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zGkaPxMQjcj4" style="background-color: white">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">65,620</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_z8B0JiWwcTt3" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2029</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">59,644</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zsaAdOylyFh7" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">406,660</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zWurP3il377b" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">730,279</td></tr>
  </table>

<p id="xdx_8A9_zC0wOOf9B20f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_853_zSMzeSVnJ7s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>





<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zTTCQ9fSGV86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_z9SkIaTMXpW">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company accounts for deferred income taxes using the asset and liability
method. Under this method, deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and
their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Temporary differences
are then measured using the enacted tax rates and laws. Determining the appropriate amount of valuation allowance requires management
exercise judgement about future operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes. After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence, we have
a recorded valuation allowance of $<span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dxL_c20241231_ze1iPjfdHWS1" title="Valuation allowance::XDX::7080843"><span style="-sec-ix-hidden: xdx2ixbrl0492">7.1</span></span> million against our net deferred tax assets as of the year ended December 31, 2024. As we continue
to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction
of the valuation allowance in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zdwN7sWFQ5wa" title="Statutory rate">21</span>%, including U.S. federal R&amp;D credits, U.S. state tax rates, stock-based compensation and changes in our valuation
allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We account for uncertain tax positions in accordance with authoritative
guidance which prescribes a minimum recognition threshold a tax position is required to meet before being recognized in the financial
statements. Our evaluations of tax positions consider various factors including, but not limited to, changes in tax law, the measurement
of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained
during in-process audit activities and changes in facts or circumstances related to a tax position. We accrue interest and penalties related
to unrecognized tax benefits as a component of income tax expense recorded in continuing operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2021 are no longer subject to examination by tax authorities.&#160;</p>

<p id="xdx_85C_zLzzV10P8xx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKAkrqmhtghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zMd54PBkEcgb">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziwyiynIzVcl" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0498">3</span></span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zV27rsSADj18" title="Estimated useful lives of property and equipment::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0500">10</span></span> years for furniture
and office equipment, <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MinimumMember_zY1pIaZnUv55" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0502">3</span></span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MaximumMember_zdCfLRbC0TG5" title="Estimated useful lives of property and equipment::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0504">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2024
and 2023 was $<span id="xdx_900_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20240101__20241231_zUHezZUXtQmh" title="Depreciation and amortization, property and equipment">704,690</span> and $<span id="xdx_905_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20230101__20231231_zBuvLy7atMcl" title="Depreciation and amortization, property and equipment">805,921</span>, respectively.</p>

<p id="xdx_854_z5VZBtLJoxSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzHwS4V0OxCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zwEKGtyX6Hrk">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are recognized as compensation expense at their grant date fair value. &#160;The entire compensation expense
of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of restricted stock awards with
time-based vesting were estimated on the date of grant at the current stock price. The fair value of restricted stock awards vesting at
certain annual sales growth thresholds were estimated as of the date of Board acknowledgement of the achievement, at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.</p>

<p id="xdx_858_zVEdXzkY4aX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p id="xdx_84F_eus-gaap--UseOfEstimates_za5euHsSBPii" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zaH4ZQWzPnIl">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

<p id="xdx_853_zH9cboNB18sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zoxRGXqDzNff" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_z0NOhPwujbR4">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs are included as a component of cost of goods
sold in the accompanying statements of operations and are generally billed to customers, and included in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#8217;s revenue recognition criteria described above. As of December 31, 2024, 2023, and 2022, the
Company has recognized a contract asset of $<span id="xdx_90D_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20240101__20241231_zwc0JIF7EJw" title="Recognition of contract asset">222,623</span>, $<span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20230101__20231231_zqNMfhOR4r8h" title="Recognition of contract asset">0</span>, and $<span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220101__20221231_zniF0Iday9i8" title="Recognition of contract asset">0</span>, respectively, which is included in other accounts receivable in the accompanying
balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_ecustom--ScheduleOfNetSalesByGeography_zGVwXFyhbU69" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zFIXZoKbmR4l">The following table summarizes net revenues by geography for the years
ended December 31, 2024 and 2023:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2024</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__country--US_zSPYR2n8G7Tb" style="text-align: right" title="Net Revenue">27,506,682</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zoejEZjgXhV8" style="text-align: right" title="Net Revenue">23,676,039</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zUPdwmzFWczg" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">6,139,781</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zDXRR3HKO4Td" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,841,627</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_981_eus-gaap--Revenues_c20240101__20241231_zbZwh9xqUJwe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">33,646,463</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--Revenues_c20230101__20231231_zzXAhVOe69kj" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">28,517,666</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zr0V0PmSMAva" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p id="xdx_85A_zj9qVXV2hvVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9KnPXGgn3Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zwPGs6ic3Pn2">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In November 2023 the FASB issued ASU 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures which expands disclosure requirements to require entities to disclose significant
segment expenses that are regularly provided to or easily computed from information regularly provided to the chief operating decision
maker. This update also requires all annual disclosures currently required by Topic 280 to be disclosed in interim periods. The new disclosure
requirements are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after
December 15, 2024. Early adoption is permitted. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have
be applied retrospectively to all prior periods presented in the financial statements. The adoption of this ASU did not have a significant
impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<p id="xdx_858_zQ45ollo4te9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z2T1YjTQiGhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zusmkpmyusWd">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2024.</p>

<p id="xdx_855_z0epJ816N1Pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8c7yIvtxlwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zoBBYZEYriXi">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2024.</p>

<p id="xdx_853_z242Ey0Ok9j3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272150784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zBCOEIkhMnzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8212; <span id="xdx_82D_zEKk7pT6yog9">INVENTORY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zwh3E8Jy1kQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_z6AVIjRjjtMg">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20241231_zj9nEQwEmqn7" style="text-align: right" title="Raw materials and work-in-process">827,768</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_z2ywVQWvu4ec" style="text-align: right" title="Raw materials and work-in-process">1,869,356</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20241231_zOqYworObv5f" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">1,979,887</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zfJzVB98T9bl" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">1,862,525</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--InventoryGross_iI_c20241231_zJhshCFEAsb4" style="text-align: right" title="Inventory, Gross">2,807,655</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zXeaoVqfviA2" style="text-align: right" title="Inventory, Gross">3,731,881</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20241231_zsgYBOtjmES3" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory">(3,986</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zp60um2BJMGb" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory">(250,580</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--InventoryNet_iI_dxL_c20241231_zsliOOC9aaP7" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory::XDX::2803669"><span style="-sec-ix-hidden: xdx2ixbrl0564">2,803,669</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zMBiLCp47QF9" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">3,481,301</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A4_zkM1N2e0wOU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272095968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z92LaPoupTwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8212; <span id="xdx_829_zP4P5CdHFyCd">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zI8IH58L1Go3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B8_z9ifDzZr2Bj9">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zlhKz8kkYAp6" style="text-align: right" title="Furniture and office equipment">1,433,622</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zqEFzpMJUT5c" style="text-align: right" title="Furniture and office equipment">1,412,164</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zHoBFfDYYB4" style="text-align: right" title="Leasehold improvements">1,953,653</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWh9j3umFTe1" style="text-align: right" title="Leasehold improvements">1,953,653</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGjBj2uUc3k1" style="border-bottom: black 1pt solid; text-align: right" title="Manufacturing equipment and tooling">4,376,147</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zjz4hCU1zOdh" style="border-bottom: black 1pt solid; text-align: right" title="Manufacturing equipment and tooling">3,193,113</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231_zBh99ndGbZdg" style="text-align: right" title="Total property and equipment">7,763,422</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zxVhlIxozcBd" style="text-align: right" title="Total property and equipment">6,558,930</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20241231_zJEAAyST5Pdh" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(3,472,907</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_z0CQp0IN5rLb" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,721,273</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20241231_zko1jGRWZyOc" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">4,290,515</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z9VRV9fNbZi2" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,837,657</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A0_zJLEi9zCh5gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373271763600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zNb9xtVVGiLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8212; <span id="xdx_827_zatQWMez0369">STOCK-BASED COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains three equity incentive plans: the 2015 Stock Option
Plan, as amended (the &#8220;2015 Plan&#8221;), the 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;), and the 2024 Omnibus
Equity Incentive Plan (the &#8220;2024 Plan&#8221;). All equity awards issued to employees, consultants, and non-employee directors on
or after May 9, 2024 are issued from the 2024 Plan. The Company has also issued restricted stock and stock options as employment inducement
awards outside of these plans to its Chief Executive Officer and Chief Commercial Officer, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2015 Plan provides for the grant of incentive
stock options and nonqualified stock options. As of December 31, 2024, there were <span id="xdx_905_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEn2UXG3NOch" title="Shares reserved for outstanding awards">2,035,000</span> shares reserved for outstanding awards under
the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2021 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units, performance share units, stock appreciation rights, and/or
other equity-based awards to employees, consultants and directors. As of December 31, 2024, there were <span id="xdx_90F_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_zUl60yTpIoRk" title="Shares reserved for outstanding awards">127,248</span> shares reserved for outstanding
awards under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2024 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units, performance share units, stock appreciation rights and/or
other equity-based awards to employees, consultants and directors. Awards previously made under the 2015 Plan and the 2021 Plan that are
forfeited or cancelled after May 9, 2024 will be available for issuance under the 2024 Plan. As of December 31, 2024, there were <span id="xdx_903_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2024Member_zNskQuoxduN7" title="Shares reserved for outstanding awards">799,254</span>
shares reserved for outstanding awards and <span id="xdx_908_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2024Member_zIuEShzJiuXj" title="Shares available for issuance">2,320,440</span> shares available for issuance under the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each non-employee director of the Company (other than
the Chairman of the Board) is eligible to receive $<span id="xdx_90C_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zhKnVPjOJ3Yg" title="Nonemployee services transaction cost">110,000</span> annually, <span id="xdx_905_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zklJTZEg7P07" title="Share-based goods and non-employee services transaction">to be paid quarterly in arrears of $12,500 in cash and $15,000 in
common stock.</span> &#160;The Chairman of the Board is eligible to receive $<span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20241231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zfeJp96k3Ayh" title="Nonemployee services transaction cost">140,000</span> annually, <span id="xdx_90D_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20241231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zvG1r0MTT44a" title="Share-based goods and non-employee services transaction">to be paid quarterly in arrears of $12,500 in
cash and $22,500 in common stock.</span> Prior to May 9, 2024 in the periods presented in this report, non-employee director equity compensation
was issued from the Non-Employee Director Compensation Plan. From and after May 9, 2024 non-employee director equity compensation is issued
from the 2024 Plan. All payments were and are pro-rated for partial service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Restricted stock units (&#8220;RSUs&#8221;) and performance
share units (&#8220;PSUs&#8221;) are equity classified and measured at the fair value of the underlying stock at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares of stock granted for non-employee director
fees are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The per share weighted average fair value of stock options granted during
the year ended December 31, 2024 and December 31, 2023 was $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zJgTextb4rWi">1.44</span> and $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zprY8FQR32vb">1.84</span>, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
year ended December 31, 2024 and December 31, 2023. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Time-Vesting Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEzP3t462Obe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the inputs into the Black-Scholes model
for all time-vesting stock options granted during the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_z81utUXWETni" style="display: none; visibility: hidden">Schedule of time based stock options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 62%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z7nDWzQxEbE7" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zBnJgQaURIBc" title="Expected volatility">51.9</span>% - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zZvflGU81ZPb" title="Expected volatility">68.04</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zhFzCu7VVjZi" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zwTcCzzSLxq4" title="Expected term (in years)::XDX::P6Y2M30D"><span style="-sec-ix-hidden: xdx2ixbrl0627">6.25</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_z2JnIwwK1amj" title="Risk-free rate">3.50</span>% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zQCCh5cKtqDl" title="Risk-free rate">4.11</span>%</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AF_zl7HlYZdhqNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEE4EiplHgug" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the time-based stock options
outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B7_zohm8epPEc8a" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 74%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zFEqBRxzHFAk" style="width: 11%; text-align: right" title="Outstanding at beginning (in shares)">3,256,250</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zgTKvRJ5gWa4" style="width: 11%; text-align: right" title="Outstanding at beginning, price">3.66</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_ziLWLRGjDJg6" style="text-align: right" title="Granted (in shares)">567,024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zScpa5HlIP3i" style="text-align: right" title="Granted">2.35</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zCiDtWteBaK8" style="text-align: right" title="Exercised (in shares)">(237,500</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z45j1tDPoaN3" style="text-align: right" title="Exercised">2.67</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zVSrDjvQ8Sqb" style="text-align: right" title="Forfeited (in shares)">(898,750</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zY6SvUp3s2w7" style="text-align: right" title="Forfeited">4.86</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at December 31</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zqjj0UoI2DY4" style="text-align: right" title="Outstanding at ending (in shares)">2,687,024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zE6vzBKy6exe" style="text-align: right" title="Outstanding at ending, price">3.07</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Options exercisable at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zPUclYjx0Uzg" style="text-align: right" title="Options exercisable (in shares)">1,383,750</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zle0yaJaSZp3" style="text-align: right" title="Options exercisable">3.40</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z0QpHXsd1I4a" style="text-align: right" title="Weighted average fair value of options granted during the period">1.44</td></tr>
  </table>
<p id="xdx_8AC_zbfvZ0v9WeB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense for time-vested stock options was
$<span id="xdx_90C_ecustom--StockBasedCompensationStockOptions_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z9VX218HCJp1" title="Stock-based compensation expense">1,530,446</span> for the years ended December 31, 2024. <span id="xdx_906_ecustom--CashReceivedFromOptionExercise_do_uUSD_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zn5UsAaELOlg" title="Cash received from option exercise"><span id="xdx_90E_ecustom--CashReceivedFromOptionExercise_do_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zBoszIMXFhCf" title="Cash received from option exercise">No</span></span> cash was received from option exercises for the years ended December 31, 2024, and
2023. As of December 31, 2024, the intrinsic value of all time-based stock options was $<span id="xdx_901_ecustom--StockbasedCompensationIntrinsicValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zg5TTd0CzhSe" title="Stock-based compensation intrinsic value">2,085,186</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_z95sK4WPWlc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to time-based stock
options outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_znHDlpGsuEmc" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.08-$3.98</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z97F722reGXj" style="text-align: right" title="Number outstanding">2,687,024</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zROvmVLqahJ6" title="Weighted average remaining contractual life::XDX::P7Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0673">7.4</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zgrvMwPMHfo" style="text-align: right" title="Weighted average exercise price">3.07</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zhGByk2yn2Ol" style="text-align: right" title="Number exercisable">1,383,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2eronAeslml" style="text-align: right" title="Weighted average exercise price">3.40</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A0_zGQgcd8mQcK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, there was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zFUy73hnfAJd" title="Total unrecognized compensation cost">1,427,181</span> of total unrecognized compensation
cost related to unvested share-based stock compensation awards granted under the Plans. &#160;That cost is expected to be recognized over
a weighted-average period of 25 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Performance-Vesting Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zpHtCUdjQQGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_z9KwfiUsN051">The following table summarizes the activities for our unvested performance-vesting
stock option awards for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 67%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zawJhSm0C2J1" style="width: 13%; text-align: right" title="Unvested at beginning, shares">200,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zfN7MUutp6A8" style="width: 16%; text-align: right" title="Unvested at beginning, price">1.48</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zD47iwi6517l" style="text-align: right" title="Granted, shares">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zuKldYTbr4ue" style="text-align: right" title="Granted, price">&#8212;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zsqIeO74Wx38" style="text-align: right" title="Vested, shares">(22,000</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zAKjer81Fvxf" style="text-align: right" title="Vested, price">1.48</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zvd4lDWavMR2" style="text-align: right" title="Forfeited/canceled, shares">(44,666</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_z1u2fXXBwMI2" style="text-align: right" title="Forfeited/canceled, price">1.48</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zlrGowkjmAtl" style="text-align: right" title="Unvested at ending, shares">133,334</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zSX1C8vq8yD" style="text-align: right" title="Unvested at ending, price">1.48</td></tr>
  </table>
<p id="xdx_8AE_z7ETHM3OOFjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense for performance-vesting stock options
was $<span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zSw9yLBPqAla" title="Total stock-based compensation expense">21,778</span> year ended December 31, 2024. <span id="xdx_90D_ecustom--CashReceivedFromOptionExercise_do_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zdUJzZ4QoW42" title="Cash received from option exercise">No</span> cash was received from option exercises for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, there was $<span id="xdx_90E_ecustom--UnrecognizedCompensationCost_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zvu37fbaOjtd" title="Unrecognized compensation cost">183,206</span> of unrecognized compensation
cost related to unvested employee performance options. This amount is expected to be recognized over a weighted-average period of 36 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Awards, RSUs, and PSUs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zn92eN7g2kDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zd7DOStXgaB9">The following table summarizes the activities for our unvested restricted
stock awards, RSUs, and PSUs for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 67%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zjqN8brKVLnh" style="width: 13%; text-align: right" title="Outstanding at beginning, shares">904,496</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zoR0DmgcChJ7" style="width: 16%; text-align: right" title="Outstanding at beginning, price">2.77</td>
    <td style="width: 0%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zDY3M1ABIITf" style="text-align: right" title="Granted, shares">458,975</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zm7cngsSnVIf" style="text-align: right" title="Granted, price">2.20</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zQAO4jZTtfvb" style="text-align: right" title="Vested, shares">(81,789</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8jxzHMwGn72" style="text-align: right" title="Vested, price">3.45</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8maZvFHhjUb" style="text-align: right" title="Forfeited/canceled, shares">(11,745</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_znpAADdIu6v" style="text-align: right" title="Forfeited/canceled, price">2.30</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zlYBBTVqFCa6" style="text-align: right" title="Outstanding at ending, shares">1,269,937</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxvGbF9OTN94" style="text-align: right" title="Outstanding at ending, price">2.54</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A4_zBSTR2OFBOqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total stock-based compensation expense for restricted stock awards, RSUs,
and PSUs was $<span id="xdx_908_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zDyaiEnzCo2j" title="Total stock-based compensation expense">579,519</span> for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, there was $<span id="xdx_90D_ecustom--UnrecognizedCompensationCost_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zg5riYiUfLk9" title="Unrecognized compensation cost">902,625</span> of unrecognized compensation
cost related to unvested employee restricted stock awards, RSUs, and PSUs. This amount is expected to be recognized over a weighted-average
period of 44 months.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272150368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT OBLIGATIONS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zvqvHLTW2DZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 &#8212; <span id="xdx_820_zvHNPpOezuvc">DEBT OBLIGATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 8, 2024, the Company entered into a loan
and security agreement with a large domestic banking institution, as lender, providing for a $<span id="xdx_90D_eus-gaap--LinesOfCreditCurrent_iI_c20240308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZeyCC8DHBch" title="Revolving credit facility">5,000,000</span> revolving credit facility and
a $<span id="xdx_900_ecustom--LinesOfCreditCurrent1_iI_c20240308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zJ8IPO4G6zJ9" title="Term loan facility">5,000,000</span> term loan facility. Borrowings are secured by a first-priority lien on substantially all of the assets of the Company, subject
to customary exceptions. The revolving credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_907_ecustom--DebtInstrumentInterestPaymentTerms_c20240308__20250308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zXTaNVDJjjmj" title="Debt instrument interest payment terms">Borrowings under the revolving credit facility will bear interest at the
greater of Prime or 6.50%, payable in arrears on a monthly basis and at maturity.</span> <span id="xdx_901_ecustom--DebtInstrumentInterestPaymentTerms_c20240308__20250308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zN8zPp0ltAob" title="Debt instrument interest payment terms">Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with our loan financings agreement dated
March 8, 2024, the Company issued common stock warrants to the lender. The fair value of each warrant is estimated on the date of the
grant using the Black-Scholes option-pricing model. All options and warrants are charged against income at their fair value. &#160;The
entire compensation expense of the grant is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The loan and security agreement contains customary affirmative covenants,
a financial maintenance covenant that requires the Company to maintain a minimum Adjusted Quick Ratio (defined as the ratio of the Company&#8217;s
(i) unrestricted and unencumbered cash and cash equivalents maintained with the lender and its affiliates, plus eligible accounts receivable,
to (ii) current liabilities) of not less than 1.50 to 1.00 tested on the last day of each month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, there were no outstanding borrowings under the
term loan nor the revolving credit facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 1, 2024, the Company renewed its commercial insurance premium
finance and security agreement with its insurance provider for the insurance period covering July 1, 2024 through June 30, 2025. As of
December 31, 2024, the aggregate principal amount of the note was $<span id="xdx_90F_eus-gaap--DebtInstrumentIssuedPrincipal_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zfioO21ApDFa" title="Aggregate principal amount of note">271,152</span>. The note bears an annual interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zgLLImB8B5X3">9.5</span>%. The Company
retains the right to terminate the agreement at any time and pay the remaining balance in full along with a minimal penalty.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373271744432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zvFT6gwFiLb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 &#8212; <span id="xdx_821_zHrNLnyMKtn7">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have finance and operating leases for our corporate office and certain
office, vehicles, and computer equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#8220;Operating lease right-of-use
assets&#8221; and lease liabilities recognized in &#8220;Operating lease liability &#8211; current&#8221; and &#8220;Operating lease liability,
net of current portion.&#8221; Finance leases are accounted for on the balance sheets recognized in &#8220;Property and equipment, net&#8221;
and lease liabilities recognized in &#8220;Finance lease liability &#8211; current&#8221; and &#8220;Finance lease liability, net of current
portion.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zuwSL6AIJcy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zmEBGrjkD0t7">The components of lease expense were as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 57%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_492_20240101__20241231_zShb2ZhqBko6" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 3%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_492_20230101__20231231_zPEyZuPWSlM4" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zifrdolfisua" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">487,960</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">448,630</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zKKYkZk8XH6l" style="vertical-align: bottom; background-color: white">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,952</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">130,483</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zZuEkMCA2foc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">493,912</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">579,113</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_z9Yc3HBZd6dk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zOL87A1XofA2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">115,585</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">110,566</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zR44tk9uxsAj" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">21,896</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,343</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zCk1pqkFSpZ3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">137,481</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">135,909</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A8_zhTW50IBbTyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_896_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHtI5UDOZb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_z2rBG3vO53E1">Supplemental cash flow information related to leases was as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 71.96%">&#160;</td>
    <td style="width: 0.98%">&#160;</td>
    <td style="width: 1.06%; text-align: center">&#160;</td>
    <td id="xdx_492_20240101__20241231_zAGVL7urrDW8" style="width: 10.98%; text-align: center">&#160;</td>
    <td style="width: 1.98%; text-align: center">&#160;</td>
    <td style="width: 1.06%; text-align: center">&#160;</td>
    <td id="xdx_492_20230101__20231231_zzVWBgMzviUh" style="width: 10.98%; text-align: center">&#160;</td>
    <td style="width: 0.98%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zyCsZUvoFrM5" style="vertical-align: bottom; background-color: white">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">501,214</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">464,104</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zKYp2GHfNZm" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">131,437</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">125,259</td>
    <td>&#160;</td></tr>
  </table>

<p id="xdx_8AD_zaOu4Bpqu8Wi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p id="xdx_896_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z1PIw2sIUuV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_z0Muv5NOao1h">Supplemental information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 58%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><b>December 31,<br/>
2024</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: top; width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20241231_zmIb4dGEugo2" title="Operating leases term::XDX::P5Y1M6D"><span style="-sec-ix-hidden: xdx2ixbrl0791">5.1</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zF5FxvE3qPud" title="Operating leases term::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0793">6.9</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20241231_zXFttH55OXo7" title="Finance leases  term::XDX::P2Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0795">2.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zMzK1h0En1D1" title="Operating leases term::XDX::P3Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0797">3.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zD4Wg9VePVna" title="Operating leases discount rate">6.52</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zQTmoa3PK0X5" title="Operating leases discount rate">5.76</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zFxOZJ43fHoc" title="Finance leases discount rate">6.34</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_905_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z5KU3gcUM807" title="Finance leases discount rate">6.19</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p id="xdx_8A4_zKOEu6GCg5Dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zwjrDeZbopqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zYzR4mV4G5fj">Maturities of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zTDTK8n3t875" style="vertical-align: bottom; text-align: right" title="2025 - Operating Leases">533,979</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zjUsCnD4icoh" style="vertical-align: bottom; text-align: right" title="2025 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zH9ljjshPew4" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases">533,979</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zT12UntsoyB3" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zwmfrBeflmF" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases">533,979</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zl2F75onMYH5" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases">74,194</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20241231_z9NnOEa1yyJ2" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases">520,985</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20241231_zPpCYm5GLIAk" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases">6,181</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_z1nEpK0z5Mo4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases">1,833,603</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_zonC4EG7RFYl" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20241231_zf3p9eKVuO16" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases">3,956,525</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20241231_zPrhrwrXfTOg" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases">343,248</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_989_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20241231_zwRLoURqG6r6" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases">(555,864</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20241231_zxrD62runzac" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases">(25,048</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_zNhTlG0JzTd2" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases">3,400,661</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_980_eus-gaap--FinanceLeaseLiability_iI_c20241231_zCdoExEUMXUk" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases">318,200</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p id="xdx_8AB_zPUoi9iI1osl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/840/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373367132800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FEDERAL AND STATE INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">FEDERAL AND STATE INCOME TAXES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zyiW3AezfoH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_821_zcZFKW4kFts2">FEDERAL AND STATE INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_894_ecustom--ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss_zObaKHPM16Pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Domestic and international pre-tax income/(loss) consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zQewyfOXe396" style="display: none; visibility: hidden">Schedule of Components of Domestic and International Pre-Tax Income (Loss)</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zO5tODJ7fD48" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zDEUY1Lei53f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zrYg1RyKPMd5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">United States</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 1.26%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right">(6,063,740</td>
    <td style="border-bottom: white 2.25pt double; width: 3.92%">)</td>
    <td style="border-bottom: black 2.25pt double; width: 1.26%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right">(9,733,582</td>
    <td style="border-bottom: white 2.25pt double; width: 0.92%">)</td></tr>
  <tr id="xdx_403_ecustom--LossBeforeIncomeTaxes_zdPRysbo8mNg" style="vertical-align: bottom">
    <td>Loss before income taxes</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(6,063,740</td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(9,733,582</td>
    <td>)</td></tr>
  </table>
<p id="xdx_8A6_zrKxQCjbhrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zg0KcHaDK7P5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense attributable to operations is comprised of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zH40JnISYQZe" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zGYKeQcDzzm9" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zE7qsNHKSDmk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zzbxTfiiFmX1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Current:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_zvU7WS6IzcRd" style="vertical-align: bottom; background-color: white">
    <td style="width: 59.94%">Federal</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">&#8212;</span></td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zgZXNN6pjf4k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(2,893</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentForeignTaxExpenseBenefit_z9jymh33Vcd3" style="vertical-align: bottom; background-color: white">
    <td>International</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentIncomeTaxExpenseBenefit_zpL6pAzdmcz4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(2,893</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zWdkpggOLgQh" style="vertical-align: bottom; background-color: white">
    <td>Deferred:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_z3gOjbuiqj8k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Federal</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(3,967,480</td>
    <td>)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_z3NdOK6ATzC2" style="vertical-align: bottom; background-color: white">
    <td>State</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zMP0YVoZZ05k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>International</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_zEf2RdW2QJX2" style="vertical-align: bottom; background-color: white">
    <td>Total Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(3,967,480</td>
    <td>)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iN_di_z6cJ0yEb8JUl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income Tax Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(2,893</td>
    <td style="border-bottom: White 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(3,967,480</td>
    <td style="border-bottom: White 2.25pt double">)</td></tr>
  </table>

<p id="xdx_8A1_zTClWbRmBpMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0c5Ey4UrK04" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes reflect the net tax effects of temporary differences
between carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant
components of our deferred tax assets and liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zkToTvMEmEcb" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zY8Mtci61Uf4" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_z5b5fugGZIv6" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsAbstract_iB_zhvnf78rDXC1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">Deferred Tax Assets:</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">&#160;</td>
    <td style="width: 15.9%; text-align: right">&#160;</td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">&#160;</td>
    <td style="width: 15.9%; text-align: right">&#160;</td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsNetOperatingLoss_iI_zhkUmSrw8zD" style="vertical-align: bottom; background-color: white">
    <td>Net Operating Loss</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">4,025,905</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,566,630</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsCredits_iI_z1rolL4edE12" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Credits</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">129,598</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,030</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zGceoJacp2J6" style="vertical-align: bottom; background-color: white">
    <td>Capitalized Research Costs</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,451,496</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,045,616</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsNQOAndRSAStockOptions_iI_zkLfJ848c1hg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NQO &amp; RSA Stock Options</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">350,484</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,047,608</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsDeferredLeaseLiability_iI_zLVuaAEQfpFa" style="vertical-align: bottom; background-color: white">
    <td>Deferred Lease Liability</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">647,446</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0905">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_z0zJkTHTaDbl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Accruals &amp; Reserves</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">712,058</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">129,923</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_z5GXDNHv8qL1" style="vertical-align: bottom; background-color: white">
    <td>Other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">48</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">42</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_zOTE2jpPoh73" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Gross Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">8,317,035</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">6,931,849</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_z2oPP38ljvY2" style="vertical-align: bottom; background-color: white">
    <td>Valuation allowance</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(7,080,843</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(6,002,777</td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iI_zyNMOInNXXWj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,236,192</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">929,072</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zs3Xn5yHq3fa" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Deferred Tax Liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxLiabilitiesIntangibles_iI_z8Gs9Wca3Ing" style="vertical-align: bottom; background-color: white">
    <td>Intangibles</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(58,170</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(408,260</td>
    <td>)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesROUAssets_iI_zYnCif48gjta" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>ROU Assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(538,632</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(5,511</td>
    <td>)</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFixedAssets_iI_zwEV2O7Q2u4e" style="vertical-align: bottom; background-color: white">
    <td>Fixed Assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(639,390</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(515,300</td>
    <td>)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNI_di_zlb7iPHNdT2j" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Deferred Tax Liabilities</td>
    <td>&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right">(1,236,192</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right">(929,071</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_zn8G5rrZqDl2" style="vertical-align: bottom; background-color: white">
    <td>Net Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<p id="xdx_8A9_z5tZ5ldOUp7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management regularly assesses the ability to realize deferred tax assets
recorded based upon the weight of available evidence, including such factors as recent earnings history and expected future taxable income
on a jurisdiction by jurisdiction basis. In the event that the Company changes its determination as to the amount of realizable deferred
tax assets, the Company will adjust its valuation allowance with a corresponding impact to the provision for income taxes in the period
in which such determination is made. The Company&#8217;s management believes that, based on a number of factors, it is more likely than
not, that all or some portion of the deferred tax assets will not be realized; and accordingly, for the year ended December 31, 2024 the
Company has provided a full valuation allowance against the Company&#8217;s U.S. net deferred tax assets. The net change in the valuation
allowance for the year ended December 31, 2024 was an increase of $<span id="xdx_90C_ecustom--NetChangeInValuationOfAllowanceOnDeferredTaxAssets_uUSD_c20240101__20241231_zEpkPsQ3yIR7" title="Valuation Allowance on Deferred Tax Assets - Net Change">1,078,066</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, the Company had net operating loss carryforwards
for federal and state income tax purposes of approximately $<span id="xdx_906_ecustom--NetOperatingLossCarryforwardsFederal_iI_c20241231_zwyHmBx8KsQg" title="Net operating loss carryforwards, federal">18,313,421</span> and $<span id="xdx_907_ecustom--NetOperatingLossCarryforwardsStateAndLocal_iI_c20241231_zkwsTGpuAr7j" title="Net operating loss carryforwards, state">3,533,499</span>, respectively. The state net operating loss carryforwards
will being to expire in 2041 and our federal net operating loss carryforward will last indefinitely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, the Company had federal and state research credit
carryforwards of approximately $<span id="xdx_900_ecustom--FederalResearchCreditCarryforward_iI_c20241231_zQJ6DKOLWKSl" title="Federal Research Credit Carryforward">129,598</span> and $<span id="xdx_901_ecustom--StateResearchCreditCarryforward_iI_c20241231_zOv154rWwAud" title="State Research Credit Carryforward">0</span> respectively. The federal research credit carryforwards will being to expire in 2036.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2024, and 2023 the Company had no gross unrecognized
tax benefits. The Company&#8217;s policy is to recognize accrued interest and penalties related to unrecognized income tax benefits in
the Provision for income taxes should such amounts occur in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company files income tax returns in the US federal and various state
jurisdictions with varying statutes of limitations. The Company is currently under audit by the Internal Revenue Service for tax year
2022. Tax years 2021 through 2023 are open to examination by major taxing jurisdictions to which the Company is subject.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjg1egs04xI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense differed from the amount computed by applying the federal
statutory income tax rate of 21% to pretax income for the years ended December 31, 2024 and December 31, 2023 as a result of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zgINPoOhGq3i" style="display: none; visibility: hidden">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_z4YQfWbICOEb" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zgx2vGgJ2059" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zzqguLtQVMz9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">Federal tax at statutory rate</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right">1,272,820</td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right">2,052,452</td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zmqbbaIgZGjj" style="vertical-align: bottom; background-color: white">
    <td>State income taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">184,595</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--IncomeTaxReconciliationChangeInValuationAllowance_zpoRsDnmFHAd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Valuation allowance</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(1,078,066</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(6,002,777</td>
    <td>)</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationDeferredTaxTrueUps_zDBVUNxZcObl" style="vertical-align: bottom; background-color: white">
    <td>Deferred tax true ups</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(352,653</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationOtherItems_zsfIFUrW7kT4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Other items</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(29,589</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(17,155</td>
    <td>)</td></tr>
  <tr id="xdx_408_ecustom--IncomeTaxReconciliationNet_zY58pErxH8tf" style="vertical-align: bottom; background-color: white">
    <td>Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(2,893</td>
    <td style="border-bottom: White 2.25pt double">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(3,967,480</td>
    <td style="border-bottom: White 2.25pt double">)</td></tr>
  </table>
<p id="xdx_8AE_zLBgYoXAwQB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272038480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">MAJOR CUSTOMERS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zdselpWU5u0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 &#8212; <span id="xdx_82D_z3oYUcShVtk7">MAJOR CUSTOMERS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the years ended December 31, 2024 and December 31, 2023, approximately
<span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zE2033bgQBi5">64</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zGo0zZOtuQ6i">66</span>%, respectively, of the Company&#8217;s net product revenues were derived from three major customers that are distributors.
&#160;As of December 31, 2024 and December 31, 2023, accounts receivable due from the three major customers was $<span id="xdx_90D_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20241231_zhRjBHfBZFVe" title="Account eceivable from customers">3.6</span> million and $<span id="xdx_906_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20231231_zeqAxBz2J5v4" title="Account eceivable from customers">2.6</span>
million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373275211424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zxnmtdBKr6L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212; <span id="xdx_828_zO0XDe5kk54">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>OTHER</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#8220;Command&#8221;), pursuant to which Command has agreed to manufacture and supply
the Company&#8217;s subassemblies, needle sets and tubing products pursuant to the Company&#8217;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#8220;Effective
Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373275005744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE BENEFITS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjdNlYCjSEy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#8212; <span id="xdx_826_zAMT8YAD0pyi">EMPLOYEE BENEFITS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;<span id="xdx_906_ecustom--DescriptionOfMatchingContribution_c20240101__20241231_zNdRfISiqFC5" title="Description of matching contribution">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation.</span> &#160;Company matching expense for the years ended December 31, 2024 and
December 31, 2023 was $<span id="xdx_907_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20240101__20241231_z8vJU3nMIUL" title="Matching expense">262,915</span> and $<span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zN1rS28jYCQi" title="Matching expense">227,447</span>, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272068304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT DISCLOSURE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT DISCLOSURE</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zbgpJk3SvH55" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 &#8212; <span id="xdx_829_zv1Dy7I1Bkc9">SEGMENT DISCLOSURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s operations are based in, and revenues are predominately
derived from, the United States, and business activities are managed on a consolidated basis.&#160; The Company operates in one reportable
segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s Chief Executive Officer is the Chief Operating Decision
Maker (&#8220;CODM&#8221;).&#160; The CODM regularly reviews disaggregated revenue data by product line.&#160; However, consolidated net
income is utilized as a measure of profit and loss to assess the performance of the business and to determine how to allocate resources.&#160;
Significant expenses within net income include cost of goods sold, selling, general and administrative, research and development, and
depreciation and amortization, which are each separately presented on the Company&#8217;s Statements of Operations.&#160; Segment asset
information is not used by the CODM to allocate resources.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273341296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NatureOfOperations_zIjNYMYmOIyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_861_zPEmyeNaHM82">NATURE OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">KORU MEDICAL SYSTEMS, INC. (the &#8220;Company,&#8221; &#8220;KORU Medical,&#8221;
&#8220;KORU,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#8220;FDA&#8221;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as <span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20241231_z9Agcpgdz5L3" title="Number of segment::XDX::1">one</span> segment.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zXI2Uody1Zmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86E_zF8Mklpghykf">BASIS OF PRESENTATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). &#160;Certain
liability balances within the accompanying December 31, 2023 balance sheet have been reclassified to conform to current period presentation.
There were no changes to the Company&#8217;s results of operations as a result of the reclassification.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPMBUvrY36ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86C_zEwql3bDypEd">CASH AND CASH EQUIVALENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;As of December
31, 2024 the Company held cash and cash-equivalents of $<span id="xdx_902_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20241231_zA7VaEMmx5a5" title="Investment securities treasury bill">9.6</span> million, the majority of which was held in a secured US-treasury money market
mutual fund.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zhTKv9KfM2ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86D_zLCvUJtAaI5k">INVENTORY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFuMhSKxU9eb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_z7BkJOfGVajg">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_za08LPcqfXFa" title="Estimated useful lives::XDX::P6Y"><span style="-sec-ix-hidden: xdx2ixbrl0465">6</span></span> to <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zCPUt66Qym8f" title="Estimated useful lives::XDX::P20Y"><span style="-sec-ix-hidden: xdx2ixbrl0467">20</span></span> years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2024 and 2023 was $<span id="xdx_904_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20240101__20241231_zr2imeJVZbW4" title="Amortization expense of intangible assets">68,197</span> and
$<span id="xdx_90F_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20230101__20231231_zbHzPE1Q4Ca4" title="Amortization expense of intangible assets">64,469</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zlKNDwImuqD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_z4bie2HRZKcl">The estimated amortization expense for the succeeding years for the intangible
assets is approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_49C_20241231_zEiqJoSjF1A8" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zxe0WBrGvaWl" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 68%">2025</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">$</td>
    <td style="vertical-align: bottom; width: 24%; text-align: right">66,766</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEB0xT345B19" style="vertical-align: bottom; background-color: white">
    <td>2026</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">65,969</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_znbomvaqq1J5" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">65,620</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zGkaPxMQjcj4" style="background-color: white">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">65,620</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_z8B0JiWwcTt3" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2029</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">59,644</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zsaAdOylyFh7" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">406,660</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zWurP3il377b" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">730,279</td></tr>
  </table>

<p id="xdx_8A9_zC0wOOf9B20f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zTTCQ9fSGV86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_862_z9SkIaTMXpW">INCOME TAXES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company accounts for deferred income taxes using the asset and liability
method. Under this method, deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and
their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Temporary differences
are then measured using the enacted tax rates and laws. Determining the appropriate amount of valuation allowance requires management
exercise judgement about future operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes. After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence, we have
a recorded valuation allowance of $<span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dxL_c20241231_ze1iPjfdHWS1" title="Valuation allowance::XDX::7080843"><span style="-sec-ix-hidden: xdx2ixbrl0492">7.1</span></span> million against our net deferred tax assets as of the year ended December 31, 2024. As we continue
to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction
of the valuation allowance in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zdwN7sWFQ5wa" title="Statutory rate">21</span>%, including U.S. federal R&amp;D credits, U.S. state tax rates, stock-based compensation and changes in our valuation
allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We account for uncertain tax positions in accordance with authoritative
guidance which prescribes a minimum recognition threshold a tax position is required to meet before being recognized in the financial
statements. Our evaluations of tax positions consider various factors including, but not limited to, changes in tax law, the measurement
of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained
during in-process audit activities and changes in facts or circumstances related to a tax position. We accrue interest and penalties related
to unrecognized tax benefits as a component of income tax expense recorded in continuing operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2021 are no longer subject to examination by tax authorities.&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKAkrqmhtghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zMd54PBkEcgb">PROPERTY AND EQUIPMENT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziwyiynIzVcl" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0498">3</span></span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zV27rsSADj18" title="Estimated useful lives of property and equipment::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0500">10</span></span> years for furniture
and office equipment, <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MinimumMember_zY1pIaZnUv55" title="Estimated useful lives of property and equipment::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0502">3</span></span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MaximumMember_zdCfLRbC0TG5" title="Estimated useful lives of property and equipment::XDX::P12Y"><span style="-sec-ix-hidden: xdx2ixbrl0504">12</span></span> years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2024
and 2023 was $<span id="xdx_900_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20240101__20241231_zUHezZUXtQmh" title="Depreciation and amortization, property and equipment">704,690</span> and $<span id="xdx_905_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20230101__20231231_zBuvLy7atMcl" title="Depreciation and amortization, property and equipment">805,921</span>, respectively.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzHwS4V0OxCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zwEKGtyX6Hrk">STOCK-BASED COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are recognized as compensation expense at their grant date fair value. &#160;The entire compensation expense
of the award is recognized over the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of restricted stock awards with
time-based vesting were estimated on the date of grant at the current stock price. The fair value of restricted stock awards vesting at
certain annual sales growth thresholds were estimated as of the date of Board acknowledgement of the achievement, at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--UseOfEstimates_za5euHsSBPii" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_867_zaH4ZQWzPnIl">USE OF ESTIMATES IN THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zoxRGXqDzNff" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86F_z0NOhPwujbR4">REVENUE RECOGNITION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#8220;Product Revenue&#8221;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#8220;PIDD&#8221;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#8220;CIDP&#8221;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#8220;NRE&#8221;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs are included as a component of cost of goods
sold in the accompanying statements of operations and are generally billed to customers, and included in Product Revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#8217;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#8217;s revenue recognition criteria described above. As of December 31, 2024, 2023, and 2022, the
Company has recognized a contract asset of $<span id="xdx_90D_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20240101__20241231_zwc0JIF7EJw" title="Recognition of contract asset">222,623</span>, $<span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20230101__20231231_zqNMfhOR4r8h" title="Recognition of contract asset">0</span>, and $<span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220101__20221231_zniF0Iday9i8" title="Recognition of contract asset">0</span>, respectively, which is included in other accounts receivable in the accompanying
balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89C_ecustom--ScheduleOfNetSalesByGeography_zGVwXFyhbU69" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zFIXZoKbmR4l">The following table summarizes net revenues by geography for the years
ended December 31, 2024 and 2023:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2024</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__country--US_zSPYR2n8G7Tb" style="text-align: right" title="Net Revenue">27,506,682</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zoejEZjgXhV8" style="text-align: right" title="Net Revenue">23,676,039</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zUPdwmzFWczg" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">6,139,781</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zDXRR3HKO4Td" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,841,627</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_981_eus-gaap--Revenues_c20240101__20241231_zbZwh9xqUJwe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">33,646,463</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--Revenues_c20230101__20231231_zzXAhVOe69kj" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">28,517,666</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zr0V0PmSMAva" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</a></td>
<td class="text"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9KnPXGgn3Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_868_zwPGs6ic3Pn2">ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In November 2023 the FASB issued ASU 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures which expands disclosure requirements to require entities to disclose significant
segment expenses that are regularly provided to or easily computed from information regularly provided to the chief operating decision
maker. This update also requires all annual disclosures currently required by Topic 280 to be disclosed in interim periods. The new disclosure
requirements are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after
December 15, 2024. Early adoption is permitted. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have
be applied retrospectively to all prior periods presented in the financial statements. The adoption of this ASU did not have a significant
impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments
&#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z2T1YjTQiGhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zusmkpmyusWd">FAIR VALUE MEASUREMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: center">&#8226;</td>
    <td style="width: 7in">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 2 &#8211; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#8226;</td>
    <td>Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2024.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">IMPAIRMENT OF LONG-LIVED ASSETS</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8c7yIvtxlwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_86A_zoBBYZEYriXi">IMPAIRMENT OF LONG-LIVED ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2024.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373367140080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">The estimated amortization expense for the succeeding years for the intangible assets is approximately:</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zlKNDwImuqD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BD_z4bie2HRZKcl">The estimated amortization expense for the succeeding years for the intangible
assets is approximately:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_49C_20241231_zEiqJoSjF1A8" style="vertical-align: bottom">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zxe0WBrGvaWl" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; width: 68%">2025</td>
    <td style="vertical-align: top; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">$</td>
    <td style="vertical-align: bottom; width: 24%; text-align: right">66,766</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEB0xT345B19" style="vertical-align: bottom; background-color: white">
    <td>2026</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">65,969</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_znbomvaqq1J5" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">65,620</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zGkaPxMQjcj4" style="background-color: white">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">65,620</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_z8B0JiWwcTt3" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2029</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">59,644</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zsaAdOylyFh7" style="background-color: white">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">406,660</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zWurP3il377b" style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Total amortization expense</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right">730,279</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfNetSalesByGeography', window );">The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023:</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfNetSalesByGeography_zGVwXFyhbU69" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_zFIXZoKbmR4l">The following table summarizes net revenues by geography for the years
ended December 31, 2024 and 2023:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 39%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 21%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>Years Ended December 31,</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2024</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b>2023</b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Net Revenues</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 9.45pt">Domestic</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>$</td>
    <td id="xdx_980_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__country--US_zSPYR2n8G7Tb" style="text-align: right" title="Net Revenue">27,506,682</td>
    <td style="vertical-align: top">&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zoejEZjgXhV8" style="text-align: right" title="Net Revenue">23,676,039</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.45pt">International</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zUPdwmzFWczg" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">6,139,781</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zDXRR3HKO4Td" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues">4,841,627</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Total</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_981_eus-gaap--Revenues_c20240101__20241231_zbZwh9xqUJwe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">33,646,463</td>
    <td style="border-bottom: white 2.25pt double; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--Revenues_c20230101__20231231_zzXAhVOe69kj" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues">28,517,666</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfNetSalesByGeography">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfNetSalesByGeography</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373363783200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists of:</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zwh3E8Jy1kQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_z6AVIjRjjtMg">Inventory consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Raw materials and work-in-process</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20241231_zj9nEQwEmqn7" style="text-align: right" title="Raw materials and work-in-process">827,768</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_z2ywVQWvu4ec" style="text-align: right" title="Raw materials and work-in-process">1,869,356</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Finished goods</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20241231_zOqYworObv5f" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">1,979,887</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zfJzVB98T9bl" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods">1,862,525</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>&#160;&#160;&#160;Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--InventoryGross_iI_c20241231_zJhshCFEAsb4" style="text-align: right" title="Inventory, Gross">2,807,655</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zXeaoVqfviA2" style="text-align: right" title="Inventory, Gross">3,731,881</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Less: reserve for obsolete inventory</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20241231_zsgYBOtjmES3" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory">(3,986</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_980_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zp60um2BJMGb" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory">(250,580</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Inventory, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_988_eus-gaap--InventoryNet_iI_dxL_c20241231_zsliOOC9aaP7" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory::XDX::2803669"><span style="-sec-ix-hidden: xdx2ixbrl0564">2,803,669</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zMBiLCp47QF9" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory">3,481,301</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373271836656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consists of the following at:</a></td>
<td class="text"><p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zI8IH58L1Go3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B8_z9ifDzZr2Bj9">Property and equipment consists of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 56%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Furniture and office equipment</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zlhKz8kkYAp6" style="text-align: right" title="Furniture and office equipment">1,433,622</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zqEFzpMJUT5c" style="text-align: right" title="Furniture and office equipment">1,412,164</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Leasehold improvements</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zHoBFfDYYB4" style="text-align: right" title="Leasehold improvements">1,953,653</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWh9j3umFTe1" style="text-align: right" title="Leasehold improvements">1,953,653</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Manufacturing equipment and tooling</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGjBj2uUc3k1" style="border-bottom: black 1pt solid; text-align: right" title="Manufacturing equipment and tooling">4,376,147</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zjz4hCU1zOdh" style="border-bottom: black 1pt solid; text-align: right" title="Manufacturing equipment and tooling">3,193,113</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;&#160;&#160;Total property and equipment</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231_zBh99ndGbZdg" style="text-align: right" title="Total property and equipment">7,763,422</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zxVhlIxozcBd" style="text-align: right" title="Total property and equipment">6,558,930</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Less: accumulated depreciation and amortization</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20241231_zJEAAyST5Pdh" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(3,472,907</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_z0CQp0IN5rLb" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization">(2,721,273</td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Property and equipment, net</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20241231_zko1jGRWZyOc" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">4,290,515</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z9VRV9fNbZi2" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net">3,837,657</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373275099904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of time based stock options</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEzP3t462Obe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the inputs into the Black-Scholes model
for all time-vesting stock options granted during the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_z81utUXWETni" style="display: none; visibility: hidden">Schedule of time based stock options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>December 31, 2024</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 62%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Dividend yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z7nDWzQxEbE7" title="Dividend yield">0.00</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Expected Volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zBnJgQaURIBc" title="Expected volatility">51.9</span>% - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zZvflGU81ZPb" title="Expected volatility">68.04</span>%</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Expected dividends</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zhFzCu7VVjZi" title="Expected dividends">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Expected term (in years)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zwTcCzzSLxq4" title="Expected term (in years)::XDX::P6Y2M30D"><span style="-sec-ix-hidden: xdx2ixbrl0627">6.25</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Risk-free rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_z2JnIwwK1amj" title="Risk-free rate">3.50</span>% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zQCCh5cKtqDl" title="Risk-free rate">4.11</span>%</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of status of time based stock options</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEE4EiplHgug" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the status of the time-based stock options
outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B7_zohm8epPEc8a" style="display: none; visibility: hidden">Schedule of status of time based stock options</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 74%">Outstanding at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zFEqBRxzHFAk" style="width: 11%; text-align: right" title="Outstanding at beginning (in shares)">3,256,250</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zgTKvRJ5gWa4" style="width: 11%; text-align: right" title="Outstanding at beginning, price">3.66</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_ziLWLRGjDJg6" style="text-align: right" title="Granted (in shares)">567,024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zScpa5HlIP3i" style="text-align: right" title="Granted">2.35</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Exercised</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zCiDtWteBaK8" style="text-align: right" title="Exercised (in shares)">(237,500</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z45j1tDPoaN3" style="text-align: right" title="Exercised">2.67</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited</td>
    <td>&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zVSrDjvQ8Sqb" style="text-align: right" title="Forfeited (in shares)">(898,750</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zY6SvUp3s2w7" style="text-align: right" title="Forfeited">4.86</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Outstanding at December 31</td>
    <td>&#160;</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zqjj0UoI2DY4" style="text-align: right" title="Outstanding at ending (in shares)">2,687,024</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zE6vzBKy6exe" style="text-align: right" title="Outstanding at ending, price">3.07</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Options exercisable at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zPUclYjx0Uzg" style="text-align: right" title="Options exercisable (in shares)">1,383,750</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zle0yaJaSZp3" style="text-align: right" title="Options exercisable">3.40</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 0.1in; text-indent: -0.1in">Weighted average fair value of options granted during the period</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z0QpHXsd1I4a" style="text-align: right" title="Weighted average fair value of options granted during the period">1.44</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock', window );">Schedule of information pertaining to options outstanding</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_z95sK4WPWlc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents information pertaining to time-based stock
options outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_znHDlpGsuEmc" style="display: none; visibility: hidden">Schedule of information pertaining to options outstanding</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid"><b>Range of Exercise Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Outstanding</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Remaining<br/>
Contractual<br/>
Life</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Number<br/>
Exercisable</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Exercise<br/>
Price</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 29%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 12%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>$2.08-$3.98</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z97F722reGXj" style="text-align: right" title="Number outstanding">2,687,024</td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zROvmVLqahJ6" title="Weighted average remaining contractual life::XDX::P7Y4M24D"><span style="-sec-ix-hidden: xdx2ixbrl0673">7.4</span></span> years</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zgrvMwPMHfo" style="text-align: right" title="Weighted average exercise price">3.07</td>
    <td>&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zhGByk2yn2Ol" style="text-align: right" title="Number exercisable">1,383,750</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2eronAeslml" style="text-align: right" title="Weighted average exercise price">3.40</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024.</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zpHtCUdjQQGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B3_z9KwfiUsN051">The following table summarizes the activities for our unvested performance-vesting
stock option awards for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 67%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zawJhSm0C2J1" style="width: 13%; text-align: right" title="Unvested at beginning, shares">200,000</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zfN7MUutp6A8" style="width: 16%; text-align: right" title="Unvested at beginning, price">1.48</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zD47iwi6517l" style="text-align: right" title="Granted, shares">&#8212;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zuKldYTbr4ue" style="text-align: right" title="Granted, price">&#8212;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zsqIeO74Wx38" style="text-align: right" title="Vested, shares">(22,000</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zAKjer81Fvxf" style="text-align: right" title="Vested, price">1.48</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zvd4lDWavMR2" style="text-align: right" title="Forfeited/canceled, shares">(44,666</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_z1u2fXXBwMI2" style="text-align: right" title="Forfeited/canceled, price">1.48</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zlrGowkjmAtl" style="text-align: right" title="Unvested at ending, shares">133,334</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zSX1C8vq8yD" style="text-align: right" title="Unvested at ending, price">1.48</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024.</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zn92eN7g2kDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_zd7DOStXgaB9">The following table summarizes the activities for our unvested restricted
stock awards, RSUs, and PSUs for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Shares</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Weighted<br/>
Average<br/>
Grant-Date<br/>
Fair Value</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 67%">Unvested at January 1</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zjqN8brKVLnh" style="width: 13%; text-align: right" title="Outstanding at beginning, shares">904,496</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zoR0DmgcChJ7" style="width: 16%; text-align: right" title="Outstanding at beginning, price">2.77</td>
    <td style="width: 0%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Granted</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zDY3M1ABIITf" style="text-align: right" title="Granted, shares">458,975</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zm7cngsSnVIf" style="text-align: right" title="Granted, price">2.20</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Vested</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zQAO4jZTtfvb" style="text-align: right" title="Vested, shares">(81,789</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8jxzHMwGn72" style="text-align: right" title="Vested, price">3.45</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>Forfeited/canceled</td>
    <td>&#160;</td>
    <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8maZvFHhjUb" style="text-align: right" title="Forfeited/canceled, shares">(11,745</td>
    <td>)</td>
    <td>&#160;</td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_znpAADdIu6v" style="text-align: right" title="Forfeited/canceled, price">2.30</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Unvested at December 31</td>
    <td>&#160;</td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zlYBBTVqFCa6" style="text-align: right" title="Outstanding at ending, shares">1,269,937</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxvGbF9OTN94" style="text-align: right" title="Outstanding at ending, price">2.54</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of share based compensation stock options activity amended table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373275205792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">The components of lease expense were as follows:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zuwSL6AIJcy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B0_zmEBGrjkD0t7">The components of lease expense were as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 57%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_492_20240101__20241231_zShb2ZhqBko6" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 3%; text-align: center">&#160;</td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td id="xdx_492_20230101__20231231_zPEyZuPWSlM4" style="width: 16%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zifrdolfisua" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Operating lease cost</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">487,960</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">448,630</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zKKYkZk8XH6l" style="vertical-align: bottom; background-color: white">
    <td>Short-term lease cost</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5,952</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">130,483</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCost_zZuEkMCA2foc" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">493,912</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">579,113</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_z9Yc3HBZd6dk" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9.1pt; text-indent: -9.1pt">Finance lease cost:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zOL87A1XofA2" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Amortization of right-of-use assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">115,585</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">110,566</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zR44tk9uxsAj" style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 27.5pt; text-indent: -9.1pt">Interest on lease liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">21,896</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,343</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zCk1pqkFSpZ3" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total finance lease cost</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">137,481</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double">$</td>
    <td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right">135,909</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Supplemental cash flow information related to leases was as follows:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHtI5UDOZb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B9_z2rBG3vO53E1">Supplemental cash flow information related to leases was as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 71.96%">&#160;</td>
    <td style="width: 0.98%">&#160;</td>
    <td style="width: 1.06%; text-align: center">&#160;</td>
    <td id="xdx_492_20240101__20241231_zAGVL7urrDW8" style="width: 10.98%; text-align: center">&#160;</td>
    <td style="width: 1.98%; text-align: center">&#160;</td>
    <td style="width: 1.06%; text-align: center">&#160;</td>
    <td id="xdx_492_20230101__20231231_zzVWBgMzviUh" style="width: 10.98%; text-align: center">&#160;</td>
    <td style="width: 0.98%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="text-align: center"><b>Years Ended</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="padding-left: 9.45pt; text-indent: -9.45pt">Cash paid for amounts included in the measurement of lease liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zyCsZUvoFrM5" style="vertical-align: bottom; background-color: white">
    <td>Operating cash flows from operating leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">501,214</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">464,104</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zKYp2GHfNZm" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Financing cash flows from finance leases</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">131,437</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">125,259</td>
    <td>&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Supplemental information related to leases was as follows:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z1PIw2sIUuV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B2_z0Muv5NOao1h">Supplemental information related to leases was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom; width: 58%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><b>December 31,<br/>
2024</b></td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td style="vertical-align: top; width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Remaining Lease Term</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20241231_zmIb4dGEugo2" title="Operating leases term::XDX::P5Y1M6D"><span style="-sec-ix-hidden: xdx2ixbrl0791">5.1</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zF5FxvE3qPud" title="Operating leases term::XDX::P6Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0793">6.9</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20241231_zXFttH55OXo7" title="Finance leases  term::XDX::P2Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0795">2.7</span></span> Years</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right"><span id="xdx_905_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zMzK1h0En1D1" title="Operating leases term::XDX::P3Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0797">3.7</span></span> Years</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom"><b>Weighted Average Discount Rate</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Operating leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zD4Wg9VePVna" title="Operating leases discount rate">6.52</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zQTmoa3PK0X5" title="Operating leases discount rate">5.76</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt">Finance leases</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zFxOZJ43fHoc" title="Finance leases discount rate">6.34</span>%</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span id="xdx_905_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z5KU3gcUM807" title="Finance leases discount rate">6.19</span>%</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liabilities are as follows:</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zwjrDeZbopqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zYzR4mV4G5fj">Maturities of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><b>Year Ending December 31,</b></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Operating Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Finance Leases</b></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2025</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zTDTK8n3t875" style="vertical-align: bottom; text-align: right" title="2025 - Operating Leases">533,979</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zjUsCnD4icoh" style="vertical-align: bottom; text-align: right" title="2025 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2026</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zH9ljjshPew4" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases">533,979</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zT12UntsoyB3" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases">131,437</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">2027</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zwmfrBeflmF" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases">533,979</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zl2F75onMYH5" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases">74,194</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">2028</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20241231_z9NnOEa1yyJ2" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases">520,985</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20241231_zPpCYm5GLIAk" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases">6,181</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom">Thereafter</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_z1nEpK0z5Mo4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases">1,833,603</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98A_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_zonC4EG7RFYl" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Total undiscounted lease payments</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20241231_zf3p9eKVuO16" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases">3,956,525</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td id="xdx_980_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20241231_zPrhrwrXfTOg" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases">343,248</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #E6E6E6">
    <td style="vertical-align: bottom; padding-left: 18.8pt">Less: imputed interest</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_989_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20241231_zwRLoURqG6r6" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases">(555,864</td>
    <td style="vertical-align: bottom">)</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td id="xdx_98B_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20241231_zxrD62runzac" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases">(25,048</td>
    <td style="vertical-align: bottom">)</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">Total lease liabilities</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_zNhTlG0JzTd2" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases">3,400,661</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom">$</td>
    <td id="xdx_980_eus-gaap--FinanceLeaseLiability_iI_c20241231_zCdoExEUMXUk" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases">318,200</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481418/840-10-55-40<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481501/840-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373271792896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FEDERAL AND STATE INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss', window );">Schedule of Components of Domestic and International Pre-Tax Income (Loss)</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss_zObaKHPM16Pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Domestic and international pre-tax income/(loss) consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zQewyfOXe396" style="display: none; visibility: hidden">Schedule of Components of Domestic and International Pre-Tax Income (Loss)</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zO5tODJ7fD48" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zDEUY1Lei53f" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zrYg1RyKPMd5" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">United States</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; width: 1.26%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right">(6,063,740</td>
    <td style="border-bottom: white 2.25pt double; width: 3.92%">)</td>
    <td style="border-bottom: black 2.25pt double; width: 1.26%">$</td>
    <td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right">(9,733,582</td>
    <td style="border-bottom: white 2.25pt double; width: 0.92%">)</td></tr>
  <tr id="xdx_403_ecustom--LossBeforeIncomeTaxes_zdPRysbo8mNg" style="vertical-align: bottom">
    <td>Loss before income taxes</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">(6,063,740</td>
    <td>)</td>
    <td>$</td>
    <td style="text-align: right">(9,733,582</td>
    <td>)</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zg0KcHaDK7P5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense attributable to operations is comprised of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B5_zH40JnISYQZe" style="display: none; visibility: hidden">Schedule of provision for income taxes</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zGYKeQcDzzm9" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zE7qsNHKSDmk" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zzbxTfiiFmX1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Current:</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_zvU7WS6IzcRd" style="vertical-align: bottom; background-color: white">
    <td style="width: 59.94%">Federal</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0856">&#8212;</span></td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zgZXNN6pjf4k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>State</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(2,893</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentForeignTaxExpenseBenefit_z9jymh33Vcd3" style="vertical-align: bottom; background-color: white">
    <td>International</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentIncomeTaxExpenseBenefit_zpL6pAzdmcz4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Current</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(2,893</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zWdkpggOLgQh" style="vertical-align: bottom; background-color: white">
    <td>Deferred:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_z3gOjbuiqj8k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Federal</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(3,967,480</td>
    <td>)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_z3NdOK6ATzC2" style="vertical-align: bottom; background-color: white">
    <td>State</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zMP0YVoZZ05k" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>International</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_zEf2RdW2QJX2" style="vertical-align: bottom; background-color: white">
    <td>Total Deferred</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(3,967,480</td>
    <td>)</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iN_di_z6cJ0yEb8JUl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Income Tax Expense</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(2,893</td>
    <td style="border-bottom: White 2.25pt double">)</td>
    <td style="border-bottom: Black 2.25pt double">$</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(3,967,480</td>
    <td style="border-bottom: White 2.25pt double">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0c5Ey4UrK04" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income taxes reflect the net tax effects of temporary differences
between carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant
components of our deferred tax assets and liabilities are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BA_zkToTvMEmEcb" style="display: none; visibility: hidden">Schedule of components of deferred tax assets</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20241231_zY8Mtci61Uf4" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49C_20231231_z5b5fugGZIv6" style="border-bottom: black 1pt solid; text-align: center"><b>December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsAbstract_iB_zhvnf78rDXC1" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">Deferred Tax Assets:</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">&#160;</td>
    <td style="width: 15.9%; text-align: right">&#160;</td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">&#160;</td>
    <td style="width: 15.9%; text-align: right">&#160;</td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsNetOperatingLoss_iI_zhkUmSrw8zD" style="vertical-align: bottom; background-color: white">
    <td>Net Operating Loss</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">4,025,905</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">3,566,630</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsCredits_iI_z1rolL4edE12" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Credits</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">129,598</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">142,030</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zGceoJacp2J6" style="vertical-align: bottom; background-color: white">
    <td>Capitalized Research Costs</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,451,496</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,045,616</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsNQOAndRSAStockOptions_iI_zkLfJ848c1hg" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>NQO &amp; RSA Stock Options</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">350,484</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,047,608</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsDeferredLeaseLiability_iI_zLVuaAEQfpFa" style="vertical-align: bottom; background-color: white">
    <td>Deferred Lease Liability</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">647,446</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0905">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_z0zJkTHTaDbl" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Accruals &amp; Reserves</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">712,058</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">129,923</td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_z5GXDNHv8qL1" style="vertical-align: bottom; background-color: white">
    <td>Other</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">48</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">42</td>
    <td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_zOTE2jpPoh73" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Gross Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">8,317,035</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">6,931,849</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_z2oPP38ljvY2" style="vertical-align: bottom; background-color: white">
    <td>Valuation allowance</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(7,080,843</td>
    <td>)</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(6,002,777</td>
    <td>)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iI_zyNMOInNXXWj" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">1,236,192</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">929,072</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zs3Xn5yHq3fa" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Deferred Tax Liabilities:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxLiabilitiesIntangibles_iI_z8Gs9Wca3Ing" style="vertical-align: bottom; background-color: white">
    <td>Intangibles</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(58,170</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(408,260</td>
    <td>)</td></tr>
  <tr id="xdx_408_ecustom--DeferredTaxLiabilitiesROUAssets_iI_zYnCif48gjta" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>ROU Assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(538,632</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(5,511</td>
    <td>)</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFixedAssets_iI_zwEV2O7Q2u4e" style="vertical-align: bottom; background-color: white">
    <td>Fixed Assets</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(639,390</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(515,300</td>
    <td>)</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNI_di_zlb7iPHNdT2j" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Total Deferred Tax Liabilities</td>
    <td>&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right">(1,236,192</td>
    <td style="border-bottom: white 2.25pt double">)</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right">(929,071</td>
    <td style="border-bottom: white 2.25pt double">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_zn8G5rrZqDl2" style="vertical-align: bottom; background-color: white">
    <td>Net Deferred Tax Asset</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">&#8212;</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjg1egs04xI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income tax expense differed from the amount computed by applying the federal
statutory income tax rate of 21% to pretax income for the years ended December 31, 2024 and December 31, 2023 as a result of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BF_zgINPoOhGq3i" style="display: none; visibility: hidden">Schedule of Effective Income Tax Rate Reconciliation</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_495_20240101__20241231_z4YQfWbICOEb" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zgx2vGgJ2059" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2024</b></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><b>Year Ended<br/>
December 31,<br/>
2023</b></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zzqguLtQVMz9" style="vertical-align: bottom; background-color: #E6E6E6">
    <td style="width: 59.94%">Federal tax at statutory rate</td>
    <td style="width: 0.9%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right">1,272,820</td>
    <td style="width: 3.92%">&#160;</td>
    <td style="width: 1.26%">$</td>
    <td style="width: 15.9%; text-align: right">2,052,452</td>
    <td style="width: 0.92%">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zmqbbaIgZGjj" style="vertical-align: bottom; background-color: white">
    <td>State income taxes</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">184,595</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_408_ecustom--IncomeTaxReconciliationChangeInValuationAllowance_zpoRsDnmFHAd" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Valuation allowance</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(1,078,066</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right">(6,002,777</td>
    <td>)</td></tr>
  <tr id="xdx_406_ecustom--IncomeTaxReconciliationDeferredTaxTrueUps_zDBVUNxZcObl" style="vertical-align: bottom; background-color: white">
    <td>Deferred tax true ups</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(352,653</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0963">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationOtherItems_zsfIFUrW7kT4" style="vertical-align: bottom; background-color: #E6E6E6">
    <td>Other items</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(29,589</td>
    <td>)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">(17,155</td>
    <td>)</td></tr>
  <tr id="xdx_408_ecustom--IncomeTaxReconciliationNet_zY58pErxH8tf" style="vertical-align: bottom; background-color: white">
    <td>Total</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(2,893</td>
    <td style="border-bottom: White 2.25pt double">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: right">(3,967,480</td>
    <td style="border-bottom: White 2.25pt double">)</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373274997936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 66,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">65,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">65,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">65,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">59,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">406,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization expense</a></td>
<td class="nump">$ 730,279<span></span>
</td>
<td class="nump">$ 754,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272080384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 33,646,463<span></span>
</td>
<td class="nump">$ 28,517,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">27,506,682<span></span>
</td>
<td class="nump">23,676,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,139,781<span></span>
</td>
<td class="nump">$ 4,841,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273364560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segment | Number</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeSecuritiesUSTreasury', window );">Investment securities treasury bill</a></td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_AmortizationOfIntangibleAssets1', window );">Amortization expense of intangible assets</a></td>
<td class="nump">68,197<span></span>
</td>
<td class="nump">$ 64,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 7,080,843<span></span>
</td>
<td class="nump">6,002,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DepreciationAndAmortizationPropertyAndEquipment', window );">Depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 704,690<span></span>
</td>
<td class="nump">805,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable', window );">Recognition of contract asset</a></td>
<td class="nump">$ 222,623<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture And Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Equipment And Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture And Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Equipment And Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember', window );">Patents And Trademarks [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember', window );">Patents And Trademarks [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_AmortizationOfIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_AmortizationOfIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DepreciationAndAmortizationPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DepreciationAndAmortizationPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetReclassifiedToReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeSecuritiesUSTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeSecuritiesUSTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_EquipmentAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_EquipmentAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=krmd_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273175568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory consists of: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work-in-process</a></td>
<td class="nump">$ 827,768<span></span>
</td>
<td class="nump">$ 1,869,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,979,887<span></span>
</td>
<td class="nump">1,862,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross</a></td>
<td class="nump">2,807,655<span></span>
</td>
<td class="nump">3,731,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: reserve for obsolete inventory</a></td>
<td class="num">(3,986)<span></span>
</td>
<td class="num">(250,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 2,803,669<span></span>
</td>
<td class="nump">$ 3,481,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272558048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment consists of the following at: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 7,763,422<span></span>
</td>
<td class="nump">$ 6,558,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,472,907)<span></span>
</td>
<td class="num">(2,721,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,290,515<span></span>
</td>
<td class="nump">3,837,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember', window );">Furniture And Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,433,622<span></span>
</td>
<td class="nump">1,412,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,953,653<span></span>
</td>
<td class="nump">1,953,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember', window );">Manufacturing Equipment And Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 4,376,147<span></span>
</td>
<td class="nump">$ 3,193,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krmd_ManufacturingEquipmentAndToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273328016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of time based stock options (Details) - Time Vesting Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">51.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.11%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273156944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of status of time based stock options (Details) - Time Vesting Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning (in shares) | shares</a></td>
<td class="nump">3,256,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning, price</a></td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">567,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(237,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">$ 2.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(898,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">$ 4.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at ending (in shares) | shares</a></td>
<td class="nump">2,687,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending, price</a></td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,383,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable</a></td>
<td class="nump">$ 3.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted during the period</a></td>
<td class="nump">$ 1.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373274297728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of information pertaining to options outstanding (Details) - Time Vesting Stock Options [Member] - Exercise Price1 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding | shares</a></td>
<td class="nump">2,687,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 3.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">1,383,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 3.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=krmd_ExercisePrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272371824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details) - Performance Vesting Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions', window );">Unvested at beginning, shares | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice', window );">Unvested at beginning, price | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants', window );">Granted, shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1', window );">Granted, price | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested', window );">Vested, shares | shares</a></td>
<td class="num">(22,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1', window );">Vested, price | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures', window );">Forfeited/canceled, shares | shares</a></td>
<td class="num">(44,666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1', window );">Forfeited/canceled, price | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions', window );">Unvested at ending, shares | shares</a></td>
<td class="nump">133,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice', window );">Unvested at ending, price | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by unvested award options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_PerformanceVestingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_PerformanceVestingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272355168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details) - Restricted Stock Awards [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at beginning, shares | shares</a></td>
<td class="nump">904,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at beginning, price | $ / shares</a></td>
<td class="nump">$ 2.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested', window );">Granted, shares | shares</a></td>
<td class="nump">458,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested', window );">Granted, price | $ / shares</a></td>
<td class="nump">$ 2.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross', window );">Vested, shares | shares</a></td>
<td class="num">(81,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice', window );">Vested, price | $ / shares</a></td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested', window );">Forfeited/canceled, shares | shares</a></td>
<td class="num">(11,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested', window );">Forfeited/canceled, price | $ / shares</a></td>
<td class="nump">$ 2.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested', window );">Outstanding at ending, shares | shares</a></td>
<td class="nump">1,269,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested', window );">Outstanding at ending, price | $ / shares</a></td>
<td class="nump">$ 2.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding number unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options vested in period gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273301952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember', window );">Time Vesting Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockBasedCompensationStockOptions', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,530,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CashReceivedFromOptionExercise', window );">Cash received from option exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StockbasedCompensationIntrinsicValue', window );">Stock-based compensation intrinsic value</a></td>
<td class="nump">2,085,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="nump">1,427,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krmd_PerformanceVestingStockOptionsMember', window );">Performance Vesting Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_CashReceivedFromOptionExercise', window );">Cash received from option exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">21,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_UnrecognizedCompensationCost', window );">Unrecognized compensation cost</a></td>
<td class="nump">183,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">579,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_UnrecognizedCompensationCost', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 902,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember', window );">Non Employee Director and Board Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsOverallDescription', window );">Share-based goods and non-employee services transaction</a></td>
<td class="text">to be paid quarterly in arrears of $12,500 in cash and $15,000 in
common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NonemployeeServicesTransactionCost', window );">Nonemployee services transaction cost</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsOverallDescription', window );">Share-based goods and non-employee services transaction</a></td>
<td class="text">to be paid quarterly in arrears of $12,500 in
cash and $22,500 in common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesReservedForOutstandingAwards', window );">Shares reserved for outstanding awards</a></td>
<td class="nump">2,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_OmnibusEquityIncentivePlan2021Member', window );">Omnibus Equity Incentive Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesReservedForOutstandingAwards', window );">Shares reserved for outstanding awards</a></td>
<td class="nump">127,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_OmnibusEquityIncentivePlan2024Member', window );">Omnibus Equity Incentive Plan 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesReservedForOutstandingAwards', window );">Shares reserved for outstanding awards</a></td>
<td class="nump">799,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_SharesAvailableForIssuanceShareBasedCompensation', window );">Shares available for issuance</a></td>
<td class="nump">2,320,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember', window );">Stock Option Plans 2015 And 2021 Combined [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_CashReceivedFromOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_CashReceivedFromOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NonemployeeServicesTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents nonemployee services transaction cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NonemployeeServicesTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_SharesAvailableForIssuanceShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents shares available for issuance share based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_SharesAvailableForIssuanceShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_SharesReservedForOutstandingAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_SharesReservedForOutstandingAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockBasedCompensationStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock based compensation stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockBasedCompensationStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StockbasedCompensationIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StockbasedCompensationIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_UnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents unrecognized compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_UnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementsOverallDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General description of deferred compensation arrangements. Deferred compensation represents currently earned compensation that, under the terms of a profit-sharing, rabbi trust, pension, employee contract, or equity-based (including stock or unit option) plan, is not actually paid until a later date and is therefore not taxable until that date. May also include some split-dollar life insurance arrangements. This type of arrangement is usually made to help employees postpone paying taxes on the income and also to retain employees longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementsOverallDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_TimeVestingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_PerformanceVestingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_PerformanceVestingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krmd_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=krmd_NonEmployeeDirectorAndBoardAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_OmnibusEquityIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_OmnibusEquityIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_OmnibusEquityIncentivePlan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_OmnibusEquityIncentivePlan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krmd_StockOptionPlans2015And2021CombinedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373274921088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT OBLIGATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=krmd_SecurityAgreementMember', window );">Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount of note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_DomesticBankLenderMember', window );">Domestic Bank Lender [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DebtInstrumentInterestPaymentTerms', window );">Debt instrument interest payment terms</a></td>
<td class="text">Borrowings under the revolving credit facility will bear interest at the
greater of Prime or 6.50%, payable in arrears on a monthly basis and at maturity.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=krmd_DomesticBankLenderMember', window );">Domestic Bank Lender [Member] | Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LinesOfCreditCurrent1', window );">Term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DebtInstrumentInterestPaymentTerms', window );">Debt instrument interest payment terms</a></td>
<td class="text">Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DebtInstrumentInterestPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DebtInstrumentInterestPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LinesOfCreditCurrent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LinesOfCreditCurrent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=krmd_SecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=krmd_SecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=krmd_DomesticBankLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=krmd_DomesticBankLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=krmd_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=krmd_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273119392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The components of lease expense were as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 487,960<span></span>
</td>
<td class="nump">$ 448,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">5,952<span></span>
</td>
<td class="nump">130,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">493,912<span></span>
</td>
<td class="nump">579,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseCost1Abstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">115,585<span></span>
</td>
<td class="nump">110,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">21,896<span></span>
</td>
<td class="nump">25,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 137,481<span></span>
</td>
<td class="nump">$ 135,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseCost1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents finance lease cost1 abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseCost1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373275180240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental cash flow information related to leases was as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 501,214<span></span>
</td>
<td class="nump">$ 464,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 131,437<span></span>
</td>
<td class="nump">$ 125,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272464048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental information related to leases was as follows: (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leases term</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 10 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Operating leases term</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating leases discount rate</a></td>
<td class="nump">6.52%<span></span>
</td>
<td class="nump">5.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance leases discount rate</a></td>
<td class="nump">6.34%<span></span>
</td>
<td class="nump">6.19%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272399088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Maturities of lease liabilities are as follows: (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025 - Operating Leases</a></td>
<td class="nump">$ 533,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025 - Finance Leases</a></td>
<td class="nump">131,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026 - Operating Leases</a></td>
<td class="nump">533,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026 - Finance Leases</a></td>
<td class="nump">131,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027 - Operating Leases</a></td>
<td class="nump">533,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027 - Finance Leases</a></td>
<td class="nump">74,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028 - Operating Leases</a></td>
<td class="nump">520,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028 - Finance Leases</a></td>
<td class="nump">6,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter - Operating Leases</a></td>
<td class="nump">1,833,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter - Finance Leases</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal', window );">Total undiscounted lease payments - Operating Leases</a></td>
<td class="nump">3,956,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal', window );">Total undiscounted lease payments - Finance Leases</a></td>
<td class="nump">343,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeOperatingLeaseImputedInterest', window );">Less: imputed interest - Operating Leases</a></td>
<td class="num">(555,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LesseeFinancingLeaseImputedInterest', window );">Less: imputed interest - Finance Leases</a></td>
<td class="num">(25,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities - Operating Leases</a></td>
<td class="nump">3,400,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities - Finance Leases</a></td>
<td class="nump">$ 318,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee financing lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee financing lease lease liability payments due total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents lessee operating lease liability payments due total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373277417568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (6,063,740)<span></span>
</td>
<td class="num">$ (9,733,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_LossBeforeIncomeTaxes', window );">Loss before income taxes</a></td>
<td class="num">$ (6,063,740)<span></span>
</td>
<td class="num">$ (9,733,582)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_LossBeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_LossBeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373272325920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of provision for income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2,893)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current</a></td>
<td class="num">(2,893)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,967,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,967,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense</a></td>
<td class="num">$ (2,893)<span></span>
</td>
<td class="num">$ (3,967,480)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273301376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of components of deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DeferredTaxAssetsAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DeferredTaxAssetsNetOperatingLoss', window );">Net Operating Loss</a></td>
<td class="nump">$ 4,025,905<span></span>
</td>
<td class="nump">$ 3,566,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DeferredTaxAssetsCredits', window );">Credits</a></td>
<td class="nump">129,598<span></span>
</td>
<td class="nump">142,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized Research Costs</a></td>
<td class="nump">2,451,496<span></span>
</td>
<td class="nump">2,045,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DeferredTaxAssetsNQOAndRSAStockOptions', window );">NQO &amp; RSA Stock Options</a></td>
<td class="nump">350,484<span></span>
</td>
<td class="nump">1,047,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DeferredTaxAssetsDeferredLeaseLiability', window );">Deferred Lease Liability</a></td>
<td class="nump">647,446<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals &amp; Reserves</a></td>
<td class="nump">712,058<span></span>
</td>
<td class="nump">129,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross Deferred Tax Asset</a></td>
<td class="nump">8,317,035<span></span>
</td>
<td class="nump">6,931,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(7,080,843)<span></span>
</td>
<td class="num">(6,002,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Asset</a></td>
<td class="nump">1,236,192<span></span>
</td>
<td class="nump">929,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DeferredTaxLiabilitiesIntangibles', window );">Intangibles</a></td>
<td class="num">(58,170)<span></span>
</td>
<td class="num">(408,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DeferredTaxLiabilitiesROUAssets', window );">ROU Assets</a></td>
<td class="num">(538,632)<span></span>
</td>
<td class="num">(5,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DeferredTaxLiabilitiesFixedAssets', window );">Fixed Assets</a></td>
<td class="num">(639,390)<span></span>
</td>
<td class="num">(515,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">(1,236,192)<span></span>
</td>
<td class="num">(929,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred Tax Asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DeferredTaxAssetsCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DeferredTaxAssetsCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DeferredTaxAssetsDeferredLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DeferredTaxAssetsDeferredLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DeferredTaxAssetsNQOAndRSAStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DeferredTaxAssetsNQOAndRSAStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DeferredTaxAssetsNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DeferredTaxAssetsNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DeferredTaxLiabilitiesIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DeferredTaxLiabilitiesIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DeferredTaxLiabilitiesROUAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DeferredTaxLiabilitiesROUAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273481088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate</a></td>
<td class="nump">$ 1,272,820<span></span>
</td>
<td class="nump">$ 2,052,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">184,595<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_IncomeTaxReconciliationChangeInValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,078,066)<span></span>
</td>
<td class="num">(6,002,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_IncomeTaxReconciliationDeferredTaxTrueUps', window );">Deferred tax true ups</a></td>
<td class="num">(352,653)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_IncomeTaxReconciliationOtherItems', window );">Other items</a></td>
<td class="num">(29,589)<span></span>
</td>
<td class="num">(17,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_IncomeTaxReconciliationNet', window );">Total</a></td>
<td class="num">$ (2,893)<span></span>
</td>
<td class="num">$ (3,967,480)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IncomeTaxReconciliationChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IncomeTaxReconciliationChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IncomeTaxReconciliationDeferredTaxTrueUps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IncomeTaxReconciliationDeferredTaxTrueUps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IncomeTaxReconciliationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IncomeTaxReconciliationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_IncomeTaxReconciliationOtherItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_IncomeTaxReconciliationOtherItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273423328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FEDERAL AND STATE INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets', window );">Valuation Allowance on Deferred Tax Assets - Net Change</a></td>
<td class="nump">$ 1,078,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NetOperatingLossCarryforwardsFederal', window );">Net operating loss carryforwards, federal</a></td>
<td class="nump">18,313,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_NetOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards, state</a></td>
<td class="nump">3,533,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_FederalResearchCreditCarryforward', window );">Federal Research Credit Carryforward</a></td>
<td class="nump">129,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_StateResearchCreditCarryforward', window );">State Research Credit Carryforward</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_FederalResearchCreditCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_FederalResearchCreditCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NetOperatingLossCarryforwardsFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NetOperatingLossCarryforwardsFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_NetOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_NetOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_StateResearchCreditCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_StateResearchCreditCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273586672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Account eceivable from customers</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=krmd_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=krmd_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46373273335680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krmd_DescriptionOfMatchingContribution', window );">Description of matching contribution</a></td>
<td class="text">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#8217;s contribution, not to exceed 3% of employee&#8217;s compensation plus 50% of employee&#8217;s pay
contributed between 3% and 5% of employee&#8217;s compensation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching expense</a></td>
<td class="nump">$ 262,915<span></span>
</td>
<td class="nump">$ 227,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krmd_DescriptionOfMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krmd_DescriptionOfMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ.+K[3=R=3Z9N>-+,O\YOSN_FA^0V;5[J&2HU=/K4JLSK%R]B?ORDJ$+8U7
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MK5^?K$]TNBS?0#RD6J>+\G"NY%1E!0!^GZ4PP&Q.BI<:U4NLP?]02P,$%
M  @ ?8-L6I'?.7P2 P  H0@  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6RMEFM/VS 4AO^*E4T32(7<+V5MI%) 3-JEHL ^3/O@)J>-A1-WMM,"OWZV
M4Z*V! ;2^J&QG7->/^^)'6>P9OQ.%  2W9>T$D.KD')Y8MLB*Z#$XI@MH5)W
MYHR76*HN7]ABR0'G)JFDMN<XD5UB4EGIP(Q->#I@M:2D@@E'HBY+S!].@;+U
MT'*MIX$KLBBD'K#3P1(O8 KR9CGAJF>W*CDIH1*$58C#?&B-W)-QHN--P"V!
MM=AJ(^UDQMB=[GS)AY:C@8!")K4"5I<5C(%2+:0P_FPTK79*G;C=?E*_,-Z5
MEQD6,&;T)\EE,;02"^4PQS655VQ]"1L_H=;+&!7F'ZV;V#"V4%8+R<I-LB(H
M2=5<\?VF#EL);O!"@K=)\-Z:X&\2?&.T(3.VSK#$Z8"S->(Z6JGIAJF-R59N
M2*6?XE1R=9>H/)F>CKZ.OH_/T?3R_/QZB@XFF$,E"Y DP_00':&;Z1DZ^'@X
ML*6:3>?8V4;YM%'V7E ^@^P8^6X/>8X7=*2/WY[N[Z;;RF-KU&N->D;/?T%O
M*K$$M?PD8G-T02I<9013-&&"F/7T:S03DJM5];O+:J,==&OKG78BECB#H:6V
MD@"^ BO]],&-G,]=QO^3V$X9_+8,_FOJJ7).)!Q1M7=R1"J)JP6944!8")"B
MI[955I<U5;7*$2X9E^01Z_IT%:69*30SZ;?%*@W")/23@;W:MOL\S.\[?N"V
M83M&@M9(\*J1,2M+]=BFDF5W/:26+6(<F8><HUM,:T 34 .%6L]=[(UXO 7E
M'#ON'OD_@G:XPY8[? >WX1-H5,N"<?((>1=K(QAM8<2A8WY[O&\(W&&.6N;H
M+<RB81:&N8>($'4W</2,(^C[<1RY\1YP5Z"3]),HZ :.6^#XW47NH1^U%&K!
MYZ1:=%''SV'"?AB[;KA'W14817T_\KJIDY8Z>97Z6AW#HN8/NX7N0DV>$?B!
MGX1>M$?:%><YH;,/:F\=(/KP_H;Y@E0"49BK3.<X5BN+-P=BTY%L:<Z4&9/J
MA#+-0GU# -<!ZOZ<,?G4T<=4^U62_@502P,$%     @ ?8-L6AF)EGN%!0
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M9YL(60,M#XU6: PMV3F5E0OCH%+O(L$IRT7\;_E *3)&CXKC.*;='28J.]O
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M@#]?9!G[?E-^!M=\B3G^'U!+ P04    " !]@VQ:@B(^18H'  #8'P  &
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M=6F=!+X+VQ+&8.=Z+O1[#IU03?_(3O^W]+4\<^+9/X%OT (N=GRGT]L,AEY
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M7#,:,Z$-U/]7G,O#%_T#U67^^&]02P,$%     @ ?8-L6OTJ005+ @  H@4
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M@%8*1*8+"IUAIAT8)L\6 '&;0#T&_L<4R0(1OE*[R&8)UQ4(S-T:,$T^B:'
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M+<#S10E'I5_H O^W)3[^+U!+ P04    " !]@VQ:Y;H3 ;@"  "^!0  &0
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MCMDVRZ+6-\/;@W5=8"81B(D2)6H$UI3R)?:[60K'\(4DH9]D(1RWFD)]X&;
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M8<DD8C&QFK#Q>,IF44"<C)G3DDG;NJV$Q8QV _4Y+46_?0A U$K;\N_>\(8
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M^($;!C%%)XW=P(_[F!PRWVUG1J' C:,)/:&P8;*GU<L4VE8%=B2Z,P=Y-+[
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MWES2!/R>"Z&'%W*PN<V?_PM02P,$%     @ ?8-L6G>=MR^A"   QQ0  !D
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M JY[C[J/8)OX!JQMH!<E'BMZPM&Q MT7UH;=!SO8_U,P^Q=02P,$%     @
M?8-L6C=&A?ZZ&@  V4@  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
MK5QM<]LXDO[.7X'*3FTE5;)CR8YL)YE4*;:2T6[\LI:=N:FK^T"1D,0)16I
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MW&]E8^R/KZ"+]S RZZH'_2B:.;C3@+XJ+E*5E*N5-DD6Y]F?^"DKBO(^)G-
M3Z,U/NJBWDOPC\D2E<=FH=5]F3<K#7,U2YHZ+G39T,)YP_:HPD.R*I5:FPSF
M+,LW"B92$1TZ*U+3+(!9CKW,!HB9;["T<:46)7XH=*IF&UYT5V2U3J-I'==
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MFB/(&N+I7"5BJ& IRK1)R(369! 3L9IV*U(%:UB2V!@V5W3(RF+Y32N(O64
M_!6(0*\0=>8-N>X(YZ63N=VMMC$,^Z72 0[L]LA@TV_W6<6VAR)V'+E02SC0
MDHQO#@3)TFE8R1Y]SJQ?96[@ 6($^2$EU"*"2RL28I]@IFH<*\5!)G-**^ Y
M'1HJS^9 <9- -WO^QQ29%!'>6 _!!AK;%4A:W#M@FGP2DXE-6+WG\7UIB,D0
MFY@I_KM@,J-HPOGHGHK3-+-^O67K RP'!*=\ ,15O"%#84C!C4Y[2M0 #@TV
MH"G</G!B\SG)F3VI->-@C+7MNRSUB;<&)_]&I6]'EY\G'[^,U6@Z'6^WT#M!
M;(^BG\!U+I4=$OP_["]D>IZQUI":%(N,/L(5Z1H,:S4=,:$/#A!X$0>1)_<B
M8DR\@NU&( FZ54YD*3JC!'"/$%4K72_A24EZZ6EFO*C3&CUO<D4186698,BI
MBNH-8:75\*37/SU6PZ/>T?"4PZ]VN=U<))3DLH 2M*$GY$OS 38Z-I5_T)XU
MDK.JK I-8+YY&_V&%92%/8XK(OB--_ $PV'O>#BD;T,U?-,['9[2YV/Z/!P<
MT.>3X/.I>G/:&QX=20 1SZ%9ZNA@V!L.#Z+;LH:<;CW)3^KX\* W.#Y5.^3L
MU,O9Z;^1L[.KB[&Z'?W7>*N([5S]G(BU(#N!L8T-A>2IGFN8/C;>)9*(.OX.
M9K?2PCQ@V?*Q7B0RLX^@,66I 8/DI]XSX)!U5%9J$'ZLH;Y0^32#^AK-0>-,
MUP\4^M&.6$*V,&/+:44@W#^33"D2:47(#-Z(M/&A;.RY+7YVEN0A@V>P41Z]
M'G\7WT348+O&BO8('AL99!C;\&==PUL%Z!!7C>GHFRYB-H-T+IN0T&GB!UCE
M<TUQ%5RPHS;).?P37K,($!'(PXKLD2-]8)MLK6,5F-9(?Z?,$93^O4GE)P47
MW#RVD+#:[-BTP)5\PS..T+14AQ--+8+02W9C&[;W4 <8_>P;E%&,/?(0&]Y!
M@7(V.+#Z!*9B.LQ*!(N(1#.7R<*A+"2MU?=DZA*]+8L93<_4;;E&HGM\=( $
M7F3JEF0*82,KJHM5*1NB<R3-BM))@@Q5H,/D)9P39Z(<E>Z1N7$)A!8;PINQ
MQ[9A +WSJD?IP -%$906P%]M_K21%:*P.,M9:!SZD"W-.4P46]\.&FQC'(>J
MQ_M]=:-I-X((U[>J$'K WC(O-/LU.H*3&68%RYL/>]3=_G1?S75*&5U$0MY(
M@,0<G:M!GWAL=9U5O2E<-$1@A1ODP;>ECPW4&2Z9"1DMFLP^8_4A$Y.8;$:2
M3(6^;-6L^,R+@B$RG9$UP%O'G:W(DCNO3B=:4=XWTW.2IID6S\U0_FP34Z_'
M4:O'^^J*J.2I*S%6YTQ.+, ",+JAZ"0!>:K6;_;4#)I!@IMG*TY^Z[+GLT9+
M)&@IIT9.KUG-GFQ6(T*D1*@-OD07Y'<+"L+8F$(RK8##4+0Z%UT%7#BXFO*N
MJIE1\$1P8F!;D[^7NC:'?S/BHDZCM!'Y"4)Z>EL*R-Y2AH<B,G!&EF0&JE+5
MDK0;G<<6[R[+]JT0&4XN@!O<.\.$#XQSWL&NC;"V*0(&LAW7A9YGM4VLJ1I0
M%O:HK8/P'M7K#1 % Q'+-72\T&R%?FR>Y7PH#\>2V-<T @6!280/2C-;8(?[
MP$M.-EBR.F]0P/P4+BF1!"LPT12NE,"AHC@=442?+6-1PMZ V"9DH?X>0TV$
M=U1$(PMK%2PC2[8C?N@?M-7Q@YT1Q/4-%4!O?^-B -4!KB^0C&XM<_\(('5M
MB ^V:$=*O!8'TTEF?3$@3O"&U7K.%SE%@"")>2;9U; C4&R1LI%-"D1@LQ7E
M1:[H9:AHL(8Q$L<B1@ALAZNIV.W:%)05$+%P*CDUI3<4013BSMCYYS;IU&14
M="2)V#K.C,W5:"\KC2G)+'8ACT#I*GEW%XT8DM6:S1@VA6_3YH'\;II55&Y)
M>S[]L[F>:%=P?!4>/Z)T*PPQV4ZN0(&T-??0O+6U&3Z X]RZ")/B!:<01IQ>
MYLR=J)1H"@4=[=8"(M@[$G+GB<6S++8D#38\LSG#<QF#S8(MT81M;04RR"0.
M5?^ _AFHXX.CWO#T0)T<(&H?]'<I1M VZN^4Y^GMU=D_]SZ.IN-SA8CX>GPY
M?;9P^X.@.F;)537(XB&13[[!@#&IUWDL]"Y713:#W2$M@D*!+Y3KP='R&PU'
MU5;*:[4 H>JJ XDC,^?+$?0E#:V&:_F&^ SQ:5YNM&\G%"0:,7O-"<0QKTJ$
M*96 !<>Z<!$LDMN,+.L(GTKT '&QC2@?J! OEGA.FF.5;ZYT#(SM61D\"6 K
M&U:24AN?T&=YJPV5/^9Q\FUOFB!V(/EA4'M4KJ'H;E6F.H>E0/CET!5%]!XG
MKMC%0'N[F9I4V8"J[,<8M*C+48@#)/E;UCMJ\,E%-_V67@>H,,K9. >6^VJZ
MC(WH@%#8T9MS+JZ/X<.<V-38+(J<1['GV.=?BCHH>1F25>1:GY,F^ZX)_*HM
M-W;9QNHMV-KG+9FZ#C>KJH8=?D7-IU9Z1"3^ DI1JP(B:%[*K+&UF#L9NWEF
M)S;3 CMH%1!<GW^%1^T4*LLYES49V9Q+?1;T]K-W:?7<T1WW <3II=W4>ZZX
M&QI7$3<JGE6/)ZH!NU=D(-1%R8"H%0W.Q"9'Q(&H,4LH+6,-^>MH4ZP? 0&]
M)\5'=XR_@IJEE\N8!"Z75G^,<)$C7%P45*:L8NY8X=B<FSFR/<8M]G[&H?>Q
M)#6%(2G*AUR[1-CI<++,]+VK1&XY0F2/\&M@69YB[RS+<U4U, 0)$O=='U?8
M) .JJ-Q)A1KBFTU&77</KCTB,X'_SW5F6\.59-\E0@BSJ[#9'[1^<;#3F=U-
MN6T^GMY.+D:WXZF:P(_],E:?)I>CR[,)=<YO\?O%<WVI_R!X%ACI?OH"]]8&
MJ"0&E F1[G.J2HU)7PT)FL&<8'9+]TQ@V+"5\Z)+2( M(K-PV)*/KRGMJ"4]
MZ<4J[L7"/W&5/7+]1:E:=W-WA(@M5G#+5%$B%QV@ZEHIE*-*7A'FJ;8JEXO7
MWU)EJ'I16UOWSWL.:0,,=Y;'^^W(27_GC,B'F_'7\>7=6-V,SZX^7TZ>#:Q^
M8-)D"VA._ T4N&BTN $J_01Q,K4=9Z25E&Y496- B[?J9?9*I8A]0=X$'#$Z
M>NEZ"@4B66G2W$V9/&>0H#1^U<,BK.K.(=!2(2(>XFD!I<Y)1 RLO+9U"7JI
MW>WI,(-#/[*;<XS QLZ6_JL-9?6 02<S5#%H9FPCN6RF4WK5M>6O;4_F1H#Z
M"0M73??S'+3)XVD/T0".^#^=C^!*D=O:$(5*4;XJ%@[$!(,E/'[1:U^3^9)-
MNR<!RE:KIB@7>3EK<E*GDCI24+MK^_*$GZ=Z3N-*1;*)SI%(Q55XQ,GYN3\7
M<VAIR@*DG13S/%ZM9';D7*\VV+>(W?C3IM -4M:X7FX\J+/)>3#$<-GEG@KX
M8<D:6;+R2>9 *Y,*^.L$.S$U:FGIOH34[OD?J[I),]+,ZR5EJ!/_(?@T>47[
MS+)RC=!K!<F'LTA8Q,B@9-I7,8A1D1T88KOF2SUM<9("1^/+B;I #JZY).I<
M3$O-RYNQ)Z97I)=M-ZEV#EE&<]I9'@?I%34[=:MSNXX ;M/\Y88+3CPA2-Z4
M3O7I9CP^O[I04QGY(?IZ\G7'H%@4X\100KNB+'>=6Z(DL)0+[K'O\[##(UW@
MBFSHP^UA'RB3KY:V?L$.M;*6L;8=]W69%2XV(*RI 3Z3G([J4J84)!&103\!
MR><SU$.GV#];KWT3F<V4S\.?%L*DG3Z7Q5%%9=-M\S/=T8UP9H4PQQ9M:@TA
MS>WHC$7?'C"L!CRB5C?2;V&EI:[8^T@_V-;"/+Y,R#5E_@57>+(ZHG:=!Z2-
M*8W +@N 2V!@*$/@OG?Z"$D^AFM*2:F#A& )U&$4NA@B?)3$F(,OL9B16$R1
M2X'!:A2,7H (-'N+,('Y)BE+0955*VBV>F3!!^=W'CFF<(UKL5S-G^79PM:P
M@%XD'&]3.@_G^<K2C9Y)=&)TARPIZ1X%D670'6V;3G0P&G&P(UZ)CKIKI$HK
MN;.BTI&?IY)!XY;L5.OT7?D>.+P=GY9-A S5[KG@9 -T&D2LJ_WHNAUHH->X
M\1-BY3!B)7?*98&$.U-MEALLKI(?E*LZ*:U,;-EQ!,KNK*([):KBE8^P)?R6
MPI:XW ZLTHAQR+AR@;//& -)"X-C2@-QYK.)]%&Z !OKS(T5A9BJ;VO$<JY/
M:KOI;DGEWH]LKN4;H+8?A "1R_8,!09;!F7B%8PA<<Q&.E+N65$!4H9OEOB]
M$KE+Z5<13R=[/#]$Z9\"3=80S%=V6BZB:D-%O0(;C#\G]$)-[E3)F%W-_7+?
M!['HVH>/H7+\_0S@E]F^WN?:1ZXEC:)J?PVK^4H,04A/@?2@686S8)2F>]Y]
M6(^"AZ&%\>6\II9MF7K5"-ME0=<DL<N<'LDD8&7KQYQZV,:4V\!"M2^"(!18
ML'!Q-REXJ)#B+:F126$1V1K]P'QQV_-2[E=I2GP2S3)I*-=T0U*.:%"_S\YP
M]V2W9#L^LIE,]6REO^U3=1#-VK::;W'%L":<M>EV*^JN>"7L5,N@4JZ(G6]L
M3?TY#/GX_O2[T<S@$P#!ZHY? [A%)>(F:7U8(B(!!#X+P[-+UKP^(XPXJZ_'
MBOW@XGI0S.X4(:F<E?[>R*2D!$%"C9?"ZTC>\2T,*=EWS9A;\XI.%8=M;5 H
M6>XU:[$1@<C90GL[YFVT'9#U""# IUD#J=USY<<FP3;%W%!#%L:-9<QK$2NV
M-BM?:G$\"W</QS-8>8-A$'^6(,3FVB>2U!)\2:D#LHXS/V/^>%JWZWN$%[:W
M4%(G@V1KNX#(7#&=C6>+Q02Y:J$CRY)CZ#IRX\>.EQT*/)T@EL5AYSNA,38X
M+AQ=6N0I36#<Z\=#KO[6AXQ"2W2&3X/N("[A%8I6H&-< .!9@@%6#0>'Z@#_
M"R,D6$NP488[XW "P1HWL^#FZGQ.@P%ESI>/V-W1#%GD>TP2[5M'&+LY;7+K
M5ACF)4'F<!= :=;%D/XEE'?'KPBEC2QJT6\>C0O#JG-CU8T*(_F>R4HDIZ4?
M'6(7DNLV^,3K+BVQ14>/2\T8RPTN=K"%KML<8$8A+G0_7B_;VQ#<VHW84SYE
ME./0H4R?V4M 3Z;/COB=Z%+[P+J*SETM +PZ[KVAR;*3 7TY[ V/A[V#P]-H
MTJD0#'O]P]/>\4E?'?5.COK@[K$=1/M)'6+1T;!W-#PD"">]-_WCWG XW-E#
M;F_D]'=?I@FO3-U<7>+SF2W0W8S/\-\OOZG1^=7U[?A\:XWG/P6<XE%*SIFP
M?%6 4\;1]*.T(%(UFM[Q@[V#XYZ:Z@4;VALNVQ'S7_+04#0X.7CUELIK;3,9
MQEA>8_%P*\^S*LG+BBNM8EP0P8#A%86N]DG'T8M1Y^_<.:IMMFM?A^!ET%GR
M9D4=5787&_Y7K<F5NR\&ICH,M"FT@VFG; FJW-0NTPY'0+:O9-N,D'0>#,.F
MB%@H'H^H&,JI&#Q7L^9J.7<#_209#S9)\3T-"&++X^Q/[.P.U$?&LD!A&PBX
MD]M.,QF!E0V[K6Y2L-'"C3KDY.S(S\1PM44&*V3<8J9AJWA(3J8SO=;UWX0&
M]-&V[BK*+E#18U!'^VK,=(U3V\JD5(!FX.K:!OK\A A.E"1)= ;$$J^=+7O6
MD$BU&6_(\7EN;,;C?WG&_K(.(R6.3//<3IVXTUG?OKM,+:3W9V&3;;%.X6[)
M+UK;'$IL&T\]=Q6)<\9_-+#;@X/^L+=502_+?7ZZUP=_/GD@DP+98,-0^%9=
MO_].G7%90'TI*Z[\B7 =#H90WXMV\HK0[[X)#+<"[CC"]CJ+';',<4H[J6^G
M3?BT<R8R^3N6=CE)U+E)518E3=%9$MSPJ^K9-YB\/F6@.-%-=0O3>.XRT#36
M LD&N.)B,<TYM0]"$(X6;<06CIQ93KIRA]6HIVP$0239)T!;+T+M[ VTU^7Z
MNR^Z?1I-;M37T9>[L;H80R)N=C23?@B2^M0V&;/*!?_VAH=-"KG_PH.IMFKI
MKH:XP2 0(>+8DVO3R!BH4Q.WX\[[CW:);6O7]DR#R4#9L5JZ+?WPK!L'?M)\
MLDUB9%"(#[(U%;0BP;B1O* MEWAD0\R^^M9/K9-ED?W1\/"V&Z^41"?HQ%K<
M5O'WS)=B>>IT3G=M$$K9ZP:4M7-VR^.=C]YLBB?OPLQLVZ_7D=I&?%\8I06H
MP6V9V"3+C8^Z(VGGY%3[KF1DD/;JT<<V!9AG!@E%_5#*H%B;H 9(.I.;QW@U
M1/^MW.L=OE-?:!?55\XB_:LI.:OP=X5B6Y!DCDD>(MK,)6M)O0+F4%7Z$?"!
M!SZ1L@@/CBD>H';;^] @P-Z[ER<"T'/F0H9%\HV4B-RW'MVR6%)&^D?G- 2P
M EL10#PW8/_DP.^VP&C/_Q1@EQ3*#T0$T8]4E6F3=WZ,SE>,MM"!TA:0BNX0
MEL:4L]+$]GI1\)+5*(0W,3VA-[E$)<9.]H"@%D^X<^BY<_=4OEM\JF9MF\.
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M?K^(YKK53!1?F"O.'5=X83+#.=Y0J= "N#[E7*TGVD![YQW^ U!+ P04
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M>HEZE8E4Y0W<(=.7<.$0^TTPC,+G@.'0\_''Z54PZA2,>A6\(;+F31,YEJ%
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M)^HW7_VA>&G>63.N\-5FABM\)E.A-^#Z@G.U_M *VH?WX#]02P,$%     @
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MQ5LE="_5.I5\SP&!5%07!#)$"BX4_4MLA6&OIXH$I*<*4GJ8W*0I0$;+-7H
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MZP"UOV!,;B?Z@+;;1W\ 4$L#!!0    ( 'V#;%HN?UM,L@4  #$E   9
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;+6::V_B.!2&_XK%KE8S4E420P-T
M 8GB=A9IN C:6:U&\\$-!JPF,6,[O:SVQZ]S(2$A>$IEOK2Y^+SV>6(?GR/<
M?6'\26P(D>#5]P+1JVVDW%[7Z\+=$!^+2[8E@7JS8MS'4MWR=5UL.<'+V,CW
MZM"RG+J/:5#K=^-G,][OLE!Z-" S#D3H^YB_W1"/O?1J=FWW8$[7&QD]J/>[
M6[PF"R(?MC.N[NJ9RI+Z)!"4!8"35:\VL*\1;$<&<8MOE+R(O6L0N?+(V%-T
M,UKV:E8T(N(15T826/U[)D/B>9&2&L?/5+26]1D9[E_OU.]BYY4SCUB0(?/^
MIDNYZ=7:-; D*QQZ<LY>_B*I0U>1GLL\$?\%+VE;JP;<4$CFI\9J!#X-DO_X
M-06Q9P [1PQ@:@#+!O"(02,U:+S7H)D:-&,RB2LQ!X0E[G<Y>P$\:JW4HHL8
M9FRMW*=!]-T7DJNW5-G)_F1P_S"_!=,[,)W=S@?WH^ED 083!!8/X_%@_D_T
M9C'Z,AG=C8:#R3T8#(?3A\G]:/(%S*9?1\/1[0)\0D1BZ@DPP9SCZ#M^[M:E
M&ES41=U-!W*3# 0>&8@-P9@%<B/ ;; DRZ) 77F5N09WKMU K2(B[B5HV!<
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MA6B?@K:C>-54TP57NC8WS;5^/4&8 #V_Y%SM.J9 ]^]Q^A=02P,$%     @
M?8-L6DC]"3J. P  W0X  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
MM5=M;]LV$/XKA#8,+9!&HJ@7V[,%M,F*!6@PHVFW#\,^,/+))DJ)+DG9[7[]
M2$F1+5M38T#Y8HO4W</G'AY/Q_E>R"]J Z#1MYP7:N%LM-[.7%>E&\BINA9;
M*,R;3,B<:C.4:U=M)=!5Y91SU_>\R,TI*YQD7LTM93(7I>:L@*5$JLQS*K^_
M R[V"P<[3Q,?V7JC[82;S+=T#0^@/V^7THS<%F7%<B@4$P62D"V<MWAV@P/K
M4%G\R6"OCIZ1#>51B"]V<+=:.)YE!!Q2;2&H^=O!#7!ND0R/KPVHTZYI'8^?
MG]#?5\&;8!ZI@AO!_V(KO5DX$P>M(*,EUQ_%_G=H @HM7BJXJG[1OK:-B8/2
M4FF1-\Z&0<Z*^I]^:X0X<C"!]COXC8/_7 ?2.) JT)I9%=8MU3292[%'TEH;
M-/M0:5-YFVA88;?Q04OSEAD_G2RER0BIOR-:K!!\+=G6[)%&J3 ;I;1"(D-Z
M R@3W&PX*]:(ZAEZ=0N:,JY>HS?H\\,M>O7SZ[FK#1N+Z:;-RN_JE?W_6?D6
MTFM$\!7R/3_H<;]YOCOINKM&@U8(OQ7"K_#(#X2X0DM.C0)6C]]:/?[^8,S1
MG89<_=,7:HT=]&/;HSA36YK"PC%G38'<@9/\\A..O%_[ A\)K",#:64@0^C)
M)Z$I1]O>K.@+O$8+*S1;,G9)'$<D\/VYNSN.Z=PN"L/)E'BM78=NT-(-!NE^
M *5FIA:D95YRJF%ECK!1)66T+A*&/LV%U.S?:J(O@GJ!Z(C9&Q+$_M2+3T+H
M,?1C'_LQZ8\A;&,(!V/H/X)7J(!>Q<,S&H$A&^+PA.ZY'9F0. KC?K91RS8:
M9/N^E 73I03TUM#](\M8"L<'Y1[R1Y"]AV00^-)#,A)81X.XU2!^P5H1CRG#
M2& =&2:M#)-1:\7D+"-Q0$AT5BOZ[+"/HZ _<Z<MW>D/:H7YW&\$7Z&[W)#>
M@>6I!C-V$/#2K1H)K!,[]@[?>>\%<[8!'TF)L="Z4ARU/'C4O&W@.@DY#4D4
MDI/$?89AE_*A.<&#'_WDGA9E9EK>4MH>[+!OM@9_$H+;V:%$'H:_>/]>HD/!
MAQ8%DY=,Y<$&Z&(I1D+K2G%H?_!P_W-Q*@=G?5A@F@(<G#8[/88$3PG&IZGL
M'MT][,7OGLHU*Q3BD!E/[SHV$+*^2]4#+;;5=>11:'.YJ1XWYOX)TAJ8]YD0
M^FE@;SCMC3;Y#U!+ P04    " !]@VQ:\$\)8S4#   '"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,RYX;6S%5MMNVS ,_17"&X866.M++DVZQ$#2;%B!
M!2N:M7LH]J#83"+$LCQ)N?W])-EUTL%QBV)#7VQ))L\YI"B+O0T72[E 5+!E
M22K[SD*I[-)U9;1 1N0YSS#57V9<,*+T5,Q=F0DDL75BB1MX7MMEA*9.V+-K
M-R+L\95*:(HW N2*,2)V0TSXIN_XSN/"+9TOE%EPPUY&YCA!=9?="#US2Y28
M,DPEY2D(G/6=@7\Y])O&P5K<4]S(@S&84*:<+\WD.NX[GE&$"4;*0!#]6N,5
M)HE!TCI^%Z!.R6D<#\>/Z%]L\#J8*9%XQ9.?-%:+OM-Q(,89627JEF^^8A%0
MR^!%/)'V"9O"UG,@6DG%6>&L%3":YF^R+1)QX!"TCC@$A4-@=>=$5N6(*!+V
M!-^ ,-8:S0QLJ-9;BZ.IV96)$OHKU7XJG.AMCE<) I^!TNFV(<:@>:,E\,QD
M3L+)"!6AB3R%,_AAC.Y1*IK.86+-OA=F#V-D4Q2_>J[2R@R^&Q4JAKF*X(@*
M/X Q3]5"PN<TQO@I@*M#*N,*'N,:!K6((XS.H>%_A, +FG W&<')^],:W$:9
MKX;%;1S+UX((/!O:)%UQI@^')+:\!D*0=(ZZ8!5,=W!H=T-V=GFP(2*&AV\:
M$JX5,EF9J9R_6<UO#NFES$B$?4>?0HEBC4[XX9W?]C[51-<LHVO6H8<CNJ8Q
MIC'L*"9QE;K<OV/]S8E?AU[/75=0MDK*5BWEYVVF#ZC.4EQPRRK:'*/U/&V[
MI&V_C%:A8'!"4]@A$?*TBKP>J9U[0@ L+^&&!S'9R9KMN"A%7M1"CVE*V8K5
M'JQ:A%>62Z?4UWGCP]#Y#]%UR^BZ+RN1-4]T6 E5NRJ).4CWL#3/6WZWNCQ]
M;_]?]FK9;ZE<GLT$(@BBL/*7ZE4P>XW6$>:#&\&OKSJR?;;JZB%>N3%^L)<8
MO''A%0+^<8#[6\:O_<V_M/8*E*<ET.YXS2,UL+\'_/J+X 75UZRJOJ;O_T7M
M'O0F#,7<=F 2(KY*5=ZFE*MEES?(>YN]>=XBCHF84]UG)#C3KM[YA;X/1-YU
MY1/%,]OI3+G2?9,=+G2GBL(8Z.\SSM7CQ!"4O6_X!U!+ P04    " !]@VQ:
M=,S;EYP#  "$"P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R=5FUO
MVS80_BN$-@PMT%@B94M*9@N(DVXKT*!!L[4?BGV@I;-%1!(UDK(38#^^)"7+
MSBRISKY()'4OSW-W/-U\Q\6CS  4>BKR4BZ<3*GJRG5EDD%!Y8174.HO:RX*
MJO16;%Q9":"I52IREWA>X!:4E4X\MV?W(I[S6N6LA'N!9%T45#PO(>>[A8.=
M_<%GMLF4.7#C>44W\ #JK^I>Z)W;64E9 :5DO$0"U@OG&E\M<6 4K,07!CMY
MM$:&RHKS1[/YD"X<SR""'!)E3%#]VL(-Y+FQI''\TQIU.I]&\7B]M_Z;):_)
MK*B$&YY_9:G*%D[DH!36M,[59[[[ UI",V,OX;FT3[1K93T');54O&B5-8*"
ME<V;/K6!.%+PR8 ":16(Q=TXLBAOJ:+Q7/ =$D9:6S,+2]5J:W"L-%EY4$)_
M95I/Q0\ZS6F= ^)K)!55M30KI0-OR:;ZD">/B%<FAA*]N05%62[?H@OTIQ'Z
M E*Q<H,>K-BG5NS;'10K$'_/7:4Q&D]NTN)9-GC( !Y,T!TO52;1^S*%]*4!
M5Y/K&)(]PR49M7@+R03Y^!TB'IFBGY&+9$8%R/8UXL'O8NA;#_Y0#(VABZ4-
MUPTO](61U);<M1"TW( N8H56S^A8[IX^V^/K'14I^O91FT0?%!2R-V:-_VF_
M?W-QKV1%$U@X^F9*$%MPXE]^PH'WZPB[:<=N.F8]_E0K71AE:K),-0_8L+(T
MFS>L;&/X%OW;&\T&?&,^L.9-D]C&/ID%9.;-W6T/KEF':_:_<+U#E6 )]"%I
M#(;'2"9!T \CZ& $HS!^URE6.J'G1B,XB<8L"'5E]J,(.Q3A.2CZ'(8GI,G$
MG_6[BSIWT:B[]T\@$B9?03LZH7U!_'#F#13!90?D\CP@?3XO>Y@'8;]#[!T:
MIC?J4O\,UL!>D_+6X ORT644#MT ?-2\\7E8>MWB$_[32310[I@<?)+7W#MH
M5F?'@IS$@@31\ 7 AR:,1[M@/ZZ19M":>]D-O*'R.'1+_(-VV?X"H:E,NM+_
MUK.#<]HJL1_YPX5RZ)7X!\WR%%4O@+X..9290X?$XRWRJQV-](6A6Q!ZU$-K
MR@3:TKRV8\=^MMBTG32MA<FAR@!5(!CO+^[@!"F>3/\+U3T:C H0&SO^293P
MNE3-C-2==B/F=3-8'<2;^?2."OV#D2B'M5;U)J$.E6A&OF:C>&7'K!57>FBS
MRTR/R2",@/Z^YESM-\9!-WC'WP%02P,$%     @ ?8-L6GTL?F;] @  J0<
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MTV!P08=7U?U,/3"R<CW$0AKJ2-QK3CT@*KN OB^E-+N!==!VE<DW4$L#!!0
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M +\M*9W9.GL^8/+[Z<DNV5EP:GO;0+G/UYKLU:66+0=W[S H03FSAVH*(I/
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M!G.Z2M0MWWR#RI!O\&*>R.(3;<I[?7USO)**IU6Q5I"RK/RF3U4C=@I<MZ7
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MT^)PJ?\/@# WZ.MSSM7+PHRH]3^,Z!]02P,$%     @ ?8-L6BQ8AC64 @
M? 8  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULK55=;YLP%/TK%INF
M5EH+@23M,H*4CTVKM$I1LVX/TQX<N E6C<WL2Y+]^]F&L+0B41_V K[V/<?G
M7.Q+O)/J2>< 2/8%%WKLY8CER/=UFD-!];4L09B5M50%11.JC:]+!31SH(+[
M81 ,_8(RX26QFUNH))85<B9@H8BNBH*J/U/@<C?V>MYAXH%M<K03?A*7= -+
MP,=RH4SDMRP9*T!H)@51L!Y[D]YH-K#Y+N$[@YT^&A/K9"7EDPWNLK$76$'
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M;?MS93QM<::#.._UADD7JK0S77B.R&$2N-$@>)0B.(CG5VEZ$>CV8Z?$P Z
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MIZFAI;KNW$U0;ER#NY5HVJ4;KLV%!I0-,.\K*?%A8@OT5Z3Y;U!+ P04
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M$Y!K!_5]P9C<3?0"Y9]'^ =02P,$%     @ ?8-L6B,"O6[U @  BP<  !D
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M$WPM01H#W)\*H;<3XZ!\?SN_ %!+ P04    " !]@VQ:YB67"Q\#  !($0
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MEC'+PQRO<*SYDG.4I'@=YE$2VQ$, +K@D'19GLQ_O4R6"[S.?D#XMRL+\AB
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M:WS^/:G.YWOC]?&7Y<])?%_4%YP#_/U=? -02P,$%     @ ?8-L6H"$^)W
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M4$L! A0#%     @ ?8-L6KL&]3GN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ?8-L6IE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !]@VQ:B:3D394'  #),0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ?8-L6M3G:NC%!@  T!H
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M965T-BYX;6Q02P$"% ,4    " !]@VQ:_2I!!4L"  "B!0  &
M    @(%/+@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M?8-L6H/$*Y], @  D@8  !@              ("!T#   'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( 'V#;%H\I3,X$0(  -T$   8
M          " @5(S  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " !]@VQ:TR8^3^$9  !G0@  &0              @(&9-0  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( 'V#;%KENA,!N (  +X%
M   9              " @;%/  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ ?8-L6@.N \D* P  @ 8  !D              ("!H%(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !]@VQ:@X5+
M).<'  "%%@  &0              @('A50  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( 'V#;%H4]Z<D404  *P+   9
M  " @?]=  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M?8-L6B:\7I%2!@  V0\  !D              ("!AV,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " !]@VQ:=YVW+Z$(  #'%   &0
M            @($0:@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( 'V#;%HAJ5LE(0,  +(&   9              " @>AR  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ?8-L6FF<<IG*!
M@@H  !D              ("!0'8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " !]@VQ:'_"79@8#  #1!@  &0              @(%!
M>P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( 'V#;%J;
MOK"&W ,  " (   9              " @7Y^  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ ?8-L6C=&A?ZZ&@  V4@  !D
M     ("!D8(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'V#;%H:D+F.< 0  /D+   9              "
M@6FL  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ?8-L
M6L%X?6X&!@  A \  !D              ("!$+$  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " !]@VQ:%/@__M@"  "Q"0  &0
M        @(%-MP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( 'V#;%K33[:#S0(  /D'   9              " @5RZ  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ?8-L6BY_6TRR!0  ,24
M !D              ("!8+T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " !]@VQ:V9FU<KX"  ";!P  &0              @(%)PP
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( 'V#;%I(_0DZ
MC@,  -T.   9              " @3[&  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ ?8-L6O!/"6,U P  !PL  !D
M ("! \H  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !]
M@VQ:=,S;EYP#  "$"P  &0              @(%OS0  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( 'V#;%I]+'YF_0(  *D'   9
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M970S.2YX;6Q02P$"% ,4    " !]@VQ:>*R":3@#  #L"0  &0
M    @($7YP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M 'V#;%IML7+UL (  ,(&   9              " @8;J  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ ?8-L6DBIMHR/ @  GP<  !D
M             ("!;>T  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " !]@VQ:B812YT\#  !M#   &0              @($S\   >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( 'V#;%HL6(8UE (
M 'P&   9              " @;GS  !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ ?8-L6@6+&D 2 P  [PP  !D              ("!
MA/8  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !]@VQ:
M?X]RU1X$  " #P  &0              @('-^0  >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( 'V#;%J->>MS) ,  "X)   9
M      " @2+^  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ ?8-L6F4]98+; @  $@<  !D              ("!?0$! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !]@VQ:6#]<2,H"  "%"
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M+G)E;'-02P$"% ,4    " !]@VQ:WEGX .L$  !+(0  #P
M@ 'O#@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ?8-L6CB#;R;$ 0
M#1X  !H              ( !!Q0! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ ?8-L6H"$^)W  0   !X  !,              ( !
M Q8! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H .@#-#P  ]!<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>313</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999012 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999013 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999014 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999015 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999016 - Disclosure - DEBT OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/DebtObligations</Role>
      <ShortName>DEBT OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999017 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999018 - Disclosure - FEDERAL AND STATE INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FederalAndStateIncomeTaxes</Role>
      <ShortName>FEDERAL AND STATE INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999019 - Disclosure - MAJOR CUSTOMERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/MajorCustomers</Role>
      <ShortName>MAJOR CUSTOMERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999021 - Disclosure - EMPLOYEE BENEFITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/EmployeeBenefits</Role>
      <ShortName>EMPLOYEE BENEFITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999022 - Disclosure - SEGMENT DISCLOSURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SegmentDisclosure</Role>
      <ShortName>SEGMENT DISCLOSURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999024 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999025 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/PropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999027 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Stock-basedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999028 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999029 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FederalAndStateIncomeTaxesTables</Role>
      <ShortName>FEDERAL AND STATE INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://korumedical.com/role/FederalAndStateIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999030 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails</Role>
      <ShortName>The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999031 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details</Role>
      <ShortName>The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999032 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Inventory consists of: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/InventoryConsistsOfDetails</Role>
      <ShortName>Inventory consists of: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Property and equipment consists of the following at: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails</Role>
      <ShortName>Property and equipment consists of the following at: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Schedule of time based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails</Role>
      <ShortName>Schedule of time based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Schedule of status of time based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails</Role>
      <ShortName>Schedule of status of time based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Schedule of information pertaining to options outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails</Role>
      <ShortName>Schedule of information pertaining to options outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999038 - Disclosure - The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details</Role>
      <ShortName>The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999039 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details</Role>
      <ShortName>The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999040 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999041 - Disclosure - DEBT OBLIGATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/DebtObligationsDetailsNarrative</Role>
      <ShortName>DEBT OBLIGATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/DebtObligations</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999042 - Disclosure - The components of lease expense were as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails</Role>
      <ShortName>The components of lease expense were as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails</Role>
      <ShortName>Supplemental cash flow information related to leases was as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Supplemental information related to leases was as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails</Role>
      <ShortName>Supplemental information related to leases was as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Maturities of lease liabilities are as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails</Role>
      <ShortName>Maturities of lease liabilities are as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails</Role>
      <ShortName>Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Schedule of provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Schedule of components of deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of components of deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999050 - Disclosure - FEDERAL AND STATE INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative</Role>
      <ShortName>FEDERAL AND STATE INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/FederalAndStateIncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999051 - Disclosure - MAJOR CUSTOMERS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/MajorCustomersDetailsNarrative</Role>
      <ShortName>MAJOR CUSTOMERS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/MajorCustomers</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999052 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://korumedical.com/role/EmployeeBenefitsDetailsNarrative</Role>
      <ShortName>EMPLOYEE BENEFITS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://korumedical.com/role/EmployeeBenefits</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form_10-k.htm">form_10-k.htm</File>
    <File>krmd-20241231.xsd</File>
    <File>krmd-20241231_cal.xml</File>
    <File>krmd-20241231_def.xml</File>
    <File>krmd-20241231_lab.xml</File>
    <File>krmd-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cbh_logo-footer.jpg</File>
    <File>cbh_logo-header.jpg</File>
    <File>cbh_signature.jpg</File>
    <File>mmq_logo-header2023.jpg</File>
    <File>mmq_signature2023.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="411">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form_10-k.htm": {
   "nsprefix": "krmd",
   "nsuri": "http://korumedical.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form_10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "krmd-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "krmd-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krmd-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "krmd-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krmd-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 249,
   "keyCustom": 64,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 13,
   "memberCustom": 17,
   "hidden": {
    "total": 76,
    "http://korumedical.com/20241231": 18,
    "http://fasb.org/us-gaap/2024": 53,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 75,
   "entityCount": 1,
   "segmentCount": 30,
   "elementCount": 529,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 411,
    "http://xbrl.sec.gov/dei/2024": 36,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://korumedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://korumedical.com/role/BalanceSheets",
     "longName": "00000002 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://korumedical.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - BALANCE SHEETS (Parenthetical)",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://korumedical.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS",
     "shortName": "STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://korumedical.com/role/StatementsOfStockholdersEquity",
     "longName": "00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://korumedical.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - STATEMENTS OF CASH FLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-09-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-09-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies",
     "longName": "999012 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://korumedical.com/role/Inventory",
     "longName": "999013 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://korumedical.com/role/PropertyAndEquipment",
     "longName": "999014 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://korumedical.com/role/Stock-basedCompensation",
     "longName": "999015 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://korumedical.com/role/DebtObligations",
     "longName": "999016 - Disclosure - DEBT OBLIGATIONS",
     "shortName": "DEBT OBLIGATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://korumedical.com/role/Leases",
     "longName": "999017 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://korumedical.com/role/FederalAndStateIncomeTaxes",
     "longName": "999018 - Disclosure - FEDERAL AND STATE INCOME TAXES",
     "shortName": "FEDERAL AND STATE INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://korumedical.com/role/MajorCustomers",
     "longName": "999019 - Disclosure - MAJOR CUSTOMERS",
     "shortName": "MAJOR CUSTOMERS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://korumedical.com/role/CommitmentsAndContingencies",
     "longName": "999020 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://korumedical.com/role/EmployeeBenefits",
     "longName": "999021 - Disclosure - EMPLOYEE BENEFITS",
     "shortName": "EMPLOYEE BENEFITS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://korumedical.com/role/SegmentDisclosure",
     "longName": "999022 - Disclosure - SEGMENT DISCLOSURE",
     "shortName": "SEGMENT DISCLOSURE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999023 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "999024 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://korumedical.com/role/InventoryTables",
     "longName": "999025 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://korumedical.com/role/PropertyAndEquipmentTables",
     "longName": "999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://korumedical.com/role/Stock-basedCompensationTables",
     "longName": "999027 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://korumedical.com/role/LeasesTables",
     "longName": "999028 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://korumedical.com/role/FederalAndStateIncomeTaxesTables",
     "longName": "999029 - Disclosure - FEDERAL AND STATE INCOME TAXES (Tables)",
     "shortName": "FEDERAL AND STATE INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "krmd:ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "krmd:ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails",
     "longName": "999030 - Disclosure - The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)",
     "shortName": "The estimated amortization expense for the succeeding years for the intangible assets is approximately: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details",
     "longName": "999031 - Disclosure - The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details)",
     "shortName": "The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_country_US",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfNetSalesByGeography",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999032 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InterestIncomeSecuritiesUSTreasury",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InterestIncomeSecuritiesUSTreasury",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://korumedical.com/role/InventoryConsistsOfDetails",
     "longName": "999033 - Disclosure - Inventory consists of: (Details)",
     "shortName": "Inventory consists of: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:InventoryWorkInProcessAndRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails",
     "longName": "999034 - Disclosure - Property and equipment consists of the following at: (Details)",
     "shortName": "Property and equipment consists of the following at: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
     "longName": "999035 - Disclosure - Schedule of time based stock options (Details)",
     "shortName": "Schedule of time based stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
     "longName": "999036 - Disclosure - Schedule of status of time based stock options (Details)",
     "shortName": "Schedule of status of time based stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_TimeVestingStockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_TimeVestingStockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
     "longName": "999037 - Disclosure - Schedule of information pertaining to options outstanding (Details)",
     "shortName": "Schedule of information pertaining to options outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details",
     "longName": "999038 - Disclosure - The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details)",
     "shortName": "The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_PerformanceVestingStockOptionsMember",
      "name": "krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_PerformanceVestingStockOptionsMember",
      "name": "krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details",
     "longName": "999039 - Disclosure - The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details)",
     "shortName": "The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_RestrictedStockAwardsMember",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_RestrictedStockAwardsMember",
      "name": "krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999040 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember",
      "name": "krmd:StockBasedCompensationStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember",
      "name": "krmd:StockBasedCompensationStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://korumedical.com/role/DebtObligationsDetailsNarrative",
     "longName": "999041 - Disclosure - DEBT OBLIGATIONS (Details Narrative)",
     "shortName": "DEBT OBLIGATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_SecurityAgreementMember",
      "name": "us-gaap:DebtInstrumentIssuedPrincipal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_SecurityAgreementMember",
      "name": "us-gaap:DebtInstrumentIssuedPrincipal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails",
     "longName": "999042 - Disclosure - The components of lease expense were as follows: (Details)",
     "shortName": "The components of lease expense were as follows: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails",
     "longName": "999043 - Disclosure - Supplemental cash flow information related to leases was as follows: (Details)",
     "shortName": "Supplemental cash flow information related to leases was as follows: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails",
     "longName": "999044 - Disclosure - Supplemental information related to leases was as follows: (Details)",
     "shortName": "Supplemental information related to leases was as follows: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails",
     "longName": "999045 - Disclosure - Maturities of lease liabilities are as follows: (Details)",
     "shortName": "Maturities of lease liabilities are as follows: (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails",
     "longName": "999046 - Disclosure - Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details)",
     "shortName": "Schedule of Components of Domestic and International Pre-Tax Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "krmd:ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "999047 - Disclosure - Schedule of provision for income taxes (Details)",
     "shortName": "Schedule of provision for income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
     "longName": "999048 - Disclosure - Schedule of components of deferred tax assets (Details)",
     "shortName": "Schedule of components of deferred tax assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "krmd:DeferredTaxAssetsNetOperatingLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "krmd:DeferredTaxAssetsNetOperatingLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "999049 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative",
     "longName": "999050 - Disclosure - FEDERAL AND STATE INCOME TAXES (Details Narrative)",
     "shortName": "FEDERAL AND STATE INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "krmd:NetChangeInValuationOfAllowanceOnDeferredTaxAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "krmd:NetChangeInValuationOfAllowanceOnDeferredTaxAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://korumedical.com/role/MajorCustomersDetailsNarrative",
     "longName": "999051 - Disclosure - MAJOR CUSTOMERS (Details Narrative)",
     "shortName": "MAJOR CUSTOMERS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative",
     "longName": "999052 - Disclosure - EMPLOYEE BENEFITS (Details Narrative)",
     "shortName": "EMPLOYEE BENEFITS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "krmd:DescriptionOfMatchingContribution",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "krmd:DescriptionOfMatchingContribution",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form_10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Account eceivable from customers",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r584"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r123",
      "r448"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r706",
      "r707",
      "r708",
      "r709",
      "r766",
      "r813"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense related to restricted stock awards",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r77"
     ]
    },
    "krmd_AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r672"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r649",
      "r675"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r667",
      "r676",
      "r680",
      "r688"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r686"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_AmortizationOfIntangibleAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "AmortizationOfIntangibleAssets1",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense of intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r94",
      "r126",
      "r147",
      "r172",
      "r179",
      "r188",
      "r191",
      "r200",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r356",
      "r358",
      "r370",
      "r442",
      "r497",
      "r563",
      "r564",
      "r584",
      "r606",
      "r727",
      "r728",
      "r774"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r131",
      "r147",
      "r200",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r356",
      "r358",
      "r370",
      "r584",
      "r727",
      "r728",
      "r774"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r620",
      "r632"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r620",
      "r632"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r620",
      "r632"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "krmd_BorrowingsFromIndebtedness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "BorrowingsFromIndebtedness",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings from insurance finance indebtedness"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r121",
      "r552"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH AND CASH EQUIVALENTS",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r63",
      "r145"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r63"
     ]
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_CashPaidDuringPeriodsForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "CashPaidDuringPeriodsForAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the years for:",
        "documentation": "The element represents cash paid during periods for abstract."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_CashReceivedFromOptionExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "CashReceivedFromOptionExercise",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash received from option exercise"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Refer to Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r87",
      "r443",
      "r483"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r224",
      "r225",
      "r537",
      "r722",
      "r724"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r598",
      "r599",
      "r601",
      "r602",
      "r603",
      "r604",
      "r706",
      "r707",
      "r709",
      "r766",
      "r812",
      "r813"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r484"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r44",
      "r484",
      "r503",
      "r813",
      "r814"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.01 par value, 75,000,000 shares authorized, 49,377,617 and 49,089,864 shares issued; 45,957,115 and 45,669,362 shares outstanding at December 31, 2024, and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r444",
      "r584"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r30",
      "r31",
      "r198",
      "r536"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r30",
      "r31",
      "r198",
      "r463",
      "r536"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r30",
      "r31",
      "r198",
      "r536",
      "r697"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/MajorCustomers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MAJOR CUSTOMERS",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r30",
      "r31",
      "r198"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r19",
      "r30",
      "r84",
      "r536"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r30",
      "r31",
      "r198",
      "r536"
     ]
    },
    "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetReclassifiedToReceivable",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of contract asset",
        "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r406"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r725"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r725",
      "r726"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r705",
      "r762"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "International",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r705"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r705"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r705",
      "r762"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r198"
     ]
    },
    "krmd_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/DebtObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT OBLIGATIONS",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r146",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r230",
      "r231",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r381"
     ]
    },
    "krmd_DebtInstrumentInterestPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DebtInstrumentInterestPaymentTerms",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument interest payment terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r242"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate principal amount of note",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_DeferredCompensationArrangementsOverallDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementsOverallDescription",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based goods and non-employee services transaction",
        "documentation": "General description of deferred compensation arrangements. Deferred compensation represents currently earned compensation that, under the terms of a profit-sharing, rabbi trust, pension, employee contract, or equity-based (including stock or unit option) plan, is not actually paid until a later date and is therefore not taxable until that date. May also include some split-dollar life insurance arrangements. This type of arrangement is usually made to help employees postpone paying taxes on the income and also to retain employees longer."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r761",
      "r762"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "International",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r761"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Deferred",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r112",
      "r705"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income taxes, net of allowance for non-realization of deferred tax asset",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r761",
      "r762"
     ]
    },
    "krmd_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DeferredTaxAssetsCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DeferredTaxAssetsCredits",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credits"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DeferredTaxAssetsDeferredLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DeferredTaxAssetsDeferredLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Deferred Tax Asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Research Costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Deferred Tax Asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "krmd_DeferredTaxAssetsNQOAndRSAStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DeferredTaxAssetsNQOAndRSAStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NQO &amp; RSA Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Deferred Tax Asset",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "krmd_DeferredTaxAssetsNetOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DeferredTaxAssetsNetOperatingLoss",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals &amp; Reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total Deferred Tax Liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DeferredTaxLiabilitiesFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DeferredTaxLiabilitiesIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DeferredTaxLiabilitiesIntangibles",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DeferredTaxLiabilitiesROUAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DeferredTaxLiabilitiesROUAssets",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROU Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Matching expense",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_DepreciationAndAmortizationPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DepreciationAndAmortizationPropertyAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization, property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r172",
      "r182",
      "r191",
      "r563",
      "r564"
     ]
    },
    "krmd_DescriptionOfMatchingContribution": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DescriptionOfMatchingContribution",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefitsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of matching contribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r279",
      "r309",
      "r310",
      "r312",
      "r576"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r620",
      "r632"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r620",
      "r632",
      "r668"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "krmd_DomesticBankLenderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "DomesticBankLenderMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Bank Lender [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r164",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r351",
      "r354",
      "r367",
      "r368",
      "r439",
      "r452",
      "r557"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r351",
      "r354",
      "r367",
      "r368",
      "r439",
      "r452",
      "r557"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r324",
      "r342",
      "r577"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued payroll and related taxes",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "krmd_EquipmentAndToolingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "EquipmentAndToolingMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment And Tooling [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r116",
      "r135",
      "r136",
      "r137",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r174",
      "r201",
      "r202",
      "r218",
      "r253",
      "r340",
      "r341",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r398",
      "r451",
      "r457",
      "r458",
      "r459",
      "r469",
      "r523"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r646",
      "r672"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r633",
      "r643",
      "r669"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "krmd_ExercisePrice1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ExercisePrice1Member",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price1 [Member]",
        "documentation": "The element represents exercise price1 member."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_FederalResearchCreditCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "FederalResearchCreditCarryforward",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Research Credit Carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total finance lease cost",
        "documentation": "The element represents finance lease cost."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_FinanceLeaseCost1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "FinanceLeaseCost1Abstract",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease cost:",
        "documentation": "The element represents finance lease cost1 abstract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r391",
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing cash flows from finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r394"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease liabilities - Finance Leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r395"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability \u2013 current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability, net current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "krmd_FinanceLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter - Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 - Finance Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance lease liability",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r394"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r391",
      "r583"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-lived intangible assets, accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r208",
      "r214",
      "r569"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r819"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r549",
      "r569"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The estimated amortization expense for the succeeding years for the intangible assets is approximately:",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r549",
      "r569"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r549",
      "r569"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r549",
      "r569"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r549",
      "r569"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r407",
      "r408",
      "r549"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r549"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/EstimatedAmortizationExpenseForSucceedingYearsForIntangibleAssetsIsApproximatelyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net of accumulated amortization of $458,538 and $390,341 at December 31, 2024 and December 31, 2023, respectively",
        "verboseLabel": "Total amortization expense",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r720"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on foreign currency exchange",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r520"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r676"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r676"
     ]
    },
    "krmd_FurnitureAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "FurnitureAndOfficeEquipmentMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture And Office Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on disposal of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r56",
      "r93",
      "r147",
      "r200",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r370",
      "r559",
      "r563",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r727"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IMPAIRMENT OF LONG-LIVED ASSETS",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r74"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r323"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE TAXES",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r453",
      "r559",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FEDERAL AND STATE INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r319",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r335",
      "r343",
      "r345",
      "r346",
      "r347",
      "r468",
      "r577"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "negatedTerseLabel": "Income Tax Expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r113",
      "r162",
      "r163",
      "r172",
      "r183",
      "r191",
      "r322",
      "r324",
      "r344",
      "r454",
      "r577"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r320",
      "r321",
      "r330",
      "r331",
      "r334",
      "r338",
      "r465"
     ]
    },
    "krmd_IncomeTaxReconciliationChangeInValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "IncomeTaxReconciliationChangeInValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Valuation allowance",
        "label": "IncomeTaxReconciliationChangeInValuationAllowance"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_IncomeTaxReconciliationDeferredTaxTrueUps": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "IncomeTaxReconciliationDeferredTaxTrueUps",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax true ups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal tax at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r577"
     ]
    },
    "krmd_IncomeTaxReconciliationNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "IncomeTaxReconciliationNet",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_IncomeTaxReconciliationOtherItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "IncomeTaxReconciliationOtherItems",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r577",
      "r757"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r144",
      "r336",
      "r337"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in accrued expenses",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in accrued payroll and related taxes",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in other liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r650",
      "r667",
      "r676",
      "r680",
      "r688"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r691"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r691"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r691"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r555",
      "r719"
     ]
    },
    "us-gaap_InterestIncomeSecuritiesUSTreasury": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeSecuritiesUSTreasury",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment securities treasury bill",
        "documentation": "Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r143"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryGross",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r553",
      "r584"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INVENTORY",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r120",
      "r128",
      "r203",
      "r204",
      "r205",
      "r402",
      "r556"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: reserve for obsolete inventory",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r700"
     ]
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/InventoryConsistsOfDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials and work-in-process",
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r583"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The components of lease expense were as follows:",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r396"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance leases discount rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "presentation": [
      "http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating leases term",
        "label": "Lessee, Finance Lease, Renewal Term",
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "krmd_LesseeFinancingLeaseImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "LesseeFinancingLeaseImputedInterest",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest - Finance Leases",
        "documentation": "The element represents lessee financing lease imputed interest.",
        "label": "Lessee Financing Lease Imputed interest"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted lease payments - Finance Leases",
        "documentation": "The element represents lessee financing lease lease liability payments due total."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "krmd_LesseeOperatingLeaseImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "LesseeOperatingLeaseImputedInterest",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest - Operating Leases",
        "documentation": "The element represents lessee operating lease imputed interest.",
        "label": "Lessee Operating Lease Imputed interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of lease liabilities are as follows:",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "krmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter - Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "krmd_LesseeOperatingLeaseLiabilityPaymentsDueTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueTotal",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total undiscounted lease payments - Operating Leases",
        "documentation": "The element represents lessee operating lease liability payments due total."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026 - Operating Leases",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://korumedical.com/role/SupplementalInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r34",
      "r35",
      "r36",
      "r39",
      "r40",
      "r41",
      "r42",
      "r147",
      "r200",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r357",
      "r358",
      "r359",
      "r370",
      "r482",
      "r558",
      "r606",
      "r727",
      "r774",
      "r775"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r88",
      "r446",
      "r584",
      "r704",
      "r718",
      "r768"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r119",
      "r147",
      "r200",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r357",
      "r358",
      "r359",
      "r370",
      "r584",
      "r727",
      "r774",
      "r775"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r703",
      "r725"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r38",
      "r231",
      "r703",
      "r725"
     ]
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving credit facility",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r86"
     ]
    },
    "krmd_LinesOfCreditCurrent1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "LinesOfCreditCurrent1",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term loan facility"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_LossBeforeIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "LossBeforeIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfComponentsOfDomesticAndInternationalPre-taxIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss before income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r573",
      "r593",
      "r596",
      "r730",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "krmd_ManufacturingEquipmentAndToolingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ManufacturingEquipmentAndToolingMember",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Equipment And Tooling [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r275",
      "r317",
      "r369",
      "r401",
      "r455",
      "r456",
      "r462",
      "r474",
      "r475",
      "r526",
      "r528",
      "r530",
      "r531",
      "r533",
      "r547",
      "r548",
      "r568",
      "r570",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r594",
      "r729",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r275",
      "r317",
      "r369",
      "r401",
      "r455",
      "r456",
      "r462",
      "r474",
      "r475",
      "r526",
      "r528",
      "r530",
      "r531",
      "r533",
      "r547",
      "r548",
      "r568",
      "r570",
      "r575",
      "r578",
      "r579",
      "r580",
      "r594",
      "r729",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "auth_ref": [
      "r198",
      "r573",
      "r593",
      "r596",
      "r730",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET CASH USED IN FINANCING ACTIVITIES",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_NetChangeInValuationOfAllowanceOnDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "NetChangeInValuationOfAllowanceOnDeferredTaxAssets",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance on Deferred Tax Assets - Net Change"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows",
      "http://korumedical.com/role/StatementsOfOperations",
      "http://korumedical.com/role/StatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net loss",
        "verboseLabel": "Net Loss",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r65",
      "r90",
      "r117",
      "r132",
      "r133",
      "r137",
      "r147",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r162",
      "r163",
      "r167",
      "r200",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r351",
      "r354",
      "r368",
      "r370",
      "r450",
      "r505",
      "r521",
      "r522",
      "r605",
      "r727"
     ]
    },
    "krmd_NetOperatingLossCarryforwardsFederal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "NetOperatingLossCarryforwardsFederal",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards, federal"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_NetOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "NetOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards, state"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_NonEmployeeDirectorAndBoardAdvisorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "NonEmployeeDirectorAndBoardAdvisorMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Employee Director and Board Advisor [Member]",
        "documentation": "The element represents non employee director and board advisor member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "krmd_NoncashLeaseAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "NoncashLeaseAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash leasing charges"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_NonemployeeServicesTransactionCost": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "NonemployeeServicesTransactionCost",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonemployee services transaction cost",
        "documentation": "The element represents nonemployee services transaction cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OTHER INCOME",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Operating Income, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r567",
      "r711"
     ]
    },
    "krmd_OmnibusEquityIncentivePlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "OmnibusEquityIncentivePlan2021Member",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Omnibus Equity Incentive Plan 2021 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_OmnibusEquityIncentivePlan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "OmnibusEquityIncentivePlan2024Member",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Omnibus Equity Incentive Plan 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Operating Loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r559",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r583"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information related to leases was as follows:",
        "documentation": "Tabular disclosure of components of income from operating lease."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/MaturitiesOfLeaseLiabilitiesAreAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease liabilities - Operating Leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability \u2013 current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/SupplementalCashFlowInformationRelatedToLeasesWasAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r394"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental information related to leases was as follows:",
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97",
      "r98",
      "r99",
      "r100"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r83"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r584"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r492",
      "r564",
      "r783"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r638",
      "r648",
      "r674"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r677"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r651",
      "r677"
     ]
    },
    "krmd_PatentsAndTrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "PatentsAndTrademarksMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents And Trademarks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_PaymentsForOtherTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForOtherTaxes",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for taxes related to net share settlement of equity awards",
        "label": "Payments for Other Taxes",
        "documentation": "Amount of cash outflow for taxes classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "krmd_PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for taxes related to net share settlement of equity awards"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_PaymentsOnIndebtedness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "PaymentsOnIndebtedness",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on insurance finance indebtedness",
        "label": "PaymentsOnIndebtedness"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r763",
      "r764",
      "r765"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EMPLOYEE BENEFITS",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r574"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "krmd_PerformanceVestingStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "PerformanceVestingStockOptionsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Vesting Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r206",
      "r207",
      "r554"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds on disposals of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r396"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r107",
      "r110",
      "r111"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r122",
      "r449"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r396",
      "r441",
      "r449",
      "r584"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r107",
      "r110",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://korumedical.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment consists of the following at:",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r396"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives of property and equipment",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r263",
      "r275",
      "r305",
      "r306",
      "r307",
      "r317",
      "r369",
      "r399",
      "r400",
      "r401",
      "r455",
      "r456",
      "r462",
      "r474",
      "r475",
      "r526",
      "r528",
      "r530",
      "r531",
      "r533",
      "r547",
      "r548",
      "r568",
      "r570",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r594",
      "r599",
      "r723",
      "r729",
      "r767",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r263",
      "r275",
      "r305",
      "r306",
      "r307",
      "r317",
      "r369",
      "r399",
      "r400",
      "r401",
      "r455",
      "r456",
      "r462",
      "r474",
      "r475",
      "r526",
      "r528",
      "r530",
      "r531",
      "r533",
      "r547",
      "r548",
      "r568",
      "r570",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r594",
      "r599",
      "r723",
      "r729",
      "r767",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r622",
      "r633",
      "r643",
      "r669"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r549",
      "r563",
      "r782"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r634",
      "r644",
      "r670"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r635",
      "r645",
      "r671"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r642",
      "r652",
      "r678"
     ]
    },
    "krmd_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]",
        "documentation": "The element represents restricted stock awards member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r77",
      "r445",
      "r460",
      "r461",
      "r467",
      "r485",
      "r584"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r201",
      "r202",
      "r218",
      "r340",
      "r341",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r360",
      "r362",
      "r363",
      "r365",
      "r366",
      "r382",
      "r383",
      "r457",
      "r459",
      "r469",
      "r813"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE RECOGNITION",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r550"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details",
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET REVENUES",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r138",
      "r147",
      "r172",
      "r180",
      "r181",
      "r187",
      "r191",
      "r194",
      "r196",
      "r198",
      "r200",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r370",
      "r440",
      "r563",
      "r727"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://korumedical.com/role/MajorCustomersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r696"
     ]
    },
    "krmd_ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Domestic and International Pre-Tax Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of provision for income taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r577",
      "r757"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory consists of:",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r50",
      "r51",
      "r52"
     ]
    },
    "krmd_ScheduleOfNetSalesByGeography": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ScheduleOfNetSalesByGeography",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes net revenues by geography for the years ended December 31, 2024 and 2023:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://korumedical.com/role/PropertyAndEquipmentConsistsOfFollowingAtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r396"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "krmd_ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information pertaining to options outstanding",
        "documentation": "The element represents schedule of share based compensation stock options activity amended table text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of status of time based stock options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of time based stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the activities for our unvested restricted stock awards, RSUs, and PSUs for the year ended December 31, 2024.",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "krmd_SecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "SecurityAgreementMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details"
     ],
     "auth_ref": [
      "r196",
      "r197",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r471",
      "r472",
      "r473",
      "r527",
      "r529",
      "r532",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r551",
      "r572",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r595",
      "r599",
      "r730",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://korumedical.com/role/SegmentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT DISCLOSURE",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r172",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r560",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense and warrant expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividends",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/canceled, shares",
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited/canceled, shares",
        "documentation": "The element represents share based compensation arrangement by share based payment award options forfeitures in period unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options forfeitures in Period Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, shares",
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted, shares",
        "documentation": "The element represents share based compensation arrangement by share based payment award options grants in period gross unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Gross Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of options granted during the period",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning (in shares)",
        "periodEndLabel": "Outstanding at ending (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning, shares",
        "periodEndLabel": "Outstanding at ending, shares",
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding number unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Number Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning, price",
        "periodEndLabel": "Outstanding at ending, price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285"
     ]
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning, price",
        "periodEndLabel": "Outstanding at ending, price",
        "documentation": "The element represents share based compensation arrangement by share based payment award options outstanding weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning, price",
        "periodEndLabel": "Unvested at ending, price",
        "documentation": "The element represents share based compensation arrangement by share based payment award options unvested weighted average exercise price.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, shares",
        "documentation": "The element represents share based compensation arrangement by share based payment award options vested."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested, shares",
        "documentation": "The element represents share based compensation arrangement by share based payment award options vested in period gross.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Vested in Period Gross"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementByUnvestedAwardOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementByUnvestedAwardOptions",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested at beginning, shares",
        "periodEndLabel": "Unvested at ending, shares",
        "documentation": "The element represents share based compensation arrangement by unvested award options.",
        "label": "Share Based Compensation Arrangement by Unvested Award Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details",
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details",
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/canceled, price",
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price1."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited/canceled, price",
        "documentation": "The element represents share based compensation arrangements by share based payment award options forfeitures in period weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options forfeitures in Period Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, price",
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price1."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted, price",
        "documentation": "The element represents share based compensation arrangements by share based payment award options grants in period weighted average exercise price unvested.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options Grants in Period Weighted Average Exercise Price Unvested"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedRestrictedStockAwardsRsusAndPsusForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested, price",
        "documentation": "The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award Options Vested in Period Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesActivitiesForOurUnvestedPerformance-vestingStockOptionAwardsForYearEndedDecember312024.Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, price",
        "documentation": "The element represents share based compensation arrangements by share based payment award options vested in period weighted average exercise price1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r283",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r313",
      "r314",
      "r315",
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The following table summarizes the activities for our unvested performance-vesting stock option awards for the year ended December 31, 2024.",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "krmd_SharesAvailableForIssuanceShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "SharesAvailableForIssuanceShareBasedCompensation",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for issuance",
        "documentation": "The element represents shares available for issuance share based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_SharesReservedForOutstandingAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "SharesReservedForOutstandingAwards",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares reserved for outstanding awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/ComponentsOfLeaseExpenseWereAsFollowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r583"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "krmd_StateResearchCreditCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StateResearchCreditCarryforward",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/FederalAndStateIncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Research Credit Carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r44",
      "r47",
      "r48",
      "r116",
      "r135",
      "r136",
      "r137",
      "r150",
      "r151",
      "r152",
      "r154",
      "r159",
      "r161",
      "r163",
      "r174",
      "r201",
      "r202",
      "r218",
      "r253",
      "r340",
      "r341",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r398",
      "r451",
      "r457",
      "r458",
      "r459",
      "r469",
      "r523"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r471",
      "r472",
      "r473",
      "r527",
      "r529",
      "r532",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r551",
      "r572",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r595",
      "r599",
      "r730",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r174",
      "r383",
      "r406",
      "r464",
      "r470",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r504",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r523",
      "r600"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r174",
      "r199",
      "r383",
      "r406",
      "r464",
      "r470",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r504",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r523",
      "r600"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r647",
      "r673"
     ]
    },
    "krmd_StockBasedCompensationStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StockBasedCompensationStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "The element represents stock based compensation stock options."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation paid in shares"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation paid (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44",
      "r77",
      "r289"
     ]
    },
    "krmd_StockIssuedDuringPeriodSharesUponOptionExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesUponOptionExercised",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance upon options exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockIssuedDuringPeriodUponOptionExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StockIssuedDuringPeriodUponOptionExercised",
     "crdr": "credit",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance upon options exercised"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockOptionPlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StockOptionPlan2015Member",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2015 [Member]",
        "documentation": "The element represents stock option plan2015 member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockOptionPlans2015And2021CombinedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StockOptionPlans2015And2021CombinedMember",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plans 2015 And 2021 Combined [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "krmd_StockbasedCompensationIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "StockbasedCompensationIntrinsicValue",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets",
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r70",
      "r486",
      "r503",
      "r524",
      "r525",
      "r584",
      "r606",
      "r704",
      "r718",
      "r768",
      "r813"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "krmd_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Facility [Member]",
        "documentation": "The element represents term loan facility member."
       }
      }
     },
     "auth_ref": []
    },
    "krmd_TimeVestingStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "TimeVestingStockOptionsMember",
     "presentation": [
      "http://korumedical.com/role/ScheduleOfInformationPertainingToOptionsOutstandingDetails",
      "http://korumedical.com/role/ScheduleOfStatusOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/ScheduleOfTimeBasedStockOptionsDetails",
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time Vesting Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r773"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://korumedical.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_TreasuryStockPreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockPreferredShares",
     "presentation": [
      "http://korumedical.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock, shares",
        "documentation": "Number of previously issued preferred shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://korumedical.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://korumedical.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, 3,438,526 and 3,420,502 shares at December 31, 2024 and December 31, 2023, respectively, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r44",
      "r47"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://korumedical.com/role/DebtObligationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://korumedical.com/role/FollowingTableSummarizesNetRevenuesByGeographyForYearsEndedDecember312024And2023Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "krmd_UnrecognizedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://korumedical.com/20241231",
     "localname": "UnrecognizedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://korumedical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "The element represents unrecognized compensation cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://korumedical.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USE OF ESTIMATES IN THE FINANCIAL STATEMENTS",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r105",
      "r106",
      "r108",
      "r109"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://korumedical.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://korumedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/840/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481418/840-10-55-40"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001161697-25-000103-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001161697-25-000103-xbrl.zip
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M8.X@VB9?H_TI^V^PM/\E^P#[QR4$="#@ZO,@<, 56.FFA"^CR LJH ,WPN"
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M^YS8/5^]C_/TU7[=JO;PBYH6ND4E*O;]JL PSI1E?)\RY25VBA.YSNW\Q'/
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M$>(@"D!N;^*;'XO3%GQ85ER4H5^>(T/D=W]G!0$52_-W#&_MR[#>XTF#\PN
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M %^_+RLO1]>SSRYQ1R&S+>_SX\1VAPY!&OQ9BW\LL%RPG2YH6\[JN)P0$*?
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M^U--,YJ$J Y:U+QX/Y1@\R[>\N,2>$<\-I>E#-5!W>?1)$; $S9REQ\">@K
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MW0-H)P"_?[[^6^.?)/_=''K:'L#*"/  ('V]-< 2*SU]*STM'\  @)[A?RP
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MR(DJ-X+C5,4.Q$>Y@]Z[1PLD8,5:0#$Z[)Z",8L-91IX8C.T@ 4]ACZN!!/
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MPX?(B+93?;L%+B^NQW"6C]O03.[1G)[>SP>:]]K\J/=?#)1V_'\ 4$L#!!0
M   ( 'V#;%J(B?*:YAP  +>)   +    97A?,3 M-2YH=&WM77EO&T>R_Y\
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M"2-DB<[;NW2G<5.I<"[!$@N 9HB*>!3"/4 <D88MJ)GV!9=9"H]1.I5$%K,
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M'L3)3+5C2QT]V*EW 8UN[M//LA)Y:4I8-Y! =&!+\# @B[8<99F(05<!L&Z
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M85I5$KLLRI5,*L;<*O:P:"X_Z7DU#^05%R+4J' DX',B%[9I27N&V?=;]40
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M8[A$..7H9.O3KYO/EB :>1B49LD"\,<0I76$9J0#+!%RB?\"%NIXDF1SF6O
MMDQ-94;(WT!U^@%C<R,"6">9*R35A8I#HEF5 PD2,</2,!= $7 "$0S^CI-<
M3%6L,B#TE4#LBAU:I<48MMFA3<WEBH:."UK1*& +FP@5OJ.5B/JJCRM29<SV
MIS0S/"OOSSLMD6T":V1FGV -_PR^[$HW7J)%5?\2_0^_\FH;4&8S*@  '/\8
M1T#N29&+%&XL"8WE)"($4 (2,$O;P)M%G34C=&'ZF1[K'%C()$OF>(TXA;U)
M_-6A4W53WR;4-XW?2)R9^JT V!HK!E%B6%"7D"8Q8^'L;A!1&KY#&DJ*3&SA
MQ"#UX**54!\!W#G"7Y)D4]\FT)NH3K@(S H6D2#(B<KQ_+&1 1*_ 4ZP2*)%
M@]=M8"=BO+J;!)I ?4Z"Z?!!9. ]K/ !F*>9)46$&L)"PS2^6@+P#!6 E3E\
M *L"3$%!N@49K>"9R84B1/^M4(:N@=0B;SG ;=41LV2I #\ZEC( V"A5<J2'
MB8CDTBZ<@1X)PL;J;B1&0&L$I"^B7*,8BI#(3 KKZ'&DB//!=E$"X+VO<,<.
M':Q$LC2)N@^IG/B9MCJ84PQA WS]'E#VQ8!D9P2J'CR'RNM*R'"!A JK^F('
M 0'HI#3 @EAE0]:R1&*AN-0@!<=*9C0(]FY@?RH.6!_&!R)8-L+'K *[T$DD
M&;2/T]C8@G+O>=^6'#>"/)"HH1BX7-+-X7D-V 5V1+L59!JNU.H<@5X ;H*Z
M/P:=GS4"'0=1P5K]/,VT26+2;G$T& 8180  -$3%+D/>(":HM>^+TR+#ZY@#
M*^V %:&C(F/..S8J(V1&1 0VL")U NX=+LSB#?%K0W,3D6C4KW5<HR5444PQ
M_A78"UTX3!UJ$^@41"8:W8R>R(,\+/'/@Z-!O9DB7W\HM1O].P/1/>O_=/'/
MG>/>Q:@WV!$7E\-WW9.>&/;_!Y9^66K=O_1/1N_0<_+B/\ V+O=V-.AU?]X[
MZIU>#GIO8*Y?NA^&.X\>73T;WUKT8.&+[:X&,>P=7P_ZHWYO^*2H$<YWT#_\
M<'DMNH,>7.U(7/4&Y_W1J'<B1I>"KAP."+\"&"Z&W>-1__)BV&X->F?=$4(%
MOWD'EMGE^57WXH,5JT,/'*([$O"-&/7/>Z)_*MQ: ,ZKR^&P-QS"C.+R5)QW
M8:U^]ZP#V[C8N[H^.NL?PRC &_@&QAP\[Q\B;+\._C\$< <%R*+O7XSW7G60
M1\R+:"I1;RYB9'E#Q23__8O=\3/+2MJM8:6/]#X"P<=3);K ,^#[[__QPX\=
M3^>QNGT((B;-0<@XI;Y2^R>9+$+81)R[[X _A45 ?!5^C>T62F=)6F2PIE'L
MDS$R(LO14^0%J5]T,&TL\P,>I5-@R791X--ZCU9VBZ(@GR8@YV-B^W<J9P_(
MX>YCA6X &@OR;'3/ $-W(M\*;H0L? I Z3@CO=UJ6E6>;ZIN2HFF>XJ=.F-I
M-'UG+\'9YAUW!_;S.(GWV!AW7W@:RWZ[1==;(HD!,3Q16<9N*UFB7$-JNZGP
M9&B&)S%(27AXFB6 ZFR(;A!V !RP2#<(1H,Z(0"%Y3M)7B?V4P7_$AQ@-TLP
M.!$CE9@K2;AE@0-GGYLF*/Q=;H>&H9T6QL"9QRI*ED^'W?B6D4P!UHJT7514
M&C3GL&<O4Q%RI':K3N+HO+2*#6$E\@CR(-65-;=(>>>H6S=6\G#U/Q&SYG.8
MR^1)<"-V\2;88.-+V".[%7:#NGG.E!*J<>ZCO_JH#6F/3"8 (%H5?CYC?)*1
M239M1%EN:A<129I;C0V0;;/;@KG@3(53.FVYVRT<;(/?@Y 3+/,LT(99*9W<
MKMTI.:P$".3V8W9\*3'5$V+[=EK_CHAHZ*!C-A;P6I!(;[_FND?FB6#U-0G+
M2I0*38S)._4V8==N 1HXB5:Z&CTH+F<:Y5@,G!GHW1B+YL"S@ 5$";* TL=9
M]YXZ"X9M2?_"^\R!UAP\8#9['AZE"9'01UIR=&1&=N$"C1"T)I$!!S=L:Q(/
M32.Y0IL4D"I'ZQ7H(Y59CL9*:6*:'% 53%2:F201\EP,&8C=!#:"-E4RQT!
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M$YC3+2Q$1+B>3^BPI)+Y&@9BZ,C^>!>Y99X*3N"PVF1\[[UX*K4-$9%KQD_
MT'HEODKB=J=V\7)8&Q2]5142LC6:+N6*2JTW_C2Q![8#IE4U?YNF+QD)=9C0
M\(8JYA),0'A2^;7DCCT[@^5BV-7<5? E%&M1"2CQJ*Q^C=?H?I4D?Z#+/V ]
M+G%GT!L*GJ %P@>;>S2F^(/F@JY9@L]0#RXVJY"YT'==L>&*\36<,AEU:H/_
M2+"OFT0Q?Z?U+BD$J,IJ!^Y>."5 !108=\--P@0'(5-#R%A(HM()?%A2'Z.X
M2T%L9+$@*3J5#AY1*/",2#> NJF#:9A-';9,!1B1Q-2]QP](2-+P94!IMEGO
MSQ<?8$8]7$$(RQWN580GR^9N%0[2@%+H76]$>RBBF/!=2696&4B2!H^H2Z,5
ME6#5]6(!LS9T(-S+,DD:9E4E"H<(5YA%B)CFJ\$DB1+NMT"$>'!*,DFY"=#K
M#5.[G.*2)  _%-L$?!0CA>XHR?YP2-\O3T>%X("5,]]]B3FJ6,C?O;UXR[LR
M (U3(2-85BPXF(LJ6)95,<WCQG&KK"/M<1P\B7:$6ASF-%8N%I[%:_W .S2-
M9B/CW3RSNIQ6+.2XYG'#2G$OH^6UM8PCJU6NOK6#]_":3O  $K61]*U>T@[!
M3=#A-!22>>1UF#]?"6]OS8]\27TAU/Y+^J#G:!CQ;1NO3;8.TD1F?/N7MG&R
M@/GY<M(?C:$_M<_F76TXGCOCA0:7]LB9=+6Z8;S#ZNS/F,_4>I!%U;!+RAJN
MM-'*.Z^T-_L.4$L#!!0    ( 'V#;%I,?S>]EP8  *,:   +    97A?,S$M
M,2YH=&W565%/VT@0?C_I_L,JTE4@&4*@Z"2@D4+B'E8#1(GIM?>VL=?)"MOK
M[MH)N5]_WZP=$I+0AC8]T1>([=F9V9EOOIFU+Z[\ZV[S]]\NKMQ6A_[[GM]U
MFQ?U\C]NU.=/+F\[G]G _]QUW]4BE>9GK'&4Y<R7B3#L1DQ97R4\=<H;#AL(
M+:,:%F)IQ_LX7SF583X^8W\>GLJT>MI[J=9SEG ]DND9.ZHUWZ1#DYU?U'L_
MKNR<Y>(A/^"Q'.$R$&DN=*WI?KKR+CV?G30.&SLQ\S_XW+_KNJQQTCIHO-UK
M[;,Z:YQVJM]MM^][[[UVR_=N;]CM^Y_H1:_OW;2]7JO+W$]N^\[W/KHP"-MN
M__4%LM;T'-:5:<B9/^9Z.'-83\LTD!F/F?L@@B*7$\%NHT@&0CO8I,YE-&/Y
MF.=G/V<[?NL2:6R[W>Z@UVI[-W^]JQW5['6OU>G,KS<4UCG;WOQ0Z5#H@T#%
M,<^,0/:J7U2=C%WX_;F%">TXX/$\S;G*2AF2ZC0;^V"-SN(&:]^2WS?O:L>(
M+1MS1$^+B113$2)JTK!6FA8(;E]D2N=,I>R]T@F</OC 5,0^W/;OV+7; 52[
M;/!YX+O7 X<!48?GUA#^]%_HXCR^S[JY)/ =ZH^_%H%+;K!O;#*9L?M436,1
MCH13!D*7$0@5$I6J'"E(<RY3QM,9*])<%X*9G.<B06%1:#A @PJ3"%[$ ]S2
M3"4RAS^EW)I *@)A#-<S$DGXO8#=)9T&]T(X Y/8V-C:((% ZJ!(()9B.3P!
M4-AT+(,Q,P7]6:R?"BTJ);2!1)I8\%"F(S:5^1@;-)D(K(.D-X-K*L0V$5 $
M93A;#L-KS>[)=V57L$BFB!^E8A$O!ZF%.![KI><RC5  /)?0 ^:)BQ ZD9.E
MX#C(I]3QC&4(*:&!4!+'BW17D38KIH&H4))BAR2*& +(L4(BK+G*H8";,8MB
M-35S!&@QDB;7')8XW2SEX*:SE$@S]V;-W=>:R[=?RZ7_9-]OM/E2J'-39:NB
M?4*V*EN!C8C'N!8V^ BF',:"8L0$,CZ,I1F3.(DEJ&JJ;+H.I0EB90JLHWK7
M*C96)M,J$"%N&[:'F(<"62P#ZSX$8YZ.!&NAE/I%#(G&"3]HG.Z)?;NT<1J6
M5^6EI#:<EMDG_8SJ;0D498[(EZT-14\,13!$^UQ%"B2([L]>9_97.N;1X;&=
M13<:W2RZQU?QL]*$2:@C#(PCH)8KOYUMAV@\X(79?@GQZ5 @<Y6EDJ%5H:$
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M7OH[0PBPF\B0D,&-2CEQ'#= %0T'!!>NPWGJ ";)!S*6V8P:R3:S!&2;99O
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M1=+\#YA-VP^=>\<T0L=;PFKM!VMC&4+HP? 76/>#OMF'P#8KZ_#F5G]%*$8
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ML#0!^9TVR%*&4(UJ<1S%4<:L8?&1 5:'^?A?EGC0OH@CZ&UY&"P3  /02NP
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M56$7F"P-/B)* @4F5)KA(LMR"E#S6:X3/T,_&@[\).41-+E22:[,D4@41IW
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M<7T:F5&!-?&K60M=LJ=-)-(%9/5\8_U2M_(NLASG*J2)'_4J[Y6RMWGAC9J
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M@_H^.>O_CEAX@M_VI5_H<\#_#U!+ P04    " !]@VQ:10,C6/NX 0!4# L
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MZ<.\)!MHEK"ZJV-Z:W%*%K'EG$D[E#Z%83^-[SK=.^D$^)DI?L3)9S@=!79
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MB^4QJY&.+T3D,(80@;1> ,86YBLA%8&@F-\,+PX89<@$V(,\!UF%'VDBJ\%
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M(L!8?^<YW]6?OU#U3\I<?P"JJ7R6EIG^D/+A,;G=?9-_,LE!;,):]I+^DM5
MZ ;+OW>.=_R/AX>_[AW\PKVRJ09B.;?_ZM("+(,!:R/7VP.G_2+(PI4X3;\(
M_(.$@C0'2($ \L](!8FN@9!R\?9F9S; K8 UKC6PHULPHH*!AFC,\M-6]X:
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MA8\H3.#\V#CY@S-0$$DOI>%$5JP:V6(%)"*F4'H&M2R)\B%6+Z1IJ)7.*$,
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M'V9PT#G9/I0ZPFW"J*L9/];6^A?((_37L<[7*?BW#5027!.3I\3RS.FIPGX
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M]Q)HJF62H@^SC/DH9L'86!89"DJ,",;8M64<!_G(UG-+EUB>ID;Y^Q#]K1#
M!6:QN<[HJ=OE>51D)7_BMBD-HSPKQVZ?=KOI!7?WI;'Q+2AEN/-N%=D79*VN
M!FIXPOKVWH^O4;M="TEZX4A)$54.8%L2:21:;=?FU&WJ,@47WM SC2>E@1K:
M *9?*1HMDE44SN:,V;*]FI)AT8AMD8ES/9!%Z$FAD--4+XC%_<QPL;+9 ^Y9
M2SJ0- <S34^$PVBQ3L_+7+KAHO2CUAA(%_P>BSV#6I=&7:V[-W AWXHK#[R%
M, FJ'L#>9*J!L>T!1):?KJ*&)]E,<U;MV54[I,$"+5(,R?E-]Q0)4 W">IU@
M7F)!6V_JV/WD[^\<5YK_ 9W<1*S7%=75<_5HQX<24,V=,9%P.ZLM)'M2WX3Z
M%E4 N:T0C3V%L%X5ZHHHZ'Y:6GF^)S,L43,$%OZ41$[Z7_>3;5IQ<25JHL?H
M/A>U**S3W-<,"CNF$:]3@XK-.VG:!1A8,W\_H"A/2ULB!#, \D;E&LO,M"0P
MH5].HF +:K]VO'@4;HF%\-L1IIQ2U0AW6E8:,$C<(/4%V;']YY2R$NIPOYXI
M-_@(4T^\-0R>P8-9?1EU4+?^#?@HQV1?KN2JLC"YG/!C@C>ISE9=CB-"CJ2%
M(10E;@O*P2C+BX8($&GUF6G^KAB4&L 79RV-%#"K"G.\@;%;[2:N@C>(J]7P
MS&$<CUK"YT-^GI??VM3 &6L<"7/"3!A"3<-5[]1D@KJ?TXA<SL;<I>GIAZ79
ME.W#W_9V5EI;8!W 8V '45 >WL.Y#VN->FC+&7M09G2SZ'>@75>E,X&Z2CO5
MP+G!3IGL!)3@\C\=^+K\-F>>^G<,!M$E(<3I@B4LE\5P<<%]M+AVEYR9TJA.
M-P@W.;$V:0[N<%*SD)- ]HBK$X&F+#X!PX!8#G$N?!?,GA?%&'^(!!(4PXM@
M@B21A9*;(/<9'87C>V3(HR/1=*#E\5<KOV$]@_0%LU+9/:<_ "S<8/([':99
M6_+^?_;>M+F-*\D"_5Z_HL*O_<*.*+)%2A2E]HPC:(FRV;:6T=*._O2B"!3(
M:@$H- H@Q?[U[^;)Y>:M*I"4M1B:44R,FR*!6NZ2-Y>3YRC;UC6;SQ%+2+PE
M-SD3!*@(PR*IR"5Z6/+D=DH!"<.5K.Y@WC/QHF+W-&<F-2]<O:LYF^*BKLFR
MG%6$PL:EX[!$ZN@(P[:XOZ(3OO=LY@IE]'3^3TDM?E[_.VP/&9\3R8"/4HO[
MYO&)659'/\ED_2*1T*YV)#QLPJ8^TXH]#09<OL03S5B8WJ:!7TE%A^S4'!QK
MQ>5P$W"25QH^G-GSD;F>DTVQ"<_ I(8<^':"5X;2KEVY#1KBKM?2]3&R6_@8
M2:Y.<_84PH/K#5^:5X9&^&**R'MWOE:1__R%+%4$FA2-<\6U21$R$E^ TX16
M7>>OENK/;B?'O9U.,T&KT MDE3()TRAZ.Q5F;8U%O1<(KE2:<B*N ^TF3O[5
M^I2I/E;$T"F$_WI44VZ5KRCF-NSFMR7\M80=[\'!MP/W$=!B!:;-E68$:C^/
MP8#("QE1GRO)J$HBHED2O!5]D$AC<R6"+0WG0WU4KNTLQ$[F!Z9PVDBGE<91
M2X+5T5)0=I*L\5"ZJ69-V!962U928K:R(CF)<F)6&I747JU(S!3'13$X^:UX
M(?9>@_]S7N3/_J[/9K4HBOEVC.962%J)!'?K N77DM6)690WN[E@]4QRPJNJ
M:VI'/)BJOZ'E=6_8S=V%'EWG?Y14AE!@,Q-G=9=;Y[+ARY1_QN*P1)-VVJ%B
MP<RC;3)1J )1-:A<SQF9%\QV86YK>TZJC6<A> \'L15_>";#QZ8,$59Z'*IE
M0%5'>0F7U6*]8F<WTYJ<$J!2T8W]+O9IRO%XR<_?>:NP;&=M[ I809%ZJ@3?
MOD*8*G"@XIZFW<I,8<:T/]G3Y08*I"EX2-S'"?XLE+O*X>)*:SVG8NM6=D\)
M)II>9RH1$3PC\97R;%UB,OR^IOI"&%/YW&6XS'D#\004M8U83EN "- =1GD)
MX</$1&A.\[>FA0E*UTKO0!S>/MA9]#CT53"!2YQ[694T144>(J!QF.26>(B#
MN6Z6^+',YT2K31%GW0)B6/#4VPX;W$X%E.ZXC*4K5U=#9M77:TYEMUY\?9)R
MBR3:$RX;!DO%KOUZ3@3=E*7<KW:P0^MRSR2/[,9MW8T2X^'AE_@4LS%)X+:\
MV.5]8IV&K#G:*D8IBZY-9,:;7I**UB!E>Y(::A1;0W4)%:Y1S\"?W[%OK)80
MJ<NLFSH-R*++ 97Q <5,XN0O,-6)<QI\'&!+7]5((IY":J3U/":$)'^F\\"5
MY)AKJ<&//Y,2>98"U4_)MRZ!J\W[WA V6<O,CKV3EB\==Y^0/6*'U>6LSI\$
MA[T>EWFC*M%^XV=B,<><'K$WWCJ+]7L%EC+4J<O8\$VV.CSN<NQY+Z\21K51
MI#N7XG21E>-F@5S#>539$;-/I?PF1#F":UN%"_Z'5=XF.S K:F.$HW--H.1Q
MN2H]8B.*3JD('[2/\)"TKV!<,I3'HY+V*,S#8'DGN!/A#:=5:[D2<,ER%[K>
M2,65BH[YU#$1SW(YVX0HRE)$46-=3H*CV+HEP3'4"TJ:JOHR25^U].E8]1E(
M<A;L89^7K"0FL5.:_:)/X'"HSMCW5MVA^9<14[V0=^4#5>IWS7J%:/R6 T3.
M?S E(IEVE>37^6])CND"6HR\_R*DDYTXQ=D,%'8Y38::X5 V!O0$NARI#0W2
M;N%+%-J@'2MXX8547#AL.6KK<N=%R7S0^O ZD3&#8\<7.@RB8)@PWEU)^TX(
M3"CH$Y8'->?9P*#%4(!L*QJCZ0$OJ9E$8+BS14/&UDB(0XP;1I#3W]!)JV+&
M?5:WJH!B-^.H;!R>CW0^*.R/4\)/J+IT^812>S!2?.RC2UFN@S>*ID=4+FJF
M&1R%Y]!SMGJ'QN.*B[WE5<6>!%D<XO*5@S'#!Q*X=271!>L81OUCYEZYH&YN
M03E%^4#*FH8W\/> 2!\3-ZM 72+Y$T[4>L5?J*9,XQD6K$J^[>:_@R[D^K?#
M8=N["<^799=Q/-;$KH[(>0PF>V8Z)UKO0L(/C:E4&IZJRO&FQ0UW;,TF>>;'
M[M;KF2;-2 I0HA2&DB0"R5('*UFJYMCU-1K[ZW@"CK7@WYR=KRHTFIZNQV?5
M2@$-LX:3%UH><JLZD?S+EJAJ2!:['87=RZM5- (!'* 5YJ-2O6C/HQY^Z6TS
MRJ]1YE@)T))?3+=I]2XL?XE_*?IG/[T2V49G PH4,*AUMT3QHFO<PR);U+!(
MN(X)MU [6[N@I) =EN02+N>R?MJ43[V#*I5CT:'WVB+C-R";2:V;83;,[,L2
MGTLJ*MQV7(^4@M8X;HGKP1]$[:(2MG 9)<J119IS>7KQ@>2]"Y3*P_8R?"+:
M$VPPH!@U->7KJ,A;D2DBA6;H1H]& A42Y8!PNM%+_M#97-:KF?KO\?3(A$FT
MB!_GLT\*--98*+_]@>T]F2ZJ:F$;8 "\$!D]XH8[)]*I>D;]P&G0\ZYI<"3J
MTQUNIR\=K?V%$RR-@B?;MHDV _ 9XU1U$9=X'UF@CL#>=;0G"U_BQ1[,7I*K
M7Q:47MPFCNA%_4KJD@B7]W[(305*?X&D6UC)L3B^7HC;*R/+KAN$X^E2X9B5
M=IV1T_"R[ GN)CVQ6/I+1=.E2QEI0F7?, Q;D?F^)\)P"8<8)SZ<ZE-7G8N\
MFJA")Y*")BF%<\1)39FD%&D_3#OTP/)']H2K\!ACP^4*.-ZD':@RKA =C^!5
M!19JI/+PS=CS7$<AKG96HJL<^FU]QN>L3CU'N8;VY+X&0%+U+: -UX%5.(A@
MJD*E^=TI:Y^W +)-7(8(;M$9G/]E%K=)VJ9N70S\ D #.O4))%][ZP4K)#Z7
M@0RA:0:M/%&HAOH *]NME_P"F6.C=1&UAA;-,GTQ$X64U^-U%>_M7S)/7W*H
M*]]>-XNOBS0=8((QW;)"5NT2OX.*-I0![4T&8W]TWGL&>IH$)="+V28=+&_?
ME-N[97<:[F88.XCE:F.&S\FU$?$H-'MRU[&* !5>_EQR6NR8(D,2@0[!*(^!
MG(I<]D278<).&,$OI6"^][5@_N>?98T$$^+%77#"BVI/K1Y%!,P-<1^CETT1
MR7=T_EYE/;,CKA&ZBER>G?QR*1<;L(B"3,UC! <3N,!8$ONWDO5XL'[!6[TP
M%?(B;5W).GUCTO[+]8-!@Z"=L=8F8GLY>,=H%]*3*,4X*2I1LBZTJ!*WU532
ME^Y,\HG4#A*0Y+")KZ4<K=%:4G+H OLFORRL4AK^32+W+,<.-L[M\RN]_N@,
MN7TI?EO0V?H.X'A:G%9G-?I^83(RY_10H9R075>Z(A7BYLLUZK6RU)@BF9(#
MP7Q=Z._Y9!&'NY@X*358RB)SJ[SCXFYU'Q %R7WJT8AS P\A>1"11&@,Y[8K
MV9YQ\BO2T122RI:631'-[;A">NR7[.FB/ <OHB,FK,T6'@7:%CZ/J)%@QIO:
M_25MT("# \6LJ0DJRT;$>[IWH!@Q>0=]6LDB86W!PQ!XH'=KK-3>HH!-5RD2
M4QB&C<3R4D]1*FU+YM<5U4&N/CF27LY>V=K3L6*:/_=P"8%1IN'LV1(E*TE+
MF-<]KU:$_11_C&&3S.R';3,?H9TH;!UW@W%P$5O#4,!_M2IC86CUEFE[@N?<
M7,XORR4URM4CWIE5BS0,4"X;AD)?[XE8AF25J86U!:OE!5!A3:YN'/(L#CFG
M0JIEPCU@CRA'E^S_;4]^/1H:I)G1CB6#)?T$W0PG7'TD)C5O 8ZDCA?+K;,M
MBX UG;\6G#WV;!!BK-MS[+BV,YM@GMB^T>0LR.M$R-HGYUQ[+R(&+KOT,AU9
MORSB6DBWM[SE#PG9G;:$ZM:'*=30->XH?@L2G=Z?Z-\;6!L$[Z+E:$Z=]NLF
M<O)T\Z2->0+$.VF6SVA-5I928_>0#A))=?N$@,Y0M-#,?:)&]C1X2F3)S1%5
M&X6V"O5)Q0]-G-.+<KJN!-"!0"RIJ7$TS(6H^$OI5@M_S:;L(U@DZ?R03J>Y
MU9P0GP=W<_26B35E/"IB\>WV,G-N.+JC+ACUK0O++'81IFW3X/82,.5Z$0X/
M="\U_BV=PFS=K=TU;=7QC7LM?)*V9LM (9+K4O2OKX$X7C\V69%](HZ$,:*K
MI,M;^M>IQ88HKD7DRO$'N%Q%O_L^7#-+Z2\LX<!OX3"$2.!/Z[?@3-B0M]RN
M3<TV[7=V==T69GBHR@5 1GU:7O(ZZN2_K7$1O@7HXP2LY+I*1/6.)MKA^@=1
M6IOX5B*[B WXUMI* J1TNZI0'TCX!5Q1-3TD3/^MR#KS4MITM-6*H6*Q<101
M:'W6@"R_FB-R80H48GPDO"@->NR=+B*UO@3!U9@:CPKN.HZQ)!5"LF3:RW78
MU")@#H\I[.T+YC-QLWX:(C%QD\3JKN<KAER)66^HJG;%7B1EJBB#'#9L[#EW
M %^8CS9;6PBG@9NM3#\8_+@:17/JMD@UO5.86_@HY:-:=OFG)=6"F5%]OE*M
M@&FPH&LNE6:J1&V>[UJ85@6M]$,\,590POXA0GF!>_HA#S<KT7\XDX&+;=4Q
MQQT,"IXIX?]D2F:TV2>^E^MJ4(-%MZW$X1J12#B3 L_'UJ?W V%K@^G,B1_)
M )<HG__ >W3%-+_B ?*=?Q!$+CLUDYJH,@70%2XF76ZR\>DA7'\6)8VJ8"N9
M>C[F.UAHDZ%?X>W+U3FC]ROF3*[G_UJ;)/.LG$8.93K$J?V9"I-7QF 6GH$8
MS%)T-2[;N^I5^H#6P=BNUK2$?_!%.T!*EBMEU0T_;IU9/XFETT*(*;"4$@"R
M-_>V+AK7OGEZE1$6GQ/+L!E/'C\Z2AG]<F9=,6(6> NIZ2NX*$Y_6 ,H7N#G
MT;2L9[1Q\'>?2^#6/.D 7#6TQ'MY'&3E9B2:@"YAD&,#,\8MJ =[=TBS>/B]
M0*CSXNF1%[J,7-,PC.OYE-UUB@5G $^QYF6T76]L6.1F!E/N=JKR<X;AGM6:
MQN<F![<SN1EV)$F3R+3$!DR%DX07O-6><\=C%8QA-,*%MJ>G#=$H^ ?3OB;C
MCM-D&F*1*2#H]!3P3BON?E6NB&BI@T<S=-MLX+:">66'5]8>!H'[; "9F3&S
M$WJE83JU'3Y] #;3,JWIU].T[HB$A$?D6U UL]UT/5H)N(Q1/?4CE?0Z. 3#
M"BN!_K9OA:BEE0:CB1J^X"NF* *K)FX:UY-)?[G4K:NP)Z1;CK;,1GV$CX7U
M%,'8I7!SX7R@&"DA^G#:R?W!#I^;#RQ@+L2GG>/4*:5;2ENWZ9O=G:7[0K K
MX1FDP9G678/<G#F;A.'.K5,I#E^ZQ6)4>/-=?=LVV9:P"C/9B@0A%GQ'I!!-
MMYYKUXI$6P)X<>W9/>A(W*UP#6K&5=IB-]Z=$9V[A!&X"E:N]PZKJP4M24 J
M4%D.KQ,.>>5K421>,)&.]AVK63(\\;48T,R.%E-APR/J$LT565@2.^:XP/]/
MO!@,6I&Z3?Y&T7/JH#HHZI\RW,H_E_94VUVB>G:(]C)F+T,FD$]BZP84=-30
MX::PD85D!HCG ?2C9/>!,L "8*@GGV[PJT\5CV1, >;*9D(OL)M'LS_T#=L0
MMOS< U["$8F3>EK)H; :?$BW$HKXK;!,?OH-M$?/PA$B1OW-' L!]-["]A >
M .&![-B)/P"A?3;T^)3'$>R:R'YUKB ;L<AH&7*6"Q5W4+,)QRK5N3J"TPQ%
MC-&@/DC=,L6ZQ"2+S7G^ BN>=!.^F*[O_:]%[#_?$_[=2 &I9R6< )6@F92=
MP+$?"04A>FV%-I+<-%[R6>)+1L<MDIU(XWB79;":G].W-,66>+<(9?LERN_2
M$O Z4DX**$EDYXR!02BTK.NELBUE%Z<WL5>0'FW8T=@#:F^M[\0P%OU2"T?=
M$W2&CV3^$VDI(9(N2SYHN)]#RVNW)E@>E>UY/IDVE\'*'%,AKP;W(TH)Z4Q&
MC]\]9(@38;K^#^EBWZP_#<?]_K"TK=Z>;HZ&L*'*+YR>FM2T_X#@[G4BND-/
M]J/RK? *)\QDS=[ 9)C:]_,\E;#@$[]OF&N*$1)'*O&L+-'DDH"Q]6%3LN3S
MOD=BJ6B;+D@;#%8@_#PM1Y'RJ,>D^WF>%!YP&FVNV\'"[';K)O]$*BE"PH;,
MW 1X".^7=5@DN(6T,+6!9G[64$MVHHQ+9X++WB2\"H[):B.QPM5@:M77Y-)K
M&M0^\\Z>9G"1U@;7<S.G6DZ/"Y'Z:*?#V5R-+TG;,(PG!VW GTK&TX4S:8_Z
M HU8.+TXRRE)SB+--MH9=<'UJ22*L9PG''NY7J+G$$^PE2"!]>' ]9PI,CC^
MGDZE4\)6R!L*LL#'\215D=][<)>41SF5/45]4@YB3MDW(!&9^'Q_)[<@+*GE
M_"I#7A^,^,*3ZN?)I?0U@TJ(#SRWNDS#W)+,ES>_\HL*TPA+8;-8*/MT)MH4
MC2N3)*G)X!CXRA[M;,K%K><N'A?HRA**2LC[J@A%-4O+B^5X38PNI72MA<CO
M=$D=A&-.GN-,<\.GQ:J2&*?;5; H!CZ1U<[#*-#SZ\816_-TV93CY ; "T5T
M4Q,B4>**Z3^#R7=RW*^C'P/_OPG^/#B#Q/F #DT:L(JXXJ25?=WB@!1GDM#4
MRJ/:+1M08U#6G9 ?PHB2-R5E\+;BYFSBXM@XL+U9):+,,8OZ<=5 CY/"'R5R
MM$R"S<KD<=P5Z \H0X2%>4:N?*[O12=KUQUO!I+ +J+FE/Y?&RV!TV6XLH1,
M[)4L+[!Y5\@4E%/7M]=VD[(M,$+HW/"+5 174K<$+>&2!U[X7NI!]"EUOM+"
M"T]R'LPZF*HYH>IA<)R_%D/%4UU[\GJN3RG;W=CB#^U"1)Z-MAG5%4EKX%QS
M"Y9&47&%6!K##HCQ0TH+5[?VR#58D!@ R34''NJ$PK.^J-E17Z*I=&KM>45"
M.4P6(:+>C<N(O8Z_FEU<-"MA9PR+)(PMN*S"Z-C''#">'KB0!EX40-U!N/FP
M&S@U(].T$=XP0^; V\7'BG9&  6L=<C!HS4A8.+0RYSR!%B+'2LVB%S\#DYA
M(*R[;^"X>.!3\/G60B$=]9;81O>XHI24 F[^OJ:$>,Q=7E?I+Z2/$2H8<^0_
M9V68[!5LF?">X-%I*6#MFL6W<H0>O]2C#NN3&'4JQ\+]ZU"[2.PG^<%H&F(
MW_IJD/03]?F&_([M5*32<KUY!)[$@=$)VY4+>>D<JI@/7J70JE2[0_MO:/[%
MIF<&:$"G4(@4;)YB05%&/Z*^I'1CU+C"V,U-1A8O@;&#PDA=9$Z%5^%+?J8R
M1AHE>Z"S'*R-FW83B9...ZB= J!Z-8(#S%K-4EJ(>A] 9Q*UXF628Y*FV_R2
M#@<&]X&5.^S(0EN>Y#5F4"T5WSU94#_DY^%V%Y3SW&!<G9OE=IX'6&5_+!,S
MD'(IQ!<?2-$8B13PT!'6AY8.%B&?7F7K.:MT&7V8L"MK;)-0VS%()-F)$^Z+
M8SHT)O,CAZ;5TIM7#-FTP\EI(3A#AO.>40N.X*EP= EAB.H6>IO.R0:XH=16
MY@WV5PZ6:.&C576=>,'V93"_S&P0_,CDZIR;E[='+<"M ;Z9]-2ZM@7MZIR:
M=/.BF1*E56+\W86D6JZ4=-%K<DG.OO[/;08^CG7^/F.=;1QKCEWI3<?+\I*K
M][W'3O4@3J^\)(2=R?7<W'4#(@UG++,_L$_X=8=VR;8= S]OP.\1L)74%>/Y
M;TT BI5*6#&*3(RXY*U0QG3&7,"#L[C\7T17+$:&M'[(EW+QI)%^M60&$X@0
MK(&8I(N&3^0L,0J\:T8=@K+C-^HVZZ(I_"EAD5"5>ABVF=MRGB*2G_ )-R@X
M,IC"L%;>:^WQ>OO62Q*-,."I<@W8*9*H4^E+SB3*4I1,+#(GU+@1<KAJ>=W:
M+9*6X;AC!9^,H>S@T9-< PKE<];;Z>W[(NO!,Y?V_7CK)P).)_Z6H?HES2GC
MCTXK<3P9:5-V;GD523-]@;^>9[;9I)F,"ZH=4G8_C,X]Z* J([/'H_.P:+')
MB/UF,:T*HRB/M=>Y5+'Q?)!#6]9G7/\"+"@]EO&:.BY/:5#CE*CA$. #7B>F
MZ,M5SV"WC":95Y><.:#S:,EJ %G#9)]G:">7DR<"1BIX&!,RQ^1F4C@(??$T
M&Q<NS"D NW"*"C$TJ26V*@+P<U9'N0<R4Y407#.SV#M[25GMDE@$QVUNA/^R
M"=3:,/EL?'L1M9/\/S=$C=:(L=2VCEUN35'POP._<\V;^=Q&(G,BR3$FY%+G
MVP9?HV$-\C'_R!@[UUD"L*S/VLY-_%U4[_42=5IY5<@>FPQ!&<05PHR1:2TU
MJ4AD@[73GM]BDG>2H.35[]5O*-+3?6Z>QESX.]GP46&!&#DBS(9*-!*G9H1-
M23?I%P-2N/L5I/#GG[#4+L#,=][H5_.+>MEP.89T3,C98K35)G<KQ%H2@=*;
MISQ>UELMY$=5@?C6MW@H%]&IIGL'CKQV0&W3E3 ]E"MS'A#K.;8KR84NM/+"
M%L0N;D<^F7EXUWK$, --/8YG_X;C<:"+M,WP!4/;4^1.!V7R-602:&/P>>(2
M??$A^#)((K"D3%= Q3N(CX26RYZS13-']8Y3HJCFA)-H0@,OCJC0 +F4-)?$
MH!0Z!,D#@K&._AE2X[R0/#\J4_)1VKG13F Z[],EAX.#^G1/JVI._;VD#%6D
M@^0Y\03YU='W0W-M[T0X26!JOX8W&U,JEGJKS$&A#T LQSS\7V+[MIEWEQ Z
MXA+E=T]_>7GT/>T0JWVR$*"]F"2YWOS:]1>52TE&B5EML 8ZU WI@T?6=\B=
M1')E^FBJ0R:O%9Z0F^CG(ACC!U*RNLZ[(,"AIW89:(Q.DO\NO4!H"/+$*?U^
MO4GI/0=R>:G5R%R#ZL84ZV;3P$=HS_J8W0':-UZ/O5>[6L(.NW51$7?.^25*
M*9>8II1"B[98MZL=R&/6//C*1IIULUW:'9\/=L=?DP'G7.2V-L0]=:JGCAR
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M8L4](^#$+81M8; 8&^FVX,;2%HR8$]\I8Q2P0R++(13*Q*]0YDLGS-U3\5#
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MR  0.&J"PCZ2OFH$.9Q7Y46MM,4)Q"#):7E?@OT$YI*<5NW-&Z37^E&WWA6
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M^I=])TL>?LC^WM1KN6U&Y7E/_LS5DT70A>J#S>4.X*RP-CKN+]E=L988JBS
M^% Q=[8.NX'*:8DJHP>H"A/UC,DII,;'.+ P/?3T_Z1^5)H9^L??:8"OV',8
ML.;D=5O],0/=_((@!QK3N%W<-_J,C946DA14SXH*'SQQ.TO.7=VQ7TRKR4J*
M3!5E(<-(OEZN9PM 4U0G--CFNE6@,LS1JLGL[1V+PZH,-YNDI5*N&B!"<VED
MAI4WTWI$NNB *CZ?YT^JT^6:8'5[!74='A1Y][%45>:<S(<9[ S[EP80VGO
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M+2+OTDMBL02):2P\#[J4ON6[-Q YF!,B[P .;NZ/-0F"(D)F"MW;1=S<1H*
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MN_G/51/-MX-<)H0$2NLA<VJ1J.-FQ9WZ"^5*H&B12A #+A?BWBH>=3D+"^/
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MD."E:G['(E+FN#X[ ST%!YY,R1#O$D'+B$2#?VE@_IC6D\RW,S,12Y@F_\0
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M<I&+)D#=TQ576 K)'(9I_-=Z?*9JD[24J_FY%'WIKZZW+7QCS0B(N9)FL+"
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MK<]4$2[HE,K5KE7)@_^N=QRWU@][5<]'?0<6N*%IV$356#E]GY7MN/RWR^O
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M/LK\4:KD/]5M*6AC[+-U5K\O!%E/W+O"_H;W&-]H?PF%(JH;LC;:RBULYW)
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M+UD4(FR>JL+/AIJSD=!!??;RV*9'&(+'/$S7/11B]7)\%3F0"$KH%QJO+Q;
MU@%)#3$MT*VS,_XX ;@,+T613?";6GH)D@?F??67NW=W[^>S$+=+1^B\BDNM
MR((/O/=@]\ZW4>"5I;*),A%?WW^P>^"_SITB,X5[Y%-2),;ML"@1M3#G<T3
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M93Q7QCP1Q^_0%VAQ6N0^W$B8G5M3S6!=(0BB/U1_'8)U5P4*@$S::.'7.5!
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M;#O8D(>L[:3D8ON1#_GN,X*E@I..L,0V<KJ@0=OE8+I.KN=J!/K70(T+FD1
M.EF1Q!Z*X:5D)U_R&^7X90("#7:4@3DCN'JBR+:=OB3A=D0J)HW\(Q<VQ7V$
M]\9@1=]("AI T486G@A-@/"8B>9S!5D1["(>TL"HBH6NE\8#%E;R1[8JJ'W
M5L4.99:FK'M)A29)/O-60#4Q%AH"'X9"<FZ""AG&ZWP7G FC%E'/*T4K1M[G
M,E&?X[D!IBJLT</%SZRIR2II4 5#,YS6=0P:L>P[@V$;PQ1/['E\)GJ# !YU
MVN?/U6Z&R=DS?#"QS[\'46H%I(>!MAEC4.O)'"*55,=Q2 <IZ&]%C@;-?K*W
M\JU+XC"NC^!I/BAQZU, P:3'BYHAJI08!C"5SUP7"!]XV%L.I$>1<F \S5F
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MHR4PIW=I L<A=DI!2WT%72P6>3D28/6G$SA*:%-G"14+^( K[5W=1=IE>A-
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M&TK5'O39+5!BDH9YVP2JQ!<CRQ#LDJB-+F-;+8)U25*Z^LV#?2[/AL=MH]$
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M5;9MY("I+3;[JM:?V 'Q>2I?-O.%]O>*@C:%8)L<)1(.F Z'=T/5[*EI*SH
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M2SYUWH,H2]A8.7YQL%VI4TE($<7X^[?Y$848-1IVA9#$8%J4,03H!:HA^M]
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M4\N0,G#X#4 ^L9G!N62HWG(:(P[B%7AD-AE.UT9XHHNA#GOE_E)%$[()%O,
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M*VS8=3L.A>!&L/Z8/5!46\(*I6JLLRIZV/Y2OVS6YHW)['=-/J@U6*GUE_)
M0^*WSJ_+H?[A*UP"^@:.$L:__C7H$ I0@]+TH-WD#YNG"E;9 3=?7WPYFHU)
M[B"Q"ZKK^ -0&8"P,/R;83AI""[IYQ@T2X)^30SI-31U79G:Z OG_O1A+35D
M$_2%;40';<)+HU("M\%4_S/X^A-3GJL;ZOKE#05VA$ KU\=RS.G.=,5MWPY[
MQ0/D8L[WCYZZ]ON[V7T\%\I1B7 ?HI&^]=0BU<32U)LC_1E=DS Y&(;+%Y2]
MJU@7S\J=?\.1 '6_#;C/V"5?_!<88V(N[DYX;\K_2K$I*V^' VLC7A3E?Z4
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M&=:7:*Y8-$I-_'MZPF3H"4/EF(Y$U$Z@)#G>G[EI/6&J$,:B43$#[HF88#(
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M]\9YH?Y][D&Z.H%%$^\H.*^HW,S$TTH'IQ-2%ZP1\4;D16D[@FN#ZM+>5-]
MTOUN7H_&K8YL%<>G1/8(V)R0NJ[B5O0B'PY?W)_DHD=RD9+<T,ZS#559E+3B
M*9%<]$@NAI%<3%V=< ?)@QA%UWI>RX4A.3M^(HWE+2(L,I)9Z?YY<H9A,#*
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M:UQY(B8*L3=)T?Y#&IK11?4WRO'[G"G$54W+P:_YN/3R^^;[' 5BQ''X:ZW
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M8WWL'R!W0\<]097Q?69@FS@KY/E0?=$T/Y._G@F87?")Z)]X#</&AP=95X9
MT81_N"K)C."N3)NDB5%VE\0\5BC7?CUO(.CJDYAFH0/#.>IB/LC.VYQ7&IW(
MLZN[:$I&1J?# 6LQ#.(8Z:1(!ROT1>K,VPX#61.$N]=Q ]XBX 05#;#_#4E;
MM#XSP^^?QQN5SWC+YA"D]AH$I4G3\!C,'1JA:23A,*R&.^!\6:T(DA"-IPGE
MR&T'*2H?T#P&U:(+JE=').L \E+8RQDWZYC N/4 -IM2BZ/4"J:DK"%,@H^1
M?O?!E&0&4"9J&?^--MP)UKC]_]E[T^7$F65=^#]7H>BSUA?=^\A^D<38[SX=
MP60;#X !V^W^0P@0(%M(6$*VX>J_RBJ-2$(# N/NWK'76FU;*E5E9>54F4]:
MQ,DX2&YFG%B[;;>$,5-$,6*.L#3;YFQ O!MY+C:6+]Z6T$VD-U@$41JJN(>"
M#>6"^W2@\R(#>#?:-Z0I2$6&O14T-5/>!"C,L??8Z$%$U!JFAIMN0\$A=(R<
M7)/,&:1N9KBRAD#3\-0;Y&V>C)4W1Q6.(7I(<;MFJTY@%F!^#S%).2H4^@#N
M"3YR:'$2*=YTI=D:NXCV")^9I1-.!3&DHD]GQDA.M.&^6Q ;5?>2PD,:M(?P
M.!O)D82$?N6>G&;/CLY -I,K0\LD)^(#HEOA"*#3H*M&^R3'N":$,DD(\] %
M5FR8S@X^U49([SLRHY:X[,E.<\)>,SECN+J2&O':+( 46*DX3(7=-#0+U?YF
M^6> GB;8 \YA_6K,7-H7>A", ;P&'>-+'FE?=44Q+I-@N:'G,@X]1WU"/><D
MA5DYH)E]NI##87;^,4#+\?*(S(0]QV8<T8EF4AVI"G.Z+R;5N_@%*O Y3%6K
M>@-2]J%CT)(4?ABM3IR&)&8A4IB!#ZPQ7PG7HSFRP7'BOG&JG2+3,%3,PD&#
M';V[A\@R-G)+5<J$NG!5CD:$ [K-Y2&G++<4=DQ?VVLF7\X#$'F&)!]TMA(<
MEDH4][;B[#P;=8S!FNTSCT_]6_%\EK)?6QFL=6W^O)BO=.UA_.7'6:79I>XK
MUW<-ZJ:!]$CWJ,%CSFS](VIF$<V25& :M5ZFXK:*W4G-I62U"$ <G,$U'!C2
M "DE &KA[;:'EN7@^A9O0*D9&&6._C/DN[;%8/6N,YL#>G!H#% VW/1K)"Z@
MNC=#YJV3*AN[--.:LG-^=H>UI3":R>(+I&#JFMG$AY0-.52U,;<YX%";=?RX
M$1<ZOT/(KS6L3BC)P[5BN(G0QI.Z['G64B5^7Z5=XD?7#"/7SBAU3!"YURJO
MCF8KJY(E0W!!)(!/T$A[&O@B#?^TRVHFHHI,Q^6;0MI'V$5?CJF:KJ'$HT>=
MB_B>/G/O-WFU&#-YU3<(OADI-X.N9&R_H"U&G2CX7W>8,Q/E+S^N8:\HAC*]
MO5M=(9WP,(P%;FI%ZMTQ]Q,WC"BWD6V#.1B=P$/X7^UM79IOJLGVJ\)(I(I*
M'(,2K$6))BEV56QCWJ2596T[&-:*?'A./FVJ>@(2*JU(X:_Y$TUI.GC"&O7B
M(CUV>@R/):#/JF=W_O49P]XL[X#N?:,LY$F/0P$?^=?JI&+5 ?O0 5Q,1"KL
MU*G(-5947#\W7#D?,D0I,J=Y^ L\B0N/B:%"OH%DD_RY68FS6.G.*X5MXFGZ
MPD S0Z1 .[$D5)05DTQ&'[*5(13-UQS6NV$U>J%B_<^GH0#N32WIT7VF)L.@
MH.#^(=N5N)383Z(F2!D8M=J*I$RQ1^C@+H=^<R".:#C<802!-BHMS1G8X'+V
M4JS8B'/%T$.7A)VLO@4 <N%_37@\EA#X+"->53&:BXEF!W5?0%4,Z0#_@ 6C
MM9.FR#X5/W0&0_$A8\@,I#L>6_ K2X.2EG/V8YL*U^S":\0R2 4P81U$?GL/
MP*LUNH":$,2(8T]@SS(ROS3JG8G7ZMADA].*GL#@J[)MO=E]I0U[P0S>^ED8
M1H\^LT#%)Z2<P2'K".Y,?K#."HO+$E-H,9T=4=_VZ\ZPGO[K<^B'!;1MJW7<
MR8J7VI-K19Y>@]%,6@!O]VR<@)A)AANL2Z/BJOFZ?)?>=L08]'%RE&KU\5?C
M415_BE]^-&\ZR,T!QP;0,Z_;K?.3Z^9]HTY5>KW&T3H[SK"$*KR*PIN&NP>>
M2-BO,20RP6HSR8_1%' ($O(TL,#.. $B7%TFP708X9ZK,Q.$V"U1-H0_="TF
M%>JX2S&!$T#? BEAH6'*SMG@UF38M<D,74#R&/3!T29&=B@&HZFQI1\T5\3"
M:)MLQ><<LL3N80]Q;DP X^+-;)^)(?,DTM>9E_V6[ R/;2R$AF;D]AIHV]=T
MU=\+[QCES80@,(=W:M,,&=G<1(+*+&+);#5^\\+GMY3-&0D&;("%!X#!<\S(
MK+?-=33H3S;'-E;9]G/YB=MWJ@N#/E?AU7/M07BH@@Q++]5E+]DKK)F]\C=]
MY=B+<7,YC\XSH7'MU(0 W>;J1[CMM<&Z6FLWFL^S&WF]:Z!N^*/5[C=,MY']
M=Z.%7(FM#]:-J^?BHE]8*=,RVJC6/=)H[>ZCI;^&GV%?/,U?[8)GB]0U<JO6
M!\T2L$?ELK/A3L0A!NNW&=<H7:Z8Y]MT;8YJ=K N5.Z;3]VGI^7-%(Z1"<3L
M0*S]OC=38[^AI_QI<;?8DUD#$EI$$N9Q[U+]&%#EZ-&3GFSO T_ 6W,9,^80
MF=H;<;Q\87O!M*FFTGPJI#+>+.4^_">9T KPZ&3W%![\Z/)O/G"=)W;K^% &
M#,XC]]5>#VCX)G2=@\$K\AA-X,;\/K3&M-MBKI_*<N/VK3%_D8MV=GG8?),7
MST6:HCO?O**U)T$%!+GD#?'8(ETLE+:GF,?;BD+2K3 2_=G5V_WMPZN>$T;'
MO16^"?_Y;-*M8.A2H4QS^9!\_WW)14AD(\ Z&(<F7!FD4G96]6,6<R;G,)&-
M@]I^>41;WQZ^YB<6=[AGOK]*,O\)1C^F>38Y;Y2+9;I4"JD<V]\^<9'WR3C%
MD\OU?;5<ZI>'TC'OD_\9SNURAEDZS^8/=(:]2M;9R\*\JEYN5!E'-CC]ZX,M
M\IX#T/W&^;R<:;/:6:.B#7/6OELOT!1^)05A;8P3^>0E;M_+TJ5LD2[D8^QH
M1))F0TEJ'*6? J_<OTQ>Q0K[,23U/R2);0Z.+B*KOQ16![TW17>-]/MWB#L*
MJI&#J R1J!&6 F6U$CJ06*WX\8"5Z](E4T3\T&H.QJ+SF&G3QVI[^31O]#B+
M)Z*L:Q>A^S4B(WGF'_V<%A);3QR-+,\0AOJVAQWT/<5;=] XU8M"5I^SU<N;
M\^$GW4%?L5!(;..P^2R=+_GA7GKW,&6EZ9"FLK#<[>PGJ7RVOM\2EB#\Q^_7
MKL,NB>UVK<SSG:)7 7S__K/^\_MWMI3E"@Y\Q*25T#C$9XQQH@FC$_']9":.
MQP)Z!DV<%=^'JH2V.4=4(T>CCUH1OD/0K;B%;H[C=5,5KVN+7/'VK.REV7[K
MQ9VSBG%P$ILH')TK,3273:)/K2R/;;7@N<'Z^89IL4+VK7W'[OV"#.W>18<]
M7ZVY:^7NZ8AS# J>PN"."MGARQ5TN5]6Y''C12?-DL+O7YSR(,XP@W69O>8[
MBK[HO^U:IV_<QW"!]S'EP;J3Z^1KXXNS50WIQDZWW6ET^X]4I56G&K=WS0YD
M''RJRYFB)^\]D/I!US)<E*US;%BSU+S(EZZ9<V77V^:-"YD28@9Q4E__4MGJ
M4QEMCS$9'#$3S)FX^@FZ$Y3YY=_KFK_7-7^O:_Y>UXQ_G.FJC)N@DU8VDPD4
MG%A"9(<+@GH4<>D36QJ$OU5=]5<+P8!!-,#%K76@!]MX%=;C)CB9-+M:EYZ?
M'RN+@AVLW+K\Y/&6[2O>YBH;*QJ$+FA#P>T0=<X!P!0;@H$9;_?+L7>?V_/N
MOS3.UHN;R[M^?G2,N\_MMOL[Q++1L:.90N[#PG2\)I#R?P?TRJY1U\)AA(_U
MM+4*)WZ,R7D72O5L4G]\K.8<(2"_57^(N#&1$+<L88/7$KNP#%W.(TF3#X&Q
M2[#?S&'$3;3]?IB5GSA]?M87F&/:\$WHR^@;GO@.(,&&IVS>W/"R#OT726V$
M[1SA.B%%@3:G![H$*![6'G(MW'H2O=4GJS:9]?RI^L3J=R/NV6;6"$3;W[7N
M[I93M*6[>;R4^$HB1W/% LWD/NS2/CYC[61J166LIW5N5KMCUNWQ[-,R%I<"
M8R6VRSF:*:/_,(<2GOX!$$^. >!Z^(2;=M7@D:)K?JD(U5FY+(_/A[_&-N;X
MMHE^A)&UP1*)C77(XN/H7")7+7KF1QPALGZ_GTG-=V4]JHZ/C_R^5S"EQ/9K
M@<[G2W29"[N]W)\Y0ZZ.^9'1C588H^DN5 $ZL%JMRPG\&/[%@320T]FOV'.K
M.Z:&_DVZ6J.-JSAF&+BI/MD0EXU*9=7KYSL.C1*3('N\5D]KX3'DR ZY.;DB
M2Y>S83;+/E(ISO;,+(9<RM9N%]EF*Z]>;R9>_/;,XBOURHD-7)8NL@S-%L/L
MD!1R-C9-$/^;K0.F;YQ%48N.M 1#4CTKS--Y]^'7JFW'&K>L9;^)"MOF'5W8
ME!/;L3F:+6?I/),@MS*5/:S%W$-#@)3ON_?E26OX2V0_X1[ZRX#$AB='ESC(
MCXWAY,9+/LDB]7[=$,OKVBP_'>\]^01][N9U>/5V]L#5'O)'G'Q2]A25VLDA
M[0F * BR9B3Q87524[2EUIOQJE"%VOT.O\)QO:!\%&=#H!U''JQ;P_+[\O[^
M7+S>$3/$3%')!::H% =(,]X^W CK+%<H?_G1Z[=K5R?52J]1IVKMFTZCU:OT
MF^W67I-4TD/!F/.BO$3_T2@"#P>R!8D948;;>0!-6*"#CVP7R.-@LTR>ZBT1
MQ:DV!M_+@%2@,8[NG("^?(7G,.Q2]E_\.#R!?V;^_48;H[ ,U9[+XE#7J ;Y
M7-/Z'#R_,0IZW#V*B3^'<<J-D3*11LJY1CJE*@#23%[DWWAUK)E(W$N%$N8+
M25D)&,E8D0$A@R>8/X#UJ\@GYM\-Z#!%!53M#(""8FC9&WY%E4TL=54P![9
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M_N+WQW2Q+G2]F!Y<$>I/8\&BAW!)K,N"L&-M$O!XQ%\N_\0LZQV%;W%>_OI
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MK<>*VG=M.VV\"1?M.^>-#8_J,278\*6'#J=455%5G$F,U"PRP;!80>)FB)B
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MF=!-6/WJ<<&>7TQ:O^:I!$3.3(0*#Z^[,]@_)!X<3(N$G+^#K\S0N330LC^
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M.R(*.J-O@,2E@PI YQX9B1(65$M;&V>(T(+HH5,@@EV"I!C+_!>89H$$I-4
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M K2-<-N4F7TRS;4,_ EB_C5LH60Y \]J-HYZ5,>EV3I#AQ*9'. ZL Z!#DP
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M3\*')CI.';4/_8Q_%2A!(B6)2P6V$P=4X,8+[;JH0DW,:,:3BDJ2OZC( A3
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M[_BT(+=Q!+NKR(880)M[HJ'I>!ZWY/[F5S,;HR)Q.='QG8SI@2.364>>-'R
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MF1C2;Z"K]3EB9&)U8/L4!K>OJ' >HSBW$.W,6T^RWW"WU&O4+-VJZ@ I!^/
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MQX;KNRFQ37!W._@=6IB@:5"!08R'\?]?WK7T)@S#X'M_12Z[H3)M[#H)[7%
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M0ELA6%A@AN(A+.5#)D<X*N$U^LH7LC:ZG!F#6A9]@OZ5X],+,LR_"!\29T+
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MB;&P_8GOJ=T!^*ZV8B^MN?%0T+7 IU /_ SXX8G/'V!("XAL@%(A=BW2D=^
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MH;=.)89NAM4@NK[)3')6F7Z:OMZZQC#.BAJZ-_:*85QD'J.&<8':P5U1KXM
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MN:X#,$V,)T<JT=L=B/?6? 10BDOUW'S(BFO*]N)\.+DJ"W:A?,CRRE;@3OG
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MXQSQQ%\^C*L^M<.EYS '9#6FJ,RN/70?"L][I I5?LBC#*LI<*EVI\8#-U&
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MT]7K4\F].,3:-C]ZI:MG39(30*.@!_"-JK8GLBBYPX#PRX[A@W5:7E4+EH5
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MEC1;5A;'*],^*>RCZ>C[H\D3&.&?F!X_?D4N2@P8>8%'%OCP?_OE"'P4G".
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MJG IK*K26P]!5+P,4;?R2QF_[?HV>-57=_NYL^J6P:JKN_D01G5+$ G57<C
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MJ2FZ NZI(4M(T7X*C Z:-!02(OC)/7&;DWB.R2J;+N<DI'!T<RDZ86>S<T;
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MO,WS* HUWX\: -#C%C7E2A"(HSA#)8XS5*U'U1GO2C"(HT$,#F)X$ =TK%$
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M[=DD0(UT"TL=1'_VOZ8L-B%KUJF5_/HX.\:I-(#QS0!3N[0 DVOM%E2'I=4
MZFJ#[_!K/O^*XQ=\FR;YLW+W^^#B?/O$/D:;?*5-6< X/=B +MLIPWY"YVCG
M8F]@#%&:C78/@O<OQM>P>BBA^Y8!AL@#@2L(7'EM(/2U;:6_XH#,OZ9[MO6Z
M%(A>N6/B$&=<%@&&NL-P2YC[QU-TO7K.6FM#<K0:CEJJ@N%F/[P*3IZR-Z7O
M[#/4-Y0#UJ,VS1SL4UDA8)@[%+F$PW\Z6;^J86\/?7"^5<56:V4P+.V+6,'.
M$_:PU_1['J )%\5 ]:]-(X>Z5U8&&-X.!"ZA[Y]/U;EJB&NO#LVUJHAJJPN&
MH#T!*XAY6+^J.NQOV99&RQP3!?/V*<A=LH!]#-TE$QA2BG=>[@U=V,[YC D.
MF. 1'*C%_MU!#.U9@)>=O_T9V4L;!A.'0-8R$)2GY%N=]VF 90'@/&/+L-X>
MD6O#X-\0R*JTF]6:*@[+_<!E.HW,G6-L+@W7Y@QD9[]2'%-TB(D=GO8I A)9
M!^ >PEAOCG2R6F_X->'%/E7;5BNH>76:"B.TKK*CXX9S/Q><2WAZ%O7-C?9X
MA:1W5/,7%!6RNU1#7EVB-<4,:EZ=GAW%M#H *6:#UYIBP*8C%6&&8N9 *>WO
M4([V3(1"U'O7:8=/EYNA<:[K9"8)^TQ' 9C^LY[K T,G'3I[,@'S4)-DD:[P
M39IE[+:9RS2A/-]0JI><3Y/L B]3@@NY>?"*LROZERR/%HK/M%>)+FEY -.;
MY-VC.# 4W]\&,8%[Q+IHGD'M: $?Q2O@D@8<<D%W09T.Z"Z,DTEYIX@1FA"C
M45GTR(7986HJC7(F[MWEE;EV:PO*;!7EQ18RTIO2 .Q1H-.\ 'L;WDH4,+@T
M[UP^F E"*H&B0/^Y $H@USAD%^,*INF_AUK+ UM-)D@HJ5*!QCL#3N% 3R$.
MA5N\2Q\EX0U]25^&F70]\,S.' G;](K0.&>%5KP%$,*9L:K5T( B>DKZ^C2E
ME@^?9C!!YM,4*M#X9< IS066\+X5CF=3Q .#@@A($5[_* X:N_0PY9,PI:IW
M<EWA):9(PL.-._8JT6U&^KU-;Z>H'UP<&$+O;X.8Q+XHT?_@HT)2!JS]W*FM
ML@_^VADDHZI>$UHRE5ZHH0Y3*B-:$>\P+MH5X8.1?8R3\=)&'RH[>V"'.:"I
MFUD1,P_TDP9E+W[2RB"IG]1J0F6B%6K80Q]#/#(LB@$590Z()$\E6M2.?RI=
M'<6.OLIJ51LJZ][[V+4TQT3?^$UHQ?;.U\"H AH?];+SJL+IFWC:?]4PTB3L
M\,9& ^#&18T*2>\MU0J>:LC&25%H[#UZLR7%'<YW^Z/23'&OIU')'TE4!JC)
MTM4 2AH%S"YYJ%AS9QH5=$6=XLI:.\;4LOZ(TH&KYD<I")06;73"RG/Q%$P<
M6<.>)/<D7> LF^$,TP_Y3$=L5_@%Q^F:'3PP!#SVQ?B(-/L:*0L];<OPSLH]
M@8NW+JPC&IY&_Z3=7Z6(V"4BSMS8W=^F%.GL8?20IXLOTS6?9+7ST')-CWVA
MSA1-ARA3\TZT_EB%KO%O4_2_@M7Z+XC*(ZZ 2@U7Y*I^T.[1[J?JCUYZ8]3\
MDNL!)9@6K#)RY]*H%H?7_]*_5+^5PT[F;<D+SFAS&BT69!/$JJRC0POSVA?W
M,EC;(UN5Y)W-!X$OW -8/J[<:*D(C][3_!FKDN&HA+W2LP582S\N"9=>37A"
MIGOV#!Y9/A)QHL,D[)4L+<!:LG!)N&1IPNN2A3^KIZEW<V&>)JP%[)^#>,.7
M:49QG'YEA[>L:D14\S.1;;. 90.Z6VVU* HJ67@M_@Y;SS!P4:^MO0%6RRPJ
M![>E[\#IEZ/LVKEKUMSLSFI:;KY3*7EBDL8 !:<D&A#9I8:I755IJ#E86FF\
M;9+D%%3T&,N/(EHH^1COZPV0C?3E&MX9U NF9&M&)>&4,[/II\*)VAO34/',
M%P&\@2VU/&2N=$%VF4*?EPNW3HER';WBL"]56DJ>R2(QP$"7A@9DPH@PQ7NY
MJ,2!2'.DT*=7;PPAU+$/<0"/P$24%A%T0PD2F0IZ-\#U&(AUM;R.R>0F:(=G
M;17OSJH?3MDN$X!#MGKSW0RS6J5F\*D(Q9Z\4774FNW[WE TVYV^^FK+ [_#
M?6J; W\>Z5;-0[P 3!,YAE6*XS$L%PH*<I15NC#NY51\ ?E1"V6@T+L4 &W#
M9*(%^U5%0.>W ;?T\,Q!4_HHQCX*N)?/% V>).IY^6:8/J 09V.CP0;68Z7>
M)4 Y0K,7>@=+$?THV8BMYF2#/ZVEP_(>RKXIJ#;(1#U1T[O[&P17.:O,.NZ<
MBJ+-VK'CXZOJDQRO^K"KJ>2;5:(!)C;M-$"S2( IW1"!(B;AEC/BN-LH[9LE
MG7&V010T+PR+H4>B GVKT(5.EW4G.DV$J0"924-*<4:=X2;6E.I?! RJ#<:M
MCIIJ943_(3F4ALX1FP<J7GL\TK9./5T&A&R7*?D:D# K!\V*SV&AYY*8UF8T
MJ6A4 D,^6Z2RF<2T/J\6LSU?BZ;V&5H>)G/($(*UAL"]#>]HPR";U"0[RK54
M3X!X,KS]Z9<=(BF(ZOZZ@MK50:?BM%[3!IG-%DKN[JFS-6!W-YU) P:Q;&&J
MYG%W9]>X)FJJ'HE,G.[]J&14<48D2_ UC0SR,$AD!U(^D7I, NV?$9/59I(7
M&>AF4?9E'CS&J@4SE;#3#)A:P*W,EU))[WRR@B<<IFT*(R:-?N/R_P6/03=1
M@F636#8*7IDD ->RJ9:&RZ@N1!M6,1W$E0!2ZQX3]D/PA-_9?H.6BE=Z2<!K
M"=:0ATLQ$:299&=HI^6=8Z,%OR^3'9GD<[@SO,#1"W.M;--,F5M8\34L=5VR
MKI<Y3?I9*8+A81^TDJ.O3!?5*HA]0K389'FZPN1X&WVS!8G6Q6S>;9 OGNDX
ME:4!)M'CAOTJBSLME!QN]+4TH+'1UZ#AG4^]8(HKAK4>2I=H56JB14/5NW^[
MPDO:HX=-<^ZI%>/5.DZWF%Q%U ;,<U22;5-HM&*-1-'\]BW4\8[/ WR SH;0
M/4KTSOF#FM%M$U7S0=B< O%X,Q!U AEFT/L?WOUTBU>/[5/Y>LG?PW3AK)+H
MNS8LD5*@Z@5,,(6UQV>,<(Q9F8C@-<7$;P#/>)Z<M'!8Z[(@M.(E?>>EHIX#
MBFWT$D0QZX>O4S+)L@U;I^)/+H*,T7/%B!1(.YB^!0"KUF'H;6N;EXZ"JGBT
M3 F*RA<43]$C>P7MKW;O\,*#NS3!A=?!#YB\1 N<S4E $2WX;K%4<A6V6056
M75OCM:S=9%<>RLH"4;XKD59JEONJS+(+P5<1P0L:TM H_2(-2#@*7Z(L)0IG
M;*L(KF+[H+:O7E37;UB6BX(D1(^L9!0417MUWJPW$7R4-C^=6056W5KC[=4!
MBTZWU3-G?FIS\8S#38RG2WG?TS1Z1#W,2Y1O1]2^D&U#H;W+'+_F%W0$\T6L
M]$.5#(P;!S;+ED+E:]F 4]6'M^F$@O+M*"A>CW(>#N04 'ID"+P0;OR*R2+*
M\#VA7=<[19<@$X)% PU"RQK%90EHS8OP'H\+3!X1PK:%,=P7VT_)"\YR'([8
MZJ72SP\K!U;-[F=$GR!=UH2#W7O0XQ9MRC>A@+W*;T]A_BX[D?M@RWYJ?J"/
M5%"R6_,PQ9X<A>QM.C"CFG+KXM5M<J$G_O:3Y-AGWE@.SK&BV+?%L99-SCE6
M>+63Y-AU2I8XRC=$DC[I@&6_+;:)ACFGW'('X21Y5P4=?\?1TS,+/EXP"9YP
M*Q ]."%M7OJVF-K#8N<4KJ/!KR4X%!3H.H,)F/S.K**>27*/291JO_^[_CP_
MX,M/C.^'M_R O,_ZA*0H2M":HS0U@'>GV0**F,Q3"^CQ\C?6 OI;[KX%E([_
MK;> 1ISHJ1GT1?#&VL) \]TWB$8X#[U5?$H(7J1/";L2JUDMT@5NG3 LKED@
MM:3%IE%2FQ?>5K/W'49,-WF6!TD8)4]W&S:Q7XTK#CY$4[X)%EN.;:;SP5BZ
M X02CJ@>GWEA[(R^FOHX^GJ^!,F_7:987]/(PF*-&:AEO9.ZH'*5E%=F!GS5
MK<? C5^V<C0GHWD7+,(<WU!/ZS&-(.>)WZOCU=D<9O6A]9F/M&K3>L?;XJK:
M0$_K.5V.GB0U)2.@H[E5S;O>%E7-AOI<#VKP]J2]:B-&U@W:70Q%;-[_MB@^
MS'BOPQ;#; GPQG"XA8WA#>+P&$ZL41SM \!?9#KQYF&_ZN%SK>F--8?>AL-?
M:3I-]O=<YSA>#S$0R!MK%_M]A1-9??+;8<PQ6=VD07(=L"S&^58Q-2P7@T4W
M+49+,N2T#!330M"R+,7G7/!UE+#CN3>8<HZMG[V3W?&JEX1512:8EK6T+(I!
M,2N'KP:^0T%9$HB*,M8/[&K9MS:\U,$-SC*,"U-8UEB&IOA/>?'9MNQALJL-
MYOG8A5KJ7P2L>AR,W[*F8UY^6>$\KRZO\O*_U3NJSC%#X0:CG+T&#"$FJ_6&
MA]K4T6-).[70@5_E<L#[U7%4E$G#FJ)0CS6Z2PP]I'5;:D.LY7[0^]5W(U<V
MY-;<_@1VK5FK [^>#]&:N[4+HC5?!MGS?1"%5QM"D17#.S;D4P:Y)@58=6F)
MUK(B%[0TVA2CD#9#5EXYN.1C3F^Q;YU_D5\;HDLGV13X_3V8I&=R7$**2"YU
MADHYKQ]9_77!?5;#]_3T&1O7(&L(*TH!^KP:<-U/W1#US5_#_>W-Z]!!?FJ;
M;^SIT\X)[=4W9,MW0[)[GJ09\$4I0!]: T[H(4M1Q&7/$)?V].4YA.<T#C')
MQO_8T'A9]N5%J=]_!//E->"Z7[YX?(9&>9'^L\@<E*+[ (9?&26A7868=  U
M#&NH&K?$4\45XIXJB6]#O"?I,I)VMXW'@#Z]#%7W*W,95 AY^K;U<+&\KU[:
MO0I"@+ZS&IMPKVH]CJU$?7_SXB;0F\Y.98T8Q.\N0:?^\H4P^I:)_\'3Y[]+
MD[0-ON2#K!*4PH"JPHQ1N."NH5'72:GDJUIV/+JFO[,LX5&RH?A*\J1)=H&7
M*<'U];DXNXV2E-!^J9K>HGU<NY2BV[K%^7-*G["5<CX;*:MHAZ\'1!T?5G?)
MV/()Q04:.R!HAP0]<BAE+(**%Z#&&\XJ*G.<9XBRG-^?D,9QP?,"L%=^4VAE
M.[O "59$- K1WS\ XXT:H:*.V37!I0;ZMM3QY6\ZFX&*$Z!E"M;FSNN+((L6
MLEKJ50"@-C\,=[=&JU)060PJRF')9(N24*.H,\0+@U735U',UC$$NWO4M:H(
M^+5M1+YG?9?E^YI9L:E3T78X_E6-3;@8E$N>-;^^KV%Z$"6L#Y\F#P%+9LUO
MTU(O/&C$ 34?&Y3"L)[J5.%,FM"FD*W3+.+;0FEKX24@K\L8M#=FTZ#X"A=_
M3I+J$K3=Y6>*N,2H!ZCN>L&51"Q<"7U;J?^!;<NM2D"[(L!4(@N%DYP&Y_)9
M'*T"Z&J3X;2LKX8JF'KJ7C-H5UE=+= UI@1K66V%DVP4 *;R[@EF.RFN\!(3
M@L-R-%-='JGN[H:5!+J2>QE@6?%EF?4HD2T^ .@QV4V@;$L.25^B$(<7VT\9
MVU553VR6UW(H/*^]-J#Z'@!:F&;$[(KZ[!E5A;"3,-^R<FA5_P'MIH5W97FJ
MWVH;Y#P=+?ZQB0BFB,,-0X753=JH!*@V[;%V*['29&NUI2[:*?MMEH)5DX2.
M@9XBVF/TJ+:N$N1J4V*UJ;:=,DAO6DSE#O6F$FU %3D =$]O6A?ESYORK:L5
M\:;4N! _YCA,L"05DUP,0(W9H%,UMK:X9Z=XG1(>.?'5$)TC; D"J $[?$J'
MQS8U%R$C5_!4"\UC<?<D2A;1.H@KC++:T"H JA4[G-W:*;405SM#M2*J-#U5
M$W.H[/]L4?$EB#&?'*KR.K('=#C3_J$A6>S+%P=&BW@3\ATIBV=V"'P6Y'B\
M7.*%=+'/+0) 1/)D>)>9K."SHF-ME'^&=J]&A0@;BG9^;&L4F)!D9,M7I@MD
MJ(*&&#94@#M%\M<6%?/;0?R1I)LUU6"WO1?K]SC<K=X?G/H]WP]H<<>+V<>C
M_8[:%23$,7'-)JK&7@['A,>+\'<:13RE"9[A1?J"R98&:G?!JK7,H98"X#4M
MP E];B&.*GE652$=&80;6D5,TT,M-)8I#36AE@12&Q8 A8V0C4QYD&JE2()]
M&:<9GJ>WR3IBS591+SI9(#5C!5$X6%9D[^9:;"9Z'JWX^83;N_L)=V/TP88O
MM?NOKSD)1X0H*JCU$$B-R#&)AW,"WC0:69Y\?^W=ZD>QCKB]3^-HL97>46Z2
M!5 7UA#%Y9I2@8:Y7 7]5O[)=!%7_B]?$QZ$;6;.M_<4,=N.RJ*3-2./15W9
MZ@*JN]Z0A9F2L@!:E:R(^H#/NFAPX.I7G@JN2/-6[#ZFN*,7S*S)"M3*_5[]
MB@%4Z_N@E^X9.^>%5?,O39\+J.IKM\/.:7*+Z5 $DQ?5I@F5-*"*M "I=+ZH
MUD&5DJ^$ HO%9K6) SHDO&*))A81AT7_'N.2DJ-52O+HG_QWI<^25>.AR@94
MZ0<W28A>=R] S3><H?H=W,\WW\*F85L]P5F[*P#E[O>XULF^,]CC)8#FEXYG
MFZXC:;ZKU9L\;I&TPV%O/$/E.\_:V\>+]YX^ 6US8#M^]=LDJY7%SB@L')BH
M\" .R&?.B4F6;7 KMU1QBH _+*VIT(92FO8N!5!?O ?X8Y*G>AO/_EQ .E'_
M)\F\?0Q?)WD-))8=T;ICTO"ZG8;</Q$?N]^P:*BC3?Z<$G:]ZZ<DQ*31;OD(
MN.7\9^PCE+^PW>2EL=;70$/  XW:OC]#SSF-BN%GG6X8<1#UKPP&M*[;]BJI
MZ@:#IA<1MMT-+ = RJF#P)>R!ID]9U5HX2XK;PF4"-I^I;+DL+?S'."E)T2Q
MP]DZE(]-N59/7E%SQ]C3=&;@;T)_(VPU&W@\BC9W0Y39!*JWGS@K3^*JS+?'
MX%YFN^&UP?N>-.&AW!;O?S+3F8G'(^W'^JK*<AMSD9P2-#_?Z'6MI\+G(YH^
MA.?90**_91?=OAR4-^F#NV;).TZ&PGN8=CQ7_+F^+K7IBD'2[XW<"'PJ=#V"
MR4?TM */W^!4A&29YF@QL.9=)\/@ YAX/,>[E*U]P>[_W_REU*="[&/;?T0_
M+:<]T+"XOMJB<7=E<1A]AA/\-8C93<[2U5N]!J#U54N@PIT=7.T,=8[:E[J(
M*;^ENQ>!.(8^4.4UULB#Q;71I'/!XENZ_Q94K=E!5=1:K0RCUBKG467CN\8A
M957<(^N\G28@/]D3<+<>*W54ZC=N#P"3I+["^) '.<NL>),N!M6IC3[ FNT%
M6UF_O!1^M(&7 [F>:91(PZYD2*O5:@*L6TO ZE9;Z$.N38K)<'&E7!)@;2D
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M[2?7BW[2,^^A%9MK8,F1'2LW?+?,YS2'VUR^823,C]"VO3$C[T+[-=Y.W]'
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M\K\J]OEE93O&R5&/DH&?$3^[D$,F(.Y ?;I:4U\8MMZK"^&BO-HYTE*N22;
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MCEW1<AT-8U\WA,TX]4'8Y#HC_NS-AO%%<&QF'OE>-+9#@U?"'#<H#?O9SZG
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M;<"H5T 7O9O _2%UQ']T(-=MG5$%ALB=<;ICB;)Q=O5ZPH64;:$GXZTO8 B
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MA*U</X)(C"F]V2C6P+TN5-%P0T!H>U.P7(:)#G(W3:X,[F4A$(A4*CP*RJD
M?+>Q"]Q %X8F+8U[/4@"96%A(E6S9=2GX=<Q<T9L%K!!$+IQ]JA[$C[3N88!
M6$W<"T):-DS4;]L)OPGY(/9%YC>( 5(4Q[T>I.5 JRB>N7^@X:]D;T*);DC
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M'#UY[C+> 9>9@C_F3<'-X'IFC:[OAI_C32V2">"2FRQ>9>61ANR1-)"A**N
M/<24-.2'CEKK;@R).\+';>E(*'C![P9\/D3J_[&8^GZ?+X?3WV,I1HL[OK\G
MQ*CG ZHBCX%R*G)]'XQ -T;!+>&0V9YPB8IT?/$SHS/[M7QD_#D_,FX'-X-)
M[R[V=\YZLX$U?.#+QH$UZ_TWUHC9ZV#F\U!4PO)Y%$0"^3Q4M=!]'EIJ"CX/
M/0C=&$GW]C\IZV^"D,O+2D?/I_SHN>_]UVAB]1_YINM^,$$:+A,W^"J.1!Y]
MAV]W;=</02<!FFHX0Z9/N31^&)_S" F-A@ZL-O(0 M&5&T0FL'1C,/$-U\H-
MXVV:S_=:T<$ \26'<A\*3X3R.>A^.!.^P_@LKC^*3MP&#WC';0J53"8JPV:P
MQB% 2-"(-&L'>6Q6HK@P5JM UXU1.UBM/;HC),W\7#94K_)#=7 _OAO].AA8
MUX.'P>UPAC<\#]D2_?F$A"XCQ^Y>T."$-X)T L#EBZ4;A<^$C2D79R]F2IS9
M:4#E%O&'JRGE^3."$\'LQK"=DN6QUF7CMA#W,AU\%O.K=3.<]N]&T\?) &?@
M)M)/R)HR82OUHU1> RE!;DX>H]$'JHP\T'04Y5/8PO'HQ@ Z(<1,$6KVH1!,
M4D.HF?6'](O_=HDZJZY%D7&Y]&5ESRV^2ZYOK0&Z5:A((LQR*NWB_P(,*+0^
M6L!N5<[,@$'GL6\'SV+'P_\0H19;VQ-[(#"-P.K@&SQ=8=$(%G02]R%J8-[D
M-8!4U7^KO"I5.N4[DWVA&K.A[2_=)X_T@H"$P:WKNR&Y<[<DO@ZP4U&LK0KD
MNO[+Z]6Y!L+1@2&9G* 8#$E9#2!-]=]UKTZ36GET=J11AF"VX"T V:O_QGQ5
M]DS!.6L#6_YPRRB]'S&,CG"X?1%@!#J36ZDQ8/^H_SY_U?YQ F1GW54>H]?
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MZY+I+RU#+1T"J8#0+M^\\ZC0-?)8IJ+6Z1Z"@GG/1^1JLU+!F2N"9D/R<!7
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MY.9S+TRROXB@A8U(YG]46$YS+8UCWQBHW UJA!:]FTA!@,R@H,J=W>[I:#:
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MD=R74)-+J,DEU.02:G()-;F$FEQ"32ZA)I=0DV\AU"2SV#6-.(%5[;R[N:;
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M#+R')PR44AZ$5YD@77=+MDB)OR?!ADZII@9J+TD!0_PX<QYT\RGVL*3'(JR
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MUCH=<_M]XM7=M%V"WW _5UYKQZPW2K\JK%PDDN%DTK>0N&ECXAC8WV-_L+&
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M)8EK7OI]Q5V_(NC,,>12?GI+I$N>UNN!+F-O7VTU8XDNR4[1OW2Z3OZS2%$
M-6>E,\BN, 54?@<FL,46Z.4\WRV'Z07F^V4FU[EMVJ([]A226 KN<I"+T8V9
M$H-$]9#P_N,!1NAN$36673Z,2$RCB*U(N31D32SGYC_%FW(/@'Z:[?V/% 5
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M\TY$^\ W;)IV!OB08VN\+T*D'L+$U5TT[P3^9PUI44)IC 9LD5):(G?LL%X
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MK]5\"_=[6GT4J;4THOWVCM\;@?K\%N"++%,W]MX7I+"%FVO;KF%0)RZ2&AG
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M'=9QKY'6T;'436&0#5@I5J*F6X"]&F..FL'.+):)52N@[CE$:6)\BG=UEW*
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M=(09X+YZ@!+%@P@FW+&/&?XM;C8C@HLZP]6O)<7I6@9RYXJSZ=Q+9=G-ES-
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MY[C"4<W7M $)M%B;5TQ3U,R8NR'7#I+*.F'PD8<RUE)50BHB7<P2JWPXE'2
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MW%\22_!0 &,EDCFD@.?$R?8/OAT'63/<\;4#TX?W#WR\4P\NHI ZO9"WB'L
M_?CD_!O!'98GB%'[7.0>5&%W.Y/67*V3WI$^Y*0?&,#][L5'B&8K0O^BXHL3
MS%_3VPV4IJ%<>KGGQBP#Q21*C[Q?T=34FC&2$4EWYGYY32TJV'&R/#SIY,^-
M&.Y;K+\F3;@Q5SV#BBX^*)6_41K/G"\@3ADHB9 ==YO^X4/Q0F*4L11<Q:!V
MI*&I?1JL'9HT1H.U+B@UVS_MG&HZ5^#\T4"Q(D:1>22N,_H&+ONXDF\S9HTS
MT9).74!H)V0"D0-:@'$#Y0CJQ:(TRFRY9[H]V"SMS1XZUTC'QPYK7^A_X)GA
M7P,GG3=W'VA3R1;A7'U5FM]K3Z6T/2Y)A%AQ1CK?,A\->CN]B(YRDO@>;8"R
M<3<[\<6Z'?Z)&AH(PE=LO'WG]=BG$]\EU'M?IV3Z[;0]8+33#J4]4X!U-9.Y
MNNVXK?Z!@1*GR.4%],<"9YT]'@1DZ(@FMN-FL*2YR-?"!Z:TF-XBORU1"Q9(
MOVR^4:M&3,9X2X<J?NI+*X;V1]X\-\EF!?6Q-_S91_>VHB)K'])4)1WL!=SC
M( G5J162U_LS$Y]!MBU4%90WNF!P8VH=:_M/ RTK-)FF3,PG1[3U(],J+/Z\
MEN]-%-X/CPJN3CQ_ZF;M6._>P?/7BZLG/4>D?Y"+_J^%JVB-35/.J%2[#_BH
MZ7S:4F]SO9M*>GE&EMM,RQ-E,GK=I;U.:F8'WXQ+[TF+_+-\_*53$G4?9EKT
ML7;:>CSE6)4OE*OLGXG?D?]5SV>F3WMV<JCM-'FM-AGH-?QBFB5C(3<9)&%!
M4D6#L/!+U$U*,^.X=_J>:GW(_11+DR0<Z+P-'O_V6_RJOH?$ZXK$.:^JZ4M4
M*Y#8Z;*L/&QFVF)"?O8_1M/]!W=2;/\_+CO\1?SH*JPIC[>8&&$]1MKY-J]!
MI#H6MZ42Y@&Z$.)Y.0T3YHHBW:DV7 ;XG+!$WR"Z"/PH6BTM7=/7$HEJM)D@
M'!,PT44_65?T$)^QN%Y-3\,WICD%NRO&;B!E,N ZF!V/E6E;]4V$Y\Z8./_5
MNM5$GP ]R!Y^+DG_='A7Z!?Z6P9*/ 36IG?QY>;:RYA7<^Y5QW$?7WA2HV*]
M,F^+\![_]0SCFEU-L=<.W_.O$PZ,4UR&R>,CP'PDM&%3[79]@2@#6C@>[0*L
M=0&\4<&CAQ4"<\(FSO$_0YL!51F4?PI+E\BR1RDHE-T[&G!4R[0"IL]&G4&&
M:FEU'_>S4==<B?W<S?>"ZHCG_BQ?_C B=:'J$5AY==9 <9G"(34L3]?> #+=
M<=YK^$E Y\WRJ_?>R9F%##/BESF9A'J1M:#%_=Z+U7_-O&WGOQ(A\9FN*K@M
M<B0II&[:NTQ@AW_YM/L6-MU%6Y88,UNFO:@O$R\A^APAB8>-.OM.?4HB6JA1
MM+'E06V+WY6VS 5T\CNF+XA]>XGEG,7OL8H])_I34Q[$Q\?7Q3M\_>LGMZM?
M1P4ZR:,S;\P-J5GR[;)]$!I*!ZM?5M]OQ!JAAG3<5A.,?I"<6;A!O*Y?H%TI
M+A@<?R7UZ- *51XV7:'1)\PS,C*>NZ\XP_GN1?S)NY3,/ET@KT=A;*"<I%XF
MU@"5+A /ZN8Y<.GH]P>>"-5)Z5-#]("I/\MWE=P"&=M['LQ BSE(9_/4< @D
MB;9$;_#K@+!#7O5HC$?K$7GLXB2Q,I1-7:P<N#&HG9E+<^99@(<R*;20YP%\
M/L=F)=,.8?+Q\US'V6QN2$W;O3$?6?7$6=]33RNCO47M07??G2=*JB?D+K>=
M!Z_5C97R[L6FQU)5,&ZWA97;G#[5@%9VT$1-12U!J*O2,G<R$NN3T.KY4\?/
MH-IIJ< ,/D4R(;\#MHLO7P;9^C-3JB*CPSC!FJ8L8MD(<(C2WTBC%WS#R6B?
MZWK*QNB!(%$=R<[WF3?(%B/*'Z)7 Y(A7E6J6.UP-NR21K\RNDQ?*G8$B6VP
M%<./<ZVM?#/9. H;<./YKK)C6'K^@X=X?.78>8^'_-43X[Y_G%]T5<@I@(PX
M)V8_)ZDI.D[ [!<MI_;N)3SHD%(@F"=>SUW4YPWE8'@T:J!<@I4U"!JA<'@W
M:@SHZ)!&T#5M3/PF7J__ 7?#)HZ +(TB_SPRV7:+TTR])-[<QUO!^\U J6=V
M&"C.'#_6()=Z=\R7GRM>":"P_$:]:R!*09F3\-0Y730W2=_$6(BS]>6PLKCY
M3A8&J??7*F_&;A^"DOU8MLYNVH-@3\#[7/WM=!7MLH&R++6.UM%LVF6@R%T[
MCGH&*?6N(2!P8ZN*?:'TS5-Z,6,S^-#&<T6OY*+34N@'V-1 45:[F(&;F((P
MRZ_B;B;AQ,!M@2U.*L$KF9:MKWO0$J#S!K$J^F7_I',J9@'-PDLQC&A]618<
M8REC#7BA@BTF'-F3TU5@5@.U"?,C9!TAP6TL>P8MH7P%>J,,<U4-75*H=Q0O
M,)WY*RDIZ602.S:6;5)=764=&2$?V;G,?G"P>U?]-C9[_MZK@?,WK93:'KPO
M799PM\"6LD;X)EW#Q.V$FO1)D2XY&A@H6A2LQBI)ROC1PT"),5#RST*/@R8G
M3GZ2C_6I3:=*=,&<+(UI]JW'*#^/>QAUC0#9:&@[W.B-Y')-*]X)3'EF[P@_
M[&9K;B[OTT2Q-\;L;%TO.S2 >ZH,E NI,%@?BMMYJJ"IOW1V^-=D.;[EG@(!
MNB7$<WB)B%_H R^!CSM#;1,/I+KUO)=R198HR54+@Q+=E_@7C6A-H7^*DI9/
M6\I8&U@5#UGFYHM8\\<<:_)QNX<CY.GD;ND1$NX<8\GGM*'9=N8%: $Q?Y0;
MW@I"E!/P)WLPJ5J1S_/#F4V/!M)TK?0.R+[EY)UW$;&%+;&)E0G-3VY7@5.S
MG6:J%SZ',,N2[ V- :[AF.OXZ(9^+QW?EI/%&IB!'/1/H-,!="T$SJDL@_:"
M)/4TG[9,[,W=WLM8R/M=T=!TP>WQ(RRT2U!$K.I+2XK<VYW<$GR_\AW-DG &
MB8'=(ID3?@P@ZD<D?3Q527.YV]2%NLR8 TV]_CX/>4&<2F+1*GWI>SB1-?RT
M36Q'2J_8@=?.\P4I6(::S3=0D@3R,I5,*KS$FP]^)RQZZE)#C%709'BF!C+A
M''JNAOA>+!=.0YN+&RA6)WWS$I[O)LD>:!2:'4LHWSC8LM7S'\'45E(?0O3?
MXIFZ6%X;(E),_L'82+P6+()/"1<2PRY4</T6\:NB(;=KNHA8@=K78'WM-*H7
M+== L<&ANC!\0Z[J^?,4M2!'7O*L+(_.6\>)"4OD%]L[.":);ZM^\C^9\J61
M%FFC+X7;@H@EO%%:0ZA$,&*L+0),C$&55RK=IF(P:A>M0?C,0+GL&'J9]&HO
M'2"C--KP*4G[>;Z$F3^ZH@$!'[#UXV^_ />$[W@>0SPW3LG^;O\@G\(-;NB0
M1&B*Y*QT&)TFH52A=35%D/(:#3T8X/OW2_D_J?"PDX9UY8&F.00;F:!9X$OO
M<7=UBW;W?\L8JDR,MNN;R9@W<I7]H&ZX=X>)(VO84\663A= C36=M)&WVBJ0
M5(,O&N(&HG*9-E5_'8XM+$[9B[$[V%E(0[&@Z"TV78A'87T=HTL'9J:-1O!4
M?84_.U9%M>(\?<:RF)$MYKBK:B[REN)KT2*Q%R8LFFR)>L#GZ1'_E0HKZ#A]
M)/)9W(E0K&GRFBX([(Q0CR;>->9<4TX7-9[TC!@9>7WL6(?EN\V1;8DI7K\V
M?U;WYFS8*^/?83:3+_X,]9DL=,#7OCZ8RI1[:JL'&,[$2]9CO61#^E"I6Q<D
M=XQ+=7976T3 K^@Q@Z<9\\#FMUVLQJ"B)!HS@PD^%UN!)W/_+.^KVUB=^Z%6
ML@4Q(CGJ)HP>0 KJ*N7'.)':9#W98\H\I.%*]H-M=R*1//S(VCX#)4$HW\6<
M'Q]BX7 U,7HK$&$,70CF=<.^ACF AV*>:K>\53\*5V(.^4?\]XSR?N%MSM4.
MZRN0X[*E8[,.I$\P-U"."X#;4#NUJ/GYBWM_!%2_G4K4I7'MT5;^A0?>F5N/
M7^KF]"EEDS4U^,X!T8[F?'92(UVN:Y]])(DQ(>C^SY4.[8I\2#2-V[MI#130
MH,[8^E$P'*1E@0'=)B[4]WZ7*,59)H6O0 TESQ+I3K@/2+\'SGI=V(G*M''@
MIFX'-P3H:^'$(&^DF.$%2K0IF$/.0PUMO@B(/J<&D6S$F4">')G%;5.TP@;]
M'=Y:\/R(&*-.PKI/N0E H/.C.<G)-9+;AL6J9[O8<AZ4RYK'LR[>(@ON2?*&
M3'@RA@D:S<?87:4AE__&$T!A_'T\N!4IW"5&;UR]0V!#'Q2ZC;PA10-SLE,'
M&2AMV\E:/Z U"CL$%$YL.TOD,'55MWW"0*&V[&]NRDEJ"<4BR9I<MQR:;-(Q
M<$\0;T>(V&<PXX[H-=V$$4?8-3H/+?\1=AOQIN7[#M:=M+MR_>XH:TT0F9^4
M34R41ICU(D]FIW3T9\]9!0KG5&0)KQMZ#$^R=1Y S,Z#[6>HP\+#Z P_C^$4
M%_WITQL&RN$2%F9ZV6LDBAT*)K"^_>ATMM@.N.[YSNC^.Q<:MKH0'/IH/.<F
M?'M8^Y?^GG@3K\^*>#6-IFM\.NG##809R?3S9U!6YUVR:4BE=-!R!QKI%D0_
M(@J:\D2E$L?RNCKB%]IC0;'HM5\$ZS+#$<22]WXY)K 3?S8F#\.0 O%&11AN
M"4ZE/O6@2XE/F5\!!*O5*L$Y<N@B8.;&9ZR,&U0TO9U*NL_['6F8&>IXX2[Q
MA;)3%5D*&R0)*2RW0X^\%ZEDEG%-$9F7FVLF-4I97G-VT^6'BR.SZD"NZLTU
M-=WJ3K7SF\=NN$Q?P5@WUL ]3W; "7)/ED+*'T=->F)(6V--](L7]#-<N3N0
MWM/<>%0@+6V:9*H59MRS0*,26"><IQ?[>]8",9S%6]7:3:S%8[#4LXO'%+;0
MZ>*@=H&Y-]_EW>BG*-)%-T^DT/I")\\I%06"1<A7PN&L9S1G_R-U'(V&=0F.
ME67Q;$&KAF8]$<I8A9D6D.(/J][FI@J=$YN'\J;+HP([(N[4J#.B]K_7L?KO
M_-0_4_;C5_TBI[*RB=K\/P%-^U!?0R9$B ^)+-_B-K&$F8&BB;)1-772C$%H
M.VTQ*1PR^= !5%NBF6 .4U6Y5SI?2"6"7)XI>K:JI-QI"$I@7G',O*[(\[>K
MXLS]P4EIIUEL\*:Y'(L;75%VN*>JAUA-%N@-W!9.SD,=YJMI.<AQ]BO.0[XN
M%+Q54@N1>/-I\H"8[P=/-<6>;>4T]E(Y"&V#3'E+)A[M0;6:3L>I68EB&6=6
MX] )%Y?,P1+Z159#DX1%8F3G$&NYT5A-.VS\6G^3W.>17L*$:*.AP<(< Z4Q
M5BJ[PG!J; 8#2LB2-RP0R:9"2',ACVJA+29\>#T,9U11Y!^B;@WN]#DJ]WY2
M?2K9FT_%O<'ARK#X1PFAH_;=+3:J%W[[^KD[OYFZ>^&POH2QB"/5>I*0+HTA
M#;P2W1%B"!91)4@Q5)_> 167;X5$LU*/%(T@CVN'>2J'I% VPQPMR?>G9MR/
MDS,*E<'4@@A3*=4YG%/;SEO0T,.E^RO,<?>4DZK,56'GAN! LI=V4:>0A\!/
M*6TW4%XU,;%=EQ$[\:;X\J7ZVXS/N'X(\!78$@MPZT?=:4*K<;E D@EI;M2>
M5$;Y18&+POCS;I*DP^I4L0L0JJE9Y3:86QXW4\F_1+/SA^\ YC:6@&NBV\.U
M >LT@B(%>I ^,J*.O8#$Y$'Q2[BKT2!M&(!U>SFY06 ;YAZLO\&CL#@E1[N3
M14(CCD+GT+6%94=LQ$. $+/1T(IP*KL&*L#MT(8HX*!4Y/N:YN))2JKU< 3O
M(O%2\(0U6:*+CI_KJM%M)'KA^3RH3?53XS\M!Y-0@9IUN26IEK,_(#IIE^6*
MEJC;<>>K1YM4@;6_5B7 P^YJ9R@D<[^?^;T'1SG'SU%,WTJ+$>5W!\=H9GA(
MBA(&:X=PNZ#MX*\*^;B+)YHK9=L3KR''EHQ/RC29COT3CMZR L+H>5T<:4F*
M<*,UR$D360%O24U[B(V$6-'MUH^OB]%G5[V62X]KA;C-<XV!4HPD"%\=UN[0
M5XE7O9/OS\*,-? DAE:J644?7QMQ6RF<DDX>M5<4=4*W393X8E>23^" L*;L
M:,_'C-;MA(&RJT]8UUBW7?M^[J5:S2R%E'?AQM?::\I4_44D-F.";4.:FB;:
M9?^=:)/R;=;'B8YXL05W*U8M,E"RB%7$*]A^55,.H6F'%HA-.,FP-:C<)W[:
MESS-6,T-[/;BY_"HI#G<;Z"$";;KJ6 U>JT=IO LN"N!M7(35_P)6(=*GD%F
M_DN:_W.C(2%8!>6ZV/9RG54]=X-C8FO"GG.],AU_C_HUMN:5O%7ZPZ#V[*/O
M+U+H>#AFH.#K^=F"Q<0ZN-T.,U:'XNZL7&+SO]^["R\3RTB[)54+^(AJ$?JF
M6DT'V\6.G*"IYG1\-<O*_XC^ICY;J5@$QX7!R9PK!DI('V,D42L,\.53$S=Q
M^)]WXX&6.?75@0_?S9UJ6%2B=M[X(7#HXRM1\%IVY:,AKY#MG[$_9IYXX68_
M5WX]PS;T?.9DBOQ8U[7MXUO<-T]$]CP0!=!WM@Y\?!X2<RQRML>KK%87F<D,
M"UF_MF: %OSHQA?-_0XAESBGD,3==^S/A-B6?.)U=<F%^)YC+(DBG[:(\ #!
M^['9=H$+H*O9%],*BT_)=F-"B<+V'<\+O7$O7?4ZY1 JR_-(G;8&R;I#/=,/
MO>B+X^1(KN@'#^'JDGU#7G7!>UK#Z)/)=>JIM92*@K4482[\)6LX@C7LKF)W
M&B@+$XXV'W-9#H2ZKP@YW)A<S[A:&SUQ=D@>*J7)8\GF(98PT^![D6V\M*>L
M2^DLBT:A]<CK/?#JFKS4J?T#:5&'UE:*!>_7__?@#_A6''@;=HJ4G-#.B#57
MU62N*]G=WP*IH46<K)"&P52:59SOB__(S]97))YG5%J^%-P?<WPH2#ES_%Y\
MD_;#L")<YEW7O[G-O3*QYW-R[[+]5ZM81H"]$V5?_*],]0DG4'+6*C[:&15F
M>T7Y2,1.W:E/CPPGW7G7['(U*?9._%G[B;_;8F,235K<.\[<58N3NPV4$ZSA
M(9*/1*,-NJ]!9%L*)X8\, 4,6U"FHA:EP=3QN2LE*K9C'&\#9BJA6R6,NF',
M2QYW6)8)\.([Y"*VD;G\\Y] T>D5V"FABFX.V!*7E?VBFZ[M#(LGZ-M!KP.F
M1MAA5:@$OD);U!*#\M4DRY*'@Z82=#@O_"")]D*#"E.?)\5(1E?VT+_?H(W(
MSN[U3[8;]"N,S,.?UCJ]\A!.QC:U/FDJAY;HKY,+AH;I6E?T29-R>CA829,@
MEWQ]"N@>;#R<GO7Q&_] C7EKP(Q#[TF,7^2]1T1WX#3I+-,R#XU(,, _UJ]&
M]<7Z04%%=79173+O3L6%A>Y7>QC+.=2.T948\[+_5@U[ <CJ+#>]QLSM$COT
M^.^I3!"O1+GRQL/,ZIWJFXN[M)G!DK_'OQXY%EPCK8V,"/CSZ(=?DU>%5;D/
M'3 *XZWM68G1<UIVJG[]<;$SO'V@<4]$V._U#R+JLCLO%Z_:IMF\//Q7CN1V
MFDG@O:U.WQ\PU4"XE9\V&9N=5) Z]SNP/([5!F-/2G3;N7M[;V%ONR;@?)>E
M@UQG4D4C>[U($?>1L$TFHNVQ1265$[[S:>:,>=S-8 ]:&]3[OE''.='K[Q";
M<G))X].\IM<T9P/EU(]<%OJ\H]3A&2UO-$!_S?_<.<W484T@1Z--Z&-8@<2.
MZ"W@Q_3*A!N^E?BV/H8K[D/R@T3F$LEY/>V!J#:4=8GM^]DS3GK/;0,CX0W]
M7L%.KQB/*BY =I#RB@(-F;[$:H GRW3+N!$8OYV=YT 3-;(>Y[:]MNEDK-7?
M:0G2"/-I#HQ/6!.,^40_-MLFR'&$._UJ92"6/G^,YX;!A1^30E4U[2],GSDF
M35K<**?7#]$G8YZRHL 'LB89^GR20Y_#C?!D#^JN'&J'7SUFRH,EOO87U;("
MUF-26*'+ FI+C(%B*RCRHKMPDF5AN?O0XNJ2 NX2_T#52' 2W.98&/DJH=RI
MOR6P>BQ4[-R?]M70:=+>WKU%;9LN1- ]5/F0]@4(N8];DNUY$6[[@K><&PZ^
M/,T-@&^_@QL<)G]&6=J] P^)56!7&H(V=2CR7.CB?L(?"([U>UGR^O9A9TM4
M@IRYDK9I2ZG:+]:Q^J&HHM!CI=1-)<"=?M8M"XOG.0S"<4QG[C=@!BMKC_!W
ML4 5';)/N#LPVF22"J9PU]:7CJJ?*VO:#)2+K/HG0I2E,FV?SFYRO-XJ+6H)
MN1-'+&O%? K%:SC\+I:5M\+NC_'1%59C!HKX(]E).YO(5B+,:E21Y]XSS+D^
MX%>=-^@[V,L]J$(6X^'Z<BA!)D]1U711:>!P%[&\'@LJ:G'##JL#2CHS9(NY
MD>ALOG>KY_ZG+?6@+%T]^%AG^2!B@_S8@0HJ@RQ*"MSFPK/B_<9SO0$5DSG;
MBW6%$:#_SPRGD3[LI+T#:C&VVD<ZH8,O23I\SBLD(9[M-#/"$]1T,ASUU\5T
MW*[7BVV!0X,SU(OE#NA0CG_([7?E=IA/MG]0TIIZ-<L80+,G"BAX4JX$=D1B
MX1&6ME)_NR529\S]2E]/II^L*-3E*FJNS0)4S%S+&O"F748:'N:C'R3EM$+M
MUV5D9&).T72,1/B3PR&@^CA&4Y<4K@:'D]1"8YS9+W;K5",.X/Y(5-]4RSH5
M^SL#)9$^?%C[0=_"<WT'-=*?48>A9Q :#,MKE&E=U6EHEE9.NJ%:%=S!E+,[
M(QSC&"M%A60R%R_@O91#7=1+Y5O 04W&W=0 5U:6)DAJH#B-P8M2IQ(/#^*N
MJ*S3]W;_1YUBS)$$=92LH _P4P45(#%,6SP9I&=H;KIK^\$T3.J!]F\R1/<=
M>0*J=?O>T9Z4M+W8#%\N]P$P]HTFC,^\(OT<&*F3UDSL!7[H"4D@2I,P%W&]
M?^J9@1=PC"5'HZ&!Y)DKQBJDG08^HY%L/M^?IMLJPZ2$&79GPL6EF\M405:\
M/T8W#2!Q;+FY9B@_:7H#OJ/<"617X\9#C&7<5>!X-;[G<3_;*V![,+P$WP>R
ME0&K3X=DRW+P,U_F. E&%R1Y>%0]+1V5CXY&ZK*?BF\LB2D('FD4/:F/+&LJ
M/O(PV?ZWER]?G/JAY=)@K_R/3PL67-UPP/3O/53<IH$P[\1,M9X@16<?CA_3
M_TBRDL"2NP&K+BEBK,,3L-"I%;K=1*^"AIP6%F@A:P-%E0@DZD_JL'G/VUB+
M9EC9B EO-;YS<(;M)+PXJ&45F)VY/<8P&_(.IBYX/1&BICYIB23U#R->T!IO
MU"EI^08*>H O-R6#4!,<!U/'RC?TM<1C/AVP0TL@FMCFLK:O)47UE+J(PV]S
M60#<T.]T.U#^,\7E@F\G',[#%W@.K+C9TC)0T_$IOA.+[=C]7KW%0.FVM#7"
M?^>D$Y;7P)Y8=$@I;*=:D?03!"NKR  XV:KYBZ3.28D2RD9L>.;X4C2W#;$*
M [5A6$ZVIM#9O!TQWGAKD/".;Q[*QZ/2?;K*[GGXAP=("V9&"A=\S$5^6DQ<
M)7YAH?M9>;1Z09=E1B3J,X7IPK@']&7^(?'W 3]27TH&KIMDAEOF[1&HB6ZM
MB3L?W8KM9<KI4D<3 Z7KN8?GL<PULYURH233Z5AOR]84C,8:Y!XJ^72LI,EE
M2=G,X@+*VHK_ZX5X0\DC3+ N]A(W"JW5O)VDUN)>0**B4H832].GC'7FW'"^
M)-J<=:5\:>GX\R/U&/1,<.4,Y_2_3R9X_F-?RQ.B'7J]A'G1Z^!+YP>N-)U\
M,.%X,J=.E>^!?VGTT6UJG8X9CE,PA\D7I%78BT8I.I "F@B:LE9!%P54W+J&
M4R8AEI3+=A221-@A*T;LO0M?)(?>Q-U1IC+T F\%OJVUOM>KE33(G=%N?5PG
M='3X8Z3"93AQCM4_@S_"22]TJ9%KIG\(*V\A)'_'([:XD?YG8BEWG;[DWT=-
MR^#V=143__X1(&45E2_O(=;P!B%'KQ?FT=B5>@/%@J]BR=<\ES@>X5]"3E*M
M.)X[^UO.W(O;Q*R-YNY#F\/"0$.[RZ;>5/Z(</@YL7"K;C4Q,.K3#,Z@H9VP
MK8B^-").VK%YC 'I?X 3F)>LQ44>4\F=^H>UF$0ID]QTG',3(?4_Y9\6F>>?
MRM&^W%V9UGSA%Z/9U;QMW(,8J\-  6MKI(H\UF/%,S+*K %^.B?>2Y=5I#VG
M:W\'_Z"""'$WSX-[!G3?^'8\E%4_-*G'_'9]R\\Y;RHI.W<Z5O^0L9[SS5O"
MGO'C_?&YH&?LW!+" CO-LB&IGWK70%%6*AI]BJ"3K%=L[0TP@;X9'=2HT[.(
M9='QBH57*N.=B:OQ6(ST_(TR=%IUME;XZC>ALR*GD4T##9+2IORD_YQ(^N3Y
MP:+KKW_B(&3C*NE@-7_R7R:. X&5$X@S$D>UB:2W"8=S50&=,T)\@X$BK]$6
M#-2ET1RXVTEE<#M2>&+,UWDV/XWJ0/0HGIA*W<&J/JZ-:D3F O[^VSFVHVG4
M!97F7?!G:G?I;\"G#)0<!#TD*/B.^!5J>-L.7T 6P">$PZZ?DP8F]#YW TBK
M -[BU=QO]!7X852AS</H67B,VMDS1-3?<JX.7P@"T#XE5 2KEF/VU0\3&A)8
M(E;>7ZW]-4,;_;>Y$D.A'TIT?KP1LCT>L8H8#.(WET_U?.0T(B\D[. .2Y\P
M(-/%$[\HC+E!NMWAW'3]$\(+9Z#,*7?=_G PJQ)(ZA93[7";7$D]_C5(J>'2
M>J<CI2X.32 V\;C2%+N1#Z/O9=O%Z#U(V0!9(<K;+%'NY#7=%N(W\M@0:XGG
MY>;H6]PV6 *;(0DB@&"N*I^+<&)D:ZR2=H'PYF9@;]MJ]#>Y9!;/=[Q3C-(Z
MUJ&TPRC< 1<0*["S/\9K(FNI2[@NZ-F+]\<'&1ZM/9]#]TO7"F]ZT4@K\\V_
MG*J&AQW:!?;^/FJAW/W9*.6:.IW/<P3'TYC6T5P&>FG"UR6;3>^PS"#S;8N;
MDF6=4")V[=WH13,&3=$].%OM;'\.WW,;I!] M8*[XS<NT';V1*=@D1IJ._.B
MBUD_;S7W:U")3BL5DILN;X,?#^ P=KA+[ 0RE77KIR/[DQHS'8<.8<S"- _7
MP/J?!M(21P(\]Q>,S[FU(LU-C4WA;J6?C2@-E#P6&D$#JYHDEC[[![A,TELL
MU?/I23-,JW>C2YN>H&Y2F((?&5#UB\9:"LUO,C\'K = &M7##;!1A[ ZY5TW
M8U1,:J1=R]!,W>:>&R>,YI*BS]P#LT?ZB VDY%9!B_"D>^_$9/WX^,F[W"/U
MC7UEJNFL&;K)A(":6NSVC'!M+3M8^ 6_DQ?P!'M87\<Y-"K=U])X;1]J6E"%
M-#=^Y[?JIX^[JZ]P*DN7+@X[5;RZ(.SF5U?"_CPPMNJ;%5^EIJVXVG_]Y(KO
MO]TF7**_)5[./0J.HT_#L)HV]H72MU.;-%.>A] _["%3KB=FK'I+IBA0&#S@
M'W@GGK<"Z2%S>F0XJKCP90O:E7L.5K,G%5:<PD!^1-:>LKV/^@]_\?1QSI?4
MA IDQ7*2YQZ!WX8..886D(>:]"]H*,T\>%Y'Z94:TTD,C96*:4^:$PLS@J[(
M#H 8W6[P<C:TR>:%J_1<3?SA7:>3_D)^"@ZSR#!0Z$@\"]"I75"1@=*8VXX,
ML[4.^IM(,C/[$=<;*[G (Z=JVT:2"D*836$2=2B9AB\@YALKV$Z<1.6H0+<U
M'J'B\6H/IRY:(Y23^N.DUW1>]&<]7C U;M1FZ/2,\)-QG_0AAU$W]'/3F7,[
M>8=HP$. V^3T1<&DYJH5G8+<N:K0T+,V?!))?=.4$,W:+^H_O28QHW7S;"2X
MK?,#03L>]ZMNKK[8.-*ZW>E-J?D/O:89\1UP[:;FO?FK3KMLM8YRWG_DZK.3
M)P,DZ^:[*+N-:S]X:H*FPG5'P5L-OP,:EI'N!TU4EG2P;0F9EK"YIN4#B>X@
MOAW<1FN5<)9_C*9UH:3+Q0J8*\V1',2,9-Y<-:MKJYB6T.S6(<PK/EWJELVS
MYGAV019?#="Y1]3TO#,<6(*<Q;\$E2K9)6BA>"5^',LL*?"F+<0_15EY>+K:
MG6K"B3R&(87)']D6\:$1XMMLU;092'YIH$0.B<(]ZE9%!IN;AYY;M:*:XS$8
MKB8R8&4IA!Z6#5]K4SPVS79#I=FDA@GD)=J?P41*'6^(UN@@40RG:[?J*_S/
MW1U'G) $>(F !OB27CP,05TNZOS&YGPD)EAL+F']3KP9*^E"%G*,F> <*;CM
MC^43I>P<UYY*"DU(JQ^:$E"G?&I)+0DA<W[V7-,SFOR:-A)C9K>LUNW@F@UP
M#U:!N>>2(+5I+K50O!207FRV(W-A7W ?L9+K2L+^161NH,P#CZ<EHQ:85Y.C
M0UXCVPY0VWW?%*;=&?K#[I]BG0ENIJ_Z$@AU^W@C"I'VZBU\"U#IPL)PDJVR
M=5LY01V^K**/S&%$"3V+XRT/1F4JD@6(Y7$)7NP\A;TH*D4MY',CL<#.B&5S
MN9<]9FZ>&)&,FK2624KWA8:V3'=2P5K33D4!RYZWEO>"AH9 %\N7ZJMYZ[A+
M,5N27L7^1#=BSTVYR]VD+X1B:?FQDMFY*@/%$M^CD2WBP%TNOF ,JVR;7<P)
M%R_';8&[JNR:,H.]>&1,L)BQADS 7U!O?4L=:';_YREYYKXA#\,!)(&?3WMB
M_U2WD1@4,_0_\-Q 5A>KT6'J-4J7B)?HRW$'-35'[ _LZH@.QLJ>)%?2;I*9
MID$-=[ 7(^U\?K1U_[1_H/)U4(=E32)A,7 "/7LMI8Y#]*F]0@EKXNI_/R;Z
MOUW&?P=IK8%)"NJDG2.7(GX1BX9&@10EJQAQ)&WT-)],OAGV^2FQZ*PZU24
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M/R/,:\R,W=.G]_U_>MW_E<O8,/P_ %!+ 0(4 Q0    ( 'V#;%J6(A7QDP4
M &P&   3              "  0    !C8FA?;&]G;RUF;V]T97(N:G!G4$L!
M A0#%     @ ?8-L6D2H/:7:*   ,2H  !,              ( !Q 4  &-B
M:%]L;V=O+6AE861E<BYJ<&=02P$"% ,4    " !]@VQ:=&&ZD34?   ;(0
M$0              @ '/+@  8V)H7W-I9VYA='5R92YJ<&=02P$"% ,4
M" !]@VQ:B(GRFN8<  "WB0  "P              @ $S3@  97A?,3 M-2YH
M=&U02P$"% ,4    " !]@VQ:7(]:9$\7  ""=@  "P              @ %"
M:P  97A?,3 M-BYH=&U02P$"% ,4    " !]@VQ:/0>BHYD#  #:#@  "P
M            @ &Z@@  97A?,3 M-RYH=&U02P$"% ,4    " !]@VQ:.OSD
M\]L:   9A@  "0              @ %\A@  97A?,3DN:'1M4$L! A0#%
M  @ ?8-L6DS_1#)W @  Z0L   L              ( !?J$  &5X7S(S+3$N
M:'1M4$L! A0#%     @ ?8-L6H11<I/  @  H@D   L              ( !
M'J0  &5X7S(S+3(N:'1M4$L! A0#%     @ ?8-L6DQ_-[V7!@  HQH   L
M             ( !!Z<  &5X7S,Q+3$N:'1M4$L! A0#%     @ ?8-L6N1\
M>%".!@  HQH   L              ( !QZT  &5X7S,Q+3(N:'1M4$L! A0#
M%     @ ?8-L6M#B:^J% P  =@H   L              ( !?K0  &5X7S,R
M+3$N:'1M4$L! A0#%     @ ?8-L6N:TV/>! P  A H   L
M ( !++@  &5X7S,R+3(N:'1M4$L! A0#%     @ ?8-L6FLE<G0&%P  %7@
M  D              ( !UKL  &5X7SDW+FAT;5!+ 0(4 Q0    ( 'V#;%I%
M R-8^[@! %0,"P -              "  0/3  !F;W)M7S$P+6LN:'1M4$L!
M A0#%     @ ?8-L6FJ,T=!9$0  5[0  !$              ( !*8P" &MR
M;60M,C R-#$R,S$N>'-D4$L! A0#%     @ ?8-L6IA6>;HD$@  B\$  !4
M             ( !L9T" &MR;60M,C R-#$R,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( 'V#;%H@-$J%71\  (SN 0 5              "  0BP @!K<FUD+3(P
M,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !]@VQ:-@:)=5=D  !\W@4 %0
M            @ &8SP( :W)M9"TR,#(T,3(S,5]L86(N>&UL4$L! A0#%
M  @ ?8-L6C5X756&10  .WP$ !4              ( !(C0# &MR;60M,C R
M-#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( 'V#;%I<@HJZP8\  $F5   7
M          "  =MY P!M;7%?;&]G;RUH96%D97(R,#(S+FIP9U!+ 0(4 Q0
M   ( 'V#;%I<V31<PS$  /HT   5              "  =$)! !M;7%?<VEG
D;F%T=7)E,C R,RYJ<&=02P4&     !8 %@ ^!0  QSL$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>form_10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krmd="http://korumedical.com/20241231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krmd-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">krmd:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EquipmentAndToolingMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EquipmentAndToolingMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:EquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krmd:ManufacturingEquipmentAndToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OmnibusEquityIncentivePlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:OmnibusEquityIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OmnibusEquityIncentivePlan2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:OmnibusEquityIncentivePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OmnibusEquityIncentivePlan2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:OmnibusEquityIncentivePlan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">krmd:NonEmployeeDirectorAndBoardAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StockOptionPlans2015And2021CombinedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krmd:StockOptionPlans2015And2021CombinedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TimeVestingStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TimeVestingStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TimeVestingStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:TimeVestingStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">krmd:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PerformanceVestingStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PerformanceVestingStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:PerformanceVestingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krmd:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-08_custom_DomesticBankLenderMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:DomesticBankLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="AsOf2024-03-08_custom_DomesticBankLenderMember_custom_TermLoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">krmd:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:DomesticBankLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="From2024-03-082025-03-08_custom_DomesticBankLenderMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:DomesticBankLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2025-03-08</endDate>
        </period>
    </context>
    <context id="From2024-03-082025-03-08_custom_DomesticBankLenderMember_custom_TermLoanFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">krmd:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">krmd:DomesticBankLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2025-03-08</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:SecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SecurityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krmd:SecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">krmd:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-09-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000704440</identifier>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="N">
        <measure>krmd:Number</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000005">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000006">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000007">0000704440</dei:EntityCentralIndexKey>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForOtherTaxes
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="xdx2ixbrl0453"
      unitRef="N">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember_srt_MinimumMember"
      id="xdx2ixbrl0465">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_PatentsAndTrademarksMember_srt_MaximumMember"
      id="xdx2ixbrl0467">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="xdx2ixbrl0492"
      unitRef="USD">7080843</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MinimumMember"
      id="xdx2ixbrl0498">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember_srt_MaximumMember"
      id="xdx2ixbrl0500">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_EquipmentAndToolingMember_srt_MinimumMember"
      id="xdx2ixbrl0502">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_custom_EquipmentAndToolingMember_srt_MaximumMember"
      id="xdx2ixbrl0504">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="xdx2ixbrl0564"
      unitRef="USD">2803669</us-gaap:InventoryNet>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      id="xdx2ixbrl0627">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member"
      id="xdx2ixbrl0673">P7Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2024-12-31" id="xdx2ixbrl0791">P5Y1M6D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2023-12-31" id="xdx2ixbrl0793">P6Y10M25D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2024-12-31" id="xdx2ixbrl0795">P2Y8M12D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2023-12-31" id="xdx2ixbrl0797">P3Y8M12D</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <krmd:FinanceLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0856"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0857"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0860"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0862"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0874"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0877"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0878"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0880"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:DeferredTaxAssetsDeferredLeaseLiability
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0905"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0937"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0938"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0957"
      unitRef="USD"
      xsi:nil="true"/>
    <krmd:IncomeTaxReconciliationDeferredTaxTrueUps
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0963"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000014">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000015">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000016">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000018">0-12305</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000019">KORU MEDICAL SYSTEMS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">13-3044880</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000022">100 Corporate Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000023">Mahwah</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000024">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000025">07430</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">845</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000027">469-2042</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000028">common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000029">KRMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000031">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000032">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000037">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000038">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000039">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000040"
      unitRef="USD">83518701</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-12"
      decimals="INF"
      id="Fact000041"
      unitRef="Shares">45957115</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-03-12"
      decimals="INF"
      id="Fact000042"
      unitRef="Shares">3438526</us-gaap:TreasuryStockCommonShares>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000043">677</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000044">Cherry Bekaert LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000045">Tampa, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">9580947</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">11482240</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">5720750</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">4045211</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">2803669</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">3481301</us-gaap:InventoryNet>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">277193</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">28889</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">749851</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">1218288</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">19132410</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">20255929</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">4290515</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">3837657</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">458538</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">390341</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">730279</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">754361</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">2966341</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">3514055</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">98970</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">98970</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">27218515</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">28460972</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">1649969</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">975193</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">3924184</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">1711427</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">271152</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">314344</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">29269</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">512520</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">811401</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">462941</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">115587</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">109540</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">400258</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">368313</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">7201820</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">4454278</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">202613</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">316623</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">3000403</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">3336300</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">10404836</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">8107201</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000138"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000140"
      unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">49377617</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">49089864</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000144"
      unitRef="Shares">45957115</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">45669362</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">493776</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">490899</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">49581303</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">47018707</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">3438526</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:TreasuryStockPreferredShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000155"
      unitRef="Shares">3420502</us-gaap:TreasuryStockPreferredShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">3882494</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">3843562</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000157"
      unitRef="USD">-29378906</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">-23312273</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">16813679</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">20353771</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">27218515</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000164"
      unitRef="USD">28460972</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">33646463</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">28517666</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">12314605</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">11809384</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">21331858</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">16708282</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">21631674</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">20365617</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">5257942</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">5742254</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">888473</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">870390</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">27778089</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">26978261</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-6446231</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">-10269979</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-45991</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">-5124</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">-16160</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">-59807</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">444642</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">561328</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">382491</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">496397</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-6063740</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-9773582</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">2893</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">3967480</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-6066633</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000220"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000221"
      unitRef="USDPShares">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000223"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000224"
      unitRef="USDPShares">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000229"
      unitRef="Shares">45802701</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000230"
      unitRef="Shares">45601346</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">45802701</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000233"
      unitRef="Shares">45601346</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000241"
      unitRef="Shares">48861891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">488619</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000236"
      unitRef="USD">44252117</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-9571211</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">31325963</us-gaap:StockholdersEquity>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">127973</krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">1280</krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000244"
      unitRef="USD">445069</krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">446349</krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000252"
      unitRef="USD">1940720</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000255"
      unitRef="USD">1940720</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000263"
      unitRef="Shares">100000</krmd:AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">380801</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">381801</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000275"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">49089864</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">490899</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">47018707</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-23312273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-3843562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000281"
      unitRef="USD">20353771</us-gaap:StockholdersEquity>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">191946</krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquityShares>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">1919</krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">452909</krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity>
    <krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000289"
      unitRef="USD">454828</krmd:StockCompensationShareBasedPaymentArrangementLiabilitySettledInEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">1509544</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">1509544</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <krmd:AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000305"
      unitRef="Shares">55061</krmd:AdjustmentsToAdditionalPaidInCapitalStockSharesIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">551</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">567369</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">-38932</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">528988</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <krmd:StockIssuedDuringPeriodSharesUponOptionExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000313"
      unitRef="Shares">40746</krmd:StockIssuedDuringPeriodSharesUponOptionExercised>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">407</krmd:StockIssuedDuringPeriodUponOptionExercised>
    <krmd:StockIssuedDuringPeriodUponOptionExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000311"
      unitRef="USD">407</krmd:StockIssuedDuringPeriodUponOptionExercised>
    <krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">-58447</krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards>
    <krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-58447</krmd:PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000322"
      unitRef="USD">91221</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">91221</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-6066633</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000331"
      unitRef="USD">-6066633</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000339"
      unitRef="Shares">49377617</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">493776</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">49581303</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">-29378906</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">-3882494</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">16813679</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">-6066633</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000345"
      unitRef="USD">-13741062</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000350"
      unitRef="USD">2623920</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000351"
      unitRef="USD">2768870</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">888473</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000354"
      unitRef="USD">870390</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">-16160</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-59807</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000360"
      unitRef="USD">3967480</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <krmd:NoncashLeaseAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">243394</krmd:NoncashLeaseAdjustments>
    <krmd:NoncashLeaseAdjustments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-21988</krmd:NoncashLeaseAdjustments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000368"
      unitRef="USD">1675540</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000369"
      unitRef="USD">486327</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000371"
      unitRef="USD">-677632</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000372"
      unitRef="USD">-2923566</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-943507</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">-220133</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">-242599</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000380"
      unitRef="USD">674776</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">-1416606</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000383"
      unitRef="USD">348460</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000384"
      unitRef="USD">-79458</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000386"
      unitRef="USD">-483250</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000387"
      unitRef="USD">255183</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000389"
      unitRef="USD">2212757</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">-1178514</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000392"
      unitRef="USD">-319718</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-4892553</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">1297427</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000399"
      unitRef="USD">782949</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000401"
      unitRef="USD">8500</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">44115</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">31648</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000407"
      unitRef="USD">-1333042</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">-814597</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <krmd:BorrowingsFromIndebtedness
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">487516</krmd:BorrowingsFromIndebtedness>
    <krmd:BorrowingsFromIndebtedness
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">565172</krmd:BorrowingsFromIndebtedness>
    <krmd:PaymentsOnIndebtedness
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">530707</krmd:PaymentsOnIndebtedness>
    <krmd:PaymentsOnIndebtedness
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000417"
      unitRef="USD">684123</krmd:PaymentsOnIndebtedness>
    <us-gaap:PaymentsForOtherTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000419"
      unitRef="USD">97379</us-gaap:PaymentsForOtherTaxes>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000422"
      unitRef="USD">107963</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">99916</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000425"
      unitRef="USD">-248533</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-218867</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000428"
      unitRef="USD">-1901293</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">-5926017</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000431"
      unitRef="USD">11482240</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">17408257</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000434"
      unitRef="USD">9580947</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">11482240</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">71934</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">50832</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">3160</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000449">&lt;p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zE6OBrRPhpjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_829_zJm2vJrCg8qh"&gt;NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NatureOfOperations_zIjNYMYmOIyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_861_zPEmyeNaHM82"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;KORU MEDICAL SYSTEMS, INC. (the &#x201c;Company,&#x201d; &#x201c;KORU Medical,&#x201d;
&#x201c;KORU,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#x201c;FDA&#x201d;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20241231_z9Agcpgdz5L3" title="Number of segment::XDX::1"&gt;one&lt;/span&gt; segment.&lt;/p&gt;

&lt;p id="xdx_856_zkmHf5d6gWia" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zXI2Uody1Zmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zF8Mklpghykf"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &#160;Certain
liability balances within the accompanying December 31, 2023 balance sheet have been reclassified to conform to current period presentation.
There were no changes to the Company&#x2019;s results of operations as a result of the reclassification.&lt;/p&gt;

&lt;p id="xdx_852_z5V4AxgymMwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPMBUvrY36ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86C_zEwql3bDypEd"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;As of December
31, 2024 the Company held cash and cash-equivalents of $&lt;span id="xdx_902_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20241231_zA7VaEMmx5a5" title="Investment securities treasury bill"&gt;9.6&lt;/span&gt; million, the majority of which was held in a secured US-treasury money market
mutual fund.&lt;/p&gt;

&lt;p id="xdx_851_zxPBRBMqpZn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zhTKv9KfM2ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zLCvUJtAaI5k"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.&lt;/p&gt;

&lt;p id="xdx_854_ztiAij2XIY6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFuMhSKxU9eb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86F_z7BkJOfGVajg"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_za08LPcqfXFa" title="Estimated useful lives::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0465"&gt;6&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zCPUt66Qym8f" title="Estimated useful lives::XDX::P20Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0467"&gt;20&lt;/span&gt;&lt;/span&gt; years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_904_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20240101__20241231_zr2imeJVZbW4" title="Amortization expense of intangible assets"&gt;68,197&lt;/span&gt; and
$&lt;span id="xdx_90F_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20230101__20231231_zbHzPE1Q4Ca4" title="Amortization expense of intangible assets"&gt;64,469&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zlKNDwImuqD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BD_z4bie2HRZKcl"&gt;The estimated amortization expense for the succeeding years for the intangible
assets is approximately:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20241231_zEiqJoSjF1A8" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zxe0WBrGvaWl" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 68%"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 4%"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 24%; text-align: right"&gt;66,766&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEB0xT345B19" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;2026&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;65,969&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_znbomvaqq1J5" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;65,620&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zGkaPxMQjcj4" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;65,620&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_z8B0JiWwcTt3" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2029&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;59,644&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zsaAdOylyFh7" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;406,660&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zWurP3il377b" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;730,279&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zC0wOOf9B20f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_853_zSMzeSVnJ7s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;





&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zTTCQ9fSGV86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_z9SkIaTMXpW"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company accounts for deferred income taxes using the asset and liability
method. Under this method, deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and
their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Temporary differences
are then measured using the enacted tax rates and laws. Determining the appropriate amount of valuation allowance requires management
exercise judgement about future operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes. After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence, we have
a recorded valuation allowance of $&lt;span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dxL_c20241231_ze1iPjfdHWS1" title="Valuation allowance::XDX::7080843"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0492"&gt;7.1&lt;/span&gt;&lt;/span&gt; million against our net deferred tax assets as of the year ended December 31, 2024. As we continue
to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction
of the valuation allowance in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of &lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zdwN7sWFQ5wa" title="Statutory rate"&gt;21&lt;/span&gt;%, including U.S. federal R&amp;amp;D credits, U.S. state tax rates, stock-based compensation and changes in our valuation
allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We account for uncertain tax positions in accordance with authoritative
guidance which prescribes a minimum recognition threshold a tax position is required to meet before being recognized in the financial
statements. Our evaluations of tax positions consider various factors including, but not limited to, changes in tax law, the measurement
of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained
during in-process audit activities and changes in facts or circumstances related to a tax position. We accrue interest and penalties related
to unrecognized tax benefits as a component of income tax expense recorded in continuing operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2021 are no longer subject to examination by tax authorities.&#160;&lt;/p&gt;

&lt;p id="xdx_85C_zLzzV10P8xx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKAkrqmhtghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zMd54PBkEcgb"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziwyiynIzVcl" title="Estimated useful lives of property and equipment::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0498"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zV27rsSADj18" title="Estimated useful lives of property and equipment::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0500"&gt;10&lt;/span&gt;&lt;/span&gt; years for furniture
and office equipment, &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MinimumMember_zY1pIaZnUv55" title="Estimated useful lives of property and equipment::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0502"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MaximumMember_zdCfLRbC0TG5" title="Estimated useful lives of property and equipment::XDX::P12Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0504"&gt;12&lt;/span&gt;&lt;/span&gt; years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2024
and 2023 was $&lt;span id="xdx_900_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20240101__20241231_zUHezZUXtQmh" title="Depreciation and amortization, property and equipment"&gt;704,690&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20230101__20231231_zBuvLy7atMcl" title="Depreciation and amortization, property and equipment"&gt;805,921&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p id="xdx_854_z5VZBtLJoxSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzHwS4V0OxCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zwEKGtyX6Hrk"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are recognized as compensation expense at their grant date fair value. &#160;The entire compensation expense
of the award is recognized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of restricted stock awards with
time-based vesting were estimated on the date of grant at the current stock price. The fair value of restricted stock awards vesting at
certain annual sales growth thresholds were estimated as of the date of Board acknowledgement of the achievement, at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.&lt;/p&gt;

&lt;p id="xdx_858_zVEdXzkY4aX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_za5euHsSBPii" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zaH4ZQWzPnIl"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.&lt;/p&gt;

&lt;p id="xdx_853_zH9cboNB18sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zoxRGXqDzNff" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86F_z0NOhPwujbR4"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#x201c;Product Revenue&#x201d;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#x201c;PIDD&#x201d;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#x201c;CIDP&#x201d;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#x201c;NRE&#x201d;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs are included as a component of cost of goods
sold in the accompanying statements of operations and are generally billed to customers, and included in Product Revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#x2019;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#x2019;s revenue recognition criteria described above. As of December 31, 2024, 2023, and 2022, the
Company has recognized a contract asset of $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20240101__20241231_zwc0JIF7EJw" title="Recognition of contract asset"&gt;222,623&lt;/span&gt;, $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20230101__20231231_zqNMfhOR4r8h" title="Recognition of contract asset"&gt;0&lt;/span&gt;, and $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220101__20221231_zniF0Iday9i8" title="Recognition of contract asset"&gt;0&lt;/span&gt;, respectively, which is included in other accounts receivable in the accompanying
balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfNetSalesByGeography_zGVwXFyhbU69" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_zFIXZoKbmR4l"&gt;The following table summarizes net revenues by geography for the years
ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__country--US_zSPYR2n8G7Tb" style="text-align: right" title="Net Revenue"&gt;27,506,682&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zoejEZjgXhV8" style="text-align: right" title="Net Revenue"&gt;23,676,039&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zUPdwmzFWczg" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;6,139,781&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zDXRR3HKO4Td" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,841,627&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--Revenues_c20240101__20241231_zbZwh9xqUJwe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;33,646,463&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231_zzXAhVOe69kj" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;28,517,666&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zr0V0PmSMAva" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_85A_zj9qVXV2hvVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9KnPXGgn3Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_868_zwPGs6ic3Pn2"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In November 2023 the FASB issued ASU 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures which expands disclosure requirements to require entities to disclose significant
segment expenses that are regularly provided to or easily computed from information regularly provided to the chief operating decision
maker. This update also requires all annual disclosures currently required by Topic 280 to be disclosed in interim periods. The new disclosure
requirements are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after
December 15, 2024. Early adoption is permitted. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have
be applied retrospectively to all prior periods presented in the financial statements. The adoption of this ASU did not have a significant
impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

&lt;p id="xdx_858_zQ45ollo4te9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z2T1YjTQiGhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zusmkpmyusWd"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2024.&lt;/p&gt;

&lt;p id="xdx_855_z0epJ816N1Pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8c7yIvtxlwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zoBBYZEYriXi"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2024.&lt;/p&gt;

&lt;p id="xdx_853_z242Ey0Ok9j3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2024-01-01to2024-12-31" id="Fact000451">&lt;p id="xdx_847_eus-gaap--NatureOfOperations_zIjNYMYmOIyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_861_zPEmyeNaHM82"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;KORU MEDICAL SYSTEMS, INC. (the &#x201c;Company,&#x201d; &#x201c;KORU Medical,&#x201d;
&#x201c;KORU,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) develops, manufactures and commercializes innovative and
patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United
States Food and Drug Administration (the &#x201c;FDA&#x201d;) quality and regulatory system and international standards for quality system
management. &#160;The Company operates as &lt;span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dxH_uN_c20240101__20241231_z9Agcpgdz5L3" title="Number of segment::XDX::1"&gt;one&lt;/span&gt; segment.&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000455">&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zXI2Uody1Zmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86E_zF8Mklpghykf"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We prepare our financial statements and accompanying
notes in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &#160;Certain
liability balances within the accompanying December 31, 2023 balance sheet have been reclassified to conform to current period presentation.
There were no changes to the Company&#x2019;s results of operations as a result of the reclassification.&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000457">&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPMBUvrY36ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86C_zEwql3bDypEd"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of the statements of cash flows, the
Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. &#160;As of December
31, 2024 the Company held cash and cash-equivalents of $&lt;span id="xdx_902_eus-gaap--InterestIncomeSecuritiesUSTreasury_dm_c20240101__20241231_zA7VaEMmx5a5" title="Investment securities treasury bill"&gt;9.6&lt;/span&gt; million, the majority of which was held in a secured US-treasury money market
mutual fund.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">9600</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000461">&lt;p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_zhTKv9KfM2ga" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86D_zLCvUJtAaI5k"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Inventories of raw materials are stated at the lower of standard cost,
which approximates average cost, or market value including allocable overhead. &#160;Work-in-process and finished goods are stated at
the lower of standard cost or market value and include direct labor and allocable overhead.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We maintain reserves for excess and obsolete inventory resulting from the
potential inability to sell certain products at prices in excess of current carrying costs. &#160;We make estimates regarding the future
recoverability of the costs of these products and record provisions based on historical experience, expiration of sterilization dates
and expected future trends. &#160;If actual product life cycles, product demand or acceptance of new product introductions are less favorable
than projected by management, additional inventory write downs may be required, which could unfavorably affect future operating results.&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000463">&lt;p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zFuMhSKxU9eb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86F_z7BkJOfGVajg"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain of our identifiable intangible assets, including patents and trademarks,
are amortized using the straight-line method over their estimated useful lives which range from &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MinimumMember_za08LPcqfXFa" title="Estimated useful lives::XDX::P6Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0465"&gt;6&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxL_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember__srt--RangeAxis__srt--MaximumMember_zCPUt66Qym8f" title="Estimated useful lives::XDX::P20Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0467"&gt;20&lt;/span&gt;&lt;/span&gt; years. &#160;All of our intangible
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be
recoverable. &#160;Our management is responsible for determining if impairment exists and considers various factors when making these
determinations. &#160;Amortization expense related to intangible assets for the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_904_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20240101__20241231_zr2imeJVZbW4" title="Amortization expense of intangible assets"&gt;68,197&lt;/span&gt; and
$&lt;span id="xdx_90F_ecustom--AmortizationOfIntangibleAssets1_uUSD_c20230101__20231231_zbHzPE1Q4Ca4" title="Amortization expense of intangible assets"&gt;64,469&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zlKNDwImuqD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BD_z4bie2HRZKcl"&gt;The estimated amortization expense for the succeeding years for the intangible
assets is approximately:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20241231_zEiqJoSjF1A8" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zxe0WBrGvaWl" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 68%"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 4%"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 24%; text-align: right"&gt;66,766&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEB0xT345B19" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;2026&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;65,969&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_znbomvaqq1J5" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;65,620&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zGkaPxMQjcj4" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;65,620&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_z8B0JiWwcTt3" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2029&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;59,644&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zsaAdOylyFh7" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;406,660&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zWurP3il377b" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;730,279&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zC0wOOf9B20f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <krmd:AmortizationOfIntangibleAssets1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000469"
      unitRef="USD">68197</krmd:AmortizationOfIntangibleAssets1>
    <krmd:AmortizationOfIntangibleAssets1
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">64469</krmd:AmortizationOfIntangibleAssets1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000473">&lt;p id="xdx_89C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zlKNDwImuqD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BD_z4bie2HRZKcl"&gt;The estimated amortization expense for the succeeding years for the intangible
assets is approximately:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_49C_20241231_zEiqJoSjF1A8" style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zxe0WBrGvaWl" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; width: 68%"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 4%"&gt;$&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 24%; text-align: right"&gt;66,766&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEB0xT345B19" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;2026&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;65,969&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_znbomvaqq1J5" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;65,620&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zGkaPxMQjcj4" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;65,620&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_z8B0JiWwcTt3" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2029&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;59,644&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zsaAdOylyFh7" style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"&gt;406,660&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_zWurP3il377b" style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total amortization expense&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"&gt;730,279&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000475"
      unitRef="USD">66766</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">65969</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000479"
      unitRef="USD">65620</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">65620</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">59644</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000485"
      unitRef="USD">406660</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000487"
      unitRef="USD">730279</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000490">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zTTCQ9fSGV86" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_862_z9SkIaTMXpW"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company accounts for deferred income taxes using the asset and liability
method. Under this method, deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and
their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Temporary differences
are then measured using the enacted tax rates and laws. Determining the appropriate amount of valuation allowance requires management
exercise judgement about future operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We evaluate our deferred tax assets to determine if they are more likely
than not to be realized by assessing both positive and negative evidence in accordance with ASC Topic 740, Income Taxes. After considering
our cumulative pretax loss (the three-year period ending with the current year), as well as analyzing all available evidence, we have
a recorded valuation allowance of $&lt;span id="xdx_909_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_dxL_c20241231_ze1iPjfdHWS1" title="Valuation allowance::XDX::7080843"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0492"&gt;7.1&lt;/span&gt;&lt;/span&gt; million against our net deferred tax assets as of the year ended December 31, 2024. As we continue
to assess the realizability of our deferred tax assets, reported pretax income and new evidence may result in a partial or full reduction
of the valuation allowance in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Recurring items cause our effective tax rate to differ from the U.S. federal
statutory rate of &lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zdwN7sWFQ5wa" title="Statutory rate"&gt;21&lt;/span&gt;%, including U.S. federal R&amp;amp;D credits, U.S. state tax rates, stock-based compensation and changes in our valuation
allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We account for uncertain tax positions in accordance with authoritative
guidance which prescribes a minimum recognition threshold a tax position is required to meet before being recognized in the financial
statements. Our evaluations of tax positions consider various factors including, but not limited to, changes in tax law, the measurement
of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained
during in-process audit activities and changes in facts or circumstances related to a tax position. We accrue interest and penalties related
to unrecognized tax benefits as a component of income tax expense recorded in continuing operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company files income tax returns in the U.S. federal jurisdiction and
in various state jurisdictions. Income tax returns for years prior to fiscal 2021 are no longer subject to examination by tax authorities.&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000494"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000496">&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zKAkrqmhtghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zMd54PBkEcgb"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Property and equipment are stated at original acquisition cost less accumulated
depreciation. &#160;Additions and improvements are capitalized which increase the value or extend the life of an asset, while maintenance
and repair costs are expensed as incurred. &#160;When assets are retired or otherwise disposed, the cost and related accumulated depreciation
or amortization is removed from the respective accounts and any resulting gain or loss is included in income. &#160;Depreciation and amortization
are calculated on the straight-line basis over the estimated useful lives of the assets which generally range from &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziwyiynIzVcl" title="Estimated useful lives of property and equipment::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0498"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zV27rsSADj18" title="Estimated useful lives of property and equipment::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0500"&gt;10&lt;/span&gt;&lt;/span&gt; years for furniture
and office equipment, &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MinimumMember_zY1pIaZnUv55" title="Estimated useful lives of property and equipment::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0502"&gt;3&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--EquipmentAndToolingMember__srt--RangeAxis__srt--MaximumMember_zdCfLRbC0TG5" title="Estimated useful lives of property and equipment::XDX::P12Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0504"&gt;12&lt;/span&gt;&lt;/span&gt; years for manufacturing equipment and tooling and shorter of the lease term or their estimated useful lives
for leasehold improvements. Depreciation and amortization expense related to property and equipment for the years ended December 31, 2024
and 2023 was $&lt;span id="xdx_900_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20240101__20241231_zUHezZUXtQmh" title="Depreciation and amortization, property and equipment"&gt;704,690&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--DepreciationAndAmortizationPropertyAndEquipment_uUSD_c20230101__20231231_zBuvLy7atMcl" title="Depreciation and amortization, property and equipment"&gt;805,921&lt;/span&gt;, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <krmd:DepreciationAndAmortizationPropertyAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">704690</krmd:DepreciationAndAmortizationPropertyAndEquipment>
    <krmd:DepreciationAndAmortizationPropertyAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000508"
      unitRef="USD">805921</krmd:DepreciationAndAmortizationPropertyAndEquipment>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000510">&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzHwS4V0OxCd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zwEKGtyX6Hrk"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains a stock option plan and omnibus equity incentive
plan under which it grants stock options to certain executives, key employees and consultants. It also has granted stock options outside
of the plans as inducement awards. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing
model. &#160;All options are recognized as compensation expense at their grant date fair value. &#160;The entire compensation expense
of the award is recognized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Shares of stock granted for director fees under the non-employee director
compensation plan and under its omnibus equity incentive plan are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company issues restricted stock awards under its omnibus equity incentive
plan and outside the plan as incentive awards. Restricted stock awards are equity classified and measured at the fair market value of
the underlying stock at the grant date. The fair value of restricted stock awards vesting at certain market capitalization thresholds
were estimated on the date of grant using the Brownian Motion Monte Carlo lattice model. The fair value of restricted stock awards with
time-based vesting were estimated on the date of grant at the current stock price. The fair value of restricted stock awards vesting at
certain annual sales growth thresholds were estimated as of the date of Board acknowledgement of the achievement, at the current stock
price. We recognize restricted stock expense using the straight-line attribution method over the requisite service period and account
for forfeitures as they occur.&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000513">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_za5euHsSBPii" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_867_zaH4ZQWzPnIl"&gt;USE OF ESTIMATES IN THE FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. &#160;Actual
results could differ from those estimates. &#160;Important estimates include but are not limited to asset lives, valuation allowances,
inventory valuation, and accruals.&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000515">&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zoxRGXqDzNff" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86F_z0NOhPwujbR4"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Our revenues are derived from three business sources: (i) domestic core
(which consists of US and Canada), (ii) international core, and (iii) novel therapies. &#160;Our core domestic and international revenues
consist of sales of our syringe drivers, tubing and needles (&#x201c;Product Revenue&#x201d;) for the delivery of subcutaneous drugs that
are FDA cleared for use with the KORU Medical infusion system, with the primary delivery for immunoglobulin to treat Primary Immunodeficiency
Diseases (&#x201c;PIDD&#x201d;) and Chronic Inflammatory Demyelinating Polyneuropathy (&#x201c;CIDP&#x201d;). Novel therapies consist of Product
Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) of biopharmaceutical companies in the drug
development process as well as non-recurring engineering services (&#x201c;NRE&#x201d;) revenues (including testing and registration services)
received from biopharmaceutical companies to ready or customize the FREEDOM System for clinical and commercial use across multiple drug
categories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For Product Revenue, we recognize revenues when shipment occurs, and at
which point the customer obtains control and ownership of the goods. &#160;Shipping costs are included as a component of cost of goods
sold in the accompanying statements of operations and are generally billed to customers, and included in Product Revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company generally does not accept return of goods shipped unless it
is a Company error. &#160;The only credits provided to customers are for defective merchandise. &#160;The Company warrants the syringe
driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. &#160;The
costs under the warranty are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Rebates are provided to distributors for the difference in selling price
to distributor and pricing specified to select customers. &#160;In addition, rebates are provided to customers for meeting growth targets.
&#160;Provisions for both distributor pricing and customer growth rebates are variable consideration and are recorded as a reduction of
revenue in the same period the related sales are recorded or when it is probable the growth target will be achieved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We recognize NRE revenue under an input method, which recognizes revenue
on the basis of our efforts or inputs (for example, resources consumed, labor hours expended, costs incurred, or time elapsed) to the
satisfaction of a performance obligation relative to the total expected inputs to the satisfaction of that performance obligation (i.e.
completion milestone). The input method that we use is based on costs incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Contracts are often modified to account for changes in contract specifications
and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations.
Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and
revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction
price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either
as an increase in or a reduction of revenue) on a cumulative catch-up basis. Contract assets primarily represent revenue earnings over
time that are not yet billable based on the terms of the contracts. Contract liabilities (i.e., deferred revenue) consist of fees invoiced
or paid by the Company&#x2019;s customers for which the associated performance obligations have not been satisfied and revenue has not
been recognized based on the Company&#x2019;s revenue recognition criteria described above. As of December 31, 2024, 2023, and 2022, the
Company has recognized a contract asset of $&lt;span id="xdx_90D_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20240101__20241231_zwc0JIF7EJw" title="Recognition of contract asset"&gt;222,623&lt;/span&gt;, $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20230101__20231231_zqNMfhOR4r8h" title="Recognition of contract asset"&gt;0&lt;/span&gt;, and $&lt;span id="xdx_903_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220101__20221231_zniF0Iday9i8" title="Recognition of contract asset"&gt;0&lt;/span&gt;, respectively, which is included in other accounts receivable in the accompanying
balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company established an allowance for charging off uncollectible trade
accounts receivable that have both of the following characteristics: (a) They have a contractual maturity of one year or less, (b) They
arose from the sale of goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfNetSalesByGeography_zGVwXFyhbU69" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_zFIXZoKbmR4l"&gt;The following table summarizes net revenues by geography for the years
ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__country--US_zSPYR2n8G7Tb" style="text-align: right" title="Net Revenue"&gt;27,506,682&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zoejEZjgXhV8" style="text-align: right" title="Net Revenue"&gt;23,676,039&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zUPdwmzFWczg" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;6,139,781&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zDXRR3HKO4Td" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,841,627&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--Revenues_c20240101__20241231_zbZwh9xqUJwe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;33,646,463&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231_zzXAhVOe69kj" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;28,517,666&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zr0V0PmSMAva" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000517"
      unitRef="USD">222623</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">0</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000521"
      unitRef="USD">0</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <krmd:ScheduleOfNetSalesByGeography contextRef="From2024-01-01to2024-12-31" id="Fact000523">&lt;p id="xdx_89C_ecustom--ScheduleOfNetSalesByGeography_zGVwXFyhbU69" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_zFIXZoKbmR4l"&gt;The following table summarizes net revenues by geography for the years
ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 39%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 7%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 21%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 3%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Net Revenues&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;Domestic&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__country--US_zSPYR2n8G7Tb" style="text-align: right" title="Net Revenue"&gt;27,506,682&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zoejEZjgXhV8" style="text-align: right" title="Net Revenue"&gt;23,676,039&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 9.45pt"&gt;International&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zUPdwmzFWczg" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;6,139,781&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zDXRR3HKO4Td" style="border-bottom: black 1pt solid; text-align: right" title="Net Revenues"&gt;4,841,627&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--Revenues_c20240101__20241231_zbZwh9xqUJwe" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;33,646,463&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231_zzXAhVOe69kj" style="border-bottom: black 2.25pt double; text-align: right" title="Revenues"&gt;28,517,666&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</krmd:ScheduleOfNetSalesByGeography>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_country_US"
      decimals="0"
      id="Fact000525"
      unitRef="USD">27506682</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_country_US"
      decimals="0"
      id="Fact000527"
      unitRef="USD">23676039</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_us-gaap_NonUsMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">6139781</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_us-gaap_NonUsMember"
      decimals="0"
      id="Fact000531"
      unitRef="USD">4841627</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">33646463</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">28517666</us-gaap:Revenues>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000538">&lt;p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z9KnPXGgn3Xg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_868_zwPGs6ic3Pn2"&gt;ACCOUNTING PRONOUNCEMENTS RECENTLY ADOPTED&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In November 2023 the FASB issued ASU 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures which expands disclosure requirements to require entities to disclose significant
segment expenses that are regularly provided to or easily computed from information regularly provided to the chief operating decision
maker. This update also requires all annual disclosures currently required by Topic 280 to be disclosed in interim periods. The new disclosure
requirements are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after
December 15, 2024. Early adoption is permitted. We adopted this ASU for the annual period ended December 31, 2024 and the amendments have
be applied retrospectively to all prior periods presented in the financial statements. The adoption of this ASU did not have a significant
impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i&gt;Financial Instruments
&#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, which amends guidance on reporting credit
losses for assets held at amortized cost basis and available for sale debt securities. &#160;For assets held at amortized cost basis,
Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current
estimate of all expected credit losses. &#160;The allowance for credit losses is a valuation account that is deducted from the amortized
cost basis of the financial assets to present the net amount expected to be collected. &#160;For available for sale debt securities, credit
losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance
rather than as a write-down. &#160;This ASU affects entities holding financial assets and net investment in leases that are not accounted
for at fair value through net income. &#160;The amendments affect loans, debt securities, trade receivables, net investments in leases,
off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the
contractual right to receive cash. &#160;The amendments in this update are effective for fiscal years beginning after December 15, 2022,
including interim periods within those fiscal years. &#160;The Company adopted this standard on January 1, 2023, and it did not have a
significant impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company considers the applicability and impact of all recently issued
accounting pronouncements. &#160;Recent accounting pronouncements not specifically identified in our disclosures are either not applicable
to the Company or are not expected to have a material effect on our financial condition or results of operations.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000540">&lt;p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z2T1YjTQiGhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zusmkpmyusWd"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Fair value is the exit price that would be received to sell an asset or
paid to transfer a liability. &#160;Fair value is a market-based measurement that should be determined using assumptions that market participants
would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs
and minimize the use of unobservable inputs. &#160;To measure fair value, the Company uses the following fair value hierarchy based on
three levels of inputs, of which the first two are considered observable and the last unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td style="width: 7in"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: center"&gt;&#x2022;&lt;/td&gt;
    &lt;td&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &#160;Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and includes instruments for which the determination of fair value requires significant judgment or estimation.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The carrying amounts of cash and cash equivalents, accounts receivable,
prepaid expenses, accounts payable and accrued expenses are considered to be representative of their fair values because of the short-term
nature of those instruments. &#160;There were no transfers between levels in the fair value hierarchy during the year ended December 31,
2024.&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000542">&lt;p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z8c7yIvtxlwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86A_zoBBYZEYriXi"&gt;IMPAIRMENT OF LONG-LIVED ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company reviews long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. &#160;An impairment loss would
be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition
are less than the carrying amount. &#160;The impairment loss, if recognized, would be based on the excess of the carrying value of the
impaired asset over its respective fair value. &#160;No impairment losses have been recorded through December 31, 2024.&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000544">&lt;p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zBCOEIkhMnzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_82D_zEKk7pT6yog9"&gt;INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zwh3E8Jy1kQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_z6AVIjRjjtMg"&gt;Inventory consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 56%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Raw materials and work-in-process&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20241231_zj9nEQwEmqn7" style="text-align: right" title="Raw materials and work-in-process"&gt;827,768&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_z2ywVQWvu4ec" style="text-align: right" title="Raw materials and work-in-process"&gt;1,869,356&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Finished goods&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20241231_zOqYworObv5f" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;1,979,887&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zfJzVB98T9bl" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;1,862,525&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--InventoryGross_iI_c20241231_zJhshCFEAsb4" style="text-align: right" title="Inventory, Gross"&gt;2,807,655&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zXeaoVqfviA2" style="text-align: right" title="Inventory, Gross"&gt;3,731,881&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Less: reserve for obsolete inventory&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20241231_zsgYBOtjmES3" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory"&gt;(3,986&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zp60um2BJMGb" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory"&gt;(250,580&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Inventory, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--InventoryNet_iI_dxL_c20241231_zsliOOC9aaP7" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory::XDX::2803669"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0564"&gt;2,803,669&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zMBiLCp47QF9" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;3,481,301&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zkM1N2e0wOU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000546">&lt;p id="xdx_899_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zwh3E8Jy1kQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_z6AVIjRjjtMg"&gt;Inventory consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 56%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Raw materials and work-in-process&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20241231_zj9nEQwEmqn7" style="text-align: right" title="Raw materials and work-in-process"&gt;827,768&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20231231_z2ywVQWvu4ec" style="text-align: right" title="Raw materials and work-in-process"&gt;1,869,356&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Finished goods&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--InventoryFinishedGoods_iI_c20241231_zOqYworObv5f" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;1,979,887&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--InventoryFinishedGoods_iI_c20231231_zfJzVB98T9bl" style="border-bottom: black 1pt solid; text-align: right" title="Finished goods"&gt;1,862,525&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--InventoryGross_iI_c20241231_zJhshCFEAsb4" style="text-align: right" title="Inventory, Gross"&gt;2,807,655&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--InventoryGross_iI_c20231231_zXeaoVqfviA2" style="text-align: right" title="Inventory, Gross"&gt;3,731,881&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Less: reserve for obsolete inventory&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--InventoryValuationReserves_iNI_di_c20241231_zsgYBOtjmES3" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory"&gt;(3,986&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--InventoryValuationReserves_iNI_di_c20231231_zp60um2BJMGb" style="border-bottom: black 1pt solid; text-align: right" title="Less: reserve for obsolete inventory"&gt;(250,580&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Inventory, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--InventoryNet_iI_dxL_c20241231_zsliOOC9aaP7" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory::XDX::2803669"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0564"&gt;2,803,669&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--InventoryNet_iI_c20231231_zMBiLCp47QF9" style="border-bottom: black 2.25pt double; text-align: right" title="Inventory"&gt;3,481,301&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">827768</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000550"
      unitRef="USD">1869356</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">1979887</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000554"
      unitRef="USD">1862525</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000556"
      unitRef="USD">2807655</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000558"
      unitRef="USD">3731881</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">3986</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000562"
      unitRef="USD">250580</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">3481301</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000568">&lt;p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z92LaPoupTwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_829_zP4P5CdHFyCd"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zI8IH58L1Go3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B8_z9ifDzZr2Bj9"&gt;Property and equipment consists of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 56%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zlhKz8kkYAp6" style="text-align: right" title="Furniture and office equipment"&gt;1,433,622&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zqEFzpMJUT5c" style="text-align: right" title="Furniture and office equipment"&gt;1,412,164&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zHoBFfDYYB4" style="text-align: right" title="Leasehold improvements"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWh9j3umFTe1" style="text-align: right" title="Leasehold improvements"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGjBj2uUc3k1" style="border-bottom: black 1pt solid; text-align: right" title="Manufacturing equipment and tooling"&gt;4,376,147&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zjz4hCU1zOdh" style="border-bottom: black 1pt solid; text-align: right" title="Manufacturing equipment and tooling"&gt;3,193,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231_zBh99ndGbZdg" style="text-align: right" title="Total property and equipment"&gt;7,763,422&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zxVhlIxozcBd" style="text-align: right" title="Total property and equipment"&gt;6,558,930&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20241231_zJEAAyST5Pdh" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(3,472,907&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_z0CQp0IN5rLb" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,721,273&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20241231_zko1jGRWZyOc" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;4,290,515&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z9VRV9fNbZi2" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,837,657&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zJLEi9zCh5gd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000570">&lt;p id="xdx_893_eus-gaap--PropertyPlantAndEquipmentTextBlock_zI8IH58L1Go3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B8_z9ifDzZr2Bj9"&gt;Property and equipment consists of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 56%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Furniture and office equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zlhKz8kkYAp6" style="text-align: right" title="Furniture and office equipment"&gt;1,433,622&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureAndOfficeEquipmentMember_zqEFzpMJUT5c" style="text-align: right" title="Furniture and office equipment"&gt;1,412,164&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zHoBFfDYYB4" style="text-align: right" title="Leasehold improvements"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zWh9j3umFTe1" style="text-align: right" title="Leasehold improvements"&gt;1,953,653&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Manufacturing equipment and tooling&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zGjBj2uUc3k1" style="border-bottom: black 1pt solid; text-align: right" title="Manufacturing equipment and tooling"&gt;4,376,147&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentAndToolingMember_zjz4hCU1zOdh" style="border-bottom: black 1pt solid; text-align: right" title="Manufacturing equipment and tooling"&gt;3,193,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&#160;&#160;Total property and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20241231_zBh99ndGbZdg" style="text-align: right" title="Total property and equipment"&gt;7,763,422&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231_zxVhlIxozcBd" style="text-align: right" title="Total property and equipment"&gt;6,558,930&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Less: accumulated depreciation and amortization&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20241231_zJEAAyST5Pdh" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(3,472,907&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20231231_z0CQp0IN5rLb" style="border-bottom: black 1pt solid; text-align: right" title="Less: accumulated depreciation and amortization"&gt;(2,721,273&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20241231_zko1jGRWZyOc" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;4,290,515&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20231231_z9VRV9fNbZi2" style="border-bottom: black 2.25pt double; text-align: right" title="Property and equipment, net"&gt;3,837,657&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">1433622</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_FurnitureAndOfficeEquipmentMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">1412164</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">1953653</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000578"
      unitRef="USD">1953653</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      id="Fact000580"
      unitRef="USD">4376147</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ManufacturingEquipmentAndToolingMember"
      decimals="0"
      id="Fact000582"
      unitRef="USD">3193113</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000584"
      unitRef="USD">7763422</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000586"
      unitRef="USD">6558930</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">3472907</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000590"
      unitRef="USD">2721273</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000592"
      unitRef="USD">4290515</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">3837657</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000596">&lt;p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zNb9xtVVGiLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 4 &#x2014; &lt;span id="xdx_827_zatQWMez0369"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company maintains three equity incentive plans: the 2015 Stock Option
Plan, as amended (the &#x201c;2015 Plan&#x201d;), the 2021 Omnibus Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), and the 2024 Omnibus
Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;). All equity awards issued to employees, consultants, and non-employee directors on
or after May 9, 2024 are issued from the 2024 Plan. The Company has also issued restricted stock and stock options as employment inducement
awards outside of these plans to its Chief Executive Officer and Chief Commercial Officer, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2015 Plan provides for the grant of incentive
stock options and nonqualified stock options. As of December 31, 2024, there were &lt;span id="xdx_905_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEn2UXG3NOch" title="Shares reserved for outstanding awards"&gt;2,035,000&lt;/span&gt; shares reserved for outstanding awards under
the 2015 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2021 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units, performance share units, stock appreciation rights, and/or
other equity-based awards to employees, consultants and directors. As of December 31, 2024, there were &lt;span id="xdx_90F_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2021Member_zUl60yTpIoRk" title="Shares reserved for outstanding awards"&gt;127,248&lt;/span&gt; shares reserved for outstanding
awards under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2024 Plan provides for the grant of incentive
stock options, nonqualified stock options, stock awards, restricted stock awards, restricted stock units, performance share units, stock appreciation rights and/or
other equity-based awards to employees, consultants and directors. Awards previously made under the 2015 Plan and the 2021 Plan that are
forfeited or cancelled after May 9, 2024 will be available for issuance under the 2024 Plan. As of December 31, 2024, there were &lt;span id="xdx_903_ecustom--SharesReservedForOutstandingAwards_pid_uShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2024Member_zNskQuoxduN7" title="Shares reserved for outstanding awards"&gt;799,254&lt;/span&gt;
shares reserved for outstanding awards and &lt;span id="xdx_908_ecustom--SharesAvailableForIssuanceShareBasedCompensation_iI_pid_uShares_c20241231__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlan2024Member_zIuEShzJiuXj" title="Shares available for issuance"&gt;2,320,440&lt;/span&gt; shares available for issuance under the 2024 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each non-employee director of the Company (other than
the Chairman of the Board) is eligible to receive $&lt;span id="xdx_90C_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zhKnVPjOJ3Yg" title="Nonemployee services transaction cost"&gt;110,000&lt;/span&gt; annually, &lt;span id="xdx_905_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20241231__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorAndBoardAdvisorMember_zklJTZEg7P07" title="Share-based goods and non-employee services transaction"&gt;to be paid quarterly in arrears of $12,500 in cash and $15,000 in
common stock.&lt;/span&gt; &#160;The Chairman of the Board is eligible to receive $&lt;span id="xdx_900_ecustom--NonemployeeServicesTransactionCost_pid_uShares_c20240101__20241231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zfeJp96k3Ayh" title="Nonemployee services transaction cost"&gt;140,000&lt;/span&gt; annually, &lt;span id="xdx_90D_eus-gaap--DeferredCompensationArrangementsOverallDescription_c20240101__20241231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zvG1r0MTT44a" title="Share-based goods and non-employee services transaction"&gt;to be paid quarterly in arrears of $12,500 in
cash and $22,500 in common stock.&lt;/span&gt; Prior to May 9, 2024 in the periods presented in this report, non-employee director equity compensation
was issued from the Non-Employee Director Compensation Plan. From and after May 9, 2024 non-employee director equity compensation is issued
from the 2024 Plan. All payments were and are pro-rated for partial service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) and performance
share units (&#x201c;PSUs&#x201d;) are equity classified and measured at the fair value of the underlying stock at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Shares of stock granted for non-employee director
fees are recorded at the fair value of the shares at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The per share weighted average fair value of stock options granted during
the year ended December 31, 2024 and December 31, 2023 was $&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zJgTextb4rWi"&gt;1.44&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--PlanNameAxis__custom--StockOptionPlans2015And2021CombinedMember_zprY8FQR32vb"&gt;1.84&lt;/span&gt;, respectively. &#160;The fair value of each award is estimated
on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the
year ended December 31, 2024 and December 31, 2023. Historical information was the primary basis for the selection of the expected volatility,
expected dividend yield and the expected lives of the options. &#160;The risk-free interest rate was selected based upon yields of the
U.S. Treasury issues with a term equal to the expected life of the option being valued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Time-Vesting Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEzP3t462Obe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the inputs into the Black-Scholes model
for all time-vesting stock options granted during the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B9_z81utUXWETni" style="display: none; visibility: hidden"&gt;Schedule of time based stock options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 62%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 32%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z7nDWzQxEbE7" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zBnJgQaURIBc" title="Expected volatility"&gt;51.9&lt;/span&gt;% - &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zZvflGU81ZPb" title="Expected volatility"&gt;68.04&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zhFzCu7VVjZi" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zwTcCzzSLxq4" title="Expected term (in years)::XDX::P6Y2M30D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_z2JnIwwK1amj" title="Risk-free rate"&gt;3.50&lt;/span&gt;% - &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zQCCh5cKtqDl" title="Risk-free rate"&gt;4.11&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zl7HlYZdhqNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEE4EiplHgug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the time-based stock options
outstanding at December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B7_zohm8epPEc8a" style="display: none; visibility: hidden"&gt;Schedule of status of time based stock options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 74%"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zFEqBRxzHFAk" style="width: 11%; text-align: right" title="Outstanding at beginning (in shares)"&gt;3,256,250&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zgTKvRJ5gWa4" style="width: 11%; text-align: right" title="Outstanding at beginning, price"&gt;3.66&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_ziLWLRGjDJg6" style="text-align: right" title="Granted (in shares)"&gt;567,024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zScpa5HlIP3i" style="text-align: right" title="Granted"&gt;2.35&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zCiDtWteBaK8" style="text-align: right" title="Exercised (in shares)"&gt;(237,500&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z45j1tDPoaN3" style="text-align: right" title="Exercised"&gt;2.67&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zVSrDjvQ8Sqb" style="text-align: right" title="Forfeited (in shares)"&gt;(898,750&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zY6SvUp3s2w7" style="text-align: right" title="Forfeited"&gt;4.86&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zqjj0UoI2DY4" style="text-align: right" title="Outstanding at ending (in shares)"&gt;2,687,024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zE6vzBKy6exe" style="text-align: right" title="Outstanding at ending, price"&gt;3.07&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Options exercisable at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zPUclYjx0Uzg" style="text-align: right" title="Options exercisable (in shares)"&gt;1,383,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zle0yaJaSZp3" style="text-align: right" title="Options exercisable"&gt;3.40&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z0QpHXsd1I4a" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.44&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zbfvZ0v9WeB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total stock-based compensation expense for time-vested stock options was
$&lt;span id="xdx_90C_ecustom--StockBasedCompensationStockOptions_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z9VX218HCJp1" title="Stock-based compensation expense"&gt;1,530,446&lt;/span&gt; for the years ended December 31, 2024. &lt;span id="xdx_906_ecustom--CashReceivedFromOptionExercise_do_uUSD_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zn5UsAaELOlg" title="Cash received from option exercise"&gt;&lt;span id="xdx_90E_ecustom--CashReceivedFromOptionExercise_do_c20230101__20231231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zBoszIMXFhCf" title="Cash received from option exercise"&gt;No&lt;/span&gt;&lt;/span&gt; cash was received from option exercises for the years ended December 31, 2024, and
2023. As of December 31, 2024, the intrinsic value of all time-based stock options was $&lt;span id="xdx_901_ecustom--StockbasedCompensationIntrinsicValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zg5TTd0CzhSe" title="Stock-based compensation intrinsic value"&gt;2,085,186&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_z95sK4WPWlc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to time-based stock
options outstanding at December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_znHDlpGsuEmc" style="display: none; visibility: hidden"&gt;Schedule of information pertaining to options outstanding&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 29%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.08-$3.98&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z97F722reGXj" style="text-align: right" title="Number outstanding"&gt;2,687,024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zROvmVLqahJ6" title="Weighted average remaining contractual life::XDX::P7Y4M24D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0673"&gt;7.4&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zgrvMwPMHfo" style="text-align: right" title="Weighted average exercise price"&gt;3.07&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zhGByk2yn2Ol" style="text-align: right" title="Number exercisable"&gt;1,383,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2eronAeslml" style="text-align: right" title="Weighted average exercise price"&gt;3.40&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zGQgcd8mQcK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2024, there was $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zFUy73hnfAJd" title="Total unrecognized compensation cost"&gt;1,427,181&lt;/span&gt; of total unrecognized compensation
cost related to unvested share-based stock compensation awards granted under the Plans. &#160;That cost is expected to be recognized over
a weighted-average period of 25 months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Performance-Vesting Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zpHtCUdjQQGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_z9KwfiUsN051"&gt;The following table summarizes the activities for our unvested performance-vesting
stock option awards for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 67%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zawJhSm0C2J1" style="width: 13%; text-align: right" title="Unvested at beginning, shares"&gt;200,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zfN7MUutp6A8" style="width: 16%; text-align: right" title="Unvested at beginning, price"&gt;1.48&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zD47iwi6517l" style="text-align: right" title="Granted, shares"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zuKldYTbr4ue" style="text-align: right" title="Granted, price"&gt;&#x2014;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zsqIeO74Wx38" style="text-align: right" title="Vested, shares"&gt;(22,000&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zAKjer81Fvxf" style="text-align: right" title="Vested, price"&gt;1.48&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zvd4lDWavMR2" style="text-align: right" title="Forfeited/canceled, shares"&gt;(44,666&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_z1u2fXXBwMI2" style="text-align: right" title="Forfeited/canceled, price"&gt;1.48&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zlrGowkjmAtl" style="text-align: right" title="Unvested at ending, shares"&gt;133,334&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zSX1C8vq8yD" style="text-align: right" title="Unvested at ending, price"&gt;1.48&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_z7ETHM3OOFjl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total stock-based compensation expense for performance-vesting stock options
was $&lt;span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zSw9yLBPqAla" title="Total stock-based compensation expense"&gt;21,778&lt;/span&gt; year ended December 31, 2024. &lt;span id="xdx_90D_ecustom--CashReceivedFromOptionExercise_do_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zdUJzZ4QoW42" title="Cash received from option exercise"&gt;No&lt;/span&gt; cash was received from option exercises for the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2024, there was $&lt;span id="xdx_90E_ecustom--UnrecognizedCompensationCost_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zvu37fbaOjtd" title="Unrecognized compensation cost"&gt;183,206&lt;/span&gt; of unrecognized compensation
cost related to unvested employee performance options. This amount is expected to be recognized over a weighted-average period of 36 months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted Stock Awards, RSUs, and PSUs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zn92eN7g2kDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B2_zd7DOStXgaB9"&gt;The following table summarizes the activities for our unvested restricted
stock awards, RSUs, and PSUs for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 67%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zjqN8brKVLnh" style="width: 13%; text-align: right" title="Outstanding at beginning, shares"&gt;904,496&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zoR0DmgcChJ7" style="width: 16%; text-align: right" title="Outstanding at beginning, price"&gt;2.77&lt;/td&gt;
    &lt;td style="width: 0%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zDY3M1ABIITf" style="text-align: right" title="Granted, shares"&gt;458,975&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zm7cngsSnVIf" style="text-align: right" title="Granted, price"&gt;2.20&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zQAO4jZTtfvb" style="text-align: right" title="Vested, shares"&gt;(81,789&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8jxzHMwGn72" style="text-align: right" title="Vested, price"&gt;3.45&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8maZvFHhjUb" style="text-align: right" title="Forfeited/canceled, shares"&gt;(11,745&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_znpAADdIu6v" style="text-align: right" title="Forfeited/canceled, price"&gt;2.30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zlYBBTVqFCa6" style="text-align: right" title="Outstanding at ending, shares"&gt;1,269,937&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxvGbF9OTN94" style="text-align: right" title="Outstanding at ending, price"&gt;2.54&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zBSTR2OFBOqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total stock-based compensation expense for restricted stock awards, RSUs,
and PSUs was $&lt;span id="xdx_908_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zDyaiEnzCo2j" title="Total stock-based compensation expense"&gt;579,519&lt;/span&gt; for the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2024, there was $&lt;span id="xdx_90D_ecustom--UnrecognizedCompensationCost_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zg5riYiUfLk9" title="Unrecognized compensation cost"&gt;902,625&lt;/span&gt; of unrecognized compensation
cost related to unvested employee restricted stock awards, RSUs, and PSUs. This amount is expected to be recognized over a weighted-average
period of 44 months.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <krmd:SharesReservedForOutstandingAwards
      contextRef="From2024-01-012024-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="Fact000598"
      unitRef="Shares">2035000</krmd:SharesReservedForOutstandingAwards>
    <krmd:SharesReservedForOutstandingAwards
      contextRef="From2024-01-012024-12-31_custom_OmnibusEquityIncentivePlan2021Member"
      decimals="INF"
      id="Fact000600"
      unitRef="Shares">127248</krmd:SharesReservedForOutstandingAwards>
    <krmd:SharesReservedForOutstandingAwards
      contextRef="From2024-01-012024-12-31_custom_OmnibusEquityIncentivePlan2024Member"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">799254</krmd:SharesReservedForOutstandingAwards>
    <krmd:SharesAvailableForIssuanceShareBasedCompensation
      contextRef="AsOf2024-12-31_custom_OmnibusEquityIncentivePlan2024Member"
      decimals="INF"
      id="Fact000604"
      unitRef="Shares">2320440</krmd:SharesAvailableForIssuanceShareBasedCompensation>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2024-01-012024-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      decimals="INF"
      id="Fact000606"
      unitRef="Shares">110000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:DeferredCompensationArrangementsOverallDescription
      contextRef="From2024-01-012024-12-31_custom_NonEmployeeDirectorAndBoardAdvisorMember"
      id="Fact000608">to be paid quarterly in arrears of $12,500 in cash and $15,000 in
common stock.</us-gaap:DeferredCompensationArrangementsOverallDescription>
    <krmd:NonemployeeServicesTransactionCost
      contextRef="From2024-01-012024-12-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="Fact000610"
      unitRef="Shares">140000</krmd:NonemployeeServicesTransactionCost>
    <us-gaap:DeferredCompensationArrangementsOverallDescription
      contextRef="From2024-01-012024-12-31_srt_BoardOfDirectorsChairmanMember"
      id="Fact000612">to be paid quarterly in arrears of $12,500 in
cash and $22,500 in common stock.</us-gaap:DeferredCompensationArrangementsOverallDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="INF"
      id="Fact000614"
      unitRef="USDPShares">1.44</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_custom_StockOptionPlans2015And2021CombinedMember"
      decimals="INF"
      id="Fact000615"
      unitRef="USDPShares">1.84</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000617">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEzP3t462Obe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the inputs into the Black-Scholes model
for all time-vesting stock options granted during the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B9_z81utUXWETni" style="display: none; visibility: hidden"&gt;Schedule of time based stock options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 3.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 62%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 32%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z7nDWzQxEbE7" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Expected Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_zBnJgQaURIBc" title="Expected volatility"&gt;51.9&lt;/span&gt;% - &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zZvflGU81ZPb" title="Expected volatility"&gt;68.04&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Expected dividends&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_d0_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zhFzCu7VVjZi" title="Expected dividends"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zwTcCzzSLxq4" title="Expected term (in years)::XDX::P6Y2M30D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MinimumMember_z2JnIwwK1amj" title="Risk-free rate"&gt;3.50&lt;/span&gt;% - &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__srt--RangeAxis__srt--MaximumMember_zQCCh5cKtqDl" title="Risk-free rate"&gt;4.11&lt;/span&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000619"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000621"
      unitRef="Pure">0.519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000623"
      unitRef="Pure">0.6804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="0"
      id="Fact000625"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000629"
      unitRef="Pure">0.0350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000631"
      unitRef="Pure">0.0411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000633">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEE4EiplHgug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the status of the time-based stock options
outstanding at December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B7_zohm8epPEc8a" style="display: none; visibility: hidden"&gt;Schedule of status of time based stock options&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 74%"&gt;Outstanding at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zFEqBRxzHFAk" style="width: 11%; text-align: right" title="Outstanding at beginning (in shares)"&gt;3,256,250&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zgTKvRJ5gWa4" style="width: 11%; text-align: right" title="Outstanding at beginning, price"&gt;3.66&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_ziLWLRGjDJg6" style="text-align: right" title="Granted (in shares)"&gt;567,024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zScpa5HlIP3i" style="text-align: right" title="Granted"&gt;2.35&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zCiDtWteBaK8" style="text-align: right" title="Exercised (in shares)"&gt;(237,500&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z45j1tDPoaN3" style="text-align: right" title="Exercised"&gt;2.67&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zVSrDjvQ8Sqb" style="text-align: right" title="Forfeited (in shares)"&gt;(898,750&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zY6SvUp3s2w7" style="text-align: right" title="Forfeited"&gt;4.86&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Outstanding at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zqjj0UoI2DY4" style="text-align: right" title="Outstanding at ending (in shares)"&gt;2,687,024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zE6vzBKy6exe" style="text-align: right" title="Outstanding at ending, price"&gt;3.07&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Options exercisable at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zPUclYjx0Uzg" style="text-align: right" title="Options exercisable (in shares)"&gt;1,383,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_zle0yaJaSZp3" style="text-align: right" title="Options exercisable"&gt;3.40&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 0.1in; text-indent: -0.1in"&gt;Weighted average fair value of options granted during the period&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember_z0QpHXsd1I4a" style="text-align: right" title="Weighted average fair value of options granted during the period"&gt;1.44&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">3256250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000637"
      unitRef="USDPShares">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">567024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000641"
      unitRef="USDPShares">2.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">237500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000645"
      unitRef="USDPShares">2.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000647"
      unitRef="Shares">898750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000649"
      unitRef="USDPShares">4.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000651"
      unitRef="Shares">2687024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000653"
      unitRef="USDPShares">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000655"
      unitRef="Shares">1383750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000657"
      unitRef="USDPShares">3.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="INF"
      id="Fact000659"
      unitRef="USDPShares">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <krmd:StockBasedCompensationStockOptions
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="0"
      id="Fact000661"
      unitRef="USD">1530446</krmd:StockBasedCompensationStockOptions>
    <krmd:CashReceivedFromOptionExercise
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">0</krmd:CashReceivedFromOptionExercise>
    <krmd:CashReceivedFromOptionExercise
      contextRef="From2023-01-012023-12-31_custom_TimeVestingStockOptionsMember"
      decimals="0"
      id="Fact000665"
      unitRef="USD">0</krmd:CashReceivedFromOptionExercise>
    <krmd:StockbasedCompensationIntrinsicValue
      contextRef="From2024-01-012024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="0"
      id="Fact000667"
      unitRef="USD">2085186</krmd:StockbasedCompensationIntrinsicValue>
    <krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000669">&lt;p id="xdx_89E_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock_z95sK4WPWlc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents information pertaining to time-based stock
options outstanding at December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_znHDlpGsuEmc" style="display: none; visibility: hidden"&gt;Schedule of information pertaining to options outstanding&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 7.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Range of Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Remaining&lt;br/&gt;
Contractual&lt;br/&gt;
Life&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Number&lt;br/&gt;
Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Exercise&lt;br/&gt;
Price&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 29%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;$2.08-$3.98&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z97F722reGXj" style="text-align: right" title="Number outstanding"&gt;2,687,024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zROvmVLqahJ6" title="Weighted average remaining contractual life::XDX::P7Y4M24D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0673"&gt;7.4&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zgrvMwPMHfo" style="text-align: right" title="Weighted average exercise price"&gt;3.07&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zhGByk2yn2Ol" style="text-align: right" title="Number exercisable"&gt;1,383,750&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20241231__us-gaap--AwardTypeAxis__custom--TimeVestingStockOptionsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2eronAeslml" style="text-align: right" title="Weighted average exercise price"&gt;3.40&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfShareBasedCompensationStockOptionsActivityAmendedTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000671"
      unitRef="Shares">2687024</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000675"
      unitRef="USDPShares">3.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000677"
      unitRef="Shares">1383750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember_custom_ExercisePrice1Member"
      decimals="INF"
      id="Fact000679"
      unitRef="USDPShares">3.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-12-31_custom_TimeVestingStockOptionsMember"
      decimals="0"
      id="Fact000681"
      unitRef="USD">1427181</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000684">&lt;p id="xdx_89F_eus-gaap--ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_zpHtCUdjQQGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B3_z9KwfiUsN051"&gt;The following table summarizes the activities for our unvested performance-vesting
stock option awards for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 67%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zawJhSm0C2J1" style="width: 13%; text-align: right" title="Unvested at beginning, shares"&gt;200,000&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zfN7MUutp6A8" style="width: 16%; text-align: right" title="Unvested at beginning, price"&gt;1.48&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_d0_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zD47iwi6517l" style="text-align: right" title="Granted, shares"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_d0_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zuKldYTbr4ue" style="text-align: right" title="Granted, price"&gt;&#x2014;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zsqIeO74Wx38" style="text-align: right" title="Vested, shares"&gt;(22,000&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zAKjer81Fvxf" style="text-align: right" title="Vested, price"&gt;1.48&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zvd4lDWavMR2" style="text-align: right" title="Forfeited/canceled, shares"&gt;(44,666&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_z1u2fXXBwMI2" style="text-align: right" title="Forfeited/canceled, price"&gt;1.48&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByUnvestedAwardOptions_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zlrGowkjmAtl" style="text-align: right" title="Unvested at ending, shares"&gt;133,334&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--PerformanceVestingStockOptionsMember_zSX1C8vq8yD" style="text-align: right" title="Unvested at ending, price"&gt;1.48&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2023-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000686"
      unitRef="Shares">200000</krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000688"
      unitRef="USDPShares">1.48</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000690"
      unitRef="Shares">0</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000692"
      unitRef="USDPShares">0</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000694"
      unitRef="Shares">-22000</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000696"
      unitRef="USDPShares">1.48</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000698"
      unitRef="Shares">-44666</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000700"
      unitRef="USDPShares">1.48</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
    <krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions
      contextRef="AsOf2024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000702"
      unitRef="Shares">133334</krmd:ShareBasedCompensationArrangementByUnvestedAwardOptions>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="INF"
      id="Fact000704"
      unitRef="USDPShares">1.48</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="0"
      id="Fact000706"
      unitRef="USD">21778</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <krmd:CashReceivedFromOptionExercise
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="0"
      id="Fact000708"
      unitRef="USD">0</krmd:CashReceivedFromOptionExercise>
    <krmd:UnrecognizedCompensationCost
      contextRef="From2024-01-012024-12-31_custom_PerformanceVestingStockOptionsMember"
      decimals="0"
      id="Fact000710"
      unitRef="USD">183206</krmd:UnrecognizedCompensationCost>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000712">&lt;p id="xdx_895_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zn92eN7g2kDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B2_zd7DOStXgaB9"&gt;The following table summarizes the activities for our unvested restricted
stock awards, RSUs, and PSUs for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average&lt;br/&gt;
Grant-Date&lt;br/&gt;
Fair Value&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 67%"&gt;Unvested at January 1&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iS_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zjqN8brKVLnh" style="width: 13%; text-align: right" title="Outstanding at beginning, shares"&gt;904,496&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iS_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zoR0DmgcChJ7" style="width: 16%; text-align: right" title="Outstanding at beginning, price"&gt;2.77&lt;/td&gt;
    &lt;td style="width: 0%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zDY3M1ABIITf" style="text-align: right" title="Granted, shares"&gt;458,975&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zm7cngsSnVIf" style="text-align: right" title="Granted, price"&gt;2.20&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zQAO4jZTtfvb" style="text-align: right" title="Vested, shares"&gt;(81,789&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8jxzHMwGn72" style="text-align: right" title="Vested, price"&gt;3.45&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Forfeited/canceled&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_z8maZvFHhjUb" style="text-align: right" title="Forfeited/canceled, shares"&gt;(11,745&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_znpAADdIu6v" style="text-align: right" title="Forfeited/canceled, price"&gt;2.30&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Unvested at December 31&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested_iE_pid_uShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zlYBBTVqFCa6" style="text-align: right" title="Outstanding at ending, shares"&gt;1,269,937&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested_iE_pid_uUSDPShares_c20240101__20241231__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_zxvGbF9OTN94" style="text-align: right" title="Outstanding at ending, price"&gt;2.54&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000714"
      unitRef="Shares">904496</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2023-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000716"
      unitRef="USDPShares">2.77</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000718"
      unitRef="Shares">458975</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000720"
      unitRef="USDPShares">2.20</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000722"
      unitRef="Shares">-81789</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000724"
      unitRef="USDPShares">3.45</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Shares">-11745</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodUnvested>
    <krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000728"
      unitRef="USDPShares">2.30</krmd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePriceUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested
      contextRef="AsOf2024-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000730"
      unitRef="Shares">1269937</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberUnvested>
    <krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested
      contextRef="AsOf2024-12-31_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact000732"
      unitRef="USDPShares">2.54</krmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceUnvested>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact000734"
      unitRef="USD">579519</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <krmd:UnrecognizedCompensationCost
      contextRef="From2024-01-012024-12-31_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact000736"
      unitRef="USD">902625</krmd:UnrecognizedCompensationCost>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000738">&lt;p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zvqvHLTW2DZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_820_zvHNPpOezuvc"&gt;DEBT OBLIGATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 8, 2024, the Company entered into a loan
and security agreement with a large domestic banking institution, as lender, providing for a $&lt;span id="xdx_90D_eus-gaap--LinesOfCreditCurrent_iI_c20240308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZeyCC8DHBch" title="Revolving credit facility"&gt;5,000,000&lt;/span&gt; revolving credit facility and
a $&lt;span id="xdx_900_ecustom--LinesOfCreditCurrent1_iI_c20240308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zJ8IPO4G6zJ9" title="Term loan facility"&gt;5,000,000&lt;/span&gt; term loan facility. Borrowings are secured by a first-priority lien on substantially all of the assets of the Company, subject
to customary exceptions. The revolving credit facility matures on December 31, 2025 and the term loan matures on December 1, 2028.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_907_ecustom--DebtInstrumentInterestPaymentTerms_c20240308__20250308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zXTaNVDJjjmj" title="Debt instrument interest payment terms"&gt;Borrowings under the revolving credit facility will bear interest at the
greater of Prime or 6.50%, payable in arrears on a monthly basis and at maturity.&lt;/span&gt; &lt;span id="xdx_901_ecustom--DebtInstrumentInterestPaymentTerms_c20240308__20250308__dei--LegalEntityAxis__custom--DomesticBankLenderMember__us-gaap--CreditFacilityAxis__custom--TermLoanFacilityMember_zN8zPp0ltAob" title="Debt instrument interest payment terms"&gt;Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with our loan financings agreement dated
March 8, 2024, the Company issued common stock warrants to the lender. The fair value of each warrant is estimated on the date of the
grant using the Black-Scholes option-pricing model. All options and warrants are charged against income at their fair value. &#160;The
entire compensation expense of the grant is recognized over the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The loan and security agreement contains customary affirmative covenants,
a financial maintenance covenant that requires the Company to maintain a minimum Adjusted Quick Ratio (defined as the ratio of the Company&#x2019;s
(i) unrestricted and unencumbered cash and cash equivalents maintained with the lender and its affiliates, plus eligible accounts receivable,
to (ii) current liabilities) of not less than 1.50 to 1.00 tested on the last day of each month.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2024, there were no outstanding borrowings under the
term loan nor the revolving credit facility.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On August 1, 2024, the Company renewed its commercial insurance premium
finance and security agreement with its insurance provider for the insurance period covering July 1, 2024 through June 30, 2025. As of
December 31, 2024, the aggregate principal amount of the note was $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentIssuedPrincipal_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zfioO21ApDFa" title="Aggregate principal amount of note"&gt;271,152&lt;/span&gt;. The note bears an annual interest rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecurityAgreementMember_zgLLImB8B5X3"&gt;9.5&lt;/span&gt;%. The Company
retains the right to terminate the agreement at any time and pay the remaining balance in full along with a minimal penalty.&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2024-03-08_custom_DomesticBankLenderMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="Fact000740"
      unitRef="USD">5000000</us-gaap:LinesOfCreditCurrent>
    <krmd:LinesOfCreditCurrent1
      contextRef="AsOf2024-03-08_custom_DomesticBankLenderMember_custom_TermLoanFacilityMember"
      decimals="0"
      id="Fact000742"
      unitRef="USD">5000000</krmd:LinesOfCreditCurrent1>
    <krmd:DebtInstrumentInterestPaymentTerms
      contextRef="From2024-03-082025-03-08_custom_DomesticBankLenderMember_us-gaap_RevolvingCreditFacilityMember"
      id="Fact000744">Borrowings under the revolving credit facility will bear interest at the
greater of Prime or 6.50%, payable in arrears on a monthly basis and at maturity.</krmd:DebtInstrumentInterestPaymentTerms>
    <krmd:DebtInstrumentInterestPaymentTerms
      contextRef="From2024-03-082025-03-08_custom_DomesticBankLenderMember_custom_TermLoanFacilityMember"
      id="Fact000746">Borrowings under the term loan will bear interest at
the greater of Prime minus 0.50% or 6.50% and will be interest-only through December 31, 2025, followed by 24 equal monthly payments of
principal plus interest.</krmd:DebtInstrumentInterestPaymentTerms>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2024-01-012024-12-31_custom_SecurityAgreementMember"
      decimals="0"
      id="Fact000749"
      unitRef="USD">271152</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31_custom_SecurityAgreementMember"
      decimals="INF"
      id="Fact000750"
      unitRef="Pure">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000752">&lt;p id="xdx_801_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zvFT6gwFiLb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_821_zHrNLnyMKtn7"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We have finance and operating leases for our corporate office and certain
office, vehicles, and computer equipment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At contract inception, we evaluate whether an arrangement is or contains
a lease for which we are the lessee (that is, arrangements which provide us with the right to control a physical asset for a period of
time). &#160;Operating leases are accounted for on the balance sheets with ROU assets being recognized in &#x201c;Operating lease right-of-use
assets&#x201d; and lease liabilities recognized in &#x201c;Operating lease liability &#x2013; current&#x201d; and &#x201c;Operating lease liability,
net of current portion.&#x201d; Finance leases are accounted for on the balance sheets recognized in &#x201c;Property and equipment, net&#x201d;
and lease liabilities recognized in &#x201c;Finance lease liability &#x2013; current&#x201d; and &#x201c;Finance lease liability, net of current
portion.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Operating lease expenses are recognized on a straight-line basis over the
lease term. &#160;With respect to finance leases, amortization of the ROU asset is presented separately from interest expense related
to the finance lease liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We have elected to combine lease and non-lease components for all lease
contracts where we are the lessee. &#160;Additionally, for arrangements with lease terms of 12 months or less, we do not recognize ROU
assets and lease liabilities and lease payments are recognized on a straight-line basis over the lease term with variable lease payments
recognized in the period in which the obligation is incurred. &#160;ROU assets are measured for impairment when a triggering event occurs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zuwSL6AIJcy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zmEBGrjkD0t7"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 57%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20240101__20241231_zShb2ZhqBko6" style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20230101__20231231_zPEyZuPWSlM4" style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zifrdolfisua" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;487,960&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;448,630&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zKKYkZk8XH6l" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5,952&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;130,483&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCost_zZuEkMCA2foc" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;493,912&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;579,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_z9Yc3HBZd6dk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zOL87A1XofA2" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;115,585&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;110,566&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zR44tk9uxsAj" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;21,896&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25,343&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zCk1pqkFSpZ3" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;137,481&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;135,909&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zhTW50IBbTyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHtI5UDOZb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B9_z2rBG3vO53E1"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 71.96%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.98%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.06%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20240101__20241231_zAGVL7urrDW8" style="width: 10.98%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.98%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.06%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20230101__20231231_zzVWBgMzviUh" style="width: 10.98%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.98%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.45pt; text-indent: -9.45pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zyCsZUvoFrM5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;501,214&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;464,104&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zKYp2GHfNZm" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;131,437&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;125,259&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zaOu4Bpqu8Wi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_896_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z1PIw2sIUuV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B2_z0Muv5NOao1h"&gt;Supplemental information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 58%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20241231_zmIb4dGEugo2" title="Operating leases term::XDX::P5Y1M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;5.1&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zF5FxvE3qPud" title="Operating leases term::XDX::P6Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0793"&gt;6.9&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20241231_zXFttH55OXo7" title="Finance leases  term::XDX::P2Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0795"&gt;2.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zMzK1h0En1D1" title="Operating leases term::XDX::P3Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0797"&gt;3.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zD4Wg9VePVna" title="Operating leases discount rate"&gt;6.52&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zQTmoa3PK0X5" title="Operating leases discount rate"&gt;5.76&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zFxOZJ43fHoc" title="Finance leases discount rate"&gt;6.34&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z5KU3gcUM807" title="Finance leases discount rate"&gt;6.19&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zKOEu6GCg5Dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zwjrDeZbopqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zYzR4mV4G5fj"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zTDTK8n3t875" style="vertical-align: bottom; text-align: right" title="2025 - Operating Leases"&gt;533,979&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zjUsCnD4icoh" style="vertical-align: bottom; text-align: right" title="2025 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zH9ljjshPew4" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases"&gt;533,979&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zT12UntsoyB3" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zwmfrBeflmF" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases"&gt;533,979&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zl2F75onMYH5" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases"&gt;74,194&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20241231_z9NnOEa1yyJ2" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases"&gt;520,985&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20241231_zPpCYm5GLIAk" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases"&gt;6,181&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_z1nEpK0z5Mo4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases"&gt;1,833,603&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_zonC4EG7RFYl" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20241231_zf3p9eKVuO16" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases"&gt;3,956,525&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20241231_zPrhrwrXfTOg" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases"&gt;343,248&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 18.8pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20241231_zwRLoURqG6r6" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases"&gt;(555,864&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20241231_zxrD62runzac" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases"&gt;(25,048&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_zNhTlG0JzTd2" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases"&gt;3,400,661&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FinanceLeaseLiability_iI_c20241231_zCdoExEUMXUk" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases"&gt;318,200&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AB_zPUoi9iI1osl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000754">&lt;p id="xdx_896_eus-gaap--LeaseCostTableTextBlock_zuwSL6AIJcy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B0_zmEBGrjkD0t7"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 4.75in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 57%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20240101__20241231_zShb2ZhqBko6" style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20230101__20231231_zPEyZuPWSlM4" style="width: 16%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseCost_maLCzGTc_zifrdolfisua" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Operating lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;487,960&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;448,630&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShortTermLeaseCost_maLCzGTc_zKKYkZk8XH6l" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Short-term lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5,952&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;130,483&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCost_zZuEkMCA2foc" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;493,912&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;579,113&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--FinanceLeaseCost1Abstract_iB_z9Yc3HBZd6dk" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9.1pt; text-indent: -9.1pt"&gt;Finance lease cost:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_i01_maFLCzAT2_zOL87A1XofA2" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Amortization of right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;115,585&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;110,566&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseInterestExpense_i01_maFLCzAT2_zR44tk9uxsAj" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 27.5pt; text-indent: -9.1pt"&gt;Interest on lease liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;21,896&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;25,343&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FinanceLeaseCost_i01_zCk1pqkFSpZ3" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total finance lease cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;137,481&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;135,909&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000756"
      unitRef="USD">487960</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000757"
      unitRef="USD">448630</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000759"
      unitRef="USD">5952</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000760"
      unitRef="USD">130483</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">493912</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000763"
      unitRef="USD">579113</us-gaap:LeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000768"
      unitRef="USD">115585</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000769"
      unitRef="USD">110566</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000771"
      unitRef="USD">21896</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000772"
      unitRef="USD">25343</us-gaap:FinanceLeaseInterestExpense>
    <krmd:FinanceLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000774"
      unitRef="USD">137481</krmd:FinanceLeaseCost>
    <krmd:FinanceLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000775"
      unitRef="USD">135909</krmd:FinanceLeaseCost>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000777">&lt;p id="xdx_896_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zHtI5UDOZb6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B9_z2rBG3vO53E1"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 6.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 71.96%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.98%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.06%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20240101__20241231_zAGVL7urrDW8" style="width: 10.98%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.98%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.06%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_492_20230101__20231231_zzVWBgMzviUh" style="width: 10.98%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.98%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="text-align: center"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="padding-left: 9.45pt; text-indent: -9.45pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeasePayments_i01_zyCsZUvoFrM5" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Operating cash flows from operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;501,214&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;464,104&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FinanceLeaseInterestPaymentOnLiability_i01_zKYp2GHfNZm" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Financing cash flows from finance leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;131,437&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;125,259&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">501214</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000783"
      unitRef="USD">464104</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000785"
      unitRef="USD">131437</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000786"
      unitRef="USD">125259</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000789">&lt;p id="xdx_896_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z1PIw2sIUuV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B2_z0Muv5NOao1h"&gt;Supplemental information related to leases was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; width: 58%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top; width: 18%; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Remaining Lease Term&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20241231_zmIb4dGEugo2" title="Operating leases term::XDX::P5Y1M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;5.1&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20231231_zF5FxvE3qPud" title="Operating leases term::XDX::P6Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0793"&gt;6.9&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20241231_zXFttH55OXo7" title="Finance leases  term::XDX::P2Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0795"&gt;2.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dxL_c20231231_zMzK1h0En1D1" title="Operating leases term::XDX::P3Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0797"&gt;3.7&lt;/span&gt;&lt;/span&gt; Years&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Weighted Average Discount Rate&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Operating leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zD4Wg9VePVna" title="Operating leases discount rate"&gt;6.52&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20231231_zQTmoa3PK0X5" title="Operating leases discount rate"&gt;5.76&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 28.25pt; text-indent: -9.45pt"&gt;Finance leases&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20241231_zFxOZJ43fHoc" title="Finance leases discount rate"&gt;6.34&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LesseeFinanceLeaseDiscountRate_iI_pid_dp_uPure_c20231231_z5KU3gcUM807" title="Finance leases discount rate"&gt;6.19&lt;/span&gt;%&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000799"
      unitRef="Pure">0.0652</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000801"
      unitRef="Pure">0.0576</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000803"
      unitRef="Pure">0.0634</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000805"
      unitRef="Pure">0.0619</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000807">&lt;p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zwjrDeZbopqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zYzR4mV4G5fj"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Finance Leases&lt;/b&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2025&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zTDTK8n3t875" style="vertical-align: bottom; text-align: right" title="2025 - Operating Leases"&gt;533,979&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20241231_zjUsCnD4icoh" style="vertical-align: bottom; text-align: right" title="2025 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2026&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zH9ljjshPew4" style="vertical-align: bottom; text-align: right" title="2026 - Operating Leases"&gt;533,979&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20241231_zT12UntsoyB3" style="vertical-align: bottom; text-align: right" title="2026 - Finance Leases"&gt;131,437&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;2027&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zwmfrBeflmF" style="vertical-align: bottom; text-align: right" title="2027 - Operating Leases"&gt;533,979&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20241231_zl2F75onMYH5" style="vertical-align: bottom; text-align: right" title="2027 - Finance Leases"&gt;74,194&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;2028&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20241231_z9NnOEa1yyJ2" style="vertical-align: bottom; text-align: right" title="2028 - Operating Leases"&gt;520,985&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20241231_zPpCYm5GLIAk" style="vertical-align: bottom; text-align: right" title="2028 - Finance Leases"&gt;6,181&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom"&gt;Thereafter&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_z1nEpK0z5Mo4" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Operating Leases"&gt;1,833,603&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20241231_zonC4EG7RFYl" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Thereafter - Finance Leases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total undiscounted lease payments&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueTotal_iI_c20241231_zf3p9eKVuO16" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Operating Leases"&gt;3,956,525&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal_iI_c20241231_zPrhrwrXfTOg" style="vertical-align: bottom; text-align: right" title="Total undiscounted lease payments - Finance Leases"&gt;343,248&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #E6E6E6"&gt;
    &lt;td style="vertical-align: bottom; padding-left: 18.8pt"&gt;Less: imputed interest&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--LesseeOperatingLeaseImputedInterest_iNI_di_c20241231_zwRLoURqG6r6" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Operating Leases"&gt;(555,864&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--LesseeFinancingLeaseImputedInterest_iNI_di_c20241231_zxrD62runzac" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Less: imputed interest - Finance Leases"&gt;(25,048&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: white"&gt;
    &lt;td style="vertical-align: bottom"&gt;Total lease liabilities&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiability_iI_c20241231_zNhTlG0JzTd2" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Operating Leases"&gt;3,400,661&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; vertical-align: bottom"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FinanceLeaseLiability_iI_c20241231_zCdoExEUMXUk" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Total lease liabilities - Finance Leases"&gt;318,200&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000809"
      unitRef="USD">533979</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000811"
      unitRef="USD">131437</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000813"
      unitRef="USD">533979</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000815"
      unitRef="USD">131437</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000817"
      unitRef="USD">533979</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000819"
      unitRef="USD">74194</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000821"
      unitRef="USD">520985</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000823"
      unitRef="USD">6181</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <krmd:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000825"
      unitRef="USD">1833603</krmd:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000829"
      unitRef="USD">3956525</krmd:LesseeOperatingLeaseLiabilityPaymentsDueTotal>
    <krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000831"
      unitRef="USD">343248</krmd:LesseeFinancingLeaseLeaseLiabilityPaymentsDueTotal>
    <krmd:LesseeOperatingLeaseImputedInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000833"
      unitRef="USD">555864</krmd:LesseeOperatingLeaseImputedInterest>
    <krmd:LesseeFinancingLeaseImputedInterest
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000835"
      unitRef="USD">25048</krmd:LesseeFinancingLeaseImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000837"
      unitRef="USD">3400661</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000839"
      unitRef="USD">318200</us-gaap:FinanceLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000841">&lt;p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zyiW3AezfoH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_821_zcZFKW4kFts2"&gt;FEDERAL AND STATE INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss_zObaKHPM16Pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Domestic and international pre-tax income/(loss) consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zQewyfOXe396" style="display: none; visibility: hidden"&gt;Schedule of Components of Domestic and International Pre-Tax Income (Loss)&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zO5tODJ7fD48" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zDEUY1Lei53f" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zrYg1RyKPMd5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 59.94%"&gt;United States&lt;/td&gt;
    &lt;td style="width: 0.9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right"&gt;(6,063,740&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 3.92%"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right"&gt;(9,733,582&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 0.92%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--LossBeforeIncomeTaxes_zdPRysbo8mNg" style="vertical-align: bottom"&gt;
    &lt;td&gt;Loss before income taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,063,740&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(9,733,582&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zrKxQCjbhrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zg0KcHaDK7P5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income tax expense attributable to operations is comprised of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zH40JnISYQZe" style="display: none; visibility: hidden"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zGYKeQcDzzm9" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zE7qsNHKSDmk" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zzbxTfiiFmX1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Current:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_zvU7WS6IzcRd" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 59.94%"&gt;Federal&lt;/td&gt;
    &lt;td style="width: 0.9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0856"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3.92%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.92%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zgZXNN6pjf4k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;State&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,893&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentForeignTaxExpenseBenefit_z9jymh33Vcd3" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentIncomeTaxExpenseBenefit_zpL6pAzdmcz4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total Current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,893&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0866"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zWdkpggOLgQh" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_z3gOjbuiqj8k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Federal&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,967,480&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_z3NdOK6ATzC2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;State&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zMP0YVoZZ05k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_zEf2RdW2QJX2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Total Deferred&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,967,480&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iN_di_z6cJ0yEb8JUl" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Income Tax Expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(2,893&lt;/td&gt;
    &lt;td style="border-bottom: White 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: White 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zTClWbRmBpMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0c5Ey4UrK04" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred income taxes reflect the net tax effects of temporary differences
between carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant
components of our deferred tax assets and liabilities are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zkToTvMEmEcb" style="display: none; visibility: hidden"&gt;Schedule of components of deferred tax assets&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zY8Mtci61Uf4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_z5b5fugGZIv6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsAbstract_iB_zhvnf78rDXC1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 59.94%"&gt;Deferred Tax Assets:&lt;/td&gt;
    &lt;td style="width: 0.9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3.92%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.92%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxAssetsNetOperatingLoss_iI_zhkUmSrw8zD" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Net Operating Loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,025,905&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,566,630&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsCredits_iI_z1rolL4edE12" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Credits&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;129,598&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zGceoJacp2J6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Capitalized Research Costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,451,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,045,616&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsNQOAndRSAStockOptions_iI_zkLfJ848c1hg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;NQO &amp;amp; RSA Stock Options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;350,484&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,047,608&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsDeferredLeaseLiability_iI_zLVuaAEQfpFa" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Deferred Lease Liability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;647,446&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_z0zJkTHTaDbl" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Accruals &amp;amp; Reserves&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;712,058&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;129,923&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_z5GXDNHv8qL1" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;48&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;42&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_zOTE2jpPoh73" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Gross Deferred Tax Asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;8,317,035&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;6,931,849&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_z2oPP38ljvY2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(7,080,843&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iI_zyNMOInNXXWj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total Deferred Tax Asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,236,192&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;929,072&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zs3Xn5yHq3fa" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Deferred Tax Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxLiabilitiesIntangibles_iI_z8Gs9Wca3Ing" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Intangibles&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(58,170&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(408,260&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxLiabilitiesROUAssets_iI_zYnCif48gjta" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;ROU Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(538,632&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,511&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFixedAssets_iI_zwEV2O7Q2u4e" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Fixed Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(639,390&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(515,300&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNI_di_zlb7iPHNdT2j" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total Deferred Tax Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;(1,236,192&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;(929,071&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_zn8G5rrZqDl2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Net Deferred Tax Asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_z5tZ5ldOUp7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Management regularly assesses the ability to realize deferred tax assets
recorded based upon the weight of available evidence, including such factors as recent earnings history and expected future taxable income
on a jurisdiction by jurisdiction basis. In the event that the Company changes its determination as to the amount of realizable deferred
tax assets, the Company will adjust its valuation allowance with a corresponding impact to the provision for income taxes in the period
in which such determination is made. The Company&#x2019;s management believes that, based on a number of factors, it is more likely than
not, that all or some portion of the deferred tax assets will not be realized; and accordingly, for the year ended December 31, 2024 the
Company has provided a full valuation allowance against the Company&#x2019;s U.S. net deferred tax assets. The net change in the valuation
allowance for the year ended December 31, 2024 was an increase of $&lt;span id="xdx_90C_ecustom--NetChangeInValuationOfAllowanceOnDeferredTaxAssets_uUSD_c20240101__20241231_zEpkPsQ3yIR7" title="Valuation Allowance on Deferred Tax Assets - Net Change"&gt;1,078,066&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2024, the Company had net operating loss carryforwards
for federal and state income tax purposes of approximately $&lt;span id="xdx_906_ecustom--NetOperatingLossCarryforwardsFederal_iI_c20241231_zwyHmBx8KsQg" title="Net operating loss carryforwards, federal"&gt;18,313,421&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--NetOperatingLossCarryforwardsStateAndLocal_iI_c20241231_zkwsTGpuAr7j" title="Net operating loss carryforwards, state"&gt;3,533,499&lt;/span&gt;, respectively. The state net operating loss carryforwards
will being to expire in 2041 and our federal net operating loss carryforward will last indefinitely.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2024, the Company had federal and state research credit
carryforwards of approximately $&lt;span id="xdx_900_ecustom--FederalResearchCreditCarryforward_iI_c20241231_zQJ6DKOLWKSl" title="Federal Research Credit Carryforward"&gt;129,598&lt;/span&gt; and $&lt;span id="xdx_901_ecustom--StateResearchCreditCarryforward_iI_c20241231_zOv154rWwAud" title="State Research Credit Carryforward"&gt;0&lt;/span&gt; respectively. The federal research credit carryforwards will being to expire in 2036.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2024, and 2023 the Company had no gross unrecognized
tax benefits. The Company&#x2019;s policy is to recognize accrued interest and penalties related to unrecognized income tax benefits in
the Provision for income taxes should such amounts occur in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company files income tax returns in the US federal and various state
jurisdictions with varying statutes of limitations. The Company is currently under audit by the Internal Revenue Service for tax year
2022. Tax years 2021 through 2023 are open to examination by major taxing jurisdictions to which the Company is subject.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





&lt;p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjg1egs04xI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income tax expense differed from the amount computed by applying the federal
statutory income tax rate of 21% to pretax income for the years ended December 31, 2024 and December 31, 2023 as a result of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zgINPoOhGq3i" style="display: none; visibility: hidden"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231_z4YQfWbICOEb" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zgx2vGgJ2059" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zzqguLtQVMz9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 59.94%"&gt;Federal tax at statutory rate&lt;/td&gt;
    &lt;td style="width: 0.9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;1,272,820&lt;/td&gt;
    &lt;td style="width: 3.92%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;2,052,452&lt;/td&gt;
    &lt;td style="width: 0.92%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zmqbbaIgZGjj" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;State income taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;184,595&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--IncomeTaxReconciliationChangeInValuationAllowance_zpoRsDnmFHAd" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,078,066&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--IncomeTaxReconciliationDeferredTaxTrueUps_zDBVUNxZcObl" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Deferred tax true ups&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(352,653&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncomeTaxReconciliationOtherItems_zsfIFUrW7kT4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Other items&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,589&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(17,155&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--IncomeTaxReconciliationNet_zY58pErxH8tf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(2,893&lt;/td&gt;
    &lt;td style="border-bottom: White 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: White 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zLBgYoXAwQB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <krmd:ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss contextRef="From2024-01-01to2024-12-31" id="Fact000843">&lt;p id="xdx_894_ecustom--ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss_zObaKHPM16Pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Domestic and international pre-tax income/(loss) consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zQewyfOXe396" style="display: none; visibility: hidden"&gt;Schedule of Components of Domestic and International Pre-Tax Income (Loss)&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zO5tODJ7fD48" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zDEUY1Lei53f" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zrYg1RyKPMd5" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 59.94%"&gt;United States&lt;/td&gt;
    &lt;td style="width: 0.9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right"&gt;(6,063,740&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 3.92%"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; width: 15.9%; text-align: right"&gt;(9,733,582&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double; width: 0.92%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--LossBeforeIncomeTaxes_zdPRysbo8mNg" style="vertical-align: bottom"&gt;
    &lt;td&gt;Loss before income taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,063,740&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(9,733,582&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</krmd:ScheduleOfComponentsOfDomesticAndInternationalPreTaxIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000845"
      unitRef="USD">-6063740</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000846"
      unitRef="USD">-9733582</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <krmd:LossBeforeIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000848"
      unitRef="USD">-6063740</krmd:LossBeforeIncomeTaxes>
    <krmd:LossBeforeIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000849"
      unitRef="USD">-9733582</krmd:LossBeforeIncomeTaxes>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000851">&lt;p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zg0KcHaDK7P5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income tax expense attributable to operations is comprised of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8B5_zH40JnISYQZe" style="display: none; visibility: hidden"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zGYKeQcDzzm9" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zE7qsNHKSDmk" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zzbxTfiiFmX1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Current:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_zvU7WS6IzcRd" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="width: 59.94%"&gt;Federal&lt;/td&gt;
    &lt;td style="width: 0.9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0856"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 3.92%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 0.92%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_zgZXNN6pjf4k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;State&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,893&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentForeignTaxExpenseBenefit_z9jymh33Vcd3" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0862"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentIncomeTaxExpenseBenefit_zpL6pAzdmcz4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total Current&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,893&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0866"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zWdkpggOLgQh" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_z3gOjbuiqj8k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Federal&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0871"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,967,480&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_z3NdOK6ATzC2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;State&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zMP0YVoZZ05k" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;International&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_zEf2RdW2QJX2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Total Deferred&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,967,480&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iN_di_z6cJ0yEb8JUl" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Income Tax Expense&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(2,893&lt;/td&gt;
    &lt;td style="border-bottom: White 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: White 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000859"
      unitRef="USD">-2893</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000865"
      unitRef="USD">-2893</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000872"
      unitRef="USD">-3967480</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000881"
      unitRef="USD">-3967480</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000883"
      unitRef="USD">2893</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000884"
      unitRef="USD">3967480</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000887">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0c5Ey4UrK04" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred income taxes reflect the net tax effects of temporary differences
between carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant
components of our deferred tax assets and liabilities are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BA_zkToTvMEmEcb" style="display: none; visibility: hidden"&gt;Schedule of components of deferred tax assets&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zY8Mtci61Uf4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20231231_z5b5fugGZIv6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsAbstract_iB_zhvnf78rDXC1" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 59.94%"&gt;Deferred Tax Assets:&lt;/td&gt;
    &lt;td style="width: 0.9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 3.92%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.92%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxAssetsNetOperatingLoss_iI_zhkUmSrw8zD" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Net Operating Loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,025,905&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,566,630&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsCredits_iI_z1rolL4edE12" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Credits&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;129,598&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;142,030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zGceoJacp2J6" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Capitalized Research Costs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,451,496&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,045,616&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsNQOAndRSAStockOptions_iI_zkLfJ848c1hg" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;NQO &amp;amp; RSA Stock Options&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;350,484&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,047,608&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsDeferredLeaseLiability_iI_zLVuaAEQfpFa" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Deferred Lease Liability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;647,446&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0905"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_z0zJkTHTaDbl" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Accruals &amp;amp; Reserves&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;712,058&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;129,923&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOther_iI_z5GXDNHv8qL1" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Other&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;48&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;42&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_zOTE2jpPoh73" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Gross Deferred Tax Asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;8,317,035&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;6,931,849&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_z2oPP38ljvY2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(7,080,843&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iI_zyNMOInNXXWj" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total Deferred Tax Asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;1,236,192&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;929,072&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zs3Xn5yHq3fa" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Deferred Tax Liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxLiabilitiesIntangibles_iI_z8Gs9Wca3Ing" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Intangibles&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(58,170&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(408,260&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DeferredTaxLiabilitiesROUAssets_iI_zYnCif48gjta" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;ROU Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(538,632&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,511&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFixedAssets_iI_zwEV2O7Q2u4e" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Fixed Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(639,390&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(515,300&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilities_iNI_di_zlb7iPHNdT2j" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Total Deferred Tax Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;(1,236,192&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: black 2.25pt double; text-align: right"&gt;(929,071&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_zn8G5rrZqDl2" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Net Deferred Tax Asset&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: white 2.25pt double"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <krmd:DeferredTaxAssetsNetOperatingLoss
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000892"
      unitRef="USD">4025905</krmd:DeferredTaxAssetsNetOperatingLoss>
    <krmd:DeferredTaxAssetsNetOperatingLoss
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000893"
      unitRef="USD">3566630</krmd:DeferredTaxAssetsNetOperatingLoss>
    <krmd:DeferredTaxAssetsCredits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000895"
      unitRef="USD">129598</krmd:DeferredTaxAssetsCredits>
    <krmd:DeferredTaxAssetsCredits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000896"
      unitRef="USD">142030</krmd:DeferredTaxAssetsCredits>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000898"
      unitRef="USD">2451496</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000899"
      unitRef="USD">2045616</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <krmd:DeferredTaxAssetsNQOAndRSAStockOptions
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000901"
      unitRef="USD">350484</krmd:DeferredTaxAssetsNQOAndRSAStockOptions>
    <krmd:DeferredTaxAssetsNQOAndRSAStockOptions
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000902"
      unitRef="USD">1047608</krmd:DeferredTaxAssetsNQOAndRSAStockOptions>
    <krmd:DeferredTaxAssetsDeferredLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000904"
      unitRef="USD">647446</krmd:DeferredTaxAssetsDeferredLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000907"
      unitRef="USD">712058</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000908"
      unitRef="USD">129923</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000910"
      unitRef="USD">48</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000911"
      unitRef="USD">42</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000913"
      unitRef="USD">8317035</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000914"
      unitRef="USD">6931849</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000916"
      unitRef="USD">7080843</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000917"
      unitRef="USD">6002777</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000919"
      unitRef="USD">1236192</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000920"
      unitRef="USD">929072</us-gaap:DeferredTaxAssetsNet>
    <krmd:DeferredTaxLiabilitiesIntangibles
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000925"
      unitRef="USD">-58170</krmd:DeferredTaxLiabilitiesIntangibles>
    <krmd:DeferredTaxLiabilitiesIntangibles
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000926"
      unitRef="USD">-408260</krmd:DeferredTaxLiabilitiesIntangibles>
    <krmd:DeferredTaxLiabilitiesROUAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000928"
      unitRef="USD">-538632</krmd:DeferredTaxLiabilitiesROUAssets>
    <krmd:DeferredTaxLiabilitiesROUAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000929"
      unitRef="USD">-5511</krmd:DeferredTaxLiabilitiesROUAssets>
    <krmd:DeferredTaxLiabilitiesFixedAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000931"
      unitRef="USD">-639390</krmd:DeferredTaxLiabilitiesFixedAssets>
    <krmd:DeferredTaxLiabilitiesFixedAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000932"
      unitRef="USD">-515300</krmd:DeferredTaxLiabilitiesFixedAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000934"
      unitRef="USD">1236192</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000935"
      unitRef="USD">929071</us-gaap:DeferredTaxLiabilities>
    <krmd:NetChangeInValuationOfAllowanceOnDeferredTaxAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000940"
      unitRef="USD">1078066</krmd:NetChangeInValuationOfAllowanceOnDeferredTaxAssets>
    <krmd:NetOperatingLossCarryforwardsFederal
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000942"
      unitRef="USD">18313421</krmd:NetOperatingLossCarryforwardsFederal>
    <krmd:NetOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000944"
      unitRef="USD">3533499</krmd:NetOperatingLossCarryforwardsStateAndLocal>
    <krmd:FederalResearchCreditCarryforward
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000946"
      unitRef="USD">129598</krmd:FederalResearchCreditCarryforward>
    <krmd:StateResearchCreditCarryforward
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000948"
      unitRef="USD">0</krmd:StateResearchCreditCarryforward>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000951">&lt;p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjg1egs04xI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Income tax expense differed from the amount computed by applying the federal
statutory income tax rate of 21% to pretax income for the years ended December 31, 2024 and December 31, 2023 as a result of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BF_zgINPoOhGq3i" style="display: none; visibility: hidden"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 5.5in; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20240101__20241231_z4YQfWbICOEb" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zgx2vGgJ2059" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zzqguLtQVMz9" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td style="width: 59.94%"&gt;Federal tax at statutory rate&lt;/td&gt;
    &lt;td style="width: 0.9%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;1,272,820&lt;/td&gt;
    &lt;td style="width: 3.92%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1.26%"&gt;$&lt;/td&gt;
    &lt;td style="width: 15.9%; text-align: right"&gt;2,052,452&lt;/td&gt;
    &lt;td style="width: 0.92%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_zmqbbaIgZGjj" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;State income taxes&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;184,595&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--IncomeTaxReconciliationChangeInValuationAllowance_zpoRsDnmFHAd" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Valuation allowance&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,078,066&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(6,002,777&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--IncomeTaxReconciliationDeferredTaxTrueUps_zDBVUNxZcObl" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Deferred tax true ups&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(352,653&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncomeTaxReconciliationOtherItems_zsfIFUrW7kT4" style="vertical-align: bottom; background-color: #E6E6E6"&gt;
    &lt;td&gt;Other items&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,589&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(17,155&lt;/td&gt;
    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--IncomeTaxReconciliationNet_zY58pErxH8tf" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(2,893&lt;/td&gt;
    &lt;td style="border-bottom: White 2.25pt double"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; text-align: right"&gt;(3,967,480&lt;/td&gt;
    &lt;td style="border-bottom: White 2.25pt double"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000953"
      unitRef="USD">1272820</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000954"
      unitRef="USD">2052452</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000956"
      unitRef="USD">184595</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <krmd:IncomeTaxReconciliationChangeInValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000959"
      unitRef="USD">-1078066</krmd:IncomeTaxReconciliationChangeInValuationAllowance>
    <krmd:IncomeTaxReconciliationChangeInValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000960"
      unitRef="USD">-6002777</krmd:IncomeTaxReconciliationChangeInValuationAllowance>
    <krmd:IncomeTaxReconciliationDeferredTaxTrueUps
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000962"
      unitRef="USD">-352653</krmd:IncomeTaxReconciliationDeferredTaxTrueUps>
    <krmd:IncomeTaxReconciliationOtherItems
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000965"
      unitRef="USD">-29589</krmd:IncomeTaxReconciliationOtherItems>
    <krmd:IncomeTaxReconciliationOtherItems
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000966"
      unitRef="USD">-17155</krmd:IncomeTaxReconciliationOtherItems>
    <krmd:IncomeTaxReconciliationNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000968"
      unitRef="USD">-2893</krmd:IncomeTaxReconciliationNet>
    <krmd:IncomeTaxReconciliationNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000969"
      unitRef="USD">-3967480</krmd:IncomeTaxReconciliationNet>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000971">&lt;p id="xdx_80A_eus-gaap--ConcentrationRiskDisclosureTextBlock_zdselpWU5u0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_82D_z3oYUcShVtk7"&gt;MAJOR CUSTOMERS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For the years ended December 31, 2024 and December 31, 2023, approximately
&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zE2033bgQBi5"&gt;64&lt;/span&gt;% and &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zGo0zZOtuQ6i"&gt;66&lt;/span&gt;%, respectively, of the Company&#x2019;s net product revenues were derived from three major customers that are distributors.
&#160;As of December 31, 2024 and December 31, 2023, accounts receivable due from the three major customers was $&lt;span id="xdx_90D_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20241231_zhRjBHfBZFVe" title="Account eceivable from customers"&gt;3.6&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_dm_c20231231_zeqAxBz2J5v4" title="Account eceivable from customers"&gt;2.6&lt;/span&gt;
million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The largest customer in both years is a domestic medical products and supplies
distributor. &#160;Although a number of larger infusion customers have elected to consolidate their purchases through one or more distributors
in recent years, we continue to maintain strong direct relationships with them. &#160;We do not believe that their continued purchase
of FREEDOM System products and related supplies is contingent upon the distributor.&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="Fact000972"
      unitRef="Pure">0.64</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="Fact000973"
      unitRef="Pure">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000975"
      unitRef="USD">3600</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000977"
      unitRef="USD">2600</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000979">&lt;p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zxnmtdBKr6L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9 &#x2014; &lt;span id="xdx_828_zO0XDe5kk54"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;LEGAL PROCEEDINGS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has been and may again become involved in legal proceedings,
claims and litigation arising in the ordinary course of business. &#160;KORU Medical is not presently a party to any litigation or other
legal proceeding that is believed to be material to its financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;OTHER&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On November 11, 2020, the Company entered into a Manufacturing and Supply
Agreement with Command Medical Products, Inc. (&#x201c;Command&#x201d;), pursuant to which Command has agreed to manufacture and supply
the Company&#x2019;s subassemblies, needle sets and tubing products pursuant to the Company&#x2019;s specifications and purchase orders.
&#160;The first binding purchase order pursuant to the Manufacturing and Supply Agreement was made on November 17, 2020 (the &#x201c;Effective
Date&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Manufacturing and Supply Agreement provides for a term of five years
from the Effective Date. &#160;Either party may terminate the Manufacturing and Supply Agreement upon a material breach by the other Party
that has not been cured within 90 days, upon the bankruptcy or insolvency of the other Party or as expressly set forth elsewhere in the
Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Manufacturing and Supply Agreement also includes customary provisions
relating to, among other things, delivery, inspection procedures, warranties, quality management, business continuity plans, handling
and transport, intellectual property, confidentiality and indemnification.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000981">&lt;p id="xdx_803_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjdNlYCjSEy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 10 &#x2014; &lt;span id="xdx_826_zAMT8YAD0pyi"&gt;EMPLOYEE BENEFITS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;We provide a safe harbor 401(k) plan for our employees that allows for
employee elective contributions, Company matching contributions and discretionary profit-sharing contributions. &#160;Employee elective
contributions are funded through voluntary payroll deductions. &#160;&lt;span id="xdx_906_ecustom--DescriptionOfMatchingContribution_c20240101__20241231_zNdRfISiqFC5" title="Description of matching contribution"&gt;The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#x2019;s contribution, not to exceed 3% of employee&#x2019;s compensation plus 50% of employee&#x2019;s pay
contributed between 3% and 5% of employee&#x2019;s compensation.&lt;/span&gt; &#160;Company matching expense for the years ended December 31, 2024 and
December 31, 2023 was $&lt;span id="xdx_907_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20240101__20241231_z8vJU3nMIUL" title="Matching expense"&gt;262,915&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zN1rS28jYCQi" title="Matching expense"&gt;227,447&lt;/span&gt;, respectively. &#160;The Company has not provided for a discretionary profit-sharing contribution.&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <krmd:DescriptionOfMatchingContribution contextRef="From2024-01-01to2024-12-31" id="Fact000983">The Company makes safe harbor matching contributions in an amount
equal to 100% of the employee&#x2019;s contribution, not to exceed 3% of employee&#x2019;s compensation plus 50% of employee&#x2019;s pay
contributed between 3% and 5% of employee&#x2019;s compensation.</krmd:DescriptionOfMatchingContribution>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000985"
      unitRef="USD">262915</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000987"
      unitRef="USD">227447</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000989">&lt;p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zbgpJk3SvH55" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 11 &#x2014; &lt;span id="xdx_829_zv1Dy7I1Bkc9"&gt;SEGMENT DISCLOSURE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&#x2019;s operations are based in, and revenues are predominately
derived from, the United States, and business activities are managed on a consolidated basis.&#160; The Company operates in one reportable
segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&#x2019;s Chief Executive Officer is the Chief Operating Decision
Maker (&#x201c;CODM&#x201d;).&#160; The CODM regularly reviews disaggregated revenue data by product line.&#160; However, consolidated net
income is utilized as a measure of profit and loss to assess the performance of the business and to determine how to allocate resources.&#160;
Significant expenses within net income include cost of goods sold, selling, general and administrative, research and development, and
depreciation and amortization, which are each separately presented on the Company&#x2019;s Statements of Operations.&#160; Segment asset
information is not used by the CODM to allocate resources.&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-09-012024-12-31" id="Fact000990">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-09-012024-12-31" id="Fact000991">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-09-012024-12-31" id="Fact000992">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-09-012024-12-31" id="Fact000993">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000994">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
